Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7879985,Half-life,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,8.82,724,DB00160,L-Alanine
,7879985,mean residence time,Half-life of 8.82 hours and mean residence time of 12.18 hours were determined for MMI.,Pharmacokinetics and short-term clinicopathologic changes after intravenous administration of a high dose of methimazole in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879985/),h,12.18,725,DB00160,L-Alanine
,33990984,t1/2,"After intravenous infusion, RDV is rapidly metabolized (t1/2 = 1 h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and then it can be found in plasma in its nucleoside analogue form (GS-441524).",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,1,1908,DB00160,L-Alanine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],<,1909,DB00160,L-Alanine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1910,DB00160,L-Alanine
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1911,DB00160,L-Alanine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1912,DB00160,L-Alanine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],122.3,1913,DB00160,L-Alanine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2637.3,1914,DB00160,L-Alanine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1915,DB00160,L-Alanine
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1916,DB00160,L-Alanine
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1917,DB00160,L-Alanine
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],3676.5,1918,DB00160,L-Alanine
>,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2610,1919,DB00160,L-Alanine
,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],140,1920,DB00160,L-Alanine
>,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],1560,1921,DB00160,L-Alanine
,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],2230,1922,DB00160,L-Alanine
,33990984,t1/2,The mean t1/2 value for GS-441524 was 26.3 h.,Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,26.3,1923,DB00160,L-Alanine
,116591,Plasma half-lives,Plasma half-lives were 20 min in rats and approximately 1 h in baboons and humans.,Phosphonopeptides as antibacterial agents: metabolism and pharmacokinetics of alafosfalin in animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/116591/),min,20,2814,DB00160,L-Alanine
,116591,Plasma half-lives,Plasma half-lives were 20 min in rats and approximately 1 h in baboons and humans.,Phosphonopeptides as antibacterial agents: metabolism and pharmacokinetics of alafosfalin in animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/116591/),h,1,2815,DB00160,L-Alanine
,3995686,peak plasma concentrations,"The drug was administered at doses of 100-550 mg/m2 in 1-h and 12-h infusions, resulting in peak plasma concentrations of CB 3717 of 40-200 microM.","The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995686/),μM,40-200,2950,DB00160,L-Alanine
,3995686,t1/2 alpha,"Following a 1-h infusion, drug levels in the plasma decayed biphasically (t1/2 alpha = 49 +/- 9 min, t1/2 beta = 739 +/- 209 min).","The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995686/),min,49,2951,DB00160,L-Alanine
,3995686,t1/2 beta,"Following a 1-h infusion, drug levels in the plasma decayed biphasically (t1/2 alpha = 49 +/- 9 min, t1/2 beta = 739 +/- 209 min).","The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995686/),min,739,2952,DB00160,L-Alanine
,3995686,Plasma protein binding,Plasma protein binding of CB 3717 was extensive (97.6% +/- 0.1%).,"The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995686/),%,97.6,2953,DB00160,L-Alanine
,1403775,total plasma,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4261,DB00160,L-Alanine
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4262,DB00160,L-Alanine
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],86,4263,DB00160,L-Alanine
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],29,4264,DB00160,L-Alanine
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],17,4265,DB00160,L-Alanine
,14503959,IC(50),"TA138 and (89)Y-TA138 retain antagonist properties and high affinity for integrin alpha(v)beta(3) (IC(50) = 12 and 18 nM, respectively), and good selectivity versus integrin alpha(IIb)beta(3) (IC(50) > 10,000 nM).","Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14503959/),nM,12,5017,DB00160,L-Alanine
,14503959,IC(50),"TA138 and (89)Y-TA138 retain antagonist properties and high affinity for integrin alpha(v)beta(3) (IC(50) = 12 and 18 nM, respectively), and good selectivity versus integrin alpha(IIb)beta(3) (IC(50) > 10,000 nM).","Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14503959/),nM,18,5018,DB00160,L-Alanine
>,14503959,IC(50),"TA138 and (89)Y-TA138 retain antagonist properties and high affinity for integrin alpha(v)beta(3) (IC(50) = 12 and 18 nM, respectively), and good selectivity versus integrin alpha(IIb)beta(3) (IC(50) > 10,000 nM).","Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14503959/),nM,"10,000",5019,DB00160,L-Alanine
,20802234,mean residence times (MRT),"The mean residence times (MRT) of the proteins, calculated by quantifying blood activity from the PET images, were: Db-DIII WT (56.7 h), H535A (25 h), H510A (20 h), H464A (17 h), compared with Db (2.9 h).",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),h,56.7,6667,DB00160,L-Alanine
,20802234,mean residence times (MRT),"The mean residence times (MRT) of the proteins, calculated by quantifying blood activity from the PET images, were: Db-DIII WT (56.7 h), H535A (25 h), H510A (20 h), H464A (17 h), compared with Db (2.9 h).",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),h,25,6668,DB00160,L-Alanine
,20802234,mean residence times (MRT),"The mean residence times (MRT) of the proteins, calculated by quantifying blood activity from the PET images, were: Db-DIII WT (56.7 h), H535A (25 h), H510A (20 h), H464A (17 h), compared with Db (2.9 h).",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),h,20,6669,DB00160,L-Alanine
,20802234,mean residence times (MRT),"The mean residence times (MRT) of the proteins, calculated by quantifying blood activity from the PET images, were: Db-DIII WT (56.7 h), H535A (25 h), H510A (20 h), H464A (17 h), compared with Db (2.9 h).",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),h,17,6670,DB00160,L-Alanine
,20802234,mean residence times (MRT),"The mean residence times (MRT) of the proteins, calculated by quantifying blood activity from the PET images, were: Db-DIII WT (56.7 h), H535A (25 h), H510A (20 h), H464A (17 h), compared with Db (2.9 h).",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),h,2.9,6671,DB00160,L-Alanine
,20802234,blood clearance,"Biodistribution confirmed the order of blood clearance from slow to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively.",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),%,4.0,6672,DB00160,L-Alanine
,20802234,blood clearance,"Biodistribution confirmed the order of blood clearance from slow to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively.",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),%,2.0,6673,DB00160,L-Alanine
,20802234,blood clearance,"Biodistribution confirmed the order of blood clearance from slow to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively.",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),%,1.8,6674,DB00160,L-Alanine
,20802234,blood clearance,"Biodistribution confirmed the order of blood clearance from slow to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively.",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),%,1.6,6675,DB00160,L-Alanine
,20802234,blood clearance,"Biodistribution confirmed the order of blood clearance from slow to fast: Db-DIII WT > H535A > H510A > H464A > Db with 4.0, 2.0, 1.8, 1.6 and 0.08 %ID/g of remaining blood activity at 51 h, respectively.",Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20802234/),%,0.08,6676,DB00160,L-Alanine
,29300135,bioavailability,"2. Rovatirelin orally administered to rats and dogs was rapidly absorbed and bioavailability was estimated to be 7.3 and 41.3%, respectively.","Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300135/),%,7.3,6877,DB00160,L-Alanine
,29300135,bioavailability,"2. Rovatirelin orally administered to rats and dogs was rapidly absorbed and bioavailability was estimated to be 7.3 and 41.3%, respectively.","Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300135/),%,41.3,6878,DB00160,L-Alanine
,29300135,plasma protein binding,"The extent of plasma protein binding of rovatirelin in rats, dogs, and humans was low in all species (∼15%).","Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300135/),%,∼15,6879,DB00160,L-Alanine
,29300135,permeability,"The permeability of rovatirelin from blood to brain (permeability-surface area) ranged from 1.04 ± 0.14 to 1.29 ± 0.28 μL/min/g in rats, and rovatirelin was stable in rat plasma and brain homogenates.","Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300135/),[μl] / [g·min],1.04,6880,DB00160,L-Alanine
,29300135,permeability,"The permeability of rovatirelin from blood to brain (permeability-surface area) ranged from 1.04 ± 0.14 to 1.29 ± 0.28 μL/min/g in rats, and rovatirelin was stable in rat plasma and brain homogenates.","Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29300135/),[μl] / [g·min],1.29,6881,DB00160,L-Alanine
,21847518,"area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))","The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[h·μg] / [ml],52.0,7645,DB00160,L-Alanine
,21847518,maximum plasma concentration (C(max)),"The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[μg] / [ml],4.5,7646,DB00160,L-Alanine
,21847518,trough plasma level (C(trough)),"The mean area under the concentration-time curve from 0 to 24 hours [AUC(0-24 h) (AUC(0-24 h,ss))], maximum plasma concentration (C(max)), and trough plasma level (C(trough)) of moxifloxacin at steady state was 52.0 μg h/ml, 4.5, and 0.9 μg/ml, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),[μg] / [ml],0.9,7647,DB00160,L-Alanine
,21847518,"AUC(0-24 h,ss)","Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,723,7648,DB00160,L-Alanine
,21847518,mi,"Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,723,7649,DB00160,L-Alanine
,21847518,MICs,"Mean AUC(0-24 h,ss)/mimimum inhibitory concentration (MIC), and C(max)/MIC ratios for patients in whom MICs of moxifloxacin were determined for pathogenic bacteria were 723 and 62, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,62,7650,DB00160,L-Alanine
,21847518,"AUC(0-24 h,ss)/MIC","The median AUC(0-24 h,ss)/MIC and C(max)/MIC ratios (based on Monte Carlo simulation employing MICs for 257 strains of S. pneumoniae collected during a respiratory infection survey by the Japanese Society of Chemotherapy in 2007) were 209.56 and 17.88, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,209.56,7651,DB00160,L-Alanine
≥,21847518,AUC/MIC ratio,"Thus, when the target for the AUC/MIC ratio was set at ≥30 and that for the C(max)/MIC ratio at ≥5, the achievement rate for these two parameters was 97.36% and 96.71%, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,30,7652,DB00160,L-Alanine
≥,21847518,C(max)/MIC ratio,"Thus, when the target for the AUC/MIC ratio was set at ≥30 and that for the C(max)/MIC ratio at ≥5, the achievement rate for these two parameters was 97.36% and 96.71%, respectively.",Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21847518/),,5,7653,DB00160,L-Alanine
,17201415,IC50,A weak human glucagon receptor antagonist with an IC50 of 7 microM was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor.,New beta-alanine derivatives are orally available glucagon receptor antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201415/),μM,7,8104,DB00160,L-Alanine
,17201415,plasma half-life,A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min.,New beta-alanine derivatives are orally available glucagon receptor antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201415/),min,90,8105,DB00160,L-Alanine
,26957110,half-life,"In patients with genotype 1-4 infection, GS-9857 exhibited linear PK and was associated with a median half-life of 29-42 h, supporting once-daily dosing.","GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26957110/),h,29-42,8154,DB00160,L-Alanine
,1310919,Liver blood flow,"2. Liver blood flow, determined from the plasma clearance of Indocyanine Green, was lower in acute illness than in convalescence [16.1 (7.0) versus 23.9 (7.2) ml min-1 kg-1, mean (SD)], but this difference was not statistically significant (P = 0.15).",Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],16.1,8606,DB00160,L-Alanine
,1310919,Liver blood flow,"2. Liver blood flow, determined from the plasma clearance of Indocyanine Green, was lower in acute illness than in convalescence [16.1 (7.0) versus 23.9 (7.2) ml min-1 kg-1, mean (SD)], but this difference was not statistically significant (P = 0.15).",Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],23.9,8607,DB00160,L-Alanine
,1310919,plasma clearance,"2. Liver blood flow, determined from the plasma clearance of Indocyanine Green, was lower in acute illness than in convalescence [16.1 (7.0) versus 23.9 (7.2) ml min-1 kg-1, mean (SD)], but this difference was not statistically significant (P = 0.15).",Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],16.1,8608,DB00160,L-Alanine
,1310919,plasma clearance,"2. Liver blood flow, determined from the plasma clearance of Indocyanine Green, was lower in acute illness than in convalescence [16.1 (7.0) versus 23.9 (7.2) ml min-1 kg-1, mean (SD)], but this difference was not statistically significant (P = 0.15).",Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],23.9,8609,DB00160,L-Alanine
,1310919,plasma clearance,3. The plasma clearance of galactose after intravenous injection was similar in the acute [15.4 (4.90) ml min-1 kg-1] and convalescent study [12.8 (2.1) ml min-1 kg-1].,Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],15.4,8610,DB00160,L-Alanine
,1310919,plasma clearance,3. The plasma clearance of galactose after intravenous injection was similar in the acute [15.4 (4.90) ml min-1 kg-1] and convalescent study [12.8 (2.1) ml min-1 kg-1].,Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1310919/),[ml] / [kg·min],12.8,8611,DB00160,L-Alanine
,25819132,apparent clearance,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),[l] / [h],0.901,9187,DB00160,L-Alanine
,25819132,apparent volume of distribution,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),l,17.4,9188,DB00160,L-Alanine
,25819132,apparent volume of distribution,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),1/[h],2.24,9189,DB00160,L-Alanine
,25819132,absorption rate constant,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),l,17.4,9190,DB00160,L-Alanine
,25819132,absorption rate constant,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),1/[h],2.24,9191,DB00160,L-Alanine
,25819132,absorption lag time,"Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h(-1) , 17.4 l, 2.24 h(-1) , and 0.263 h, respectively.",Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819132/),h,0.263,9192,DB00160,L-Alanine
,6995479,steady-state plasma epinephrine concentrations,"These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[pg] / [ml],"24 to 1,020",9497,DB00160,L-Alanine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],52,9498,DB00160,L-Alanine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],89,9499,DB00160,L-Alanine
,12742279,International Normalized Ratio,"In a fourth group, warfarin (n = 67) was managed and monitored according to normal routines, aiming for an International Normalized Ratio of 2.0 to 3.0.","Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742279/),,2.0 to 3.0,9596,DB00160,L-Alanine
,18444516,half-life,"Streptokinase mainly undergoes renal elimination with a half-life of 11-17 min, while alteplase is eliminating by the liver with a half-life of 4-6 min.",Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444516/),min,11-17,10493,DB00160,L-Alanine
,18444516,half-life,"Streptokinase mainly undergoes renal elimination with a half-life of 11-17 min, while alteplase is eliminating by the liver with a half-life of 4-6 min.",Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18444516/),min,4-6,10494,DB00160,L-Alanine
,11124749,S(f),"In addition, we studied the effect of cafestol on the composition of VLDL(1) and VLDL(2) (S(f) 20-60).",The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11124749/),,20-60,11688,DB00160,L-Alanine
,22023340,di,"Furthermore, it had a low in-vitro and in-vivo disintegration time (11 s) and it reached 100% of drug release within 30 s.",Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22023340/),s,11,12387,DB00160,L-Alanine
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.33,12391,DB00160,L-Alanine
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.29,12392,DB00160,L-Alanine
,26832752,AUC24,"Patients with ALT ≥51 IU/L showed significantly higher isoniazid exposure than those with ALT <51 IU/L (mean AUC24 of 58.33 versus 31.28 mg·h/L, P < 0.001).",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],58.33,14292,DB00160,L-Alanine
,26832752,AUC24,"Patients with ALT ≥51 IU/L showed significantly higher isoniazid exposure than those with ALT <51 IU/L (mean AUC24 of 58.33 versus 31.28 mg·h/L, P < 0.001).",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],31.28,14293,DB00160,L-Alanine
≥,26832752,AUC24,"The probabilities of ALT elevation were 0.82 and 0.12 for isoniazid AUC24 ≥55.0 and <55.0 mg·h/L, respectively.",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],55.0,14294,DB00160,L-Alanine
<,26832752,AUC24,"The probabilities of ALT elevation were 0.82 and 0.12 for isoniazid AUC24 ≥55.0 and <55.0 mg·h/L, respectively.",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],55.0,14295,DB00160,L-Alanine
,26832752,AUC24,"Use of a logistic regression model estimated a likelihood of developing hepatotoxicity of 0.5 and 0.9 when in the presence of an isoniazid AUC24 of 53.7 and 70.0 mg·h/L, respectively.",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],53.7,14296,DB00160,L-Alanine
,26832752,AUC24,"Use of a logistic regression model estimated a likelihood of developing hepatotoxicity of 0.5 and 0.9 when in the presence of an isoniazid AUC24 of 53.7 and 70.0 mg·h/L, respectively.",Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26832752/),[h·mg] / [l],70.0,14297,DB00160,L-Alanine
,28326681,apparent drug clearance (CL/F) from the central compartment,The apparent drug clearance (CL/F) from the central compartment was 13.5 L/hr (RSE 4.9%).,Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28326681/),[l] / [h],13.5,14474,DB00160,L-Alanine
,1352223,intrinsic clearance of total drug (CLint),"When vitamin K3 (20 mg/kg) in polyethylene glycol 300 (PEG 300) was coinfused with (+)-propranolol (2 mg/kg) into the pyloric vein (a tributary flowing directly into the hepatic portal vein), a significant decrease in the intrinsic clearance of total drug (CLint) from 94.1 +/- 50.1 to 32.9 +/- 11.5 ml/min/kg was observed (p less than 0.01 vs. vehicle control).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],94.1,15194,DB00160,L-Alanine
,1352223,intrinsic clearance of total drug (CLint),"When vitamin K3 (20 mg/kg) in polyethylene glycol 300 (PEG 300) was coinfused with (+)-propranolol (2 mg/kg) into the pyloric vein (a tributary flowing directly into the hepatic portal vein), a significant decrease in the intrinsic clearance of total drug (CLint) from 94.1 +/- 50.1 to 32.9 +/- 11.5 ml/min/kg was observed (p less than 0.01 vs. vehicle control).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],32.9,15195,DB00160,L-Alanine
,1352223,CLint,"Interestingly, the PEG 300 vehicle control group exhibited a significantly (p less than 0.05) higher CLint than that observed in a saline control group (94.1 +/- 50.1 vs. 45.9 +/- 13.7 ml/min/kg).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],94.1,15196,DB00160,L-Alanine
,1352223,CLint,"Interestingly, the PEG 300 vehicle control group exhibited a significantly (p less than 0.05) higher CLint than that observed in a saline control group (94.1 +/- 50.1 vs. 45.9 +/- 13.7 ml/min/kg).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],45.9,15197,DB00160,L-Alanine
,20551237,apparent half-life,"The 1-O-acylglucuronide, in addition to minor hydrolysis to the aglycon, underwent nonenzymatic acyl migration in aqueous solution, resulting in the formation of the 2-O-, 3-O-, and 4-O-acylglucuronides with an apparent half-life of 1 h (37 degrees C, pH 7.4).","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),h,1,15724,DB00160,L-Alanine
,20551237,K(m),"The glucuronidation of dabigatran was catalyzed by human hepatic and intestinal microsomes with K(m) values in the range of 180 to 255 and 411 to 759 microM, respectively.","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),μM,180 to 255,15725,DB00160,L-Alanine
,20551237,K(m),"The glucuronidation of dabigatran was catalyzed by human hepatic and intestinal microsomes with K(m) values in the range of 180 to 255 and 411 to 759 microM, respectively.","Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551237/),μM,411 to 759,15726,DB00160,L-Alanine
,1642673,disappearance half-lives,The disappearance half-lives of M1 from plasma were much longer in dogs (6.3-9.3 h) than in rats (0.9-2.3 h).,"Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642673/),h,6.3-9.3,16990,DB00160,L-Alanine
,1642673,disappearance half-lives,The disappearance half-lives of M1 from plasma were much longer in dogs (6.3-9.3 h) than in rats (0.9-2.3 h).,"Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642673/),h,0.9-2.3,16991,DB00160,L-Alanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,6.28,17149,DB00160,L-Alanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,9.63,17150,DB00160,L-Alanine
,27765756,progression-free survival,"Three, three, six, and one patient achieved partial response while median progression-free survival was 6.28, 9.63 months, not reached, and 3.15 months in arms A, B, C, and D, respectively.",Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765756/),month,3.15,17151,DB00160,L-Alanine
,18472234,Clast,"Clast (concentration at the last time point) of SACV was observed to be 8+/-2.6microM in aqueous humor which is two and three times higher than VACV and ACV, respectively.",Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18472234/),μM,8,17477,DB00160,L-Alanine
<,33253776,T1/2,"In contrast to angiotensin II which has a T1/2 in plasma of < 1 min, LP2 has a T1/2 of approximately 2.1-2.6 hours.","LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33253776/),min,1,18257,DB00160,L-Alanine
,33253776,T1/2,"In contrast to angiotensin II which has a T1/2 in plasma of < 1 min, LP2 has a T1/2 of approximately 2.1-2.6 hours.","LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33253776/),h,2.1-2.6,18258,DB00160,L-Alanine
,33253776,fraction of the dose excreted unchanged in urine,The fraction of the dose excreted unchanged in urine ranged from 84.73 ± 10.4 % at a dose of 0.001 mg to 66.4 ± 3.9 % at 0.1 mg.,"LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33253776/),%,84.73,18259,DB00160,L-Alanine
,33253776,fraction of the dose excreted unchanged in urine,The fraction of the dose excreted unchanged in urine ranged from 84.73 ± 10.4 % at a dose of 0.001 mg to 66.4 ± 3.9 % at 0.1 mg.,"LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33253776/),%,66.4,18260,DB00160,L-Alanine
,12689410,plasma trough concentrations,The median (range) NVP plasma trough concentrations were similar in 32 HCV antibody-positive and 38 HCV antibody-negative patients (5.8 [0.7-29] vs. 6.1 [0.9-9.6] microg/ml).,"Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689410/),[μg] / [ml],5.8,18578,DB00160,L-Alanine
,12689410,plasma trough concentrations,The median (range) NVP plasma trough concentrations were similar in 32 HCV antibody-positive and 38 HCV antibody-negative patients (5.8 [0.7-29] vs. 6.1 [0.9-9.6] microg/ml).,"Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689410/),[μg] / [ml],6.1,18579,DB00160,L-Alanine
,28930776,terminal half-life,"CPT had a terminal half-life of 0.90 to 1.27 hours at the 5 dose levels, and no accumulation was observed with repeated doses.",A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28930776/),h,0.90 to 1.27,18825,DB00160,L-Alanine
,28930776,overall response rate,The overall response rate (complete and partial response) was 18.5%.,A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28930776/),%,18.5,18826,DB00160,L-Alanine
,20075192,T(max),"After a single 140-mg dose of [(14)C]semagacestat administered as an oral solution to six healthy male subjects, semagacestat was rapidly absorbed (T(max) approximately 0.5 h) and eliminated from the systemic circulation (terminal t(1/2) approximately 2.4 h).","Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20075192/),h,0.5,19483,DB00160,L-Alanine
,20075192,terminal t(1/2),"After a single 140-mg dose of [(14)C]semagacestat administered as an oral solution to six healthy male subjects, semagacestat was rapidly absorbed (T(max) approximately 0.5 h) and eliminated from the systemic circulation (terminal t(1/2) approximately 2.4 h).","Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20075192/),h,2.4,19484,DB00160,L-Alanine
,29941652,ratio of the area under free drug plasma concentration-time curve over 24 h (fAUC) to MIC90 (fAUC/MIC),"Monte Carlo simulation showed that for children with normal liver function, a loading-dose strategy (a loading dose of 15 mg/kg of body weight followed by maintenance doses of 10 mg/kg) would achieve the ratio of the area under free drug plasma concentration-time curve over 24 h (fAUC) to MIC90 (fAUC/MIC) target of 3 h in 53.2% of hypothetical patients, using a normative MIC susceptibility breakpoint of 2 mg/liter.",Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941652/),h,3,19912,DB00160,L-Alanine
,29941652,MIC sus,"Monte Carlo simulation showed that for children with normal liver function, a loading-dose strategy (a loading dose of 15 mg/kg of body weight followed by maintenance doses of 10 mg/kg) would achieve the ratio of the area under free drug plasma concentration-time curve over 24 h (fAUC) to MIC90 (fAUC/MIC) target of 3 h in 53.2% of hypothetical patients, using a normative MIC susceptibility breakpoint of 2 mg/liter.",Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29941652/),[mg] / [l],2,19913,DB00160,L-Alanine
,10778949,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2.,A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778949/),[μg] / [ml],50-70,20081,DB00160,L-Alanine
,10778949,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2.,A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778949/),μM,8-13,20082,DB00160,L-Alanine
,10778949,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) reached 50-70 microg/ml (8-13 microM) at dose 360 mg/m2 and 27-32 microg/ml at dose 240 mg/m2.,A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778949/),[μg] / [ml],27-32,20083,DB00160,L-Alanine
,10778949,plasma half-life,The plasma half-life was about 1.5 h.,A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778949/),h,1.5,20084,DB00160,L-Alanine
,34371742,loading capacity (LC),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,14.9,21067,DB00160,L-Alanine
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),%,15.2,21068,DB00160,L-Alanine
,34371742,encapsulation efficiency (EE),"The loading capacity (LC) and encapsulation efficiency (EE) percentages for MTF-loaded LCS and MTF-loaded DPP microcapsules were 14.9% ± 0.7, 29.8 ± 0.8, and 15.2% ± 0.7, 30.3 ± 1.0, respectively.",Sustained In Vitro and In Vivo Delivery of Metformin from Plant Pollen-Derived Composite Microcapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34371742/),,30.3,21069,DB00160,L-Alanine
<,24195794,t(1/2),"Despite the potential therapeutic usage for type 2 diabetes (T2D), GLP-1 has a short half-life in vivo (t(1/2) <2 min).",Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24195794/),min,2,21659,DB00160,L-Alanine
,24342124,AUC,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],139.70,22350,DB00160,L-Alanine
,24342124,Cmax,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],42.99,22351,DB00160,L-Alanine
,24342124,CLoral,"AUC (139.70±24.97 μg h/mL), Cmax (42.99±2.98 μg/mL), and CLoral (0.08±0.02 L/h/kg) values of diclofenac in diclofenac plus rebamipide group altered when compared to those of diclofenac treated groups.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.08,22352,DB00160,L-Alanine
,24342124,Cmax,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[μg] / [ml],7.80,22353,DB00160,L-Alanine
,24342124,AUC,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[h·μg] / [ml],56.46,22354,DB00160,L-Alanine
,24342124,Vd/F,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [kg],7.55,22355,DB00160,L-Alanine
,24342124,CLoral,"Cmax (7.80±1.22 μg/mL), AUC (56.46±7.30 μg h/mL), Vd/F (7.55±1.37 L/kg), and CLoral (0.58±0.09 L/h/kg) of rebamipide were significantly altered when diclofenac was co-administered with rebamipide.",Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342124/),[l] / [h·kg],0.58,22356,DB00160,L-Alanine
,29577579,half-life,The estimated half-life of Fc-apelin-13 in blood was approximately 33 hours.,Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29577579/),h,33,22691,DB00160,L-Alanine
,25459109,distribution half-life (t1/2α),(111)In-BzDTPA-pertuzumab exhibited a biphasic elimination from the blood with a distribution half-life (t1/2α) of 3.8h and an elimination half-life (t1/2β) of 228.2h.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),h,3.8,22880,DB00160,L-Alanine
,25459109,elimination half-life (t1/2β),(111)In-BzDTPA-pertuzumab exhibited a biphasic elimination from the blood with a distribution half-life (t1/2α) of 3.8h and an elimination half-life (t1/2β) of 228.2h.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),h,228.2,22881,DB00160,L-Alanine
,25459109,radiation absorbed dose,The projected whole-body radiation absorbed dose in humans was 0.05mSv/MBq corresponding to a total of 16.8mSv for three separate administrations of (111)In-BzDTPA-pertuzumab (111MBq) planned for the Phase I/II trial.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),[msv] / [Mbq],0.05,22882,DB00160,L-Alanine
,25459109,radiation absorbed dose,The projected whole-body radiation absorbed dose in humans was 0.05mSv/MBq corresponding to a total of 16.8mSv for three separate administrations of (111)In-BzDTPA-pertuzumab (111MBq) planned for the Phase I/II trial.,"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459109/),msv,16.8,22883,DB00160,L-Alanine
,1518120,peak plasma levels,"2. After 30 minutes intravenous infusion of PAPM/BP at a dose of 10 mg/10 mg/kg in 1 and of 20 mg/20 mg/kg in 2 children, peak plasma levels of PAPM ranged from 33.21 to 75.66 micrograms/ml at the end of the infusion.",[Laboratory and clinical studies on panipenem/betamipron in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518120/),[μg] / [ml],33.21 to 75.66,24208,DB00160,L-Alanine
,1518120,half-lives,The half-lives were 0.81 to 0.93 hours.,[Laboratory and clinical studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518120/),h,0.81 to 0.93,24209,DB00160,L-Alanine
,1518120,cumulative urinary recovery rates,The cumulative urinary recovery rates in the first 6 hours after the start of drip infusion ranged from 10.7 to 40.4%.,[Laboratory and clinical studies on panipenem/betamipron in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518120/),%,10.7 to 40.4,24210,DB00160,L-Alanine
,12191883,biological half-life,"On the other hand, bromine ion persisted longer in both blood and urine; the biological half-life of bromine ion was 4.7-15.0 days in blood and 5.0-7.5 days in urine.",Effects of inhaled 1-bromopropane vapor on rat metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12191883/),d,4.7-15.0,25330,DB00160,L-Alanine
,12191883,biological half-life,"On the other hand, bromine ion persisted longer in both blood and urine; the biological half-life of bromine ion was 4.7-15.0 days in blood and 5.0-7.5 days in urine.",Effects of inhaled 1-bromopropane vapor on rat metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12191883/),d,5.0-7.5,25331,DB00160,L-Alanine
,27716340,plasma half-life,"The plasma half-life for both agents was around 4 h, however, the volume of distribution of calycopterin appeared to be about 8 times greater than xanthomicrol.","Pharmacokinetics of calycopterin and xanthmicrol, two polymethoxylated hydroxyflavones with anti-angiogenic activities from Dracocephalum kotschyi Bioss. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27716340/),h,4,26444,DB00160,L-Alanine
,2760849,biological half-life,"When cystathionine (100 mg/kg) was administered i.p. in rats, it was eliminated from rat serum with a biological half-life of 1.19 +/- 0.23 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.19,26756,DB00160,L-Alanine
,2760849,half-life,"Subsequent to the decrease of serum cystathionine, the concentration of cyst(e)ine increased up to 14.5 +/- 1.2 mg/l, and then decreased with a half-life of 4.12 +/- 0.82 hr.",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,4.12,26757,DB00160,L-Alanine
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,1.42,26758,DB00160,L-Alanine
,2760849,half-life,"The concomitant administration of taurine (100 mg/kg) did not change the half-life of cystathionine (1.42 +/- 0.33 hr), but significantly increased the half-life of cyst(e)ine (19.1 +/- 0.56 hr).",Hepatoprotective effects of cystathionine against acetaminophen-induced necrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760849/),h,19.1,26759,DB00160,L-Alanine
,2124217,elimination half-life,The mean elimination half-life of the morpholinol metabolite was significantly prolonged in subjects with alcoholic liver disease (32.2 +/- 13.5 vs.,Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124217/),,32.2,27665,DB00160,L-Alanine
,22452401,molecular weight (Mw),"Earlier described dextran-based contrast agents for magnetic resonance imaging (MRI) comprising the gadolinium chelate diethylenetriamine pentaacetic acid (GdDTPA, 1) have shown significantly shorter in vivo contrast duration in rat than what would be expected from the initial average molecular weight (Mw) of the dextran fraction (71.4 kD).",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),k,71.4,28466,DB00160,L-Alanine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,10.4,28467,DB00160,L-Alanine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,41.0,28468,DB00160,L-Alanine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,71.4,28469,DB00160,L-Alanine
,22452401,molecular weight (Mw),"To investigate this further, four dextran fractions with given initial average molecular weight (Mw) of 10.4, 41.0, 71.4 and 580 kD were used as starting material to prepare products 2-5 where one of the carboxylic acid functionalities in GdDTPA was used as a direct covalent ester linker to hydroxyl groups in dextrans.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),,580,28470,DB00160,L-Alanine
,22452401,Mw,A fifth derivative (6) was an amide-ester bound β-alanine-DTPAGd conjugate with dextran having Mw 71.4 kD.,In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),kd,71.4,28471,DB00160,L-Alanine
,22452401,t 1/2,"Pharmacokinetic parameters showed that when GdDTPA is ester-bound directly to dextran hydroxyls, the cleavage rates of 2-5 were only moderately dependent on the molecular weights of the dextrans, having blood pool half-lives comparable to the low-molecular reference compound (t 1/2,β 0.3 - 0.5 hrs.).",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),h,0.3 - 0.5,28472,DB00160,L-Alanine
,22452401,"plasma half-life t 1/2,β","Presence of a β-alanine spacer in 6 prolonged the plasma half-life t 1/2,β to 6.9 hours, rendering a blood residence time suitable for blood pool slow release of GdDTPA.",In vivo cleavage rate of a dextran-bound magnetic resonance imaging contrast agent: preparation and intravascular pharmacokinetic characteristics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22452401/),h,6.9,28473,DB00160,L-Alanine
,21726141,half-lives,"Chlorpyriphos-methyl and pendimethalin degraded quickly with half-lives of 1.7 and 14.5 days, respectively, whereas metalaxyl proved more persistent (a half-life of 84 days).","The adsorption and degradation of chlorpyriphos-methyl, pendimethalin and metalaxyl in solid urban waste compost. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726141/),d,1.7,28584,DB00160,L-Alanine
,21726141,half-lives,"Chlorpyriphos-methyl and pendimethalin degraded quickly with half-lives of 1.7 and 14.5 days, respectively, whereas metalaxyl proved more persistent (a half-life of 84 days).","The adsorption and degradation of chlorpyriphos-methyl, pendimethalin and metalaxyl in solid urban waste compost. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726141/),d,14.5,28585,DB00160,L-Alanine
,21726141,half-life,"Chlorpyriphos-methyl and pendimethalin degraded quickly with half-lives of 1.7 and 14.5 days, respectively, whereas metalaxyl proved more persistent (a half-life of 84 days).","The adsorption and degradation of chlorpyriphos-methyl, pendimethalin and metalaxyl in solid urban waste compost. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726141/),d,84,28586,DB00160,L-Alanine
,21726141,half-life,Adding ammonium nitrate to the compost accelerated metalaxyl degradation to a half-life of 15 days.,"The adsorption and degradation of chlorpyriphos-methyl, pendimethalin and metalaxyl in solid urban waste compost. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21726141/),d,15,28587,DB00160,L-Alanine
,20133508,half-life,"No significant differences in exposure or mean half-life (range, 11-13 days) were observed between Japanese and Caucasian subjects at the same dose level.",Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133508/),d,11-13,29739,DB00160,L-Alanine
,20133508,apparent clearance,Mean apparent clearance ranged from 12 to 19 mL/kg/d.,Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133508/),[ml] / [d·kg],12 to 19,29740,DB00160,L-Alanine
,20133508,apparent volume of distribution,Mean apparent volume of distribution (224-262 mL/kg) remained constant with an increase in dose.,Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133508/),[ml] / [kg],224-262,29741,DB00160,L-Alanine
,19995932,association constant,"Atazanavir was found to bind AAG on a high-affinity saturable site (association constant, 4.61x10(5) liters/mol) and albumin on a low-affinity nonsaturable site.",Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19995932/),[l] / [mol],4.61x10(5),29964,DB00160,L-Alanine
,19995932,absorption rate constant (ka),"Atazanavir pharmacokinetic parameters and their interindividual variabilities were as follows: absorption rate constant (ka), 0.73 h(-1) (139.3%); apparent clearance (CL/F), 13.3 liters/h (26.7%); and apparent volume of distribution (V/F), 79.7 liters (27.0%).",Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19995932/),1/[h],0.73,29965,DB00160,L-Alanine
,19995932,apparent clearance (CL/F),"Atazanavir pharmacokinetic parameters and their interindividual variabilities were as follows: absorption rate constant (ka), 0.73 h(-1) (139.3%); apparent clearance (CL/F), 13.3 liters/h (26.7%); and apparent volume of distribution (V/F), 79.7 liters (27.0%).",Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19995932/),[l] / [h],13.3,29966,DB00160,L-Alanine
,19995932,apparent volume of distribution (V/F),"Atazanavir pharmacokinetic parameters and their interindividual variabilities were as follows: absorption rate constant (ka), 0.73 h(-1) (139.3%); apparent clearance (CL/F), 13.3 liters/h (26.7%); and apparent volume of distribution (V/F), 79.7 liters (27.0%).",Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19995932/),l,79.7,29967,DB00160,L-Alanine
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],4.9,30181,DB00160,L-Alanine
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],5.7,30182,DB00160,L-Alanine
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],32.1,30183,DB00160,L-Alanine
,8097691,total plasma clearance (CL),"Intravenous administration of 200 kU/kg of BM 06.022 or alteplase over 15 sec to rats with hepatic failure or olive oil pretreatment as control did not significantly alter the total plasma clearance (CL) of BM 06.022 vs. control (4.9 +/- 0.5 vs. 5.7 +/- 0.5 ml.min-1 x kg-1, NS) in contrast to alteplase (32.1 +/- 6.5 vs. 82.3 +/- 12.9 ml.min-1 x kg-1, p < 0.05).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],82.3,30184,DB00160,L-Alanine
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],3.1,30185,DB00160,L-Alanine
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],6.3,30186,DB00160,L-Alanine
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],33.2,30187,DB00160,L-Alanine
,8097691,CL,"Renal insufficiency increased the CL of BM 06.022 vs. sham surgery (3.1 +/- 0.4 vs. 6.3 +/- 0.5 ml.min-1 x kg-1, p < 0.05) in contrast to alteplase (33.2 +/- 5.2 vs. 37.2 +/- 7.2 ml.min-1 x kg-1, NS).",Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),[ml] / [kg·min],37.2,30188,DB00160,L-Alanine
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,71.9,30189,DB00160,L-Alanine
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,130,30190,DB00160,L-Alanine
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,62.9,30191,DB00160,L-Alanine
,8097691,half-life,In vitro incubation of 2000 U/ml BM 06.022 or alteplase in citrate blood and plasma demonstrated a decrease of the plasma concentration with a shorter (p < 0.001) half-life for BM 06.022 than for alteplase in blood (71.9 +/- 3.1 vs. 130 +/- 3.3 min) and in plasma (62.9 +/- 1.2 vs. 129.9 +/- 5.3 min).,Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097691/),min,129.9,30192,DB00160,L-Alanine
,25791363,MTD,MTD was 1.3 mg/m(2) trabectedin and 60 mg/m(2) docetaxel for patients with limited and 1.1 mg/m(2) trabectedin and 60 mg/m(2) docetaxel for patients with unlimited prior chemotherapy.,Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791363/),[mg] / [m],1.3,30401,DB00160,L-Alanine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],218-324,32594,DB00160,L-Alanine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],0.47-1.56,32595,DB00160,L-Alanine
,33210382,area under the plasma concentration-time curve from time 0 to last measurable time,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],0.284-0.522,32596,DB00160,L-Alanine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],309-889,32597,DB00160,L-Alanine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[h·μg] / [ml],0.47-1.56,32598,DB00160,L-Alanine
,33210382,maximum concentration,"The median estimates of area under the plasma concentration-time curve from time 0 to last measurable time and maximum concentration were highest for NUC-1031 (218-324 μg•h/mL and 309-889 μg/mL, respectively) and lowest for di-fluoro-deoxycytidine (0.47-1.56 μg•h/mL and 0.284-0.522 μg/mL, respectively).",A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210382/),[μg] / [ml],0.284-0.522,32599,DB00160,L-Alanine
,19701261,pulse,"Her pulse was 70 bpm, BP 149/63 mmHg with an unremarkable physical examination.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),bpm,70,32876,DB00160,L-Alanine
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,262,32877,DB00160,L-Alanine
,19701261,concentration,"Two-hour paracetamol concentration was 2628 micromol/L falling to 2216 micromol/L, 4 hours post-ingestion.",Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701261/),,2216,32878,DB00160,L-Alanine
,29563636,TTP,Phase-II: patients (N = 93) were randomised to nintedanib (n = 62) or sorafenib (n = 31); TTP was 5.5 vs.,"A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29563636/),,5.5,33221,DB00160,L-Alanine
,31560741,plasma concentration,"At week 24, median TAF plasma concentration was 11.05 ng/mL (range, 2.84-147.1 ng/mL) 2 hours postdose but was below assay sensitivity 6 hours after dosing.",Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31560741/),[ng] / [ml],11.05,33527,DB00160,L-Alanine
,10070890,oral bioavailability,"As oral bioavailability is high (70-100%), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and dose escalated from 80 to 572 mg m(-2) day(-1) in 23 patients.",A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070890/),%,70-100,34743,DB00160,L-Alanine
,10070890,plasma concentrations,"Nolatrexed plasma concentrations 1 h after dosing were 6-16 microg ml(-1), and trough 3-8 microg ml(-1), at 572 mg m(-2) day(-1).",A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070890/),[μg] / [ml],6-16,34744,DB00160,L-Alanine
,10070890,trough,"Nolatrexed plasma concentrations 1 h after dosing were 6-16 microg ml(-1), and trough 3-8 microg ml(-1), at 572 mg m(-2) day(-1).",A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070890/),[μg] / [ml],3-8,34745,DB00160,L-Alanine
,10565855,plasma elimination half-life,TXU-PAP showed favorable pharmacokinetics in chimpanzees with a plasma elimination half-life of 5.1 to 12.0 h and a systemic clearance of 5.8 to 15.1 ml/h/kg.,"Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),h,5.1 to 12.0,35297,DB00160,L-Alanine
,10565855,systemic clearance,TXU-PAP showed favorable pharmacokinetics in chimpanzees with a plasma elimination half-life of 5.1 to 12.0 h and a systemic clearance of 5.8 to 15.1 ml/h/kg.,"Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),[ml] / [h·kg],5.8 to 15.1,35298,DB00160,L-Alanine
,10565855,plasma elimination half-life,"TXU-PAP showed very favorable pharmacokinetics in these patients with a relatively long plasma elimination half-life of 12.4 +/- 1.4 h, a mean residence time of 17.9 +/- 2.0 h, and a slow systemic clearance of 2.7 +/- 0.7 ml/h/kg.","Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),h,12.4,35299,DB00160,L-Alanine
,10565855,mean residence time,"TXU-PAP showed very favorable pharmacokinetics in these patients with a relatively long plasma elimination half-life of 12.4 +/- 1.4 h, a mean residence time of 17.9 +/- 2.0 h, and a slow systemic clearance of 2.7 +/- 0.7 ml/h/kg.","Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),h,17.9,35300,DB00160,L-Alanine
,10565855,systemic clearance,"TXU-PAP showed very favorable pharmacokinetics in these patients with a relatively long plasma elimination half-life of 12.4 +/- 1.4 h, a mean residence time of 17.9 +/- 2.0 h, and a slow systemic clearance of 2.7 +/- 0.7 ml/h/kg.","Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),[ml] / [h·kg],2.7,35301,DB00160,L-Alanine
,10565855,AUC,"Concentrations of TXU-PAP required for effective inhibition of HIV-1 replication in preclinical models were achieved in HIV-1-infected patients at the 5 microg/kg dose level without any adverse reactions, and the mean value for AUC was 3059 +/- 721 ng.","Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565855/),ng,3059,35302,DB00160,L-Alanine
,30299489,minimum effective dose,We found a median minimum effective dose of 6.55 mg/kg of body weight.,Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299489/),[mg] / [kg],6.55,35533,DB00160,L-Alanine
,25661675,plasma elimination half-life,"The plasma elimination half-life of dabigatran was 1.5-4.9 h during IHD, and 14.0-27.5 h during CRRT.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,1.5-4.9,36723,DB00160,L-Alanine
,25661675,plasma elimination half-life,"The plasma elimination half-life of dabigatran was 1.5-4.9 h during IHD, and 14.0-27.5 h during CRRT.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,14.0-27.5,36724,DB00160,L-Alanine
,25661675,plasma clearance,Mean dabigatran plasma clearance during IHD was 85-169 mL/min in three patients.,Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),[ml] / [min],85-169,36725,DB00160,L-Alanine
,25661675,Time to obtain,"Time to obtain a subtherapeutic dabigatran concentration depended on the initial concentration, being 8-18 h for IHD in three patients while 4 h was insufficient in a supratherapeutic case.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,8-18,36726,DB00160,L-Alanine
,25661675,Time to obtain,"Time to obtain a subtherapeutic dabigatran concentration depended on the initial concentration, being 8-18 h for IHD in three patients while 4 h was insufficient in a supratherapeutic case.",Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25661675/),h,4,36727,DB00160,L-Alanine
,23687633,EC50,"3-Hydroxymethyl-4-methyl-DCK (3, HMDCK) was discovered previously as a potent HIV non-nucleoside reverse transcriptase inhibitor (NNRTIs) (EC50: 0.004 μM, TI: 6225) with a novel mechanism of action.","Prodrug design, synthesis and pharmacokinetic evaluation of (3' R, 4' R)-3-hydroxymethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687633/),μM,0.004,37075,DB00160,L-Alanine
,23687633,oral bioavailability,"The l-alanine ester prodrug 10 exhibited desirable pharmacokinetic properties in vitro and in vivo and showed improved oral bioavailability of 26% in rat, and would be a potential clinical candidate as a new anti-AIDS drug.","Prodrug design, synthesis and pharmacokinetic evaluation of (3' R, 4' R)-3-hydroxymethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23687633/),%,26,37076,DB00160,L-Alanine
,1687590,kBO/beta,In rabbits the equilibration is much slower (kBO/beta approximately 1).,"Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687590/),,1,37166,DB00160,L-Alanine
,1687590,Part,"Partition coefficients between brain and plasma calculated from areas under the brain and plasma concentration-time curves, are 0.479, 0.549 and 0.864, in mice, rats and rabbits, respectively.","Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687590/),,0.479,37167,DB00160,L-Alanine
,1687590,Part,"Partition coefficients between brain and plasma calculated from areas under the brain and plasma concentration-time curves, are 0.479, 0.549 and 0.864, in mice, rats and rabbits, respectively.","Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687590/),,0.549,37168,DB00160,L-Alanine
,1687590,Part,"Partition coefficients between brain and plasma calculated from areas under the brain and plasma concentration-time curves, are 0.479, 0.549 and 0.864, in mice, rats and rabbits, respectively.","Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687590/),,0.864,37169,DB00160,L-Alanine
,28940525,volume of distribution,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),[l] / [kg],0.49,37197,DB00160,L-Alanine
,28940525,clearance,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),[l] / [h·kg],0.0045,37198,DB00160,L-Alanine
,28940525,half-life,"In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively.",Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28940525/),h,75.1,37199,DB00160,L-Alanine
,17350841,IC(50),"The phenylalanine series afforded compounds such as 10 that were potent and selective (DPP-4, IC(50)=28nM), but exhibited limited oral bioavailability.","4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350841/),nM,28,37368,DB00160,L-Alanine
,28889763,Cmax1,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),[ng] / [ml],5.9,37780,DB00160,L-Alanine
,28889763,2,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),[ng] / [ml],7.9,37781,DB00160,L-Alanine
,28889763,Tmax1,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),h,1.7,37782,DB00160,L-Alanine
,28889763,Tmax1,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),h,3.1,37783,DB00160,L-Alanine
,28889763,2,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),h,1.7,37784,DB00160,L-Alanine
,28889763,2,"Pharmacokinetics of AVA-O showed a bimodal distribution with Cmax1 and 2 for AVA-O at 5.9 ± 5.2 and 7.9 ± 7.0 ng/mL and Tmax1 and 2 at 1.7 ± 0.7 and 3.1 ± 1.2 h, respectively.",Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),h,3.1,37785,DB00160,L-Alanine
,28889763,Cmax,Only the methyl-AVA-O showed a single Cmax at 14 ± 9.9 ng/mL AVA-O equivalents and a Tmax of 2.4 ± 2.7 h.,Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),[ng] / [ml],14,37786,DB00160,L-Alanine
,28889763,Tmax,Only the methyl-AVA-O showed a single Cmax at 14 ± 9.9 ng/mL AVA-O equivalents and a Tmax of 2.4 ± 2.7 h.,Identification of methylated metabolites of oat avenanthramides in human plasma using UHPLC QToF-MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889763/),h,2.4,37787,DB00160,L-Alanine
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,5.8-13,37800,DB00160,L-Alanine
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,0.4-2.4,37801,DB00160,L-Alanine
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,0.026-1.337,37802,DB00160,L-Alanine
,12739060,plasma C(max),"The plasma C(max) values of FT, 5-FU, oxonic acid and CDHP increased dose-dependently and after 1-2 h were in the ranges 5.8-13 microM, 0.4-2.4 microM, 0.026-1.337 microM, and 1.1-3.6 microM, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),μM,1.1-3.6,37803,DB00160,L-Alanine
,12739060,areas under the plasma concentration curves (AUC),"The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),[min·μM] / [l],418-1735,37804,DB00160,L-Alanine
,12739060,areas under the plasma concentration curves (AUC),"The areas under the plasma concentration curves (AUC) for CDHP and uracil were in the ranges 418-1735 and 2281-8627 micromol x min/l, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),[min·μM] / [l],2281-8627,37805,DB00160,L-Alanine
,12739060,t(1/2),"The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),min,213-692,37806,DB00160,L-Alanine
,12739060,t(1/2),"The t(1/2) values were in the ranges 213-692 and 216-354 min, respectively.","Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),min,216-354,37807,DB00160,L-Alanine
,12739060,urinary excretion,Cumulative urinary excretion of FT was predominantly as 5-FU and was 2.2-11.9%; the urinary excretion of both fluoro-beta-alanine and uracil was generally maximal between 6 and 18 h.,"Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739060/),%,2.2-11.9,37808,DB00160,L-Alanine
,25300944,steady-state half-life,"PK results were consistent with solid tumors, confirming a relatively short steady-state half-life (mean 4.61 h).","Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25300944/),h,4.61,38895,DB00160,L-Alanine
,27765666,AUCtau,"The mean AUCtau for elvitegravir was 23 840 ng × h per mL (coefficient of variation [CV] 25·5%), and the mean AUClast for tenofovir alafenamide was 189 ng × h per mL (CV 55·8%).","Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765666/),[h·ng] / [ml],23 840,38949,DB00160,L-Alanine
,27765666,AUClast,"The mean AUCtau for elvitegravir was 23 840 ng × h per mL (coefficient of variation [CV] 25·5%), and the mean AUClast for tenofovir alafenamide was 189 ng × h per mL (CV 55·8%).","Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27765666/),[h·ng] / [ml],189,38950,DB00160,L-Alanine
,9197300,Cl,"During the paleohepatic and anhepatic periods, the typical value of Cl was 2.47 ml x kg(-1) x min(-1) and was not influenced by the magnitude of preexisting liver disease (as evidenced by prothrombin time, bilirubin, serum albumin, alanine transaminase [ALT], and aspartate transaminase [AST]).",Pharmacokinetics of rocuronium during the three stages of liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197300/),[ml] / [kg·min],2.47,39904,DB00160,L-Alanine
,9197300,Cl,"During the neohepatic period, the typical value of Cl varied as a function of the duration of warm ischemia of the hepatic allograft and was 2.72 ml x kg(-1) x min(-1) for a patient with an average 60-min period of warm ischemia; time to neuromuscular recovery varied as a function of Cl.",Pharmacokinetics of rocuronium during the three stages of liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197300/),[ml] / [kg·min],2.72,39905,DB00160,L-Alanine
,8745042,clearances,"After IV injection, clearances were 10.6 and 30.2 ml-1 for D7-sorbin and C7-sorbin, respectively, and MRT were 34 and 18 min.","Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745042/),1/[ml],10.6,40347,DB00160,L-Alanine
,8745042,clearances,"After IV injection, clearances were 10.6 and 30.2 ml-1 for D7-sorbin and C7-sorbin, respectively, and MRT were 34 and 18 min.","Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745042/),1/[ml],30.2,40348,DB00160,L-Alanine
,8745042,MRT,"After IV injection, clearances were 10.6 and 30.2 ml-1 for D7-sorbin and C7-sorbin, respectively, and MRT were 34 and 18 min.","Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745042/),min,34,40349,DB00160,L-Alanine
,8745042,MRT,"After IV injection, clearances were 10.6 and 30.2 ml-1 for D7-sorbin and C7-sorbin, respectively, and MRT were 34 and 18 min.","Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745042/),min,18,40350,DB00160,L-Alanine
,8745042,bioavailability,The IP route showed a 45-min delay before Cmax and a 100% bioavailability for both peptides.,"Pharmacokinetic, metabolic, and antidiarrheal properties of (D and L) heptapeptides of sorbin in rodent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745042/),%,100,40351,DB00160,L-Alanine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.,40669,DB00160,L-Alanine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.13,40670,DB00160,L-Alanine
,18331613,to peak concentrations,"The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001).",The citrulline generation test: proposal for a new enterocyte function test. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],0.09,40671,DB00160,L-Alanine
,18331613,iAUC T90,"The iAUC T90 was 447 +/- 179 and 1039 +/- 178 micromol/L/min in non-adapted and adapted SBS, respectively (P = 0.04).",The citrulline generation test: proposal for a new enterocyte function test. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],447,40672,DB00160,L-Alanine
,18331613,iAUC T90,"The iAUC T90 was 447 +/- 179 and 1039 +/- 178 micromol/L/min in non-adapted and adapted SBS, respectively (P = 0.04).",The citrulline generation test: proposal for a new enterocyte function test. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18331613/),[μM] / [l·min],1039,40673,DB00160,L-Alanine
,26663719,clearance,"Median clearance was 22.8, 16.4, and 11.3 L/h/m(2) in Categories 1, 2, and 3, respectively, representing 28% and 50% reduced clearance in mild and moderate liver dysfunction patients, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·l] / [m(2],22.8,41062,DB00160,L-Alanine
,26663719,clearance,"Median clearance was 22.8, 16.4, and 11.3 L/h/m(2) in Categories 1, 2, and 3, respectively, representing 28% and 50% reduced clearance in mild and moderate liver dysfunction patients, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·l] / [m(2],16.4,41063,DB00160,L-Alanine
,26663719,clearance,"Median clearance was 22.8, 16.4, and 11.3 L/h/m(2) in Categories 1, 2, and 3, respectively, representing 28% and 50% reduced clearance in mild and moderate liver dysfunction patients, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·l] / [m(2],11.3,41064,DB00160,L-Alanine
,26663719,area under the concentration-time curve,"Median area under the concentration-time curve was 1.74, 1.83, and 1.77 mg·h/L in Categories 1, 2, and 3, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·mg] / [l],1.74,41065,DB00160,L-Alanine
,26663719,area under the concentration-time curve,"Median area under the concentration-time curve was 1.74, 1.83, and 1.77 mg·h/L in Categories 1, 2, and 3, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·mg] / [l],1.83,41066,DB00160,L-Alanine
,26663719,area under the concentration-time curve,"Median area under the concentration-time curve was 1.74, 1.83, and 1.77 mg·h/L in Categories 1, 2, and 3, respectively.",Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663719/),[h·mg] / [l],1.77,41067,DB00160,L-Alanine
below,19151039,C(trough),"In 3/5 cirrhotic patients (60%) and in 2/14 non-cirrhotic patients (14%), C(trough) was below the minimum target concentration of 400 ng/mL; nonetheless, in all these patients, HIV viral load was undetectable.",Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151039/),[ng] / [ml],400,42087,DB00160,L-Alanine
below,19151039,minimum target concentration,"In 3/5 cirrhotic patients (60%) and in 2/14 non-cirrhotic patients (14%), C(trough) was below the minimum target concentration of 400 ng/mL; nonetheless, in all these patients, HIV viral load was undetectable.",Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151039/),[ng] / [ml],400,42088,DB00160,L-Alanine
,34139982,V1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,1.42,42331,DB00160,L-Alanine
,34139982,V2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,5.52,42332,DB00160,L-Alanine
,34139982,V3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,63.9,42333,DB00160,L-Alanine
,34139982,Cl1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.30,42334,DB00160,L-Alanine
,34139982,Cl2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.21,42335,DB00160,L-Alanine
,34139982,Cl3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],0.584,42336,DB00160,L-Alanine
,18006647,bioavailability,"Dabigatran etexilate was rapidly converted to dabigatran, with peak plasma dabigatran concentrations being attained after approximately 1.5 h; the bioavailability of dabigatran after p.o. administration of dabigatran etexilate was 7.2%.","The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006647/),%,7.2,42385,DB00160,L-Alanine
,18006647,terminal half-life,The mean terminal half-life of dabigatran was approximately 8 h.,"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18006647/),h,8,42386,DB00160,L-Alanine
,485125,peak levels,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],41,42968,DB00160,L-Alanine
,485125,peak levels,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],93,42969,DB00160,L-Alanine
,485125,peak levels,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],160,42970,DB00160,L-Alanine
,485125,steady-state serum concentrations,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],27,42971,DB00160,L-Alanine
,485125,steady-state serum concentrations,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],64,42972,DB00160,L-Alanine
,485125,steady-state serum concentrations,"The loading doses produced mean peak levels of 41, 93, and 160 mug/ml, and mean steady-state serum concentrations were 27, 64, and 138 mug/ml, respectively.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[μg] / [ml],138,42973,DB00160,L-Alanine
,485125,terminal half-life,The mean terminal half-life was 75 +/- 7 min.,"Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),min,75,42974,DB00160,L-Alanine
,485125,total volume of distribution,The total volume of distribution averaged 0.22 +/- 0.03 liters/kg of body weight.,"Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[l] / [kg],0.22,42975,DB00160,L-Alanine
,485125,Total body,"Total body and renal clearances were 232 +/- 30 and 145 +/- 24 ml/min per 1.73 m(2), respectively; 63 +/- 9% of the administered dose was excreted through the kidneys in 24 h.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[1.73·min·ml] / [m(2],232,42976,DB00160,L-Alanine
,485125,renal clearances,"Total body and renal clearances were 232 +/- 30 and 145 +/- 24 ml/min per 1.73 m(2), respectively; 63 +/- 9% of the administered dose was excreted through the kidneys in 24 h.","Human pharmacology of cefotaxime (HR 756), a new cephalosporin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/485125/),[1.73·min·ml] / [m(2],145,42977,DB00160,L-Alanine
,33048175,50% effective concentration,"According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%.",Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33048175/),[mg] / [l],16.7,43860,DB00160,L-Alanine
,24676873,maximum plasma concentration,"The maximum plasma concentration of paracetamol glucuronide tended to be higher in group PC 213.27 μg/mL (90 % CI 1.06, 1.25; p = 0.0267).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),[μg] / [ml],213.27,44107,DB00160,L-Alanine
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,15,44108,DB00160,L-Alanine
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,20,44109,DB00160,L-Alanine
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,10.0,44110,DB00160,L-Alanine
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,7.0,44111,DB00160,L-Alanine
,34100149,C0h,"Estimated DRV mean (SD) C0h and AUC24h, respectively, were 1899 (759) ng/mL and 87,909 (20,232) ng*h/mL in AMBER; 1813 (859) ng/mL and 85,972 (22,413) ng*h/mL in EMERALD.",Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100149/),[ng] / [ml],1899,44728,DB00160,L-Alanine
,34100149,C0h,"Estimated DRV mean (SD) C0h and AUC24h, respectively, were 1899 (759) ng/mL and 87,909 (20,232) ng*h/mL in AMBER; 1813 (859) ng/mL and 85,972 (22,413) ng*h/mL in EMERALD.",Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100149/),[ng] / [ml],1813,44729,DB00160,L-Alanine
,34100149,AUC24h,"Estimated DRV mean (SD) C0h and AUC24h, respectively, were 1899 (759) ng/mL and 87,909 (20,232) ng*h/mL in AMBER; 1813 (859) ng/mL and 85,972 (22,413) ng*h/mL in EMERALD.",Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100149/),[h·ng] / [ml],"87,909",44730,DB00160,L-Alanine
,34100149,AUC24h,"Estimated DRV mean (SD) C0h and AUC24h, respectively, were 1899 (759) ng/mL and 87,909 (20,232) ng*h/mL in AMBER; 1813 (859) ng/mL and 85,972 (22,413) ng*h/mL in EMERALD.",Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100149/),[h·ng] / [ml],"85,972",44731,DB00160,L-Alanine
,34100149,AUC24h,Estimated TAF mean (SD) AUC24h was 132 (41) ng*h/mL.,Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100149/),[h·ng] / [ml],132,44732,DB00160,L-Alanine
,18031504,AUC(0-8 h),"The area under the concentration-time curve of plasma MTX in the interval 0-8 h post-dose (AUC(0-8 h)) was measured after a test bolus dose of 10 mg, and the starting weekly dose was individualized in order to achieve the target AUC(0-8 h) of 1800 nmol.h/L.",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[h·nM] / [l],1800,46582,DB00160,L-Alanine
,18031504,AUC(0-8 h ),"The AUC(0-8 h )achieved 1360 +/- 425 nmol.h/L (mean +/- SD: range, 778-2400 nmol.h/L).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[h·nM] / [l],1360,46583,DB00160,L-Alanine
,18031504,steady-state concentration,"The mean (SD) steady-state concentration of total MTXPGs observed between days 85 to 110 reached 113 (34.6) nmol/L (range, 66.1-174 nmol/L).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),[nM] / [l],113,46584,DB00160,L-Alanine
,18031504,PASI,The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001).,A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),,24.0,46585,DB00160,L-Alanine
,18031504,PASI,The PASI decreased from 24.0 +/- 8.0 (mean +/- SD) at baseline to 8.0 +/- 6.1 at day 110 (P < 0.001).,A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),,8.0,46586,DB00160,L-Alanine
,18031504,corpuscular volume,"Throughout the study period, there was a continuous increasing trend in the geometric mean values of the mean corpuscular volume from 92.6 to 96.4 fL (P < 0.001) and of plasma homocysteine from 9.5 to 12.3 micromol/L (P < 0.005).",A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18031504/),fl,92.6 to 96.4,46587,DB00160,L-Alanine
,3530119,elimination half-lives,"Following bolus injection, the mean CSF elimination half-lives for morphine sulfate and DADL were 94 and 115 minutes, respectively.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),min,94,46841,DB00160,L-Alanine
,3530119,elimination half-lives,"Following bolus injection, the mean CSF elimination half-lives for morphine sulfate and DADL were 94 and 115 minutes, respectively.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),min,115,46842,DB00160,L-Alanine
,3530119,L/C ratios,"With the catheter tip at L2, the ratio of lumbar to cisternal (L/C) concentrations of morphine sulfate was about 7:1, and with the catheter tip at T10, the L/C ratios of morphine sulfate and DADL were approximately 2:1, indicating that this ratio is dependent in part on the level of intrathecal drug administration.",Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530119/),,2,46843,DB00160,L-Alanine
under,22060284,bioavailability,"Consequently, the bioavailability of rebamipide is under 10% in humans.",Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22060284/),%,10,47169,DB00160,L-Alanine
,7711280,elimination half-life (t1/2),"The elimination half-life (t1/2) for glycyrrhizin in the hepatitis and cirrhosis groups varied significantly in the range of 2.7-7.6 h and 6.2-40.1 h, and the total body clearance (CLtot) in the range of 2.8-23.2 mL h-1 kg-1 and 1.4-12.9 mL h-1 kg-1, respectively.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),h,2.7-7.6,49726,DB00160,L-Alanine
,7711280,elimination half-life (t1/2),"The elimination half-life (t1/2) for glycyrrhizin in the hepatitis and cirrhosis groups varied significantly in the range of 2.7-7.6 h and 6.2-40.1 h, and the total body clearance (CLtot) in the range of 2.8-23.2 mL h-1 kg-1 and 1.4-12.9 mL h-1 kg-1, respectively.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),h,6.2-40.1,49727,DB00160,L-Alanine
,7711280,total body clearance (CLtot),"The elimination half-life (t1/2) for glycyrrhizin in the hepatitis and cirrhosis groups varied significantly in the range of 2.7-7.6 h and 6.2-40.1 h, and the total body clearance (CLtot) in the range of 2.8-23.2 mL h-1 kg-1 and 1.4-12.9 mL h-1 kg-1, respectively.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),[ml] / [h·kg],2.8-23.2,49728,DB00160,L-Alanine
,7711280,total body clearance (CLtot),"The elimination half-life (t1/2) for glycyrrhizin in the hepatitis and cirrhosis groups varied significantly in the range of 2.7-7.6 h and 6.2-40.1 h, and the total body clearance (CLtot) in the range of 2.8-23.2 mL h-1 kg-1 and 1.4-12.9 mL h-1 kg-1, respectively.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),[ml] / [h·kg],1.4-12.9,49729,DB00160,L-Alanine
,7711280,CLtot,"With improvement of the liver function, the CLtot for glycyrrhizin increased from 2.8 ml h-1 kg-1 to 11.4 mL h-1 kg-1, and the t1/2 shortened from 7.6 h to 3.4 h.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),[ml] / [h·kg],2.8,49730,DB00160,L-Alanine
,7711280,CLtot,"With improvement of the liver function, the CLtot for glycyrrhizin increased from 2.8 ml h-1 kg-1 to 11.4 mL h-1 kg-1, and the t1/2 shortened from 7.6 h to 3.4 h.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),[ml] / [h·kg],11.4,49731,DB00160,L-Alanine
,7711280,t1/2,"With improvement of the liver function, the CLtot for glycyrrhizin increased from 2.8 ml h-1 kg-1 to 11.4 mL h-1 kg-1, and the t1/2 shortened from 7.6 h to 3.4 h.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),h,7.6,49732,DB00160,L-Alanine
,7711280,t1/2,"With improvement of the liver function, the CLtot for glycyrrhizin increased from 2.8 ml h-1 kg-1 to 11.4 mL h-1 kg-1, and the t1/2 shortened from 7.6 h to 3.4 h.",The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711280/),h,3.4,49733,DB00160,L-Alanine
,15082032,peak plasma concentrations,The absorption of safinamide was rapid with peak plasma concentrations ranging from 2 to 4 h.,"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,2 to 4,49953,DB00160,L-Alanine
,15082032,accumulation factor,"In repeat dose regimen once daily, the steady state was reached on the 5th study day with a marginal accumulation factor of 1.5-1.7.","Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),,1.5-1.7,49954,DB00160,L-Alanine
,15082032,t(1/2),The drug was cleared with a t(1/2) of about 22 h.,"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,22,49955,DB00160,L-Alanine
,15082032,t(1/2),"The drug is cleared from the body with a t(1/2) of approximately equal to 22 h, without producing any clinically relevant accumulation at steady state.","Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15082032/),h,22,49956,DB00160,L-Alanine
,25207550,Apparent clearance (CL/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 5.72 L/h and 131 L, respectively.",Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),[l] / [h],5.72,50858,DB00160,L-Alanine
,25207550,apparent volumes of distribution (V/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 5.72 L/h and 131 L, respectively.",Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),l,131,50859,DB00160,L-Alanine
,25207550,absorption rate constant (Ka),The absorption rate constant (Ka) was fixed in 4.48 h-1.,Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),1/[h],4.48,50860,DB00160,L-Alanine
,11432431,absorption half-life,"The absorption half-life, elimination half-life, apparent volume of distribution and total body clearance of 2-PAM were 1.08 +/- 0.19 h, 3.14-3.19 h, 0.83-1.01 L/kg and 184.9-252.1 ml/(kg h), respectively.",Intramuscular kinetics and dosage regimens for pralidoxime in buffalo calves (Bubalus bubalis). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432431/),h,1.08,50861,DB00160,L-Alanine
,11432431,total body clearance,"The absorption half-life, elimination half-life, apparent volume of distribution and total body clearance of 2-PAM were 1.08 +/- 0.19 h, 3.14-3.19 h, 0.83-1.01 L/kg and 184.9-252.1 ml/(kg h), respectively.",Intramuscular kinetics and dosage regimens for pralidoxime in buffalo calves (Bubalus bubalis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432431/),[ml] / [h·kg],184.9-252.1,50862,DB00160,L-Alanine
,2667604,Plasma elimination half-life,Plasma elimination half-life ranges between 5 and 7 h in normal volunteers.,Clinical pharmacology of vigabatrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2667604/),h,5 and 7,51046,DB00160,L-Alanine
,33632668,overall objective response rate,"The overall objective response rate was 6.3%, with 2 partial responses.",A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33632668/),%,6.3,52652,DB00160,L-Alanine
,33632668,time to response,"Median time to response was 11.0 weeks (range, 7.7-14.3 weeks).",A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33632668/),weeks,11.0,52653,DB00160,L-Alanine
,33632668,progression-free survival,"Median progression-free survival was 7.4 weeks (range, 0.1-31.4 weeks), and median overall survival was 28.0 weeks (range, 1.9-115.4 weeks).",A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33632668/),weeks,7.4,52654,DB00160,L-Alanine
,33632668,overall survival,"Median progression-free survival was 7.4 weeks (range, 0.1-31.4 weeks), and median overall survival was 28.0 weeks (range, 1.9-115.4 weeks).",A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33632668/),weeks,28.0,52655,DB00160,L-Alanine
,29138048,Zeta potential,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),mv,24.35-34.37,53939,DB00160,L-Alanine
,29138048,polydispersity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),,0.365-0.512,53940,DB00160,L-Alanine
,29138048,entra,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,70.60-86.52,53941,DB00160,L-Alanine
,29138048,loading capacity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,30.92-56.81,53942,DB00160,L-Alanine
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,17.19,53943,DB00160,L-Alanine
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,15.46,53944,DB00160,L-Alanine
,26580099,clearance,"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),[l] / [h],6.8,54824,DB00160,L-Alanine
,26580099,apparent volume of distribution (V),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),l,159,54825,DB00160,L-Alanine
,26580099,duration of absorption (D1),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,2,54826,DB00160,L-Alanine
,26580099,elimination half-life,"The elimination half-life was 16 hours (range, 3-42 hours).",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,16,54827,DB00160,L-Alanine
,8251615,elimination half-life (t1/2),"The mean elimination half-life (t1/2) and the total body clearance (CLtot) were 6.0 h (range 4.3-10.7 h) and 7.9 ml h-1 kg-1 (4.5-12.7 ml h-1 kg-1), respectively.",Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251615/),h,6.0,54948,DB00160,L-Alanine
,8251615,total body clearance (CLtot),"The mean elimination half-life (t1/2) and the total body clearance (CLtot) were 6.0 h (range 4.3-10.7 h) and 7.9 ml h-1 kg-1 (4.5-12.7 ml h-1 kg-1), respectively.",Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251615/),[ml] / [h·kg],7.9,54949,DB00160,L-Alanine
,9597646,peak plasma concentration,"Mean peak plasma concentration of 2.5 +/- 0.4 micrograms/mL, occurring at 0.5 h, was found for CP-163505 following a 5 mg/kg dose (n = 5).",Disposition and metabolism of the novel macrolide antibiotic CP-163505 in cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597646/),[μg] / [ml],2.5,55395,DB00160,L-Alanine
,9597646,terminal elimination phase (t1/2,"The pharmacokinetic profile consisted of a distribution phase, followed by an extended terminal elimination phase (t1/2 of 19 h).",Disposition and metabolism of the novel macrolide antibiotic CP-163505 in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597646/),h,19,55396,DB00160,L-Alanine
,9597646,lung to plasma ratios,"The disposition of CP-163505 was characterized by distribution from the plasma into the tissue resulting in lung to plasma ratios of 103 and 87 at 72 h following a single 5 or 10 mg/kg dose, respectively.",Disposition and metabolism of the novel macrolide antibiotic CP-163505 in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597646/),,103,55397,DB00160,L-Alanine
,9597646,lung to plasma ratios,"The disposition of CP-163505 was characterized by distribution from the plasma into the tissue resulting in lung to plasma ratios of 103 and 87 at 72 h following a single 5 or 10 mg/kg dose, respectively.",Disposition and metabolism of the novel macrolide antibiotic CP-163505 in cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597646/),,87,55398,DB00160,L-Alanine
,8009568,extraction efficiency,The extraction efficiency is 70% and the sensitivity limit is 100 ng/ml.,Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009568/),%,70,56098,DB00160,L-Alanine
,8009568,distribution space,The mean distribution space was 4.44 L/m2 and the mean plasma clearance was 302 ml/min/m2.,Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009568/),[l] / [m2],4.44,56099,DB00160,L-Alanine
,8009568,plasma clearance,The mean distribution space was 4.44 L/m2 and the mean plasma clearance was 302 ml/min/m2.,Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009568/),[ml] / [m2·min],302,56100,DB00160,L-Alanine
,8009568,elimination half-life,The elimination half-life was 11.95 +/- 8.55 min.,Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009568/),min,11.95,56101,DB00160,L-Alanine
,9816177,spin-lattice relaxation time,"The spin-lattice relaxation time of FBAL in liver, measured using a variable nutation angle method, was 1.6 +/- 0.2 s (mean +/- SD; n = 5).",Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),s,1.6,56561,DB00160,L-Alanine
,9816177,concentration,The concentration of FBAL at 60 +/- 10 min after injection was 1.0 +/- 0.2 mm in liver (mean +/- SD; n = 7).,Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),mm,1.0,56562,DB00160,L-Alanine
,9816177,FBAL,The concentration of FBAL at 60 +/- 10 min after injection was 1.0 +/- 0.2 mm in liver (mean +/- SD; n = 7).,Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816177/),mm,1.0,56563,DB00160,L-Alanine
,32916310,progression-free survival,Median progression-free survival was 11.0 months (95% CI: 9.5-not reached) months.,"Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32916310/),month,11.0,56891,DB00160,L-Alanine
,1662599,Onset time,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.3,57479,DB00160,L-Alanine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,109,57480,DB00160,L-Alanine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,2.8,57481,DB00160,L-Alanine
,1662599,clinical duration,"Onset time and clinical duration were 2.3 and 109 min and 2.8 and 39 min in Groups L and C, respectively.","The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,39,57482,DB00160,L-Alanine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,101.5,57483,DB00160,L-Alanine
,1662599,Terminal half-lives,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),min,179,57484,DB00160,L-Alanine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.339,57485,DB00160,L-Alanine
,1662599,distribution volumes at steady state,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[l] / [kg],0.506,57486,DB00160,L-Alanine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],3.4,57487,DB00160,L-Alanine
,1662599,plasma clearance,Terminal half-lives were 101.5 min (Group L) and 179 min (Group C) in a three-exponent decay; the distribution volumes at steady state 0.339 l kg-1 (Group L) and 0.506 l kg-1 (Group C); the plasma clearance 3.4 ml kg-1 min-1 (Group L) and 2.5 ml kg-1 min-1 (Group C).,"The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662599/),[ml] / [kg·min],2.5,57488,DB00160,L-Alanine
,18923390,k(e),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),1/[days],0.486,57729,DB00160,L-Alanine
,18923390,half-life,"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),d,1.47,57730,DB00160,L-Alanine
,18923390,C(max),"The mean (+/-SD)k(e) and half-life were 0.486 +/- 0.084 days(-1) and 1.47+/- 0.30 days, respectively, and the C(max) was 1.2 (+/-2.92) nmol/ml serum.",Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18923390/),[nM] / [ml·serum],1.2,57731,DB00160,L-Alanine
,15729484,clearances,"The clearances of panipenem in patients were 9.53 +/- 1.26 l/h with hemodialysis, and 2.92 +/- 0.238 l/h without hemodialysis.",Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729484/),[l] / [h],9.53,57899,DB00160,L-Alanine
,15729484,clearances,"The clearances of panipenem in patients were 9.53 +/- 1.26 l/h with hemodialysis, and 2.92 +/- 0.238 l/h without hemodialysis.",Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15729484/),[l] / [h],2.92,57900,DB00160,L-Alanine
,16050814,LD50,"Tested LD50 in CD-1 mice were 38.72 mg/kg for i.m. and 431.95 mg/kg for oral administration, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),[mg] / [kg],38.72,58190,DB00160,L-Alanine
,16050814,LD50,"Tested LD50 in CD-1 mice were 38.72 mg/kg for i.m. and 431.95 mg/kg for oral administration, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),[mg] / [kg],431.95,58191,DB00160,L-Alanine
,16050814,Cmax,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),[μg] / [ml],3.73,58192,DB00160,L-Alanine
,16050814,Cmax,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),[μg] / [ml],6.40,58193,DB00160,L-Alanine
,16050814,Tmax,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),min,32,58194,DB00160,L-Alanine
,16050814,Tmax,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),min,34,58195,DB00160,L-Alanine
,16050814,t(1/2beta),"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),min,256,58196,DB00160,L-Alanine
,16050814,t(1/2beta),"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),min,264,58197,DB00160,L-Alanine
,16050814,absolute bioavailability,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),%,95.94,58198,DB00160,L-Alanine
,16050814,absolute bioavailability,"Pharmacokinetic studies revealed Cmax of 3.73 +/- 0.28 and 6.40 +/- 0.18 microg/mL, Tmax of 32 +/- 1.5 and 34 +/- 1.8 min, t(1/2beta) of 256 +/- 14 and 264 +/- 29 min, and absolute bioavailability of 95.94 and 88.45% for colistin sulfate intramuscularly injected to piglets at 2.5 and 5.0 mg/kg, respectively.","Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050814/),%,88.45,58199,DB00160,L-Alanine
,8165632,recoveries,"The rscu-PA-32k moieties were expressed in High Five Trichoplasiani cells, and purified to homogeneity from the conditioned cell culture medium, with recoveries of 0.8 to 3.7 mg/l.",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),[mg] / [l],0.8 to 3.7,58443,DB00160,L-Alanine
,8165632,plasma clearance,"Following bolus injection in hamsters, all rscu-PA-32k moieties had a comparably rapid plasma clearance (1.3 to 2.7 ml/min), as a result of a short initial half-life (1.4 to 2.5 min).",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),[ml] / [min],1.3 to 2.7,58444,DB00160,L-Alanine
,8165632,initial half-life,"Following bolus injection in hamsters, all rscu-PA-32k moieties had a comparably rapid plasma clearance (1.3 to 2.7 ml/min), as a result of a short initial half-life (1.4 to 2.5 min).",Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165632/),min,1.4 to 2.5,58445,DB00160,L-Alanine
,2903762,renal clearance,"5. After multiple dosing, renal clearance was similar for the two doses (11.6 +/- 2.11 l h-1 for the low dose and 17.0 +/- 2.0 l h-1 for the high dose).",Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903762/),[l] / [h],11.6,58511,DB00160,L-Alanine
,2903762,renal clearance,"5. After multiple dosing, renal clearance was similar for the two doses (11.6 +/- 2.11 l h-1 for the low dose and 17.0 +/- 2.0 l h-1 for the high dose).",Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903762/),[l] / [h],17.0,58512,DB00160,L-Alanine
,2903762,Plasma half-life (t1/2 lambda 2),Plasma half-life (t1/2 lambda 2) was 16.0 +/- 3.0 h after the 10 mg dose and 11.9 +/- 1.2 h after 20 mg.,Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903762/),h,16.0,58513,DB00160,L-Alanine
,2903762,Plasma half-life (t1/2 lambda 2),Plasma half-life (t1/2 lambda 2) was 16.0 +/- 3.0 h after the 10 mg dose and 11.9 +/- 1.2 h after 20 mg.,Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903762/),h,11.9,58514,DB00160,L-Alanine
,25654695,serum half-life,"Intravenous administration of human albumin to Tg32-Alb(-/-) mFcRn(-/-) hFcRn(Tg/Tg)) mice results in a remarkably extended human albumin serum half-life of ∼24 days, comparable to that found in humans, and in contrast to half-lives of 2.6-5.8 d observed in B6, B6-Alb(-/-) and Tg32 strains.",Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25654695/),d,∼24,58584,DB00160,L-Alanine
,25654695,half-lives,"Intravenous administration of human albumin to Tg32-Alb(-/-) mFcRn(-/-) hFcRn(Tg/Tg)) mice results in a remarkably extended human albumin serum half-life of ∼24 days, comparable to that found in humans, and in contrast to half-lives of 2.6-5.8 d observed in B6, B6-Alb(-/-) and Tg32 strains.",Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25654695/),d,2.6-5.8,58585,DB00160,L-Alanine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,208,58597,DB00160,L-Alanine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,135,58598,DB00160,L-Alanine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,116,58599,DB00160,L-Alanine
,3417643,rate of disappearance,"(a) N terminus: the rate of disappearance of Ala-Leu was greater (p less than 0.01) than those of Gly-Leu, Phe-Leu, and Arg-Leu (208 +/- 13, 135 +/- 13, 116 +/- 12, and 127 +/- 12, respectively).",Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,127,58600,DB00160,L-Alanine
,3417643,rate of disappearance,(b) C terminus: the rate of disappearance of Leu-Ala (244 +/- 18) was significantly greater (p less than 0.01) than that of Leu-Gly (145 +/- 16).,Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,244,58601,DB00160,L-Alanine
,3417643,rate of disappearance,(b) C terminus: the rate of disappearance of Leu-Ala (244 +/- 18) was significantly greater (p less than 0.01) than that of Leu-Gly (145 +/- 16).,Specificity and mechanism of influence of amino acid residues on hepatic clearance of oligopeptides. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3417643/),,145,58602,DB00160,L-Alanine
,15521332,Cl,"The Cl, V(ss) and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0 +/- 3.2 ml/min/kg, 0.3 +/- 0.0 L/kg, and 0.4 +/- 0.1 hr, respectively.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[ml] / [kg·min],21.0,58941,DB00160,L-Alanine
,15521332,V(ss),"The Cl, V(ss) and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0 +/- 3.2 ml/min/kg, 0.3 +/- 0.0 L/kg, and 0.4 +/- 0.1 hr, respectively.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[l] / [kg],0.3,58942,DB00160,L-Alanine
,15521332,t1/2,"The Cl, V(ss) and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0 +/- 3.2 ml/min/kg, 0.3 +/- 0.0 L/kg, and 0.4 +/- 0.1 hr, respectively.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),h,0.4,58943,DB00160,L-Alanine
,15521332,absolute oral bioavailability,"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),%,5.1,58944,DB00160,L-Alanine
,15521332,absolute oral bioavailability,"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),%,4.8,58945,DB00160,L-Alanine
,15521332,AUC,"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[h·ng] / [ml],407.8,58946,DB00160,L-Alanine
,15521332,AUC,"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[h·ng] / [ml],383.6,58947,DB00160,L-Alanine
,15521332,C(max),"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[ng] / [ml],87.4,58948,DB00160,L-Alanine
,15521332,C(max),"Despite improved solubility profiles, the absolute oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng x hr/ml) and C(max) (87.4 vs. 77.0 ng/ml) compared with rebamipide free acid.",Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15521332/),[ng] / [ml],77.0,58949,DB00160,L-Alanine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,70,60120,DB00160,L-Alanine
,11534935,glucose-to-lipids ratio,Eight healthy volunteers received peripheral PN for 10 h providing 10.5 mg N x kg(-1) x h(-1) and 2.0 kcal x kg(-1) x h(-1) (glucose-to-lipids ratio: 70/30%).,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,30,60121,DB00160,L-Alanine
,11534935,DeltaN,DeltaN was: 0.8+/-0.5 gN/10 h.,Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[gn] / [10·h],0.8,60122,DB00160,L-Alanine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.5,60123,DB00160,L-Alanine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],1.5,60124,DB00160,L-Alanine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,99,60125,DB00160,L-Alanine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,99,60126,DB00160,L-Alanine
<,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],0.6,60127,DB00160,L-Alanine
,11534935,Cl,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[l] / [min],2.8,60128,DB00160,L-Alanine
<,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],3,60129,DB00160,L-Alanine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],6.8,60130,DB00160,L-Alanine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.2,60131,DB00160,L-Alanine
,11534935,Clr,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),[ml] / [min],8.8,60132,DB00160,L-Alanine
>,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,98,60133,DB00160,L-Alanine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60134,DB00160,L-Alanine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60135,DB00160,L-Alanine
,11534935,Reab,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60136,DB00160,L-Alanine
>,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),%,97,60137,DB00160,L-Alanine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,94,60138,DB00160,L-Alanine
,11534935,Reten,"Metabolic characteristics for essential AAs were: Cl<0.5 l min(-1), Clr <1.5 ml x min(-1) Reab >or= 99%, Reten >or=99% and for non-essential AAs: Cl <0.6 l x min(-1) except aspartate (2.8+/-0.3 l x min(-1)), Clr < 3 ml x min(-1) except glycine (6.8+/-0.7), aspartate (8.2+/-3.5) and histidine (8.8+/-1.3); Reab >or= 98% except glycine (95+/-1), aspartate (94+/-2) and histidine (94+/-1), Reten >or=97% except histidine (94+/-1), glycine (95+/-3).",Amino acid metabolism during total parenteral nutrition in healthy volunteers: evaluation of a new amino acid solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11534935/),,95,60139,DB00160,L-Alanine
,32578227,AUC0-∞,"The AUC0-∞ (1.08 [0.91-1.27]) and Cmax (0.95 [0.75-1.2]) of 1-hydroxymidazolam, the primary metabolite of midazolam, were also within the no-effect range.",The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32578227/),,1.08,61107,DB00160,L-Alanine
,32578227,Cmax,"The AUC0-∞ (1.08 [0.91-1.27]) and Cmax (0.95 [0.75-1.2]) of 1-hydroxymidazolam, the primary metabolite of midazolam, were also within the no-effect range.",The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32578227/),,0.95,61108,DB00160,L-Alanine
,28344057,Overall response rate,Overall response rate was 45%.,Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344057/),%,45,61156,DB00160,L-Alanine
,27793950,MTD,The MTD of buparlisib was declared as 100 mg/day.,Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27793950/),[mg] / [d],100,62813,DB00160,L-Alanine
,9205733,systemic peak concentrations,"The systemic peak concentrations were 3-6 ng NIV/ml, mostly occurring 2.5-4.5 h after feeding.",Absorption and metabolism of nivalenol in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205733/),[ng·niv] / [ml],3-6,64796,DB00160,L-Alanine
,18638532,C(max(T)) (maximum concentration),C(max(T)) (maximum concentration) of SACV was observed to be 39+/-22 microM in plasma which is 2 times better than VACV and 15 times better than ACV.,Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638532/),μM,39,65321,DB00160,L-Alanine
,18638532,C(last(T)),C(last(T)) (concentration at the last time point) of SACV was observed to be 0.18+/-0.06 microM in plasma which is two times better than VACV and three times better than ACV.,Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638532/),μM,0.18,65322,DB00160,L-Alanine
,2447682,LD50,This natural product was only slightly toxic to Sprague-Dawley rats following a single sc injection: the LD50 was 5.9 +/- 1 8 g/kg in adult rats and 5.0 +/- 1.0 g/kg in 10-day-old rats.,Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),[g] / [kg],5.9,65412,DB00160,L-Alanine
,2447682,LD50,This natural product was only slightly toxic to Sprague-Dawley rats following a single sc injection: the LD50 was 5.9 +/- 1 8 g/kg in adult rats and 5.0 +/- 1.0 g/kg in 10-day-old rats.,Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),[g] / [kg],5.0,65413,DB00160,L-Alanine
,2447682,systemic clearance,"Following a single dose of 2.0 g/kg, the systemic clearance value for canavanine in adult rats was 0.114 liter/hr, the volume of distribution at steady state was 0.154 liter, and the half-life was 1.56 hr.",Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),[l] / [h],0.114,65414,DB00160,L-Alanine
,2447682,volume of distribution at steady state,"Following a single dose of 2.0 g/kg, the systemic clearance value for canavanine in adult rats was 0.114 liter/hr, the volume of distribution at steady state was 0.154 liter, and the half-life was 1.56 hr.",Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),l,0.154,65415,DB00160,L-Alanine
,2447682,half-life,"Following a single dose of 2.0 g/kg, the systemic clearance value for canavanine in adult rats was 0.114 liter/hr, the volume of distribution at steady state was 0.154 liter, and the half-life was 1.56 hr.",Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),h,1.56,65416,DB00160,L-Alanine
,2447682,Bioavailability,Bioavailability of a 2.0 g/kg sc dose was 72%.,Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),%,72,65417,DB00160,L-Alanine
,2447682,Bioavailability,"Bioavailability of a 2.0 g/kg po dose was 43%, and only 1% of the administered canavanine was recovered in the urine.",Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),%,43,65418,DB00160,L-Alanine
,2447682,Bioavailability,"Bioavailability of a 2.0 g/kg po dose was 43%, and only 1% of the administered canavanine was recovered in the urine.",Toxicity and pharmacokinetics of the nonprotein amino acid L-canavanine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2447682/),%,1,65419,DB00160,L-Alanine
,28735378,maximal mithramycin plasma concentration,The average maximal mithramycin plasma concentration in four patients was 17.8 ± 4.6 ng/mL.,A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28735378/),[ng] / [ml],17.8,65429,DB00160,L-Alanine
,24283396,AUC24hr,"The AUC24hr of Ag(+) was 3.81 ± 0.57 μg/d/ml when rats were treated with a single dose of 20 mg/kg, whereas that of AgNP was 1.58 ± 0.25 μg/d/ml.",Toxicokinetic differences and toxicities of silver nanoparticles and silver ions in rats after single oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24283396/),[μg] / [d·ml],3.81,65987,DB00160,L-Alanine
,24283396,AUC24hr,"The AUC24hr of Ag(+) was 3.81 ± 0.57 μg/d/ml when rats were treated with a single dose of 20 mg/kg, whereas that of AgNP was 1.58 ± 0.25 μg/d/ml.",Toxicokinetic differences and toxicities of silver nanoparticles and silver ions in rats after single oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24283396/),[μg] / [d·ml],1.58,65988,DB00160,L-Alanine
,8887440,Vmax,"For CCl4 alone, Vmax was 0.11 mg/hr (Vmaxc = 0.37 mg/hr/kg) and Km was 1.3 mg/liter.",Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h],0.11,65989,DB00160,L-Alanine
,8887440,Vmaxc,"For CCl4 alone, Vmax was 0.11 mg/hr (Vmaxc = 0.37 mg/hr/kg) and Km was 1.3 mg/liter.",Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h·kg],0.37,65990,DB00160,L-Alanine
,8887440,Km,"For CCl4 alone, Vmax was 0.11 mg/hr (Vmaxc = 0.37 mg/hr/kg) and Km was 1.3 mg/liter.",Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [l],1.3,65991,DB00160,L-Alanine
,8887440,Vmax,Vmax was 0.48 mg/hr (Vmaxc = 1.6 mg/hr/kg) for the 24-hr MeOH + CCl4 group and Vmax was 0.18 mg/hr (Vmaxc = 0.6 mg/hr/kg) for the 48-hr MeOH + CCl4 group.,Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h],0.48,65992,DB00160,L-Alanine
,8887440,Vmaxc,Vmax was 0.48 mg/hr (Vmaxc = 1.6 mg/hr/kg) for the 24-hr MeOH + CCl4 group and Vmax was 0.18 mg/hr (Vmaxc = 0.6 mg/hr/kg) for the 48-hr MeOH + CCl4 group.,Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h·kg],1.6,65993,DB00160,L-Alanine
,8887440,Vmax,Vmax was 0.48 mg/hr (Vmaxc = 1.6 mg/hr/kg) for the 24-hr MeOH + CCl4 group and Vmax was 0.18 mg/hr (Vmaxc = 0.6 mg/hr/kg) for the 48-hr MeOH + CCl4 group.,Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h],0.18,65994,DB00160,L-Alanine
,8887440,Vmaxc,Vmax was 0.48 mg/hr (Vmaxc = 1.6 mg/hr/kg) for the 24-hr MeOH + CCl4 group and Vmax was 0.18 mg/hr (Vmaxc = 0.6 mg/hr/kg) for the 48-hr MeOH + CCl4 group.,Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887440/),[mg] / [h·kg],0.6,65995,DB00160,L-Alanine
,3396115,half-life,"Mean values of 77.8 min for the half-life, 510.8 ml/min for the total plasma clearance and 0.69 l/kg for the volume of distribution were found.",Pharmacokinetics of PTT-119 in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396115/),min,77.8,66047,DB00160,L-Alanine
,3396115,total plasma clearance,"Mean values of 77.8 min for the half-life, 510.8 ml/min for the total plasma clearance and 0.69 l/kg for the volume of distribution were found.",Pharmacokinetics of PTT-119 in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396115/),[ml] / [min],510.8,66048,DB00160,L-Alanine
,3396115,volume of distribution,"Mean values of 77.8 min for the half-life, 510.8 ml/min for the total plasma clearance and 0.69 l/kg for the volume of distribution were found.",Pharmacokinetics of PTT-119 in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396115/),[l] / [kg],0.69,66049,DB00160,L-Alanine
,27798825,Area under the curve (AUC),"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"246,425",66134,DB00160,L-Alanine
,27798825,elimination half-life (t1/2),"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"83,591",66135,DB00160,L-Alanine
,27798825,AUC,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),[ng] / [h·ml],"83,591",66136,DB00160,L-Alanine
,27798825,t1/2,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,5.77,66137,DB00160,L-Alanine
,27798825,t1/2,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,1.99,66138,DB00160,L-Alanine
,27798825,MRT,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,4.45,66139,DB00160,L-Alanine
,27798825,MRT,"Area under the curve (AUC), elimination half-life (t1/2), and mean residence time (MRT) of P-GEM treated group were significantly higher compared to those of F-GEM treated group: 246,425 ± 1605 vs 83,591 ± 1844 ng/mL × h as AUC, 5.77 ± 2.02 vs 1.99 ± 0.09 h as t1/2, and 4.45 ± 0.15 vs 1.12 ± 0.13 h as MRT.",Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798825/),h,1.12,66140,DB00160,L-Alanine
,12374677,EC(50),"Peak plasma concentrations occurred between 1 and 2 h after dosing, and doses above 200 mg/day exceeded the known in vitro EC(50) (1-2 micro M) for apoptosis in cancer cells.",Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374677/),μM,1-2,66452,DB00160,L-Alanine
,12374677,terminal half-life,"No drug was detectable after 24 h of administration, and the terminal half-life was 6.7 h.",Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374677/),h,6.7,66453,DB00160,L-Alanine
,2723114,Bioavailability (F),Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,43.2,66668,DB00160,L-Alanine
,2723114,FWR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,43.5,66669,DB00160,L-Alanine
,2723114,FWH,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,36.4,66670,DB00160,L-Alanine
,2723114,CLSR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],849,66671,DB00160,L-Alanine
,2723114,CLWR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],380,66672,DB00160,L-Alanine
,2723114,CLWH,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],559,66673,DB00160,L-Alanine
,26590007,IC50,"Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50 value of 4.29 ± 1.29 mm.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),mm,4.29,66918,DB00160,L-Alanine
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],171,66919,DB00160,L-Alanine
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],244,66920,DB00160,L-Alanine
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],338,66921,DB00160,L-Alanine
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],399,66922,DB00160,L-Alanine
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,41.7,66923,DB00160,L-Alanine
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,49.2,66924,DB00160,L-Alanine
,23334261,response rate,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),%,50,67587,DB00160,L-Alanine
,23334261,progression-free survival (PFS),"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,10.5,67588,DB00160,L-Alanine
,23334261,overall survival times,"The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,21.2,67589,DB00160,L-Alanine
,23334261,PFS,"In EGFR mutation-positive patients (n = 9), seven patients achieved an objective response and the median PFS was 12.4 months, whereas none with wild-type EGFR (n = 6) responded.",Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23334261/),month,12.4,67590,DB00160,L-Alanine
,28490463,plasma half-life,"TAK-117 (100-1,200 mg) exhibited moderately fast oral absorption, a generally dose proportional increase in exposure, and plasma half-life of approximately 11 hours.","A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28490463/),h,11,67736,DB00160,L-Alanine
,8044665,Cmax,"On the first day of dosing, Cmax ranged from 0.45-6.94 micrograms ml-1 flunixin and the mean plasma concentration was greatest at 1 h (2.46 micrograms ml-1).","Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044665/),[μg] / [ml],0.45-6.94,67962,DB00160,L-Alanine
,8044665,Cmax,"After 7 days dosing, Cmax ranged from 0.47-2.46 micrograms ml-1.","Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044665/),[μg] / [ml],0.47-2.46,67963,DB00160,L-Alanine
,8044665,mean plasma concentration,The mean plasma concentration was again greatest at 1 h but was lower (1.68 micrograms ml-1) than on the first day of treatment.,"Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044665/),,1.68,67964,DB00160,L-Alanine
,8044665,area under the plasma concentration time curve 0-24 h,The area under the plasma concentration time curve 0-24 h on the first day was 6.82 +/- 1.85 micrograms ml-1h-1 and 3.32 +/- 0.73 micrograms ml-1h-1 on the seventh day.,"Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044665/),[μg] / [ml],6.82,67965,DB00160,L-Alanine
,8044665,area under the plasma concentration time curve 0-24 h,The area under the plasma concentration time curve 0-24 h on the first day was 6.82 +/- 1.85 micrograms ml-1h-1 and 3.32 +/- 0.73 micrograms ml-1h-1 on the seventh day.,"Flunixin in the cat: a pharmacodynamic, pharmacokinetic and toxicological study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044665/),[μg] / [ml],3.32,67966,DB00160,L-Alanine
,18041883,C(av),"Median C(av) and C(max) were 611 and 635 ng/ml, respectively, in these five patients and were 922 and 1360 ng/ml, respectively, in the 241 patients without invasive fungal infection.",Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18041883/),[ng] / [ml],611,68555,DB00160,L-Alanine
,18041883,C(av),"Median C(av) and C(max) were 611 and 635 ng/ml, respectively, in these five patients and were 922 and 1360 ng/ml, respectively, in the 241 patients without invasive fungal infection.",Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18041883/),[ng] / [ml],922,68556,DB00160,L-Alanine
,18041883,C(max),"Median C(av) and C(max) were 611 and 635 ng/ml, respectively, in these five patients and were 922 and 1360 ng/ml, respectively, in the 241 patients without invasive fungal infection.",Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18041883/),[ng] / [ml],635,68557,DB00160,L-Alanine
,18041883,C(max),"Median C(av) and C(max) were 611 and 635 ng/ml, respectively, in these five patients and were 922 and 1360 ng/ml, respectively, in the 241 patients without invasive fungal infection.",Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18041883/),[ng] / [ml],1360,68558,DB00160,L-Alanine
,28128722,CL/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),[l] / [h],9.16,71715,DB00160,L-Alanine
,28128722,V2/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),l,34.3,71716,DB00160,L-Alanine
,28128722,Q/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),[l] / [h],16.4,71717,DB00160,L-Alanine
,28128722,V3/F,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),l,250,71718,DB00160,L-Alanine
,28128722,ka,"The PPK parameter estimates were 9.16 L/h for CL/F, 34.3 L for V2/F, 16.4 L/h for Q/F, 250 L for V3/F, and 0.522 h<sup>-1</sup> for ka, based on the final model.",Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors . ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28128722/),1/[h<sup>·sup>],0.522,71719,DB00160,L-Alanine
,32816246,number of transit compartments,Brigatinib plasma concentrations were best described by a three-compartment model with a transit compartment input (number of transit compartments = 2.35; mean transit time = 0.9 h).,Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816246/),h,2.35,72313,DB00160,L-Alanine
,32816246,mean transit time,Brigatinib plasma concentrations were best described by a three-compartment model with a transit compartment input (number of transit compartments = 2.35; mean transit time = 0.9 h).,Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816246/),h,0.9,72314,DB00160,L-Alanine
,33528890,maximum tolerated dose,The maximum tolerated dose was determined to be 3.6 mg/kg.,"Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33528890/),[mg] / [kg],3.6,72385,DB00160,L-Alanine
,26554649,Maximum tolerated dose,"Maximum tolerated dose was 8 μg kg(-1) for MOC31PE alone, and 6.5 μg kg(-1) when combined with CsA.","Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),[μg] / [kg],8,72552,DB00160,L-Alanine
,26554649,Maximum tolerated dose,"Maximum tolerated dose was 8 μg kg(-1) for MOC31PE alone, and 6.5 μg kg(-1) when combined with CsA.","Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),[μg] / [kg],6.5,72553,DB00160,L-Alanine
,26554649,half-life,The pharmacokinetic profile of MOC31PE was characterised by linear kinetics and with a half-life of ∼3 h.,"Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),h,∼3,72554,DB00160,L-Alanine
<,23394180,K(i)(app),We report here their further optimization to produce extremely potent inhibitors of Eg5 (K(i)(app) < 10 nM) with broad-spectrum activity against cancer cell lines comparable to the Phase II drug candidates ispinesib and SB-743921.,Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23394180/),nM,10,72696,DB00160,L-Alanine
,8968267,half-life,The half-life of diaspirin cross-linked hemoglobin solution was 2.5 hrs for the 25- and 50-mg/kg doses and 3.3 hrs for the 100-mg/kg dose.,Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968267/),h,2.5,72738,DB00160,L-Alanine
,8968267,half-life,The half-life of diaspirin cross-linked hemoglobin solution was 2.5 hrs for the 25- and 50-mg/kg doses and 3.3 hrs for the 100-mg/kg dose.,Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8968267/),h,3.3,72739,DB00160,L-Alanine
,24517189,trough concentration,The multivariate model confirm that tenofovir was associated with lower atazanavir trough concentration (-284.1 ng/mL; p=0.005) while AST values significantly increased atazanavir concentrations (+114.5 ng/mL; p=0.03).,Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24517189/),[ng] / [ml],-,73264,DB00160,L-Alanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,85.8,73658,DB00160,L-Alanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,80.0,73659,DB00160,L-Alanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,66.4,73660,DB00160,L-Alanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,57.1,73661,DB00160,L-Alanine
>,30865315,half-life,"Geometric mean area under the plasma concentration-time curve from time zero to time of last quantifiable concentration increased 357% and 518% vs normal in ESRD with and without hemodialysis, respectively, with half-life >100 hours in both groups.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),h,100,73662,DB00160,L-Alanine
,12105253,plasma level,The back-extrapolated initial ibandronate plasma level was 38.9+/-15.9 ng/ml; this decreased during first haemodialysis (after 4 h) to 4.9+/-0.9 ng/ml and after two subsequent haemodialysis treatments to 0.38+/-0.16 ng/ml.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),[ng] / [ml],38.9,74374,DB00160,L-Alanine
,12105253,plasma level,The back-extrapolated initial ibandronate plasma level was 38.9+/-15.9 ng/ml; this decreased during first haemodialysis (after 4 h) to 4.9+/-0.9 ng/ml and after two subsequent haemodialysis treatments to 0.38+/-0.16 ng/ml.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),[ng] / [ml],4.9,74375,DB00160,L-Alanine
,12105253,plasma level,The back-extrapolated initial ibandronate plasma level was 38.9+/-15.9 ng/ml; this decreased during first haemodialysis (after 4 h) to 4.9+/-0.9 ng/ml and after two subsequent haemodialysis treatments to 0.38+/-0.16 ng/ml.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),[ng] / [ml],0.38,74376,DB00160,L-Alanine
,12105253,plasma clearance,The ibandronate dialysis plasma clearance was determined at 92+/-19 ml/min.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),[ml] / [min],92,74377,DB00160,L-Alanine
,12105253,total amount excreted,The total amount excreted at the first dialysis using the recovery rate measure was 364+/-98 microg and using the mean difference in inflow/outflow (arteriovenous) concentration (A-V difference method) it was 371+/-132 microg.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),μg,364,74378,DB00160,L-Alanine
,12105253,total amount excreted,The total amount excreted at the first dialysis using the recovery rate measure was 364+/-98 microg and using the mean difference in inflow/outflow (arteriovenous) concentration (A-V difference method) it was 371+/-132 microg.,Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12105253/),μg,371,74379,DB00160,L-Alanine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00160,L-Alanine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00160,L-Alanine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00160,L-Alanine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00160,L-Alanine
,30856016,elimination half-life,Initial paracetamol elimination half-life was 14.5 h.,A case of accidental neonatal paracetamol overdose with prolonged half-life and measured metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30856016/),h,14.5,75216,DB00160,L-Alanine
,16923981,Maximum plasma concentrations,"Maximum plasma concentrations were 651 ng/mL and 42.8 ng/mL for the 100- to 300-microm and 700- to 900-microm DEB groups, respectively, observed at 1 minute for both groups.",Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16923981/),[ng] / [ml],651,75730,DB00160,L-Alanine
,16923981,Maximum plasma concentrations,"Maximum plasma concentrations were 651 ng/mL and 42.8 ng/mL for the 100- to 300-microm and 700- to 900-microm DEB groups, respectively, observed at 1 minute for both groups.",Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16923981/),[ng] / [ml],42.8,75731,DB00160,L-Alanine
,2372928,half life,"Argininosuccinate synthetase disappeared from the serum with a half life of about 15 min, while the half lives of alanine aminotransferase and aspartate aminotransferase were 4 and 5 h, respectively, under the same conditions.",Clearance of argininosuccinate synthetase from the circulation in acute liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2372928/),min,15,76322,DB00160,L-Alanine
,2372928,half lives,"Argininosuccinate synthetase disappeared from the serum with a half life of about 15 min, while the half lives of alanine aminotransferase and aspartate aminotransferase were 4 and 5 h, respectively, under the same conditions.",Clearance of argininosuccinate synthetase from the circulation in acute liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2372928/),h,4,76323,DB00160,L-Alanine
,2372928,half lives,"Argininosuccinate synthetase disappeared from the serum with a half life of about 15 min, while the half lives of alanine aminotransferase and aspartate aminotransferase were 4 and 5 h, respectively, under the same conditions.",Clearance of argininosuccinate synthetase from the circulation in acute liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2372928/),h,5,76324,DB00160,L-Alanine
,32557753,half-life,"The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h).",Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557753/),h,12.85,76661,DB00160,L-Alanine
,32557753,half-life,"The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h).",Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557753/),h,5.62,76662,DB00160,L-Alanine
,32557753,apparent total clearance (Clt /F),"The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h).",Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557753/),[l] / [h],3.32,76663,DB00160,L-Alanine
,32557753,apparent total clearance (Clt /F),"The half-life of rebamipide in rats (12.85 ± 7.86 h) was longer than that in dogs (5.62 ± 2.24 h), and the apparent total clearance (Clt /F) of rebamipide in rats (3.32 ± 1.18 L/h) was lower than that in dogs (105.01 ± 42.37 L/h).",Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557753/),[l] / [h],105.01,76664,DB00160,L-Alanine
,21600385,AUC(ss),Vandetanib pharmacokinetics were linear over the dose range studied with AUC(ss) for the 300 mg once daily group (38611 ng/h/mL) being 3.6-fold higher than that for the 100 mg once daily group (10826 ng/h/mL).,"Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),[ng] / [h·ml],38611,77819,DB00160,L-Alanine
,21600385,AUC(ss),Vandetanib pharmacokinetics were linear over the dose range studied with AUC(ss) for the 300 mg once daily group (38611 ng/h/mL) being 3.6-fold higher than that for the 100 mg once daily group (10826 ng/h/mL).,"Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),[ng] / [h·ml],10826,77820,DB00160,L-Alanine
,21600385,T(max),"Absorption was relatively slow following a single 100- or 300-mg dose, with T(max) ranging from 2 to 10 hours.","Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),h,2 to 10,77821,DB00160,L-Alanine
,21600385,plasma clearance,Vandetanib plasma clearance was slow (7.8-9.2 L/h) and was independent of dose.,"Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),[l] / [h],7.8-9.2,77822,DB00160,L-Alanine
,21600385,plasma clearance,"The pharmacokinetic properties of vandetanib in these Chinese patients were characterized by low plasma clearance of approximately 8 L/h, a long half-life of approximately 8 to 10 days, and an accumulation of approximately 8-fold to 15-fold on multiple dosing.","Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),[l] / [h],8,77823,DB00160,L-Alanine
,21600385,half-life,"The pharmacokinetic properties of vandetanib in these Chinese patients were characterized by low plasma clearance of approximately 8 L/h, a long half-life of approximately 8 to 10 days, and an accumulation of approximately 8-fold to 15-fold on multiple dosing.","Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21600385/),d,8 to 10,77824,DB00160,L-Alanine
,27030023,t1/2β,"A double mutation in the binding site is necessary to abrogate binding to murine FcRn, whereas a single mutation in the FcRn binding site is sufficient to no longer detect binding to human FcRn and create hu3S193 IgG1 variants with a half-life similar to previously studied hu3S193 F(ab')2 (t1/2β, I253A, 12.23 h; H310A, 12.94; H435A, 12.57; F(ab')2, 12.6 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,12.23,78687,DB00160,L-Alanine
,27030023,t1/2β,"A double mutation in the binding site is necessary to abrogate binding to murine FcRn, whereas a single mutation in the FcRn binding site is sufficient to no longer detect binding to human FcRn and create hu3S193 IgG1 variants with a half-life similar to previously studied hu3S193 F(ab')2 (t1/2β, I253A, 12.23 h; H310A, 12.94; H435A, 12.57; F(ab')2, 12.6 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,12.94,78688,DB00160,L-Alanine
,27030023,t1/2β,"A double mutation in the binding site is necessary to abrogate binding to murine FcRn, whereas a single mutation in the FcRn binding site is sufficient to no longer detect binding to human FcRn and create hu3S193 IgG1 variants with a half-life similar to previously studied hu3S193 F(ab')2 (t1/2β, I253A, 12.23 h; H310A, 12.94; H435A, 12.57; F(ab')2, 12.6 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,12.57,78689,DB00160,L-Alanine
,27030023,t1/2β,"A double mutation in the binding site is necessary to abrogate binding to murine FcRn, whereas a single mutation in the FcRn binding site is sufficient to no longer detect binding to human FcRn and create hu3S193 IgG1 variants with a half-life similar to previously studied hu3S193 F(ab')2 (t1/2β, I253A, 12.23 h; H310A, 12.94; H435A, 12.57; F(ab')2, 12.6 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,12.6,78690,DB00160,L-Alanine
,27030023,t1/2β,"Alanine substitutions in S254 in the CH2 domain and Y436 in the CH3 domain showed reduced binding in vitro to human FcRn and reduced elimination half-lives in huFcRn transgenic mice (t1/2β, S254A, 37.43 h; Y436A, 39.53 h; wild-type, 83.15 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,37.43,78691,DB00160,L-Alanine
,27030023,t1/2β,"Alanine substitutions in S254 in the CH2 domain and Y436 in the CH3 domain showed reduced binding in vitro to human FcRn and reduced elimination half-lives in huFcRn transgenic mice (t1/2β, S254A, 37.43 h; Y436A, 39.53 h; wild-type, 83.15 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,39.53,78692,DB00160,L-Alanine
,27030023,t1/2β,"Alanine substitutions in S254 in the CH2 domain and Y436 in the CH3 domain showed reduced binding in vitro to human FcRn and reduced elimination half-lives in huFcRn transgenic mice (t1/2β, S254A, 37.43 h; Y436A, 39.53 h; wild-type, 83.15 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,83.15,78693,DB00160,L-Alanine
,27030023,t1/2β,"These variants had minimal effect on half-life in BALB/c nu/nu mice (t1/2β, S254A, 119.9 h; Y436A, 162.1 h; wild-type, 163.1 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,119.9,78694,DB00160,L-Alanine
,27030023,t1/2β,"These variants had minimal effect on half-life in BALB/c nu/nu mice (t1/2β, S254A, 119.9 h; Y436A, 162.1 h; wild-type, 163.1 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,162.1,78695,DB00160,L-Alanine
,27030023,t1/2β,"These variants had minimal effect on half-life in BALB/c nu/nu mice (t1/2β, S254A, 119.9 h; Y436A, 162.1 h; wild-type, 163.1 h).",Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030023/),h,163.1,78696,DB00160,L-Alanine
,15930351,total body clearance,"No correlation was observed between dose and C(max), total body clearance (mean, 26.15 +/- 10.88 L per hour per m(2)), volume of distribution at steady state (mean, 39.51 +/- 17.91 L/m(2)), or half-life (mean, 2.63 +/- 1.81 hours); a moderate correlation existed between dose given and systemic drug exposure (AUC).",Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930351/),[h·l] / [m(2],26.15,78941,DB00160,L-Alanine
,15930351,volume of distribution at steady state,"No correlation was observed between dose and C(max), total body clearance (mean, 26.15 +/- 10.88 L per hour per m(2)), volume of distribution at steady state (mean, 39.51 +/- 17.91 L/m(2)), or half-life (mean, 2.63 +/- 1.81 hours); a moderate correlation existed between dose given and systemic drug exposure (AUC).",Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930351/),[l] / [m(2],39.51,78942,DB00160,L-Alanine
,15930351,half-life,"No correlation was observed between dose and C(max), total body clearance (mean, 26.15 +/- 10.88 L per hour per m(2)), volume of distribution at steady state (mean, 39.51 +/- 17.91 L/m(2)), or half-life (mean, 2.63 +/- 1.81 hours); a moderate correlation existed between dose given and systemic drug exposure (AUC).",Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930351/),h,2.63,78943,DB00160,L-Alanine
,29367424,ALT,"The mean hemoglobin values at the first and final visits were 160 ± 9 and 153 ± 9 g/L, respectively (p > 0.05); the mean ALT values were 18 ± 6 and 21 ± 10 IU/L (p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[iu] / [l],18,79250,DB00160,L-Alanine
,29367424,ALT,"The mean hemoglobin values at the first and final visits were 160 ± 9 and 153 ± 9 g/L, respectively (p > 0.05); the mean ALT values were 18 ± 6 and 21 ± 10 IU/L (p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[iu] / [l],21,79251,DB00160,L-Alanine
,29367424,AUC,"Total testosterone exposure was comparable with subcutaneous versus i.m. injection (mean AUC, 1.7 ± 0.6 nmol·days/L/mg versus 1.9 ± 0.6 nmol·days/L/mg; p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[d·nM] / [l·mg],1.7,79252,DB00160,L-Alanine
,29367424,AUC,"Total testosterone exposure was comparable with subcutaneous versus i.m. injection (mean AUC, 1.7 ± 0.6 nmol·days/L/mg versus 1.9 ± 0.6 nmol·days/L/mg; p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[d·nM] / [l·mg],1.9,79253,DB00160,L-Alanine
,15545085,elimination half-life,"While the conventional liposomes had a short elimination half-life (28 min), the liposomes modified with library-PE had a much longer half-life (170 min), while library-SA provided no improvement of the liposome pharmacokinetics.",Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,28,79458,DB00160,L-Alanine
,15545085,half-life,"While the conventional liposomes had a short elimination half-life (28 min), the liposomes modified with library-PE had a much longer half-life (170 min), while library-SA provided no improvement of the liposome pharmacokinetics.",Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,170,79459,DB00160,L-Alanine
,15545085,half-life,PEG-PE greatly improved the half-life of the liposomes (400 min) while PEG-SA only provided a marginal improvement.,Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545085/),min,400,79460,DB00160,L-Alanine
,9207985,half-life,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,85.54,80044,DB00160,L-Alanine
,9207985,liver clearance,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),[ml] / [g·min],0.52,80045,DB00160,L-Alanine
,9207985,extraction ratio,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,0.517,80046,DB00160,L-Alanine
,9207985,half-life,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),min,123.95,80047,DB00160,L-Alanine
,9207985,liver clearance,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),[ml] / [g·min],0.1164,80048,DB00160,L-Alanine
,9207985,extraction ratio,"Concentration profiles showed that group B had a better metabolizing capacity, reflected in a 85.54 +/- 37.05 min half-life, a 0.52 +/- 0.19 mL min-1 g-1 liver clearance and a 0.517 +/- 0.188 extraction ratio, compared to group A, which presented a 123.95 +/- 88.13 min half-life, a 0.1164 +/- 0.067 mL min-1 g-1 liver clearance (P < 0.002) and a 0.116 +/- 0.680 extraction ratio (P < 0.002).",Pharmacokinetics and hepatotoxicity of diclofenac using an isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9207985/),,0.116,80049,DB00160,L-Alanine
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],0.42,80091,DB00160,L-Alanine
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],1.19,80092,DB00160,L-Alanine
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],0.67,80093,DB00160,L-Alanine
,7987979,plasma concentrations,"Mean plasma concentrations of 5FU and FBAL increased significantly from the 1st day (0.42 and 1.19 micrograms/ml for 5FU and FBAL, respectively) to the 4th day of 5FU infusion (0.67 and 1.78 micrograms/ml for 5FU and FBAL, respectively).",Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987979/),[μg] / [ml],1.78,80094,DB00160,L-Alanine
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,14,80160,DB00160,L-Alanine
,24060438,liver-to-serum ratios,The average liver-to-serum ratios 24 hours and 72 hours after treatment were approximately 14 and 22.,Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24060438/),,22,80161,DB00160,L-Alanine
,22348451,time to maximum level,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.3,80194,DB00160,L-Alanine
,22348451,time to maximum level,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.5,80195,DB00160,L-Alanine
,22348451,elimination half-life,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,1.8,80196,DB00160,L-Alanine
,22348451,elimination half-life,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),h,2.1,80197,DB00160,L-Alanine
,22348451,apparent total clearance,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[l] / [h],379,80198,DB00160,L-Alanine
,22348451,apparent total clearance,"The time to maximum level (1.3hrs versus 1.5hrs), elimination half-life (1.8hrs versus 2.1hrs), and apparent total clearance (379L/hr versus 478L/hr) did not differ significantly between the low- and high-dose arms, respectively.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[l] / [h],478,80199,DB00160,L-Alanine
,22348451,maximum concentration,"The maximum concentration was 405 ±93pg/mL for the low-dose arm and 3999±700pg/mL for the high-dose arm, both of which are substantially higher than physiologic melatonin levels for this age group.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[pg] / [ml],405,80200,DB00160,L-Alanine
,22348451,maximum concentration,"The maximum concentration was 405 ±93pg/mL for the low-dose arm and 3999±700pg/mL for the high-dose arm, both of which are substantially higher than physiologic melatonin levels for this age group.",Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22348451/),[pg] / [ml],3999,80201,DB00160,L-Alanine
,9706952,gas flow,Ten patients (aged 40-70 yr) who had received sevoflurane anesthesia with a gas flow of 6 L/min for neurosurgery twice in 30-90 days were studied.,Inorganic fluoride kinetics and renal and hepatic function after repeated sevoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706952/),[l] / [min],6,80280,DB00160,L-Alanine
,32534811,dose AUC,All patients received carboplatin at dose AUC 6 mg/mL·min (AUC6) Q3W for up to 6 cycles.,Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534811/),[mg] / [min·ml],6,80911,DB00160,L-Alanine
,32534811,AUC6,All patients received carboplatin at dose AUC 6 mg/mL·min (AUC6) Q3W for up to 6 cycles.,Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534811/),[mg] / [min·ml],6,80912,DB00160,L-Alanine
,32534811,duration of progression-free survival,"The median duration of progression-free survival was 10.71 months (95% CI: 8.54, 13.86) with confirmed complete/partial responses in 24 (59%) patients.",Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534811/),month,10.71,80913,DB00160,L-Alanine
,17260668,run time,"The shorter run time (5.5 min vs 16 min) has led the authors to prefer the two LC-MS-MS methods to the HPLC-FD bioassay, even if all the performances of the three methods were excellent.",Bioassay of safinamide in biological fluids of humans and various animal species. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17260668/),min,5.5,80975,DB00160,L-Alanine
,17260668,run time,"The shorter run time (5.5 min vs 16 min) has led the authors to prefer the two LC-MS-MS methods to the HPLC-FD bioassay, even if all the performances of the three methods were excellent.",Bioassay of safinamide in biological fluids of humans and various animal species. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17260668/),min,16,80976,DB00160,L-Alanine
,34281773,Fe',Anaesthesia was maintained with isoflurane in 50% oxygen (Fe'Iso 1.3-1.5%).,Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),%,1.3-1.5,81318,DB00160,L-Alanine
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.41,81319,DB00160,L-Alanine
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.72,81320,DB00160,L-Alanine
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.52,81321,DB00160,L-Alanine
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.60,81322,DB00160,L-Alanine
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,2.45,81323,DB00160,L-Alanine
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,3.57,81324,DB00160,L-Alanine
,3730557,characteristic time,"The results of radioreceptor assay were presented as a biexponential curve with a fast main phase of activity changes (90%, characteristic time 1.5-5.0 min) and a slow ""clearance"" phase (10% of the substance, characteristic time 85-200 min).",[Radioimmunologic and radioreceptor studies of the pharmacokinetics of the enkephalin analog dalargin in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730557/),min,1.5-5.0,81414,DB00160,L-Alanine
,3730557,characteristic time,"The results of radioreceptor assay were presented as a biexponential curve with a fast main phase of activity changes (90%, characteristic time 1.5-5.0 min) and a slow ""clearance"" phase (10% of the substance, characteristic time 85-200 min).",[Radioimmunologic and radioreceptor studies of the pharmacokinetics of the enkephalin analog dalargin in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730557/),min,85-200,81415,DB00160,L-Alanine
,32423957,release rates,"TAF, TFV, and TFV-DP concentrations for release rates between 1.0 and 1.6 mg/day were simulated.",Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423957/),[mg] / [d],1.0 and 1.6,82207,DB00160,L-Alanine
,32423957,minimum release,The PBPK model indicated that a minimum release of 1.4 mg/day TAF is necessary to achieve TFV-DP concentrations above the identified target in peripheral blood mononuclear cells (PBMCs).,Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423957/),[mg] / [d],1,82208,DB00160,L-Alanine
,32423957,release rates,"TFV-DP cervical and rectal tissue concentrations were predicted to be between 1.5 and 2.0 fmol/106 cells and 0.9 and 1.1 fmol/106 cells, respectively, for release rates between 1.3 and 1.6 mg/day.",Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423957/),[mg] / [d],1.3 and 1.6,82209,DB00160,L-Alanine
,11896120,steady-state plasma concentration (C(P)),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[ng] / [ml],104,82231,DB00160,L-Alanine
,11896120,steady-state plasma concentration (C(P)),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[ng] / [ml],38.1,82232,DB00160,L-Alanine
,11896120,area under the curve (AUC)(144-168h),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[h·ng] / [ml],"2,350",82233,DB00160,L-Alanine
,11896120,area under the curve (AUC)(144-168h),"The mean +/- SD steady-state plasma concentration (C(P)) and area under the curve (AUC)(144-168h) for CVI 5-FU (104 +/- 45 ng/mL and 2,350 +/- 826 ng x h/mL, respectively) were three-fold greater than those for oral 5-FU (38.1 +/- 7.7 ng/mL and 722 +/- 182 ng x h/mL, respectively [P <.00001]).",Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896120/),[h·ng] / [ml],722,82234,DB00160,L-Alanine
,2390689,"""half times""","Following intravenous administration, 5 FU decayed with ""half times"" ranging from 5 to 17 min.",Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390689/),min,5 to 17,82640,DB00160,L-Alanine
,1518128,half life,"The mean blood concentration of PAPM was 14.8 micrograms/ml at the peak, and the mean half life was 0.9 hours in blood.",[Pharmacokinetics and clinical studies of panipenem/betamipron in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518128/),h,0.9,83260,DB00160,L-Alanine
,1732048,area under the CI-941 plasma concentration x time curve (AUC),"Due to the steep dose lethality relationship and nonlinear pharmacokinetics in mice, a target area under the CI-941 plasma concentration x time curve (AUC) of 110 microM x min (i.e., 40% of the mouse 10% lethal dose AUC) was chosen.",Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732048/),min·μM,110,83644,DB00160,L-Alanine
,1732048,t1/2 alpha,"CI-941 was rapidly cleared from plasma, and a triexponential open model could be fitted to the data (t1/2 alpha = 7.6 +/- 2 min, t1/2 beta = 65 +/- 27 min, t1/2 zeta = 21 +/- 9 h).",Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732048/),min,7.6,83645,DB00160,L-Alanine
,1732048,t1/2 beta,"CI-941 was rapidly cleared from plasma, and a triexponential open model could be fitted to the data (t1/2 alpha = 7.6 +/- 2 min, t1/2 beta = 65 +/- 27 min, t1/2 zeta = 21 +/- 9 h).",Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732048/),min,65,83646,DB00160,L-Alanine
,1732048,t1/2 zeta,"CI-941 was rapidly cleared from plasma, and a triexponential open model could be fitted to the data (t1/2 alpha = 7.6 +/- 2 min, t1/2 beta = 65 +/- 27 min, t1/2 zeta = 21 +/- 9 h).",Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732048/),h,21,83647,DB00160,L-Alanine
,1732048,AUC,"In patients treated at 40 mg/m2, the AUC values (156 to 415 microM x min) approximated or exceeded the target AUC.",Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1732048/),min·μM,156 to 415,83648,DB00160,L-Alanine
,26898300,apparent oral clearance,"Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %).","Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898300/),[l] / [h],9.5,84263,DB00160,L-Alanine
,26898300,apparent volume of distribution at steady state,"Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %).","Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898300/),l,9163,84264,DB00160,L-Alanine
,26898300,accumulation ratio,"Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %).","Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898300/),l,9163,84265,DB00160,L-Alanine
,26898300,elimination half-life,"Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %).","Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898300/),,21,84266,DB00160,L-Alanine
,26898300,elimination half-life,"Population-predicted geometric means (inter-individual variability, CV%) of apparent oral clearance, apparent volume of distribution at steady state, accumulation ratio, and elimination half-life were 9.5 L/h (71.4 %), 9163 L (74.9 %), 21 (131 %) and 29.6 days (109 %).","Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26898300/),d,29.6,84267,DB00160,L-Alanine
,1512930,Maximum serum levels,"Maximum serum levels of PAPM, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg of PAPM/BP, were 27.37 micrograms/ml, 59.3 micrograms/ml, 91.7 micrograms/ml, respectively, at the end of infusion.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],27.37,85290,DB00160,L-Alanine
,1512930,Maximum serum levels,"Maximum serum levels of PAPM, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg of PAPM/BP, were 27.37 micrograms/ml, 59.3 micrograms/ml, 91.7 micrograms/ml, respectively, at the end of infusion.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],59.3,85291,DB00160,L-Alanine
,1512930,Maximum serum levels,"Maximum serum levels of PAPM, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg of PAPM/BP, were 27.37 micrograms/ml, 59.3 micrograms/ml, 91.7 micrograms/ml, respectively, at the end of infusion.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],91.7,85292,DB00160,L-Alanine
,1512930,half-lives,The half-lives of the 3 dose levels were all within 0.90-0.96 hour.,[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),h,0.90-0.96,85293,DB00160,L-Alanine
,1512930,peak serum levels,"Mean peak serum levels of BP, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 21.77 micrograms/ml, 35.29 micrograms/ml, 50.08 micrograms/ml, respectively, with half-lives of 0.55-0.63 hour.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],21.77,85294,DB00160,L-Alanine
,1512930,peak serum levels,"Mean peak serum levels of BP, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 21.77 micrograms/ml, 35.29 micrograms/ml, 50.08 micrograms/ml, respectively, with half-lives of 0.55-0.63 hour.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],35.29,85295,DB00160,L-Alanine
,1512930,peak serum levels,"Mean peak serum levels of BP, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 21.77 micrograms/ml, 35.29 micrograms/ml, 50.08 micrograms/ml, respectively, with half-lives of 0.55-0.63 hour.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),[μg] / [ml],50.08,85296,DB00160,L-Alanine
,1512930,half-lives,"Mean peak serum levels of BP, at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 21.77 micrograms/ml, 35.29 micrograms/ml, 50.08 micrograms/ml, respectively, with half-lives of 0.55-0.63 hour.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),h,0.55-0.63,85297,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,15.9-31.1,85298,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,15.3-36.9,85299,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,11.0-40.5,85300,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,33.1-79.1,85301,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,41.3-93.4,85302,DB00160,L-Alanine
,1512930,Urinary recovery rates,"Urinary recovery rates of PAPM in the first 8 hours after administration at dose levels of 10 mg/10 mg/kg, 20 mg/20 mg/kg and 30 mg/30 mg/kg, were 15.9-31.1%, 15.3-36.9%, 11.0-40.5%, respectively, and those of BP during the same time were 33.1-79.1%, 41.3-93.4%, 12.9-94.4%, respectively.",[Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512930/),%,12.9-94.4,85303,DB00160,L-Alanine
,17503670,IC50,"Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml).","A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17503670/),[μg] / [ml],0.5-5.0,85407,DB00160,L-Alanine
,28711678,trough concentration,"For LiMAx < 100 µg/kg/h, 64% of linezolid trough concentrations were above the recommended trough concentration of 8 mg/L, indicating the necessity of therapeutic drug monitoring in these patients.",Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28711678/),[mg] / [l],8,86315,DB00160,L-Alanine
,17089341,flow rate,"Good separation was achieved at 20 degrees C using cellulose tris-(3,5-dimethylphenylcarbamate) as chiral stationary phase, a mixture of n-hexane and 2-propanol (97:3) as mobile phase at a flow rate of 1.0 ml/min.",Stereoselective determination of benalaxyl in plasma by chiral high-performance liquid chromatography with diode array detector and application to pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089341/),[ml] / [min],1.0,86640,DB00160,L-Alanine
greater,17089341,recovery,The assay method was linear over a range of concentrations (0.25-25 microg/ml) in plasma and the mean recovery was greater than 90% for both enantiomers.,Stereoselective determination of benalaxyl in plasma by chiral high-performance liquid chromatography with diode array detector and application to pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17089341/),%,90,86641,DB00160,L-Alanine
,23389759,Cmax,Plasma concentration-time profiles were similar in both periods on Day 3 (Cmax: 176 and 159 ng/ml).,Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ng] / [ml],176,86684,DB00160,L-Alanine
,23389759,Cmax,Plasma concentration-time profiles were similar in both periods on Day 3 (Cmax: 176 and 159 ng/ml).,Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ng] / [ml],159,86685,DB00160,L-Alanine
,23389759,targeted blood flow,"Four hours of haemodialysis removed 48.8% and 59.3% of total dabigatran from the central compartment with 200 and 400 ml/minute targeted blood flow, respectively.",Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ml] / [min],200,86686,DB00160,L-Alanine
,23389759,targeted blood flow,"Four hours of haemodialysis removed 48.8% and 59.3% of total dabigatran from the central compartment with 200 and 400 ml/minute targeted blood flow, respectively.",Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23389759/),[ml] / [min],400,86687,DB00160,L-Alanine
,8061515,t1/2 alpha,A biphasic plasma clearance with t1/2 alpha of 20-25 min and t1/2 beta of 27-41 hr was observed.,Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061515/),min,20-25,86710,DB00160,L-Alanine
,8061515,t1/2 beta,A biphasic plasma clearance with t1/2 alpha of 20-25 min and t1/2 beta of 27-41 hr was observed.,Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061515/),h,27-41,86711,DB00160,L-Alanine
,27627050,time to progression,"Median time to progression was 2.8 months (95% confidence interval, 1.05-5.52) for group I and 3.2 months (95% confidence interval, 0.95-6.70) for group II.",Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27627050/),month,2.8,87042,DB00160,L-Alanine
,27627050,time to progression,"Median time to progression was 2.8 months (95% confidence interval, 1.05-5.52) for group I and 3.2 months (95% confidence interval, 0.95-6.70) for group II.",Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27627050/),month,3.2,87043,DB00160,L-Alanine
,21126019,IC(50),"Therefore, a smaller scaffold was desired, and a series of phosphonic acid-containing thiazoles, which exhibited high potency against human liver FBPase (IC(50) of 10-30 nM) and high selectivity relative to other 5'-adenosinemonophosphate (AMP)-binding enzymes, were discovered using a structure-guided drug design approach.","Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21126019/),nM,10-30,87543,DB00160,L-Alanine
,21126019,oral bioavailability (OBAV),"Various phosphonate prodrugs were explored without success, until a novel phosphonic diamide prodrug approach was implemented, which delivered compound 30j with good oral bioavailability (OBAV) (22-47%).","Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21126019/),%,22-47,87544,DB00160,L-Alanine
,31031221,total run time,"Chromatography separation was achieved on a Waters Acquity UHPLC HSS T3 column (100 * 2.1 mm, 1.8 μm) with a total run time of 10 min.",Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31031221/),min,10,87613,DB00160,L-Alanine
,29899700,particle size,The mean particle size of drug entrapped PLGA-nanoformulation was 251.1 ± 12.6 nm.,Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29899700/),nm,251.1,87984,DB00160,L-Alanine
,29899700,drug,The drug entrapment efficiency was 22.3 ± 0.4%.,Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29899700/),%,22.3,87985,DB00160,L-Alanine
,29899700,entrapment efficiency,The drug entrapment efficiency was 22.3 ± 0.4%.,Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29899700/),%,22.3,87986,DB00160,L-Alanine
,8584609,tmax,The plasma drug concentration curves indicated a fast absorption with tmax at 0.5-1 h and an apparent elimination half-life of 3-4 h.,"Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,0.5-1,88118,DB00160,L-Alanine
,8584609,apparent elimination half-life,The plasma drug concentration curves indicated a fast absorption with tmax at 0.5-1 h and an apparent elimination half-life of 3-4 h.,"Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,3-4,88119,DB00160,L-Alanine
,8584609,tmax,"When administered just after lunch, the Cmax was reduced by 50-60% and the tmax increased to 3 h, but without change of AUC.","Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8584609/),h,3,88120,DB00160,L-Alanine
,17112298,V(1),For children aged < or =10 years: CL (L/h) = 0.287 . TBW(0.876); V(1) (L) = 0.465 .,Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112298/),l,0.465,88231,DB00160,L-Alanine
higher,12064818,COR,"After ingestion of rebamipide, each COR was higher than 10(-4) M (37 microg/g tissue) at 1 or 2 hr.",Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064818/),M,10(-4),88787,DB00160,L-Alanine
lower,12064818,COR,"On the other hand, the COR in serum did depend on the amount ingested and was lower than 10(-6) M (0.37 microg/ml) at every time tested.",Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064818/),M,10(-6,88788,DB00160,L-Alanine
,12064818,COR,"On the other hand, the COR in serum did depend on the amount ingested and was lower than 10(-6) M (0.37 microg/ml) at every time tested.",Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12064818/),,0.37,88789,DB00160,L-Alanine
,24009420,encapsulation efficiency,"The encapsulation efficiency was 48.34% ± 2.76%, drug loading was 8.06% ± 0.42%, particle size was 111.0 ± 1.56 nm, polydispersity index was 0.287 ± 0.01, and zeta potential was -23.8 ± 0.36 mV for the optimized NLCs.","Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009420/),%,48.34,88838,DB00160,L-Alanine
,24009420,drug loading,"The encapsulation efficiency was 48.34% ± 2.76%, drug loading was 8.06% ± 0.42%, particle size was 111.0 ± 1.56 nm, polydispersity index was 0.287 ± 0.01, and zeta potential was -23.8 ± 0.36 mV for the optimized NLCs.","Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009420/),%,8.06,88839,DB00160,L-Alanine
,24009420,polydispersity index,"The encapsulation efficiency was 48.34% ± 2.76%, drug loading was 8.06% ± 0.42%, particle size was 111.0 ± 1.56 nm, polydispersity index was 0.287 ± 0.01, and zeta potential was -23.8 ± 0.36 mV for the optimized NLCs.","Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009420/),,0.287,88840,DB00160,L-Alanine
,24009420,zeta potential,"The encapsulation efficiency was 48.34% ± 2.76%, drug loading was 8.06% ± 0.42%, particle size was 111.0 ± 1.56 nm, polydispersity index was 0.287 ± 0.01, and zeta potential was -23.8 ± 0.36 mV for the optimized NLCs.","Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24009420/),mv,-23.8,88841,DB00160,L-Alanine
,23086487,time to maximum plasma concentration (t(max)),"Their time to maximum plasma concentration (t(max)) were both 0.25 h, the maximum concentration (C(max)) were 4.533 μg/mL and 6.885 μg/mL, and their area under concentration-time curve (AUC)(0→24h) were 16.272 and 32.981, respectively.","Changes of pharmacokinetics of 6,7-dimethoxycoumarin in a rat model of alpha-naphthylisothiocyanate-induced experimental hepatic injury after Yinchenhao Decoction () treatment. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23086487/),h,0.25,89317,DB00160,L-Alanine
,23086487,maximum concentration (C(max)),"Their time to maximum plasma concentration (t(max)) were both 0.25 h, the maximum concentration (C(max)) were 4.533 μg/mL and 6.885 μg/mL, and their area under concentration-time curve (AUC)(0→24h) were 16.272 and 32.981, respectively.","Changes of pharmacokinetics of 6,7-dimethoxycoumarin in a rat model of alpha-naphthylisothiocyanate-induced experimental hepatic injury after Yinchenhao Decoction () treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23086487/),[μg] / [ml],4.533,89318,DB00160,L-Alanine
,23086487,maximum concentration (C(max)),"Their time to maximum plasma concentration (t(max)) were both 0.25 h, the maximum concentration (C(max)) were 4.533 μg/mL and 6.885 μg/mL, and their area under concentration-time curve (AUC)(0→24h) were 16.272 and 32.981, respectively.","Changes of pharmacokinetics of 6,7-dimethoxycoumarin in a rat model of alpha-naphthylisothiocyanate-induced experimental hepatic injury after Yinchenhao Decoction () treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23086487/),[μg] / [ml],6.885,89319,DB00160,L-Alanine
,23086487,area under concentration-time curve (AUC)(0→24h),"Their time to maximum plasma concentration (t(max)) were both 0.25 h, the maximum concentration (C(max)) were 4.533 μg/mL and 6.885 μg/mL, and their area under concentration-time curve (AUC)(0→24h) were 16.272 and 32.981, respectively.","Changes of pharmacokinetics of 6,7-dimethoxycoumarin in a rat model of alpha-naphthylisothiocyanate-induced experimental hepatic injury after Yinchenhao Decoction () treatment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23086487/),,16.272,89320,DB00160,L-Alanine
,23086487,area under concentration-time curve (AUC)(0→24h),"Their time to maximum plasma concentration (t(max)) were both 0.25 h, the maximum concentration (C(max)) were 4.533 μg/mL and 6.885 μg/mL, and their area under concentration-time curve (AUC)(0→24h) were 16.272 and 32.981, respectively.","Changes of pharmacokinetics of 6,7-dimethoxycoumarin in a rat model of alpha-naphthylisothiocyanate-induced experimental hepatic injury after Yinchenhao Decoction () treatment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23086487/),,32.981,89321,DB00160,L-Alanine
,31295008,AUC0-inf,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],315.2,89450,DB00160,L-Alanine
,31295008,AUC0-inf,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],104.4,89451,DB00160,L-Alanine
,31295008,AUC0-T,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],296.0,89452,DB00160,L-Alanine
,31295008,AUC0-T,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],96.8,89453,DB00160,L-Alanine
,31295008,t1/2,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,8.0,89454,DB00160,L-Alanine
,31295008,t1/2,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,9.2,89455,DB00160,L-Alanine
,31295008,Cmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ng] / [ml],23.0,89456,DB00160,L-Alanine
,31295008,Cmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ng] / [ml],7.0,89457,DB00160,L-Alanine
,31295008,Tmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,3.9,89458,DB00160,L-Alanine
,31295008,Tmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,4.0,89459,DB00160,L-Alanine
,31295008,CL/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ml] / [h],6996.3,89460,DB00160,L-Alanine
,31295008,CL/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ml] / [h],6837.1,89461,DB00160,L-Alanine
,31295008,Vz/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),ml,"75,874.5",89462,DB00160,L-Alanine
,31295008,Vz/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),ml,"84,140.0",89463,DB00160,L-Alanine
,19228747,MTD,"The MTD was determined to be 1,000 mg orally every 6 hours.",Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19228747/),mg,"1,000",90813,DB00160,L-Alanine
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,17,90896,DB00160,L-Alanine
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,8,90897,DB00160,L-Alanine
,32958685,initial clearance (t1/2α,Pharmacokinetic studies in mice revealed that GrB(C210A)-Fc-IT4 displayed a bi-exponential clearance from plasma with a fast initial clearance (t1/2α=0.36 hour) followed by a prolonged terminal-phase plasma half-life (t1/2β=35 hours).,Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32958685/),h,0.36,90987,DB00160,L-Alanine
,32958685,terminal-phase plasma half-life (t1/2β,Pharmacokinetic studies in mice revealed that GrB(C210A)-Fc-IT4 displayed a bi-exponential clearance from plasma with a fast initial clearance (t1/2α=0.36 hour) followed by a prolonged terminal-phase plasma half-life (t1/2β=35 hours).,Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32958685/),h,35,90988,DB00160,L-Alanine
,20671097,time to reach the maximal plasma concentration,"The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13.8 h, and geometric mean apparent oral clearance was 14.7 l/h.","Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671097/),h,1,91014,DB00160,L-Alanine
,20671097,maximal plasma concentration,"The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13.8 h, and geometric mean apparent oral clearance was 14.7 l/h.","Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671097/),[ng] / [ml],6146,91015,DB00160,L-Alanine
,20671097,terminal half-life,"The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13.8 h, and geometric mean apparent oral clearance was 14.7 l/h.","Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671097/),h,13.8,91016,DB00160,L-Alanine
,20671097,apparent oral clearance,"The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma concentration was 6146 ng/ml, mean terminal half-life was 13.8 h, and geometric mean apparent oral clearance was 14.7 l/h.","Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20671097/),[l] / [h],14.7,91017,DB00160,L-Alanine
,3145331,elimination t1/2,Both peptides were rapidly cleared from plasma (estimated elimination t1/2: 4 min for the glycyl peptide and less than 2 min for the alanyl peptide).,In vivo utilization of cystine-containing synthetic short-chain peptides after intravenous bolus injection in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145331/),min,4,91528,DB00160,L-Alanine
less,3145331,elimination t1/2,Both peptides were rapidly cleared from plasma (estimated elimination t1/2: 4 min for the glycyl peptide and less than 2 min for the alanyl peptide).,In vivo utilization of cystine-containing synthetic short-chain peptides after intravenous bolus injection in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145331/),min,2,91529,DB00160,L-Alanine
,30414214,en,"The optimized TPAR-NL produced fairly stable spherical nanoparticles (˂ 200 nm) with encapsulation efficiency (%EE) of 85.77%, as well as enhanced in vitro release and improved oral bioavailability.","Preparation, optimization, and pharmacokinetic study of nanoliposomes loaded with triacylglycerol-bound punicic acid for increased antihepatotoxic activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30414214/),%,85.77,93250,DB00160,L-Alanine
,9469995,peak serum aspartate aminotransferase level,"The mean peak serum aspartate aminotransferase level was 10,225 IU/L (n = 45), and the mean serum alanine aminotransferase level was 7355 IU/L (n = 31), which were significantly higher (both p < 0.001) than the mean serum aspartate aminotransferase level of 3500 IU/L and alanine aminotransferase level of 3098 IU/L found in children (n = 12) with non-acetaminophen-associated hepatic failure.",Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469995/),[iu] / [l],"10,225",93855,DB00160,L-Alanine
,3829006,apparent elimination half-life,FUra plasma levels declined rapidly with an apparent elimination half-life of 12.9 +/- 7.3 min.,"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,12.9,94037,DB00160,L-Alanine
,3829006,maximum peak levels,"Dihydrofluorouracil was detected within 5 min in most patients, demonstrating rapid catabolism and reached maximum peak levels of 23.7 +/- 9.9 microM at approximately 60 min.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),μM,23.7,94038,DB00160,L-Alanine
,3829006,apparent elimination half-life,The apparent elimination half-life of dihydrofluorouracil (61.9 +/- 39.0 min) was consistently greater than that of the unchanged drug.,"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,61.9,94039,DB00160,L-Alanine
,3829006,apparent elimination half-lives,"The apparent elimination half-lives of the subsequent metabolites alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine were prolonged with values of 238.9 +/- 175.4 min and 1976 +/- 358 min, respectively.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,238.9,94040,DB00160,L-Alanine
,3829006,apparent elimination half-lives,"The apparent elimination half-lives of the subsequent metabolites alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine were prolonged with values of 238.9 +/- 175.4 min and 1976 +/- 358 min, respectively.","Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829006/),min,1976,94041,DB00160,L-Alanine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB00160,L-Alanine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB00160,L-Alanine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB00160,L-Alanine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB00160,L-Alanine
,3099249,maximum increase,"Alanine caused hyperammonemia: maximum increase 107, 28-411 microM (geometric mean, 95% confidence interval); ammonia increments were nearly identical after alanine + benzoate (60, 17-213 microM) and alanine + phenylacetate (79, 13-467 microM) (NS).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),μM,107,94455,DB00160,L-Alanine
,3099249,upper therapeutic plasma concentrations,"Transient toxicity (dizziness, nausea, vomiting) occurred in four patients at the end of combined infusions, and we suggest upper therapeutic plasma concentrations of 4.5 mM for benzoate and 3.5 mM for phenylacetate.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,4.5,94456,DB00160,L-Alanine
,3099249,upper therapeutic plasma concentrations,"Transient toxicity (dizziness, nausea, vomiting) occurred in four patients at the end of combined infusions, and we suggest upper therapeutic plasma concentrations of 4.5 mM for benzoate and 3.5 mM for phenylacetate.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,3.5,94457,DB00160,L-Alanine
,3099249,t1/2S,"Benzoate and phenylacetate then decreased following first-order kinetics with t1/2S of 273 and 254 min, respectively.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),min,273,94458,DB00160,L-Alanine
,3099249,t1/2S,"Benzoate and phenylacetate then decreased following first-order kinetics with t1/2S of 273 and 254 min, respectively.",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),min,254,94459,DB00160,L-Alanine
,3099249,Maximal plasma hippurate,"Maximal plasma hippurate (0.24, 0.14-0.40 mM) was lower than maximal phenylacetylglutamine (0.48, 0.22-1.06 mM, p = 0.008).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,0.24,94460,DB00160,L-Alanine
,3099249,maximal,"Maximal plasma hippurate (0.24, 0.14-0.40 mM) was lower than maximal phenylacetylglutamine (0.48, 0.22-1.06 mM, p = 0.008).",Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099249/),mM,0.48,94461,DB00160,L-Alanine
,28968087,oral bioavailability,"On the basis of plasma concentrations of compound 1 and SN38 (14), the oral bioavailability of compound 3a and 15 in beagle dogs was found to be 97.6% and 34.1%, respectively.",Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968087/),%,97.6,94663,DB00160,L-Alanine
,28968087,oral bioavailability,"On the basis of plasma concentrations of compound 1 and SN38 (14), the oral bioavailability of compound 3a and 15 in beagle dogs was found to be 97.6% and 34.1%, respectively.",Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968087/),%,34.1,94664,DB00160,L-Alanine
,31948451,time to Cmax,"The median time to Cmax ranged from 2.0 to 3.5 h, and the plasma concentration of BPI-9016M declined rapidly after Tmax fitting a single-compartment model.","First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31948451/),h,2.0 to 3.5,94688,DB00160,L-Alanine
,10849251,elimination half-life (t1/2),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,20.1,94701,DB00160,L-Alanine
,10849251,area under the plasma concentration-time curve (AUC),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,637,94702,DB00160,L-Alanine
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.14 +/- 0.05 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.14,94703,DB00160,L-Alanine
,10849251,elimination half-life (t1/2),"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,22.2,94704,DB00160,L-Alanine
,10849251,AUC,"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,3824.2,94705,DB00160,L-Alanine
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.17 +/- 0. 01 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.17,94706,DB00160,L-Alanine
,23979257,terminal elimination half-life,BMAA pharmacokinetic parameters measured in plasma show a rapid distribution phase and a terminal elimination half-life of 1.7 days following bolus intravenous administration.,Cerebral uptake and protein incorporation of cyanobacterial toxin β-N-methylamino-L-alanine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23979257/),d,1.7,94975,DB00160,L-Alanine
,12083775,half-life,"The effectiveness of PET as a diagnostic tool, the convenient half-life of (18)F (110 min) and the favorable pharmacokinetics of 6-[(18)F]FDOPA have combined to make this an extremely valuable reagent to study dopaminergic activity.","Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083775/),min,110,95910,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],131,95961,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],29,95962,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],262,95963,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],112,95964,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],202,95965,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],28,95966,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],252,95967,DB00160,L-Alanine
,25765839,systemic clearance,"After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers.",Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25765839/),[l] / [h],117,95968,DB00160,L-Alanine
,1557660,serum half-life times,5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,4.5 to 13,96571,DB00160,L-Alanine
,1557660,half-life,"After administration of the commercially available d,l-folinic acid (d,l-CHO-THF), the biologically inactive d-form is cleared very slowly with a median half-life of 438 +/- 63 minutes.",Clinical pharmacokinetics of fluorouracil and folinic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,438,96572,DB00160,L-Alanine
,1557660,elimination half-lives,l-CHO has short elimination half-lives of 56.5 +/- 10.5 minutes.,Clinical pharmacokinetics of fluorouracil and folinic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),min,56.5,96573,DB00160,L-Alanine
,1557660,body clearance,The high body clearance of 222 +/- 27 mL/min is partially caused by metabolism to l-methyltetrahydrofolic acid (l-CH3-THF).,Clinical pharmacokinetics of fluorouracil and folinic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1557660/),[ml] / [min],222,96574,DB00160,L-Alanine
,3323680,t1/2,"The half-life of endotoxin (E. coli O26: B6, phenol extracted) in plasma was significantly prolonged in aged rats as measured by both the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month-old, and 3.3 +/- 0.3 h in 24-36-month-old rats) and 51Cr-labeled endotoxin radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month old and 7.7 +/- 0.6 h in 24 36-month-old rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,2.1,97863,DB00160,L-Alanine
,3323680,t1/2,"The half-life of endotoxin (E. coli O26: B6, phenol extracted) in plasma was significantly prolonged in aged rats as measured by both the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month-old, and 3.3 +/- 0.3 h in 24-36-month-old rats) and 51Cr-labeled endotoxin radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month old and 7.7 +/- 0.6 h in 24 36-month-old rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,3.3,97864,DB00160,L-Alanine
,3323680,t1/2,"The half-life of endotoxin (E. coli O26: B6, phenol extracted) in plasma was significantly prolonged in aged rats as measured by both the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month-old, and 3.3 +/- 0.3 h in 24-36-month-old rats) and 51Cr-labeled endotoxin radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month old and 7.7 +/- 0.6 h in 24 36-month-old rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,5.3,97865,DB00160,L-Alanine
,3323680,t1/2,"The half-life of endotoxin (E. coli O26: B6, phenol extracted) in plasma was significantly prolonged in aged rats as measured by both the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month-old, and 3.3 +/- 0.3 h in 24-36-month-old rats) and 51Cr-labeled endotoxin radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month old and 7.7 +/- 0.6 h in 24 36-month-old rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,7.7,97866,DB00160,L-Alanine
,3323680,t1/2,"In subacute hypervitaminosis A, the half-life of endotoxin was significantly decreased in the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month old and 1.4 +/- 0.2 h in subacutely hypervitaminotic A rats), but not in the radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month-old and 5.0 +/- 0.4 h in subacutely hypervitaminotic A rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,2.1,97867,DB00160,L-Alanine
,3323680,t1/2,"In subacute hypervitaminosis A, the half-life of endotoxin was significantly decreased in the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month old and 1.4 +/- 0.2 h in subacutely hypervitaminotic A rats), but not in the radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month-old and 5.0 +/- 0.4 h in subacutely hypervitaminotic A rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,1.4,97868,DB00160,L-Alanine
,3323680,t1/2,"In subacute hypervitaminosis A, the half-life of endotoxin was significantly decreased in the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month old and 1.4 +/- 0.2 h in subacutely hypervitaminotic A rats), but not in the radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month-old and 5.0 +/- 0.4 h in subacutely hypervitaminotic A rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,5.3,97869,DB00160,L-Alanine
,3323680,t1/2,"In subacute hypervitaminosis A, the half-life of endotoxin was significantly decreased in the Limulus assay (t1/2 = 2.1 +/- 0.1 h in 3-6-month old and 1.4 +/- 0.2 h in subacutely hypervitaminotic A rats), but not in the radioactivity assay (t1/2 = 5.3 +/- 0.3 h in 3-6-month-old and 5.0 +/- 0.4 h in subacutely hypervitaminotic A rats).",Endotoxin-induced liver injury in aged and subacutely hypervitaminotic A rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323680/),h,5.0,97870,DB00160,L-Alanine
,25212606,MTDs,The MTDs were established to be 400 mg once daily and 150 mg twice daily.,"A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212606/),mg,400,98957,DB00160,L-Alanine
,25212606,half-life,"OSI-906 was rapidly absorbed with a half-life of 5 hours, and steady-state plasma concentrations were achieved by day 8.","A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212606/),h,5,98958,DB00160,L-Alanine
,18566043,AUC(0-24h),"Area under the curve (AUC(0-24h)) for the sum of total silymarin flavonolignans was 2.4-, 3.3-, and 4.7-fold higher for hepatitis C virus (HCV) noncirrhosis, nonalcoholic fatty liver disease (p <or= 0.03), and HCV cirrhosis cohorts (p <or= 0.03), respectively, compared with healthy volunteers (AUC(0-24h) = 2021 ng . h/ml).",The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18566043/),[h·ng] / [ml],2021,99255,DB00160,L-Alanine
,24846496,time (tmax ) to reach the,The median time (tmax ) to reach the maximum plasma-free dabigatran concentration (Cmax ) was 2 hours (range 1-3 hours).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2,99542,DB00160,L-Alanine
,24846496,Cmax,The mean free dabigatran Cmax was 95.5 ± 33.4 ng/mL.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),[ng] / [ml],95.5,99543,DB00160,L-Alanine
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,2.6,99544,DB00160,L-Alanine
,24846496,elimination half-lives,"The mean elimination half-lives on and off hemodialysis were, respectively, 2.6 ± 1.3 and 30.2 ± 7.8 hours.",An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),h,30.2,99545,DB00160,L-Alanine
,24846496,extraction ratio,Hemodialysis effectively removed dabigatran with an extraction ratio of 0.63 ± 0.07.,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,0.63,99546,DB00160,L-Alanine
,24846496,maximal TT ratio,The maximal TT ratio was 2.1 and the TT ratio demonstrated a strong linear dependence on free dabigatran concentration (r(2) = 0.741).,An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24846496/),,2.1,99547,DB00160,L-Alanine
,32277364,time to reach maximum concentration (Tmax),Bentysrepinine was rapidly absorbed and metabolised with a mean time to reach maximum concentration (Tmax) between 1-2 h and a mean terminal elimination half-life (t1/2) of approximately 1-3 h.,"Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),h,1-2,99864,DB00160,L-Alanine
,32277364,terminal elimination half-life (t1/2),Bentysrepinine was rapidly absorbed and metabolised with a mean time to reach maximum concentration (Tmax) between 1-2 h and a mean terminal elimination half-life (t1/2) of approximately 1-3 h.,"Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),h,1-3,99865,DB00160,L-Alanine
,32277364,urinary excretion,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,2.98,99866,DB00160,L-Alanine
,32277364,f,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,2.98,99867,DB00160,L-Alanine
,32277364,f,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,4,99868,DB00160,L-Alanine
,33191320,maximum concentration,"The maximum concentration and area under the blood concentration-time curve were 3,417.5 ng/mL and 4.35 μg・hr/mL (mean), respectively.",A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33191320/),[ng] / [ml],"3,417.5",100364,DB00160,L-Alanine
,33191320,area under the blood concentration-time curve,"The maximum concentration and area under the blood concentration-time curve were 3,417.5 ng/mL and 4.35 μg・hr/mL (mean), respectively.",A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33191320/),[μg・hr] / [ml],4.35,100365,DB00160,L-Alanine
,25581063,apparent clearance (CL/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),[l] / [h],10.8,100930,DB00160,L-Alanine
,25581063,volume (V/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),l,267,100931,DB00160,L-Alanine
,33142014,time to maximum plasma concentration,"Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half-life of ~ 11 hours, and no evidence of accumulation after once-daily dosing.",Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33142014/),h,2,101355,DB00160,L-Alanine
,33142014,apparent terminal half-life,"Atogepant is rapidly absorbed (median time to maximum plasma concentration, ~ 2 hours) with an apparent terminal half-life of ~ 11 hours, and no evidence of accumulation after once-daily dosing.",Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33142014/),h,11,101356,DB00160,L-Alanine
,30198929,clearance,"A typical child after liver transplantation with an international normalized ratio (INR) of 1.8 was found to have a whole blood DEX clearance of 52 L/h (95% confidence interval [CI], 31-73 L/h).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [h],52,101784,DB00160,L-Alanine
,30198929,intercompartmental clearance,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [h],246,101785,DB00160,L-Alanine
,30198929,central volume of distribution,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),[l] / [70·kg],186,101786,DB00160,L-Alanine
,30198929,peripheral volume of distribution,"In addition, intercompartmental clearance was 246 L/h (95% CI, 139-391 L/h), central volume of distribution was 186 L/70 kg (95% CI, 140-301 L/70 kg), and peripheral volume of distribution was 203 L (95% CI, 123-338 L).",Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198929/),l,203,101787,DB00160,L-Alanine
,9270007,Extrahepatic clearance,"Extrahepatic clearance of 5-FU was estimated as 0.66 +/- 0.33 liters/min, whereas the hepatic clearance was 0.52 +/- 0.25 liters/min.",Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[l] / [min],0.66,102718,DB00160,L-Alanine
,9270007,hepatic clearance,"Extrahepatic clearance of 5-FU was estimated as 0.66 +/- 0.33 liters/min, whereas the hepatic clearance was 0.52 +/- 0.25 liters/min.",Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[l] / [min],0.52,102719,DB00160,L-Alanine
,9270007,Km,The Michaelis-Menten parameters describing the nonlinear conversion of 5-FU to FBAL were Km = 11.3 +/- 6.4 micromol and Vmax = 147.1 +/- 130.7 micromol/min.,Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),μM,11.3,102720,DB00160,L-Alanine
,9270007,Vmax,The Michaelis-Menten parameters describing the nonlinear conversion of 5-FU to FBAL were Km = 11.3 +/- 6.4 micromol and Vmax = 147.1 +/- 130.7 micromol/min.,Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9270007/),[μM] / [min],147.1,102721,DB00160,L-Alanine
,19889612,area under the curve,"Patients with advanced gynecological malignancies received BIBF 1120 twice-daily (b.i.d.) continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min.mg/ml) every 3 weeks.",A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889612/),[mg·min] / [ml],5,102862,DB00160,L-Alanine
,19889612,MTD,The MTD was defined as 200 mg b.i.d.,A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889612/),,200,102863,DB00160,L-Alanine
,24692809,Tmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,6.0,102865,DB00160,L-Alanine
,24692809,Tmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,7.4,102866,DB00160,L-Alanine
,24692809,Tmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,5.6,102867,DB00160,L-Alanine
,24692809,tl/2,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,13.0,102868,DB00160,L-Alanine
,24692809,tl/2,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,12.6,102869,DB00160,L-Alanine
,24692809,tl/2,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,9.4,102870,DB00160,L-Alanine
,24692809,AUC0-t,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ml·ng] / [h],3344,102871,DB00160,L-Alanine
,24692809,AUC0-t,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ml·ng] / [h],8389,102872,DB00160,L-Alanine
,24692809,AUC0-t,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ml·ng] / [h],9361,102873,DB00160,L-Alanine
,24692809,Cmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ng] / [ml],218.7,102874,DB00160,L-Alanine
,24692809,Cmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ng] / [ml],435.7,102875,DB00160,L-Alanine
,24692809,Cmax,"The mean (SD) values of the single-dose genistein 50-, 100-, and 300-mg groups were as follows: Tmax, 6.0 (2.4), 7.4 (2.4), and 5.6 (1.2) hours, respectively; tl/2, 13.0 (4.0), 12.6 (5.8), and 9.4 (1.1) hours; AUC0-t, 3344 (1635), 8389 (5164), and 9361 (2428) ng/mL · h(-1); and Cmax , 218.7 (68.6), 435.7 (202.1), and 553.4 (152.8) ng/mL.","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ng] / [ml],553.4,102876,DB00160,L-Alanine
,24692809,Tmax,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,6.0,102877,DB00160,L-Alanine
,24692809,Tmax,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,5.9,102878,DB00160,L-Alanine
,24692809,tl/2,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,9.5,102879,DB00160,L-Alanine
,24692809,tl/2,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),h,9.1,102880,DB00160,L-Alanine
,24692809,AUC0-t,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ml·ng] / [h],2830,102881,DB00160,L-Alanine
,24692809,AUC0-t,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ml·ng] / [h],2078,102882,DB00160,L-Alanine
,24692809,Cmax,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ng] / [ml],203.1,102883,DB00160,L-Alanine
,24692809,Cmax,"In the multiple-dose group, the mean (SD) steady-state pharmacokinetic parameters on day 9 were similar to those following a single dose of genistein on day 1 (Tmax, 6.0 [1.0] vs 5.9 [1.5] hours, respectively; tl/2, 9.5 [1.5] vs 9.1 [1.5] hours; AUC0-t, 2830 [1541] vs 2078 [1308] ng/mL · h(-1); Cmax, 203.1 [130.9] vs 168.4 [105.7] ng/mL).","Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: A phase I, randomized, open-label study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692809/),[ng] / [ml],168.4,102884,DB00160,L-Alanine
,29263070,AUC0-12,"The respective AUC0-12 values based on mean ELF and AM concentrations were 172.6 and 35.3 mg · h/liter, respectively.",Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263070/),[h·mg] / [l],172.6,103025,DB00160,L-Alanine
,29263070,AUC0-12,"The respective AUC0-12 values based on mean ELF and AM concentrations were 172.6 and 35.3 mg · h/liter, respectively.",Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263070/),[h·mg] / [l],35.3,103026,DB00160,L-Alanine
,29263070,penetration ratios,"The penetration ratios for ELF and AM levonadifloxacin concentrations to unbound plasma levonadifloxacin concentrations were 7.66 and 1.58, respectively.",Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263070/),,7.66,103027,DB00160,L-Alanine
,29263070,penetration ratios,"The penetration ratios for ELF and AM levonadifloxacin concentrations to unbound plasma levonadifloxacin concentrations were 7.66 and 1.58, respectively.",Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29263070/),,1.58,103028,DB00160,L-Alanine
,25500057,overall response rate,"For all (21) patients with ovarian cancer, overall response rate was 29% [1 complete response, 5 partial responses (PR)], disease control rate 76%, and median progression-free survival was 7 months.",A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500057/),%,29,103209,DB00160,L-Alanine
,25500057,progression-free survival,"For all (21) patients with ovarian cancer, overall response rate was 29% [1 complete response, 5 partial responses (PR)], disease control rate 76%, and median progression-free survival was 7 months.",A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500057/),month,7,103210,DB00160,L-Alanine
,1168111,half-life,Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.9,103500,DB00160,L-Alanine
,1168111,biochemical half-life,Saralasin pharmacologic half-life of 3.9 min after intravenous administration to rats was similar to the biochemical half-life of 4.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,4.2,103501,DB00160,L-Alanine
,1168111,half-life,The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),,8.2,103502,DB00160,L-Alanine
,1168111,biochemical half-life,The pharmacologic half-life in high-renin hypertensive patients averaged 8.2 with a biochemical half-life of 3.2 min.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.2,103503,DB00160,L-Alanine
,1168111,biochemical half-life,The biochemical half-life of 3.2 min is consistent with infusion time of less than 20 min required to achieve a stable plasma concentration and pharmacologic activity of saralasin during constant saralasin infusion into hypertensive man.,Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1168111/),min,3.2,103504,DB00160,L-Alanine
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,1.2-2.5,104192,DB00160,L-Alanine
,3876873,t1/2,"The levels declined rapidly with a two-phase elimination pattern (t1/2 = 1.2-2.5 hours, t1/2 = 18-32 hours).",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),h,18-32,104193,DB00160,L-Alanine
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),M,5 X 10(-7),104194,DB00160,L-Alanine
,3876873,folate level,"The folate level in the plasma ranged from 5 X 10(-7) M to 1.4 X 10(-6) M when CF was administered every six hours or every three hours, respectively.",Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3876873/),,1.4 X 10(-6),104195,DB00160,L-Alanine
,33835812,A2,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104512,DB00160,L-Alanine
,33835812,EC50,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104513,DB00160,L-Alanine
,2862190,half-life,"In a concurrent pharmacokinetic study, the half-life of ceftazidime was 7.4 (SD +/- 4.1) h following iv administration.",Ceftazidime in the treatment of neonatal infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2862190/),h,7.4,104827,DB00160,L-Alanine
,2862190,C max,Other pharmacokinetic values were C max 74 (SD +/- 20) mg l-1 trough concentration 20 (SD +/- 10) mg l-1.,Ceftazidime in the treatment of neonatal infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2862190/),l-·mg,74,104828,DB00160,L-Alanine
,2862190,trough concentration,Other pharmacokinetic values were C max 74 (SD +/- 20) mg l-1 trough concentration 20 (SD +/- 10) mg l-1.,Ceftazidime in the treatment of neonatal infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2862190/),[mg] / [l],20,104829,DB00160,L-Alanine
,2862190,Total body clearance,Total body clearance ranged from 0.13 to 2.10 ml min-1 per kg and increased with increasing postnatal age.,Ceftazidime in the treatment of neonatal infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2862190/),[ml] / [kg·min],0.13 to 2.10,104830,DB00160,L-Alanine
,25869250,Apparent clearance (CL/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 17.6 L/h and 225 L, respectively.","Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),[l] / [h],17.6,106064,DB00160,L-Alanine
,25869250,apparent volumes of distribution (V/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 17.6 L/h and 225 L, respectively.","Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),l,225,106065,DB00160,L-Alanine
,25869250,absorption rate constant (Ka),The absorption rate constant (Ka) was fixed at 4.48 h(-1).,"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),1/[h],4.48,106066,DB00160,L-Alanine
,23755309,IC50,"In the infected monkeys, DB829 attained a median C(max) (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold (10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900.","Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23755309/),[nM] / [l],14,106549,DB00160,L-Alanine
,30265243,Ctrough,"Plasma trough concentration (Ctrough) was assessed at baseline before switching to generic RTV and week 24 in all participants, with the target ATV Ctrough of 0.15 mg/l.",Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265243/),[mg] / [l],0.15,106880,DB00160,L-Alanine
,30265243,Ctrough,There were no significant changes in mean (sd) Ctrough of RTV (0.20 [0.33] versus 0.23 [0.39]; P=0.21) and ATV (0.83 [0.93] versus 0.88 [0.95]; P=0.62) between baseline and week 24.,Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265243/),,0.20,106881,DB00160,L-Alanine
,30265243,Ctrough,There were no significant changes in mean (sd) Ctrough of RTV (0.20 [0.33] versus 0.23 [0.39]; P=0.21) and ATV (0.83 [0.93] versus 0.88 [0.95]; P=0.62) between baseline and week 24.,Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265243/),,0.23,106882,DB00160,L-Alanine
,30265243,Ctrough,There were no significant changes in mean (sd) Ctrough of RTV (0.20 [0.33] versus 0.23 [0.39]; P=0.21) and ATV (0.83 [0.93] versus 0.88 [0.95]; P=0.62) between baseline and week 24.,Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265243/),,0.,106883,DB00160,L-Alanine
,30265243,Ctrough,There were no significant changes in mean (sd) Ctrough of RTV (0.20 [0.33] versus 0.23 [0.39]; P=0.21) and ATV (0.83 [0.93] versus 0.88 [0.95]; P=0.62) between baseline and week 24.,Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30265243/),,0.88,106884,DB00160,L-Alanine
,29626621,overall response rate,"When all evaluated doses and patients negative for T790M were included, the overall response rate was 36.5%.","First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626621/),%,36.5,107042,DB00160,L-Alanine
,29626621,overall response rate,"At daily doses of 350 mg or higher, the overall response rate was 50.0% and the median progression-free survival estimated by the Kaplan-Meier method ranged from 14.0 to 35.6 weeks across a daily dose level from 350 mg to 600 mg.","First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626621/),%,50.0,107043,DB00160,L-Alanine
,29626621,progression-free survival,"At daily doses of 350 mg or higher, the overall response rate was 50.0% and the median progression-free survival estimated by the Kaplan-Meier method ranged from 14.0 to 35.6 weeks across a daily dose level from 350 mg to 600 mg.","First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29626621/),weeks,14.0 to 35.6,107044,DB00160,L-Alanine
,29805770,Objective response rate,Objective response rate was 58.3% in patients with target lesions (n = 12) and 66.7% in crizotinib-naïve patients (n = 9).,Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29805770/),%,58.3,107176,DB00160,L-Alanine
,29805770,Objective response rate,Objective response rate was 58.3% in patients with target lesions (n = 12) and 66.7% in crizotinib-naïve patients (n = 9).,Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29805770/),%,66.7,107177,DB00160,L-Alanine
,25819742,absorption rate constant,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),1/[h],3.98,107233,DB00160,L-Alanine
,25819742,absorption rate constant,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),l,48.8,107234,DB00160,L-Alanine
,25819742,volume of distribution,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),l,48.8,107235,DB00160,L-Alanine
,25819742,absorption rate constant,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),[l] / [h],12.3,107236,DB00160,L-Alanine
,25819742,volume of distribution,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),[l] / [h],12.3,107237,DB00160,L-Alanine
,25819742,oral clearance,"Population parameter estimates were 3.98 h(-1), 48.8 l and 12.3 l h(-1) for the absorption rate constant, volume of distribution and oral clearance, respectively.",Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25819742/),[l] / [h],12.3,107238,DB00160,L-Alanine
,30377854,apparent linear clearances,"The typical values (between subject variability) of AL-335 and ALS-022399 apparent linear clearances were 3300 L/h (33.9%) and 1910 L/h (30.0%), respectively.","Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377854/),[l] / [h],3300,107241,DB00160,L-Alanine
,30377854,apparent linear clearances,"The typical values (between subject variability) of AL-335 and ALS-022399 apparent linear clearances were 3300 L/h (33.9%) and 1910 L/h (30.0%), respectively.","Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377854/),[l] / [h],1910,107242,DB00160,L-Alanine
,30377854,Vmax,"ALS-022227 elimination was characterized as a nonlinear process, with typical values of Vmax,ALS-022227 and Km,ALS-022227 estimated to be 84,799 ng/h (14.9%) and 450.2 ng/mL, respectively.","Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377854/),[ng] / [h],"84,799",107243,DB00160,L-Alanine
,30377854,Km,"ALS-022227 elimination was characterized as a nonlinear process, with typical values of Vmax,ALS-022227 and Km,ALS-022227 estimated to be 84,799 ng/h (14.9%) and 450.2 ng/mL, respectively.","Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377854/),[ng] / [h],"84,799",107244,DB00160,L-Alanine
,30377854,Km,"ALS-022227 elimination was characterized as a nonlinear process, with typical values of Vmax,ALS-022227 and Km,ALS-022227 estimated to be 84,799 ng/h (14.9%) and 450.2 ng/mL, respectively.","Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377854/),[ng] / [ml],450.2,107245,DB00160,L-Alanine
,31617509,retention time,Ex vivo organ fluorescence imaging and pharmacokinetic analysis suggested that TP-MNPs possessed excellent kidney-targeting capability with long retention time (7 days).,Kidney-targeted triptolide-encapsulated mesoscale nanoparticles for high-efficiency treatment of kidney injury. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31617509/),d,7,107464,DB00160,L-Alanine
,11948110,maximum tolerated dose,The maximum tolerated dose was set at 0.21 mg/m(2).,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),[mg] / [m(2],0.21,107813,DB00160,L-Alanine
,11948110,t(1/2 A),Crotoxin pharmacokinetics showed rapid absorption from the injection site to blood (t(1/2 A) = 5.2 +/- 0.6 min).,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),min,5.2,107814,DB00160,L-Alanine
,11948110,C(max),Plasma concentration reached a peak (C(max) = 0.79 +/- 0.1 ng/ml) at tau(max) = 19 +/- 3 min.,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),[ng] / [ml],0.79,107815,DB00160,L-Alanine
,11948110,tau(max),Plasma concentration reached a peak (C(max) = 0.79 +/- 0.1 ng/ml) at tau(max) = 19 +/- 3 min.,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),min,19,107816,DB00160,L-Alanine
,11948110,half-life of the distribution (alpha) phase,The half-life of the distribution (alpha) phase is 22 +/- 2 min.,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),min,22,107817,DB00160,L-Alanine
,11948110,half-life,The profile is dominated by the elimination (beta) phase with a half-life of 5.2 +/- 0.6 h.,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),h,5.2,107818,DB00160,L-Alanine
,11948110,area under plasma concentration versus time curve,The area under plasma concentration versus time curve was 0.19 +/- 0.05 microg/min/ml.,"Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),[μg] / [min·ml],0.19,107819,DB00160,L-Alanine
,11948110,availability (F),"Assuming availability (F) approximately 1, the clearance is C(L) = 26.3 +/- 7 ml/min, and the apparent volume of distribution is V(d) = 12 +/- 3 liter/kg.","Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),,1,107820,DB00160,L-Alanine
,11948110,clearance is C(L),"Assuming availability (F) approximately 1, the clearance is C(L) = 26.3 +/- 7 ml/min, and the apparent volume of distribution is V(d) = 12 +/- 3 liter/kg.","Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),[ml] / [min],26.3,107821,DB00160,L-Alanine
,11948110,apparent volume of distribution is V(d),"Assuming availability (F) approximately 1, the clearance is C(L) = 26.3 +/- 7 ml/min, and the apparent volume of distribution is V(d) = 12 +/- 3 liter/kg.","Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948110/),[l] / [kg],12,107822,DB00160,L-Alanine
,7515977,IC50,"Thiorphan and CGS 24128 inhibited NEP in vitro with IC50 values of 5.0 +/- 0.2 and 4.3 +/- 0.2 nM, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),nM,5.0,108101,DB00160,L-Alanine
,7515977,IC50,"Thiorphan and CGS 24128 inhibited NEP in vitro with IC50 values of 5.0 +/- 0.2 and 4.3 +/- 0.2 nM, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),nM,4.3,108102,DB00160,L-Alanine
,7515977,urinary sodium excretion (UNaV),"The change in urinary sodium excretion (UNaV) produced by ANP was 28.8 +/- 4.0 and 15.8 +/- 1.8 muEq/kg/min in CGS 24128- and vehicle-treated rats, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],28.8,108103,DB00160,L-Alanine
,7515977,urinary sodium excretion (UNaV),"The change in urinary sodium excretion (UNaV) produced by ANP was 28.8 +/- 4.0 and 15.8 +/- 1.8 muEq/kg/min in CGS 24128- and vehicle-treated rats, respectively.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],15.8,108104,DB00160,L-Alanine
,7515977,delta UNaV,"ANP-induced natriuresis was also greater during continuous infusion of thiorphan (5 mg/kg bolus + 0.1 mg/kg/min i.v.; delta UNaV = 29.2 +/- 5.8 and 13.8 +/- 3.2 muEq/kg/min in drug- and vehicle-treated rats, respectively) but not when thiorphan was administered as a bolus (10 mg/kg i.v.) 60 min before the ANP challenge.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],29.2,108105,DB00160,L-Alanine
,7515977,delta UNaV,"ANP-induced natriuresis was also greater during continuous infusion of thiorphan (5 mg/kg bolus + 0.1 mg/kg/min i.v.; delta UNaV = 29.2 +/- 5.8 and 13.8 +/- 3.2 muEq/kg/min in drug- and vehicle-treated rats, respectively) but not when thiorphan was administered as a bolus (10 mg/kg i.v.) 60 min before the ANP challenge.","Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7515977/),[mueq] / [kg·min],13.8,108106,DB00160,L-Alanine
,10632330,MTD,"The s.c. MTD was determined to be 12 MIU/m2, although there was great variability in the individual patient's ability to tolerate IFN beta-1a.",A phase I study of recombinant interferon-beta in patients with advanced malignant disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632330/),[Miu] / [m2],12,108197,DB00160,L-Alanine
,10632330,MTD,"For the s.c. route, the MTD was determined to be 12 MIU/m2, but there was great interpatient variability, with some patients able to tolerate higher doses.",A phase I study of recombinant interferon-beta in patients with advanced malignant disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632330/),[Miu] / [m2],12,108198,DB00160,L-Alanine
>,12707718,half-life,"EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to >5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%.","Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12707718/),h,5,108587,DB00160,L-Alanine
,9816117,total clearance,"Over the 50-1000 mg/m2/day dose range, mean total clearance ranged from 11.6 to 30.0 liters/h/m2, and volume of distribution at steady state ranged from 279.5 to 758.7 liters/m2.",Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816117/),[l] / [h·m2],11.6 to 30.0,108610,DB00160,L-Alanine
,9816117,volume of distribution at steady state,"Over the 50-1000 mg/m2/day dose range, mean total clearance ranged from 11.6 to 30.0 liters/h/m2, and volume of distribution at steady state ranged from 279.5 to 758.7 liters/m2.",Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816117/),[l] / [m2],279.5 to 758.7,108611,DB00160,L-Alanine
,9816117,terminal half-life,The harmonic mean terminal half-life of AG331 was 20.2 h.,Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816117/),h,20.2,108612,DB00160,L-Alanine
,31168820,EE,Cuminaldehyde self-emulsified nanoemulsion with acceptable characteristics (mean DS-48.83 ± 1.06 nm; PDI-0.232 ± 0.140; ZP-29.92 ± 1.66 mV; EE-91.51 ± 0.44%; and drug-loading capacity (DL)-9.77 ± 0.75%) was formulated.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,91.51,108904,DB00160,L-Alanine
,31168820,drug-loading capacity (DL),Cuminaldehyde self-emulsified nanoemulsion with acceptable characteristics (mean DS-48.83 ± 1.06 nm; PDI-0.232 ± 0.140; ZP-29.92 ± 1.66 mV; EE-91.51 ± 0.44%; and drug-loading capacity (DL)-9.77 ± 0.75%) was formulated.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,9.77,108905,DB00160,L-Alanine
,31168820,oral relative bioavailability,In-vitro drug release of CuA-SEN significantly increased with an oral relative bioavailability of 171.02%.,Novel cuminaldehyde self-emulsified nanoemulsion for enhanced antihepatotoxicity in carbon tetrachloride-treated mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168820/),%,171.02,108906,DB00160,L-Alanine
,1903599,Km,Glutamine was nearly quantitatively absorbed over the 30-cm study segment; estimated Km and Vmax of glutamine absorption were 2.48 and 2.32 mmol/min over the 30-cm study segment.,Absorption and metabolic effects of enterally administered glutamine in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mM] / [min],2.48,108961,DB00160,L-Alanine
,1903599,Vmax,Glutamine was nearly quantitatively absorbed over the 30-cm study segment; estimated Km and Vmax of glutamine absorption were 2.48 and 2.32 mmol/min over the 30-cm study segment.,Absorption and metabolic effects of enterally administered glutamine in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mM] / [min],2.32,108962,DB00160,L-Alanine
,1903599,appearance rate (Ra),"Enteral glutamine administration induced 1) a dose-dependent increase in plasma glutamine level; 2) a rise in the plasma level and appearance rate (Ra) of alanine (from 191 +/- 42 to 213 +/- 51 mumols.kg-1.h-1, P less than 0.05, for 0 and 46.8-mmol/h glutamine infusion rates, respectively) and in plasma levels of glutamate, citrulline, aspartate, and urea; 3) a decline in plasma free fatty acid and glycerol levels; and 4) no change in leucine or glucose Ra.",Absorption and metabolic effects of enterally administered glutamine in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1903599/),[mumols] / [h·kg],213,108963,DB00160,L-Alanine
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,53.87,109020,DB00160,L-Alanine
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],101.05,109021,DB00160,L-Alanine
,3841222,t beta 1/2,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,2.087,109022,DB00160,L-Alanine
,3841222,AUC,"Rats, given CC14 (6670 mg/Kg, sc), exhibited a significant increase in SGPT (425.7 +/- 51.3 mU/ml), together with impaired pharmacokinetics of intravenous diazepam (t beta 1/2: 53.87 h; AUC: 101.05 micrograms/ml/h) when compared with saline treated animal (SGPT: 33.6 +/- 3.8 mU/ml; t beta 1/2: 2.087 h; AUC: 1.37 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],1.37,109023,DB00160,L-Alanine
,3841222,t beta 1/2,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),h,0.167,109024,DB00160,L-Alanine
,3841222,AUC,"FCE 20700 (5 micrograms/ml, sc) did not change, by itself, either SGPT or diazepam pharmacokinetic parameters, but significantly antagonized the changes induced by CC14 (SGPT: 45.3 +/- 5.3 mU/ml; t beta 1/2: 0.167 h; AUC: 2.426 micrograms/ml/h).",Carbon tetrachloride-induced pharmacokinetic changes of diazepam in rats are reduced by a stable analogue of prostaglandin E2 : FCE 20700. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841222/),[μg] / [h·ml],2.426,109025,DB00160,L-Alanine
,29888206,MTD,The MTD was 200 mg in both groups.,"A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888206/),mg,200,109100,DB00160,L-Alanine
,29888206,CIR TTP,"For nintedanib and sorafenib, respectively, the median CIR TTP was 2.8 vs.","A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888206/),,2.8,109101,DB00160,L-Alanine
,23820209,elimination half-lives,"Following intravenous amoxicillin (10 mg/kg bw) in control and lead-intoxicated goats, elimination half-lives were 4.14 and 1.26 h, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),h,4.14,109131,DB00160,L-Alanine
,23820209,elimination half-lives,"Following intravenous amoxicillin (10 mg/kg bw) in control and lead-intoxicated goats, elimination half-lives were 4.14 and 1.26 h, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),h,1.26,109132,DB00160,L-Alanine
,23820209,volumes of distribution,"The volumes of distribution based on the terminal phase were 1.19 and 0.38 L/kg, respectively, and those at steady-state were 0.54 and 0.18 L/kg, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[l] / [kg],1.19,109133,DB00160,L-Alanine
,23820209,volumes of distribution,"The volumes of distribution based on the terminal phase were 1.19 and 0.38 L/kg, respectively, and those at steady-state were 0.54 and 0.18 L/kg, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[l] / [kg],0.38,109134,DB00160,L-Alanine
,23820209,volumes of distribution,"The volumes of distribution based on the terminal phase were 1.19 and 0.38 L/kg, respectively, and those at steady-state were 0.54 and 0.18 L/kg, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[l] / [kg],0.54,109135,DB00160,L-Alanine
,23820209,volumes of distribution,"The volumes of distribution based on the terminal phase were 1.19 and 0.38 L/kg, respectively, and those at steady-state were 0.54 and 0.18 L/kg, respectively.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[l] / [kg],0.18,109136,DB00160,L-Alanine
,23820209,Peak serum concentrations,"Peak serum concentrations of 21.89 and 12.19 μg/mL were achieved at 1 h and 2 h, respectively, in lead-intoxicated and control goats.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[μg] / [ml],21.89,109137,DB00160,L-Alanine
,23820209,Peak serum concentrations,"Peak serum concentrations of 21.89 and 12.19 μg/mL were achieved at 1 h and 2 h, respectively, in lead-intoxicated and control goats.",Effect of chronic lead intoxication on the distribution and elimination of amoxicillin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23820209/),[μg] / [ml],12.19,109138,DB00160,L-Alanine
,1413885,tmax,They all had the same tmax of 2 h and t1/2 lambda 1 of the order of 1 h.,The metabolism of 14C-tazadolene succinate in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413885/),h,2,109469,DB00160,L-Alanine
,1413885,t1/2 lambda 1,They all had the same tmax of 2 h and t1/2 lambda 1 of the order of 1 h.,The metabolism of 14C-tazadolene succinate in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413885/),h,1,109470,DB00160,L-Alanine
,32529924,half-life time,"A pioneering mathematical model is proposed, from which the half-life time of silver in the liver (17 days), spleen (23 days), lungs (30 days), and kidneys (35 days) was extracted.",Acute reproductive toxicology after intratesticular injection of silver nanoparticles (AgNPs) in Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529924/),d,17,110035,DB00160,L-Alanine
,32529924,half-life time,"A pioneering mathematical model is proposed, from which the half-life time of silver in the liver (17 days), spleen (23 days), lungs (30 days), and kidneys (35 days) was extracted.",Acute reproductive toxicology after intratesticular injection of silver nanoparticles (AgNPs) in Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529924/),d,23,110036,DB00160,L-Alanine
,32529924,half-life time,"A pioneering mathematical model is proposed, from which the half-life time of silver in the liver (17 days), spleen (23 days), lungs (30 days), and kidneys (35 days) was extracted.",Acute reproductive toxicology after intratesticular injection of silver nanoparticles (AgNPs) in Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529924/),d,30,110037,DB00160,L-Alanine
,32529924,half-life time,"A pioneering mathematical model is proposed, from which the half-life time of silver in the liver (17 days), spleen (23 days), lungs (30 days), and kidneys (35 days) was extracted.",Acute reproductive toxicology after intratesticular injection of silver nanoparticles (AgNPs) in Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32529924/),d,35,110038,DB00160,L-Alanine
,11368105,total duration,"The mean total duration of intravenous and oral administration was 12.2 +/- 6.2 days (range, 6 to 41 days).",Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368105/),d,12.2,111183,DB00160,L-Alanine
,11368105,peak,"The mean peak and trough plasma concentrations of linezolid were 9.5 +/- 4.8 and 0.8 +/- 1.2 microg/ml, respectively.",Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368105/),[μg] / [ml],9.5,111184,DB00160,L-Alanine
,11368105,trough plasma concentrations,"The mean peak and trough plasma concentrations of linezolid were 9.5 +/- 4.8 and 0.8 +/- 1.2 microg/ml, respectively.",Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368105/),[μg] / [ml],0.8,111185,DB00160,L-Alanine
,21131369,MTD,The MTD was 800 mg/day.,"A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21131369/),[mg] / [d],800,111568,DB00160,L-Alanine
up to,26111126,Tmax,Plasma concentration-time profiles of TAK-438 at all dose levels showed rapid absorption (median Tmax up to 2 h).,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111126/),h,2,111904,DB00160,L-Alanine
up to,26111126,elimination half-life,Estimated mean elimination half-life was up to 9 h.,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111126/),h,9,111905,DB00160,L-Alanine
,26111126,pH ≥4 holding time ratio,The 24-h intragastric pH ≥4 holding time ratio with 40 mg TAK-438 was 92% in Japan and 87% in the UK.,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111126/),%,92,111906,DB00160,L-Alanine
,26111126,pH ≥4 holding time ratio,The 24-h intragastric pH ≥4 holding time ratio with 40 mg TAK-438 was 92% in Japan and 87% in the UK.,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111126/),%,87,111907,DB00160,L-Alanine
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,9,112236,DB00160,L-Alanine
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,4,112237,DB00160,L-Alanine
,30679780,MTD,"The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase.",Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30679780/),[mg] / [m2],1.4,112238,DB00160,L-Alanine
,30679780,MTD,"The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase.",Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30679780/),[mg] / [m],1.5,112239,DB00160,L-Alanine
,30679780,half-life,"The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve.",Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30679780/),h,30,112240,DB00160,L-Alanine
,10070885,plasma half-life,"Mean fostriecin plasma half-life was 0.36 h (initial; 95% CI, 0-0.76 h) and 1.51 h (terminal; 95% CI, 0.41-2.61 h).",Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070885/),h,0.36,112840,DB00160,L-Alanine
,10070885,plasma half-life,"Mean fostriecin plasma half-life was 0.36 h (initial; 95% CI, 0-0.76 h) and 1.51 h (terminal; 95% CI, 0.41-2.61 h).",Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070885/),h,1.51,112841,DB00160,L-Alanine
,29883728,Cmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),[μg] / [ml],0.92,113395,DB00160,L-Alanine
,29883728,Tmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),min,14,113396,DB00160,L-Alanine
,29883728,Cmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),[μg] / [ml],0.29,113397,DB00160,L-Alanine
,29883728,Tmax,Acyclovir administered by semisolid SMEDDS reached twice higher Cmax (0.92 ± 0.21 μg/ml) and has significantly shorter Tmax (14 ± 10.84 min) compared to the suspension of acyclovir (Cmax 0.29 ± 0.09 μg/ml and Tmax 26.00 ± 5.48 min).,Semisolid self-microemulsifying drug delivery systems (SMEDDSs): Effects on pharmacokinetics of acyclovir in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883728/),min,26.00,113398,DB00160,L-Alanine
,20509027,T (max),"Peginterferon α-2b was well-absorbed following SC administration, with a median T (max) of 24 h.",Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,24,114159,DB00160,L-Alanine
,20509027,half-life,Mean half-life estimates ranged from 43 to 51 h.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),h,43 to 51,114160,DB00160,L-Alanine
,20509027,accumulation factor,The accumulation factor was 1.69 after induction therapy.,Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20509027/),,1.69,114161,DB00160,L-Alanine
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.07,114342,DB00160,L-Alanine
,1965042,ED50,The potency of NPC 168 to antagonize morphine-induced analgesia was slightly less than that of naltrexone and nalmefene following either intraperitoneal (ED50 = 0.07 mg/kg) or oral (ED50 = 0.82 mg/kg) administration.,"Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),[mg] / [kg],0.82,114343,DB00160,L-Alanine
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,8,114344,DB00160,L-Alanine
,1965042,duration of action,"The duration of action of NPC 168 was approximately 8 hr following subcutaneous administration, compared to 4 hr for nalmefene, to antagonize oxymorphonazine-induced analgesia.","Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1965042/),h,4,114345,DB00160,L-Alanine
,18651858,DNA,Mitochondrial DNA (copies/cell) content increased from 672+/-254 to 682+/-269.,Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651858/),[copies] / [cell],672,114503,DB00160,L-Alanine
,9838910,maximum tolerated dose (MTD),These results suggested that the maximum tolerated dose (MTD) of ZD-1694 was 3.5 n (3.5 mg/m2).,[Phase I study of raltitrexed (ZD-1694)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9838910/),n,3.5,115146,DB00160,L-Alanine
,9838910,elimination half life,A pharmacokinetic investigation showed the mean elimination half life of ZD-1694 plasma concentration was 91.5 hours in the single-dose group and 119.1 hours in the repeated dose group.,[Phase I study of raltitrexed (ZD-1694)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9838910/),h,91.5,115147,DB00160,L-Alanine
,9838910,elimination half life,A pharmacokinetic investigation showed the mean elimination half life of ZD-1694 plasma concentration was 91.5 hours in the single-dose group and 119.1 hours in the repeated dose group.,[Phase I study of raltitrexed (ZD-1694)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9838910/),h,119.1,115148,DB00160,L-Alanine
,30325939,maximum reductions,"In non-cirrhotic, GT1-4-infected subjects receiving AL-335 800 mg QD, potent antiviral activity was observed, regardless of genotype (mean maximum reductions in HCV-RNA of 4.0-4.8 log10 IU/mL).","Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30325939/),[iu] / [ml],4.0-4.8,116266,DB00160,L-Alanine
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],3.55,116498,DB00160,L-Alanine
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],8.52,116499,DB00160,L-Alanine
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],5.06,116500,DB00160,L-Alanine
,1712992,Vmaxc,Dietary exposures resulted in increased Vmaxc value for BrCCl3 metabolism as compared to control (3.55 +/- 0.14 mg/hr/kg) for PB (8.52 +/- 0.28 mg/hr/kg) and M (5.06 +/- 0.19 mg/hr/kg) but not for CD (3.92 +/- 0.19 mg/hr/kg).,"PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),[mg] / [h·kg],3.92,116501,DB00160,L-Alanine
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],12.9,116502,DB00160,L-Alanine
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],17.6,116503,DB00160,L-Alanine
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],15.5,116504,DB00160,L-Alanine
,1712992,Kfc,"Kfc, the first-order rate constant for BrCCl3 metabolism, was decreased after PB (12.9 +/- 0.5 hr-1/kg) and increased after M (17.6 +/- 0.5 hr-1/kg), but unchanged after CD (15.5 +/- 0.6 hr-1/kg) exposure as compared to control (15.0 +/- 0.3 hr-1/kg).","PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712992/),1/[h·kg],15.0,116505,DB00160,L-Alanine
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,2.3,116519,DB00160,L-Alanine
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,6.4,116520,DB00160,L-Alanine
,30672747,midazolam,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117232,DB00160,L-Alanine
,30672747,clearance,The estimated midazolam clearance was 0.61 L/min/70kg.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),[l] / [70kg·min],0.61,117233,DB00160,L-Alanine
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,1.0,117234,DB00160,L-Alanine
,30672747,Time to reach 50% complete mature midaz,Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age.,Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30672747/),years,0.97,117235,DB00160,L-Alanine
,21212157,PFS,"Median PFS was 6.9 weeks, with no significant difference between treatment arms.",A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21212157/),weeks,6.9,117457,DB00160,L-Alanine
,21212157,overall survival (OS),Median overall survival (OS) was 21.9 weeks.,A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21212157/),weeks,21.9,117458,DB00160,L-Alanine
,21212157,PFS,Eastern Cooperative Oncology Group (ECOG) 0-1 patients (n = 56) had a median PFS of 11.6 weeks and a median OS of 37.7 weeks.,A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21212157/),weeks,11.6,117459,DB00160,L-Alanine
,2167278,urea synthesis rate,The urea synthesis rate during amino acid infusion was 27 mumols/kg per minute (normal range 20-24 mumols/kg per minute).,Increased amino acid clearance and urea synthesis in a patient with glucagonoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2167278/),[mumols] / [kg·min],27,118359,DB00160,L-Alanine
,14742742,terminal t(1/2),"Pharmacokinetic analysis in the rat demonstrated rapid clearance after i.v., i.p., and s.c. administration with terminal t(1/2) ranging from 46 to 51 min.","Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742742/),min,46 to 51,118893,DB00160,L-Alanine
,14742742,absolute bioavailability,"Low absolute bioavailability after p.o. administration was seen (2.7-4%), but portal drug concentrations after oral administration were 3-fold higher than systemic concentrations with a 3.7-fold increase in the terminal t(1/2), indicating a significant first-pass effect.","Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742742/),%,2.7-4,118894,DB00160,L-Alanine
,14742742,C(max),"Liver concentrations remained constant after oral administration for at least a 4-h period, reaching a C(max) of 2558 ng/g liver at 120 min.","Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742742/),[ng] / [g],2558,118895,DB00160,L-Alanine
,20523346,Ka,The final model formula is Cl/F=5.9x[1-0.412 x SPI] x [1-0.0101x(WT-62.9)] x [1-0.0012x(Cr-126.8)] (L/h); Ka=1.63 (h(-1)); V(d)/F=550 (L).,Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),,1.63,119245,DB00160,L-Alanine
,20523346,V(d)/F,The final model formula is Cl/F=5.9x[1-0.412 x SPI] x [1-0.0101x(WT-62.9)] x [1-0.0012x(Cr-126.8)] (L/h); Ka=1.63 (h(-1)); V(d)/F=550 (L).,Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),l,550,119246,DB00160,L-Alanine
,20523346,Cl/F,"The population estimates for Cl/F and V(d)/F were 5.9 L/h and 550 L, respectively.",Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),[l] / [h],5.9,119247,DB00160,L-Alanine
,20523346,V(d)/F,"The population estimates for Cl/F and V(d)/F were 5.9 L/h and 550 L, respectively.",Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20523346/),l,550,119248,DB00160,L-Alanine
,27815358,MTD,"The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each).","Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815358/),mg,60,119769,DB00160,L-Alanine
,27815358,half-life,The GDC-0425 half-life was approximately 15 hours.,"Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27815358/),h,15,119770,DB00160,L-Alanine
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],794,120155,DB00160,L-Alanine
,10720166,Peak increments,Peak increments of plasma Gln concentration were 794+/-107 micromol/L (mean +/- SEM) after bolus intake of 20 g of Ala-Gln and 398+/-61 micromol/L after intermittent intake of the same cumulative dosage of the dipeptide (P<0.01).,The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720166/),[μM] / [l],398,120156,DB00160,L-Alanine
,28406088,clearance,"The typical population parameter estimates of clearance and distribution volume were 0.46 L/h and 4.45 L, respectively.",Population pharmacokinetics of vancomycin in Chinese infants . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406088/),[l] / [h],0.46,120184,DB00160,L-Alanine
,28406088,distribution volume,"The typical population parameter estimates of clearance and distribution volume were 0.46 L/h and 4.45 L, respectively.",Population pharmacokinetics of vancomycin in Chinese infants . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406088/),l,4.45,120185,DB00160,L-Alanine
,27085586,Tmax,"PF-06260414 had fast absorption (median Tmax, approximately 1-2 hours), a mean t½ of approximately 6.9 to 12.8 hours, time-independent PK properties and dose proportionality.","Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085586/),h,1-2,120409,DB00160,L-Alanine
,27085586,t½,"PF-06260414 had fast absorption (median Tmax, approximately 1-2 hours), a mean t½ of approximately 6.9 to 12.8 hours, time-independent PK properties and dose proportionality.","Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085586/),h,6.9 to 12.8,120410,DB00160,L-Alanine
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],120,122370,DB00160,L-Alanine
,33547201,RP2D,"The RP2D of ribociclib and everolimus was 120 and 1.2 mg/m2 for 21 and 28 days, respectively.",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),[mg] / [m2],1.2,122371,DB00160,L-Alanine
,33547201,tumor-to-plasma ratio,"The mean tumor-to-plasma ratio of ribociclib was 19.8 (range, 2.22-53.4).",A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33547201/),,19.8,122372,DB00160,L-Alanine
,26433581,AUC,Carboplatin (AUC 6 mg/mL min) and paclitaxel (200 mg/m(2)) were administered on day 3 of a 21-day cycle.,A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433581/),[mg] / [min·ml],6,123105,DB00160,L-Alanine
,26433581,RPTD,The RPTD was determined to be 120 mg BID.,A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433581/),mg,120,123106,DB00160,L-Alanine
,10772370,half-life,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),h,10.9,124267,DB00160,L-Alanine
,10772370,clearance at steady state,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[ml] / [min],161.3,124268,DB00160,L-Alanine
,10772370,volume of distribution,"Calculated (mean +/- SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 +/- 1.8 hours, 161.3 +/- 41.1 ml/minute, and 1.4 +/- 0.4 L/kg.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[l] / [kg],1.4,124269,DB00160,L-Alanine
,10772370,maximum concentration,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[mg] / [l],3.6,124270,DB00160,L-Alanine
,10772370,minimum concentration,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[mg] / [l],0.6,124271,DB00160,L-Alanine
,10772370,area under the curve from 0-24 hours,"In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 +/- 0.5 mg/L, 0.6 +/- 0.3 mg/L, and 34.2 +/- 10.6 mg x hr/L, respectively.",Pharmacokinetics of intravenous trovafloxacin in critically ill adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772370/),[h·mg] / [l],34.2,124272,DB00160,L-Alanine
,26798966,tmax,"LY900009 absorption was rapid, with median tmax at 1-4 h post-dose.","A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26798966/),h,1-4,124432,DB00160,L-Alanine
,22738467,oral bioavailability,"GS-7340 showed concentration-dependent permeability through monolayers of caco-2 cells and dose-dependent oral bioavailability in dogs, increasing from 1.7% at 2 mg/kg to 24.7% at 20 mg/kg, suggesting saturable intestinal efflux transport.",Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738467/),%,1.7,124452,DB00160,L-Alanine
,22738467,oral bioavailability,"GS-7340 showed concentration-dependent permeability through monolayers of caco-2 cells and dose-dependent oral bioavailability in dogs, increasing from 1.7% at 2 mg/kg to 24.7% at 20 mg/kg, suggesting saturable intestinal efflux transport.",Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22738467/),%,24.7,124453,DB00160,L-Alanine
,6122294,total clearance rate,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),[l] / [h],0.255,124557,DB00160,L-Alanine
,6122294,relative clearance rate,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),[ml] / [h·kg],4.0,124558,DB00160,L-Alanine
,6122294,elimination half-life,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),h,95,124559,DB00160,L-Alanine
,6122294,elimination rate constant,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),1/[h],0.0071,124560,DB00160,L-Alanine
,6122294,apparent volume of distribution,"The means of the total clearance rate (0.255 L/h), the relative clearance rate (4.0 ml/h/kg of body weight), the elimination half-life (95 h), the elimination rate constant (0.0071/h), and the apparent volume of distribution (35.49 L) were within the ranges observed in nonpregnant subjects.",Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122294/),l,35.49,124561,DB00160,L-Alanine
,21986100,AUC(0-8),"The AUC(0-8) (ng.min/ml) was determined to be 268848±924 and 40019±495 for CMD-Cys-DALCE and DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),[min·ng] / [ml],268848,125354,DB00160,L-Alanine
,21986100,AUC(0-8),"The AUC(0-8) (ng.min/ml) was determined to be 268848±924 and 40019±495 for CMD-Cys-DALCE and DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),[min·ng] / [ml],40019,125355,DB00160,L-Alanine
,21986100,mean residence time (MRT),"The mean residence time (MRT) was determined to be 256±8 and 53.1±9.5 min for CMD-Cys-DALCE and for DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),min,256,125356,DB00160,L-Alanine
,21986100,mean residence time (MRT),"The mean residence time (MRT) was determined to be 256±8 and 53.1±9.5 min for CMD-Cys-DALCE and for DALCE, respectively.",Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986100/),min,53.1,125357,DB00160,L-Alanine
,10663639,area under the curve (AUC),The mean area under the curve (AUC) for docetaxel was 3.1 +/- 0.9 h.,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),h,3.1,125407,DB00160,L-Alanine
,10663639,clearance,mg/l and the clearance was 34.8 +/- 9.3 l/h per m(2).,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),[h·l] / [m(2],34.8,125408,DB00160,L-Alanine
,10663639,maximal concentrations,The cyclized oxazolidinedione metabolite M4 was most frequently present and was detected in 8 out of 24 patients with maximal concentrations between 0.022 and 0.23 mg/l.,Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663639/),[mg] / [l],0.022 and 0.23,125409,DB00160,L-Alanine
,25500866,V2/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),l,22.7,125516,DB00160,L-Alanine
,25500866,Q/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],76.3,125517,DB00160,L-Alanine
,25500866,V3/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),l,916,125518,DB00160,L-Alanine
,25500866,CL/F,"The estimated CL/F in the volunteers and liver transplant recipients was 32.8 and 18.4 L/h, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],32.8,125519,DB00160,L-Alanine
,25500866,CL/F,"The estimated CL/F in the volunteers and liver transplant recipients was 32.8 and 18.4 L/h, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],18.4,125520,DB00160,L-Alanine
,30196732,water-solubility,"The conjugates with RH content of 9.65% were successfully synthesized and featured a satisfactory water-solubility of 9.73 mg/mL, which exhibited a sustained release pattern over 72 h, and the enzymes present may promote the degradation of the conjugate to increase the release of Rhein.","Low molecular weight chitosan-based conjugates for efficient Rhein oral delivery: synthesis, characterization, and pharmacokinetics. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30196732/),[mg] / [ml],9.73,126159,DB00160,L-Alanine
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],15,126304,DB00160,L-Alanine
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],180,126305,DB00160,L-Alanine
,23676788,T-bil,"Thereafter, the levels of AST and ALT as well as the T-bil were successfully decreased to 73 U/L, 83 U/L, and 3.0 mg/dL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[mg] / [dl],3.0,126306,DB00160,L-Alanine
,17145830,MTD,"The MTD of pemetrexed was 2,400 mg/m(2) (combined with cyclophosphamide, 600 mg/m(2)) with dose-limiting toxicities of grade 4 neutropenia with grade 4 infection and grade 3 diarrhea.",A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145830/),[mg] / [m],"2,400",126316,DB00160,L-Alanine
,30073583,objective response,"The objective response and disease control rates were 40 and 70%, respectively.",An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073583/),%,40,126550,DB00160,L-Alanine
,30073583,disease control rates,"The objective response and disease control rates were 40 and 70%, respectively.",An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30073583/),%,70,126551,DB00160,L-Alanine
,31446987,mPFS,"Per investigator assessment of DLL3 high patients, 17% (3/18) had confirmed partial responses, and the disease control rate was 56%, mPFS was 2.9 months, and mOS was 7.4 months.","Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446987/),month,2.9,126569,DB00160,L-Alanine
,31446987,mOS,"Per investigator assessment of DLL3 high patients, 17% (3/18) had confirmed partial responses, and the disease control rate was 56%, mPFS was 2.9 months, and mOS was 7.4 months.","Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31446987/),month,7.4,126570,DB00160,L-Alanine
,20530693,overall response rate,"The overall response rate (complete response plus partial response plus minimal response) was 13% with plitidepsin alone and 22% in the cohort of patients with the addition of dexamethasone (n = 19, 18 evaluable).",Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20530693/),%,13,127031,DB00160,L-Alanine
,20530693,overall response rate,"The overall response rate (complete response plus partial response plus minimal response) was 13% with plitidepsin alone and 22% in the cohort of patients with the addition of dexamethasone (n = 19, 18 evaluable).",Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20530693/),%,22,127032,DB00160,L-Alanine
,18639607,maximum inhibition,"The maximum inhibition in plasma and erythrocyte cholinesterase activity was observed 22.5%, 18.9% and 8.6%, 9% after one and seven days, respectively.",Toxicological evaluation and bioavailability of (14)C-fenitrothion bound residues on soybeans towards experimental animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639607/),%,22.5,129041,DB00160,L-Alanine
,18639607,maximum inhibition,"The maximum inhibition in plasma and erythrocyte cholinesterase activity was observed 22.5%, 18.9% and 8.6%, 9% after one and seven days, respectively.",Toxicological evaluation and bioavailability of (14)C-fenitrothion bound residues on soybeans towards experimental animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639607/),%,18.9,129042,DB00160,L-Alanine
,18639607,maximum inhibition,"The maximum inhibition in plasma and erythrocyte cholinesterase activity was observed 22.5%, 18.9% and 8.6%, 9% after one and seven days, respectively.",Toxicological evaluation and bioavailability of (14)C-fenitrothion bound residues on soybeans towards experimental animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639607/),%,8.6,129043,DB00160,L-Alanine
,18639607,maximum inhibition,"The maximum inhibition in plasma and erythrocyte cholinesterase activity was observed 22.5%, 18.9% and 8.6%, 9% after one and seven days, respectively.",Toxicological evaluation and bioavailability of (14)C-fenitrothion bound residues on soybeans towards experimental animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639607/),%,9,129044,DB00160,L-Alanine
,8842341,mucosal concentration,"The mean mucosal concentration of rebamipide between 30 and 120 min after ingestion was 60.0 +/- 109.8 micrograms/g of tissue, which was higher than 0.1 mmol/l (37 micrograms/g of tissue).",Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842341/),[μg] / [g],60.0,129276,DB00160,L-Alanine
higher,8842341,mucosal concentration,"The mean mucosal concentration of rebamipide between 30 and 120 min after ingestion was 60.0 +/- 109.8 micrograms/g of tissue, which was higher than 0.1 mmol/l (37 micrograms/g of tissue).",Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842341/),[mM] / [l],0.1,129277,DB00160,L-Alanine
,19760364,area under the curve [AUC],"Eligible patients received paclitaxel (200 mg/m(2)) and carboplatin (area under the curve [AUC]of 6 mg min mL(-1)) on day 1 and sorafenib (400 mg, twice daily) on days 2 through 19 of a 21-day cycle.",Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],6,129762,DB00160,L-Alanine
,19760364,AUC,The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL(-1) and paclitaxel 200 mg/m(2) is feasible in Japanese patients with advanced NSCLC.,Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19760364/),[mg·min] / [ml],5,129763,DB00160,L-Alanine
,8105057,steady-state plasma BA concentrations,"Enprofylline was administered intravenously at a dosage of 2.5 mg kg-1 under three different steady-state plasma BA concentrations (100, 200 and 400 micrograms mL-1) which were achieved by constant infusion rates.","The effects of N-benzoyl-beta-alanine, a new nephroprotective drug, on the distribution and renal excretion of enprofylline in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105057/),,100,129775,DB00160,L-Alanine
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,6.9,130075,DB00160,L-Alanine
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,225,130076,DB00160,L-Alanine
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,7.6,130077,DB00160,L-Alanine
,2060083,half-life,"The estimated mean half-life was 6.9 +/- 3.9 min for unchanged 5-FU and 225 +/- 352, 7.6 +/- 4, and 9.6 +/- 7.7 min, respectively, for the three measured catabolites dihydrofluorouracil (FUH2), alpha-fluoro-beta-ureidopropionic acid (FUPA), and alpha-fluoro-beta-alanine (FBAL).",A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060083/),min,9.6,130078,DB00160,L-Alanine
,1437854,apparent distribution volume,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),l,33,132023,DB00160,L-Alanine
,1437854,half-life,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),min,41,132024,DB00160,L-Alanine
,1437854,total body clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[l] / [min],0.56,132025,DB00160,L-Alanine
,1437854,renal clearance,"The apparent distribution volume for the excess glycine was 33 +/- 9 L, the half-life was 41 +/- 7 min, and the total body clearance was 0.56 +/- 0.08 L/min, while the renal clearance for glycine was 36 +/- 14 ml/min (mean +/- SD).",Amino acid concentrations in serum and urine after intravenous infusion of 1.5% glycine in prostatectomy patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1437854/),[ml] / [min],36,132026,DB00160,L-Alanine
,23466964,IC2x LT,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.10,132118,DB00160,L-Alanine
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.063,132119,DB00160,L-Alanine
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.18,132120,DB00160,L-Alanine
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.50,132121,DB00160,L-Alanine
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.55,132122,DB00160,L-Alanine
,23676510,time to progression,The median time to progression was three months (range 1-18 months).,Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676510/),month,three,133612,DB00160,L-Alanine
,2072299,Vd,"After single dose i.v. injection, BMAA was cleared from plasma in a rapid distribution phase (Vd approximately 16 liters/kg) followed by a slower elimination phase (t1/2 approximately 1 day).",2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072299/),[l] / [kg],16,134204,DB00160,L-Alanine
,2072299,t1/2,"After single dose i.v. injection, BMAA was cleared from plasma in a rapid distribution phase (Vd approximately 16 liters/kg) followed by a slower elimination phase (t1/2 approximately 1 day).",2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072299/),d,1,134205,DB00160,L-Alanine
,2072299,blood-brain barrier permeability-surface area,Brain uptake was limited by a low blood-brain barrier permeability-surface area product of 2 to 5 x 10(-5) ml/sed/g.,2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072299/),[ml] / [g·sed],2 to 5 x 10(-5),134206,DB00160,L-Alanine
,2072299,steady-state brain concentrations,"After two weeks of continuous infusion (100 mg/kg/day), steady-state brain concentrations equalled 10 to 30 micrograms/g, and only moderately exceeded those in plasma.",2-amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072299/),[μg] / [g],10 to 30,134207,DB00160,L-Alanine
,17575227,maximum tolerated dose,The maximum tolerated dose was declared to be 30 microg/kg for both regimens.,"An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17575227/),[μg] / [kg],30,134975,DB00160,L-Alanine
,26857784,clearance (CL),"The respective typical values for clearance (CL), V1, V2, Q2, Q3, and V3 were 0.883 L×min(-1), 17.6 L, 51.5 L, 2.37 L×min(-1), 0.517 L×min(-1), and 44.00 L.",Population pharmacokinetics study of dexmedetomidine in Chinese adult patients during spinal anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857784/),[l] / [min],0.883,135432,DB00160,L-Alanine
,26857784,V3,"The respective typical values for clearance (CL), V1, V2, Q2, Q3, and V3 were 0.883 L×min(-1), 17.6 L, 51.5 L, 2.37 L×min(-1), 0.517 L×min(-1), and 44.00 L.",Population pharmacokinetics study of dexmedetomidine in Chinese adult patients during spinal anesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857784/),l,44.00,135433,DB00160,L-Alanine
,11695617,half-life,The half-life value of metalaxyl was found in the range of 36-73 d in non-sterile soil.,Influence of biotic and abiotic factors on dissipating metalaxyl in soil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695617/),d,36-73,136025,DB00160,L-Alanine
,11695617,half-life,Metalaxyl was found photostable in soil showing half-life of 188- 502 h under simulated sunlight.,Influence of biotic and abiotic factors on dissipating metalaxyl in soil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695617/),h,188- 502,136026,DB00160,L-Alanine
,11695617,Adsorption,Adsorption and desorption kD values ranged between 53.5 and 151.1.,Influence of biotic and abiotic factors on dissipating metalaxyl in soil. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695617/),,53.5,136027,DB00160,L-Alanine
,11695617,desorption kD,Adsorption and desorption kD values ranged between 53.5 and 151.1.,Influence of biotic and abiotic factors on dissipating metalaxyl in soil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695617/),,151,136028,DB00160,L-Alanine
,32649736,Ctrough,"The mean Ctrough of GLS4 was 205-218 ng/mL, which was approximately 3.7-3.9 times the 90% effective concentration (55.8 ng/mL), with a lower accumulation (accumulation rate, 1.1-2.0).",Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649736/),[ng] / [ml],205-218,136058,DB00160,L-Alanine
,32649736,accumulation (accumulation rate,"The mean Ctrough of GLS4 was 205-218 ng/mL, which was approximately 3.7-3.9 times the 90% effective concentration (55.8 ng/mL), with a lower accumulation (accumulation rate, 1.1-2.0).",Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32649736/),,1.1-2.0,136059,DB00160,L-Alanine
,34160752,overall disease control rate,"The overall disease control rate was 44.4%, including 2 patients with stable disease.","Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34160752/),%,44.4,136288,DB00160,L-Alanine
,11106122,terminal half-life,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),h,5.5,136377,DB00160,L-Alanine
,11106122,systemic clearance,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),[l] / [h],6.6,136378,DB00160,L-Alanine
,11106122,apparent volume of distribution,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),[l] / [h],6.6,136379,DB00160,L-Alanine
,11106122,apparent volume of distribution,"Mean values for terminal half-life, systemic clearance, and apparent volume of distribution for oral 5-FU during treatments A/B/C were 5.5/5.6/5.6 hours, 6.6/6.6/6.5 liters/hour, and 50.7/51.5/50.0 liters, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),l,50.7,136380,DB00160,L-Alanine
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),%,52.2,136381,DB00160,L-Alanine
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),%,56.1,136382,DB00160,L-Alanine
,11106122,urinary excretion,"The urinary excretion of unchanged 5-FU over 24 hours following treatments A, B, and C averaged 52.2%, 56.1%, and 50.8'%, of the administered dose of 5-FU, respectively.","Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106122/),'%,50.8,136383,DB00160,L-Alanine
,24492365,maximum drug concentration in blood serum (Cmax),"Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax) was 5.63 μg/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time curve from 2 to 5 h (AUC2-5) was 13.56 μg · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was 0.15 h(-1).",Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492365/),[μg] / [ml],5.63,136392,DB00160,L-Alanine
,24492365,time after drug administration to reach CmaxTmax),"Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax) was 5.63 μg/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time curve from 2 to 5 h (AUC2-5) was 13.56 μg · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was 0.15 h(-1).",Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492365/),h,2,136393,DB00160,L-Alanine
,24492365,area under the concentration-time curve from 2 to 5 h (AUC2-5),"Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax) was 5.63 μg/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time curve from 2 to 5 h (AUC2-5) was 13.56 μg · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was 0.15 h(-1).",Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492365/),[h·μg] / [ml],13.56,136394,DB00160,L-Alanine
,24492365,half-life (t1/2),"Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax) was 5.63 μg/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time curve from 2 to 5 h (AUC2-5) was 13.56 μg · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was 0.15 h(-1).",Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492365/),h,4.69,136395,DB00160,L-Alanine
,24492365,elimination constant rate (kel),"Using a noncompartmental analysis approach, the median maximum drug concentration in blood serum (Cmax) was 5.63 μg/ml, the time after drug administration to reach CmaxTmax) was 2 h, the area under the concentration-time curve from 2 to 5 h (AUC2-5) was 13.56 μg · h/ml, the half-life (t1/2) was 4.69 h, and the elimination constant rate (kel) was 0.15 h(-1).",Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492365/),1/[h],0.15,136396,DB00160,L-Alanine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],2.09,136631,DB00160,L-Alanine
,28741453,maximum concentration (Cmax),"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[mg] / [l],1.78,136632,DB00160,L-Alanine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],68.1,136633,DB00160,L-Alanine
,28741453,area under the curve,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),[h·mg] / [l],64.3,136634,DB00160,L-Alanine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.00,136635,DB00160,L-Alanine
,28741453,time to Cmax,"The geometric mean (%CV) sorafenib maximum concentration (Cmax) without and with levothyroxine was 2.09 (68.1) and 1.78 (63.9) mg/L, respectively, with a corresponding geometric mean area under the curve of 68.1 (68.2) and 64.3 (66.3) mg·h/L. Median (range) time to Cmax was 4.00 (2.98-16.0) and 4.02 (1.98-36.0) hours, respectively.",No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,4.02,136636,DB00160,L-Alanine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,24.0,136637,DB00160,L-Alanine
,28741453,half-life,Mean (%CV) half-life was 24.0 (25.3) and 25.7 (21.0) hours.,No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741453/),h,25.7,136638,DB00160,L-Alanine
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],35 to 358,137097,DB00160,L-Alanine
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],27.12-1006.42,137098,DB00160,L-Alanine
,24662525,Area under curve (AUC),Area under curve (AUC) of IMI ranged from 35 to 358μg/ml/h; 6-CNA: 27.12-1006.42μg/ml/h and 6-HNA: 14.98-302.74μg/ml/h in different organs and bodily fluids.,Disposition and acute toxicity of imidacloprid in female rats after single exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24662525/),[μg] / [h·ml],14.98-302.74,137099,DB00160,L-Alanine
,12238936,IC(50),"Among these compounds, the glycine derivative 3a and beta-alanine derivative 3f exhibited the most potent inhibition of squalene synthase prepared from HepG2 cells (IC(50) = 15 nM).","Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238936/),nM,15,137142,DB00160,L-Alanine
,12238936,ED(50),"On the other hand, the piperidine-4-acetic acid derivative 4a, which was prepared by acetylation of 3j, was the most effective inhibitor of cholesterol synthesis in rat liver (ED(50) = 2.9 mg/kg, po).","Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238936/),[mg] / [kg],2.9,137143,DB00160,L-Alanine
,24610297,half-life,Cohorts receiving doses of 5.2 mg/m(2) and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min).,"Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610297/),min,7.1,137317,DB00160,L-Alanine
,24610297,half-life,Cohorts receiving doses of 5.2 mg/m(2) and above achieved therapeutic levels from in vitro studies Clearance was rapid (mean half-life 7.1 ± 3.8 to 15.9 ± 3.6 min).,"Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610297/),min,15.9,137318,DB00160,L-Alanine
,29334548,plasma concentrations,"In 30 participants with evaluable data, TFV plasma concentrations decreased 90% [TDF: 99.98 (2.24) ng/ml vs. TAF: 10.2 (1.6) ng/ml, P < 0.001] after the switch while cell-associated TFV-DP increased 2.41-fold [TAF: 834.7 (2.49) vs. TDF: 346.85 (3.75) fmol/10 cells, P = 0.004].",Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334548/),[ng] / [m],99.,137847,DB00160,L-Alanine
,29334548,plasma concentrations,"In 30 participants with evaluable data, TFV plasma concentrations decreased 90% [TDF: 99.98 (2.24) ng/ml vs. TAF: 10.2 (1.6) ng/ml, P < 0.001] after the switch while cell-associated TFV-DP increased 2.41-fold [TAF: 834.7 (2.49) vs. TDF: 346.85 (3.75) fmol/10 cells, P = 0.004].",Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334548/),ng,10,137848,DB00160,L-Alanine
,29334548,plasma concentrations,"In 30 participants with evaluable data, TFV plasma concentrations decreased 90% [TDF: 99.98 (2.24) ng/ml vs. TAF: 10.2 (1.6) ng/ml, P < 0.001] after the switch while cell-associated TFV-DP increased 2.41-fold [TAF: 834.7 (2.49) vs. TDF: 346.85 (3.75) fmol/10 cells, P = 0.004].",Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334548/),[fmol] / [10·cells],834.7,137849,DB00160,L-Alanine
,29334548,plasma concentrations,"In 30 participants with evaluable data, TFV plasma concentrations decreased 90% [TDF: 99.98 (2.24) ng/ml vs. TAF: 10.2 (1.6) ng/ml, P < 0.001] after the switch while cell-associated TFV-DP increased 2.41-fold [TAF: 834.7 (2.49) vs. TDF: 346.85 (3.75) fmol/10 cells, P = 0.004].",Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334548/),[fmol] / [10·cells],346.85,137850,DB00160,L-Alanine
,25975046,C1,"The mean of population parameters of the final model, C1, SYAX on C1, V, Ka1, CLII, and VII, were measured to be 37.6 L/h, 0.427 L, 123 L/h, 0.12/h, 0.3056, and 1.446, respectively.",Effect of naringenin in Qianggu capsule on population pharmacokinetics in Chinese women with primary osteoporosis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975046/),[l] / [h],37.6,138432,DB00160,L-Alanine
,11801542,maximum tolerated dose,The maximum tolerated dose of ET-743 that could be administered repetitively was 325 microg/m(2)/day.,A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801542/),μg,325,139596,DB00160,L-Alanine
,11801542,volume of distribution at steady state,"The volume of distribution at steady state was large (mean, 1037 liters/m(2)), and the mean terminal half life on day 5 was 26.81 h.",A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801542/),[l] / [m(2],1037,139597,DB00160,L-Alanine
,11801542,terminal half life,"The volume of distribution at steady state was large (mean, 1037 liters/m(2)), and the mean terminal half life on day 5 was 26.81 h.",A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11801542/),h,26.81,139598,DB00160,L-Alanine
,11045890,area under the plasma concentration-time curve from time zero to time infinity,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[mg·min] / [ml],6,139656,DB00160,L-Alanine
,11045890,area under the plasma concentration-time curve from time zero to time infinity,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[mg·min] / [ml],3.34,139657,DB00160,L-Alanine
,11045890,total body,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],7.74,139658,DB00160,L-Alanine
,11045890,total body,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],15.0,139659,DB00160,L-Alanine
,11045890,renal,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],2.55,139660,DB00160,L-Alanine
,11045890,renal,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],5.10,139661,DB00160,L-Alanine
,11045890,nonrenal,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],5.07,139662,DB00160,L-Alanine
,11045890,nonrenal,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],9.65,139663,DB00160,L-Alanine
,11045890,biliary,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],1.48,139664,DB00160,L-Alanine
,11045890,biliary,"In the CCl4-intoxicated rats the plasma concentrations of DDB-S were significantly higher, the area under the plasma concentration-time curve from time zero to time infinity was significantly greater (6-46 vs 3.34 mg min mL(-1)), and the total body (7.74 vs 15.0 mL min(-1) kg(-1)), renal (2.55 vs 5.10 mL min(-1) kg(-1)), nonrenal (5.07 vs 9.65 mL min(-1) kg(-1)), and biliary (1.48 vs 2.69 mL min(-1) kg(-1)) clearances were significantly slower compared with the control rats.","Pharmacokinetics and hepatoprotective effects of 2-methylaminoethyl-4,4'-dimethoxy-5 ,6,5',6'dimethylenedioxybiphenyl-2-carboxylic acid-2'-carboxylate monohydrochloride in rats with CCl4-induced acute hepatic failure. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11045890/),[ml] / [kg·min],2.69,139665,DB00160,L-Alanine
,12936974,V(SS),"The elimination half-life was four times longer (280 min) than that observed after administration of SSG (71 min) (P = 0.01), and the volume of distribution at steady state (V(SS)) was also increased (V(SS) for SSG, 0.21 liters/kg; V(SS) for SSG-NIV-dextran, 0.34 liters/kg [P = 0.02]), thus indicating that drug encapsulation favors the distribution of Sb into organs and increases its residence time in tissues.","Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12936974/),[l] / [kg],0.21,141137,DB00160,L-Alanine
,12936974,V(SS),"The elimination half-life was four times longer (280 min) than that observed after administration of SSG (71 min) (P = 0.01), and the volume of distribution at steady state (V(SS)) was also increased (V(SS) for SSG, 0.21 liters/kg; V(SS) for SSG-NIV-dextran, 0.34 liters/kg [P = 0.02]), thus indicating that drug encapsulation favors the distribution of Sb into organs and increases its residence time in tissues.","Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12936974/),[l] / [kg],0.34,141138,DB00160,L-Alanine
,18628265,clearance (CL),Standardized population parameter estimates for a term neonate were clearance (CL) 5.24 (CV 30.5%) litre h(-1) 70 kg(-1) and volume of distribution (V) 76 (29.6%) litre 70 kg(-1).,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],5.24,141294,DB00160,L-Alanine
,18628265,volume of distribution (V),Standardized population parameter estimates for a term neonate were clearance (CL) 5.24 (CV 30.5%) litre h(-1) 70 kg(-1) and volume of distribution (V) 76 (29.6%) litre 70 kg(-1).,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·kg],76,141295,DB00160,L-Alanine
,18628265,CL,CL increased with PMA from 4.4 litre h(-1) 70 kg(-1) at 34 weeks to 6.3 litre h(-1) 70 kg(-1) at 46 weeks.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],4.4,141296,DB00160,L-Alanine
,18628265,CL,CL increased with PMA from 4.4 litre h(-1) 70 kg(-1) at 34 weeks to 6.3 litre h(-1) 70 kg(-1) at 46 weeks.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[l] / [70·h·kg],6.3,141297,DB00160,L-Alanine
,18628265,CL,The presence of unconjugated hyperbilirubinaemia was associated with reduced CL: 150 micromol litre(-1) associated with 40% CL reduction.,I.V. acetaminophen pharmacokinetics in neonates after multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18628265/),[μM] / [litre],150,141298,DB00160,L-Alanine
,8164250,IC50,"Various aliphatic constraints were introduced on the benzyl moiety of the potent NEP inhibitor N-[2-(mercaptomethyl)-3-phenylpropanoyl]-L-tyrosine (IC50 NEP = 2 nM, IC50 ACE = 25 nM) to improve the fit between the computed most stable conformers of these molecules and the ACE template.","New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164250/),nM,2,141304,DB00160,L-Alanine
,8164250,IC50,"Various aliphatic constraints were introduced on the benzyl moiety of the potent NEP inhibitor N-[2-(mercaptomethyl)-3-phenylpropanoyl]-L-tyrosine (IC50 NEP = 2 nM, IC50 ACE = 25 nM) to improve the fit between the computed most stable conformers of these molecules and the ACE template.","New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8164250/),nM,25,141305,DB00160,L-Alanine
,10604282,absolute oral bioavailability,The absolute oral bioavailability of PG (administered as an HPB complex) in rats was low (5%) suggesting extensive metabolism or incomplete absorption.,Influence of dosing vehicles on the preclinical pharmacokinetics of phenolic antioxidants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604282/),%,5,141620,DB00160,L-Alanine
,9580325,Ka,L-glucose: Ka = 3.05 +/- 0.97 h-1; Ke = 0.40 +/- 0.12 h-1; BA(a) = 94% +/- 4%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],3.05,143185,DB00160,L-Alanine
,9580325,Ke,L-glucose: Ka = 3.05 +/- 0.97 h-1; Ke = 0.40 +/- 0.12 h-1; BA(a) = 94% +/- 4%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],0.40,143186,DB00160,L-Alanine
,9580325,BA(a),L-glucose: Ka = 3.05 +/- 0.97 h-1; Ke = 0.40 +/- 0.12 h-1; BA(a) = 94% +/- 4%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),%,94,143187,DB00160,L-Alanine
,9580325,Ka,D-alanine: Ka = 1.08 +/- 0.40 h-1; Ke = 0.11 +/- 0.06 h-1; BAa = 90% +/- 11%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],1.08,143188,DB00160,L-Alanine
,9580325,Ke,D-alanine: Ka = 1.08 +/- 0.40 h-1; Ke = 0.11 +/- 0.06 h-1; BAa = 90% +/- 11%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],0.11,143189,DB00160,L-Alanine
,9580325,BAa,D-alanine: Ka = 1.08 +/- 0.40 h-1; Ke = 0.11 +/- 0.06 h-1; BAa = 90% +/- 11%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),%,90,143190,DB00160,L-Alanine
,9580325,Ka,L-alanine: Ka = 1.75 +/- 0.273 h-1; Ke = 0.02 +/- 0.01 h-1; BA(a) = 99% +/- 1%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],1.75,143191,DB00160,L-Alanine
,9580325,Ke,L-alanine: Ka = 1.75 +/- 0.273 h-1; Ke = 0.02 +/- 0.01 h-1; BA(a) = 99% +/- 1%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),1/[h],0.02,143192,DB00160,L-Alanine
,9580325,BA(a),L-alanine: Ka = 1.75 +/- 0.273 h-1; Ke = 0.02 +/- 0.01 h-1; BA(a) = 99% +/- 1%.,A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),%,99,143193,DB00160,L-Alanine
,9580325,absolute bioavailability,"Eight hours after i.p. injection an absolute bioavailability almost as high as after i.v. injection (i.e., close to 100%) was achieved.",A pharmacokinetic study of peritoneal absorption of glucose and alanine in rats: nutritional implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9580325/),%,100,143194,DB00160,L-Alanine
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],333,143674,DB00160,L-Alanine
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],327.1,143675,DB00160,L-Alanine
,22358992,peak,"Normalized serum irinotecan reached a peak of 333 ng/ml (range 198.8-502.5) for IV, 327.1 ng/ml (range 277.1-495.6) for IA, and 189.7 ng/ml (range 111.1-261.9) for DEBIRI (P < 0.001) delivery.",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),[ng] / [ml],189.7,143676,DB00160,L-Alanine
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,25,143677,DB00160,L-Alanine
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,60,143678,DB00160,L-Alanine
,22358992,tumor necrosis,"At 24 h, tumor necrosis was 25% (10-30), 60% (40-91.25), and 95% (76.25-95) for IV, IA, and DEBIRI, respectively (P = 0.03).",Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358992/),%,95,143679,DB00160,L-Alanine
,23242257,Half-life periods,"Half-life periods for mancozeb were 3.76 and 4.14 days, whereas for metalaxyl these values were 1.29 and 0.41 days at single and double the application rates, respectively.",Dissipation of residues of mancozeb and metalaxyl in tomato (Solanum lycopersicum L.). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242257/),d,3.76,143739,DB00160,L-Alanine
,23242257,Half-life periods,"Half-life periods for mancozeb were 3.76 and 4.14 days, whereas for metalaxyl these values were 1.29 and 0.41 days at single and double the application rates, respectively.",Dissipation of residues of mancozeb and metalaxyl in tomato (Solanum lycopersicum L.). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242257/),d,4.14,143740,DB00160,L-Alanine
,23242257,Half-life periods,"Half-life periods for mancozeb were 3.76 and 4.14 days, whereas for metalaxyl these values were 1.29 and 0.41 days at single and double the application rates, respectively.",Dissipation of residues of mancozeb and metalaxyl in tomato (Solanum lycopersicum L.). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242257/),d,1.29,143741,DB00160,L-Alanine
,23242257,Half-life periods,"Half-life periods for mancozeb were 3.76 and 4.14 days, whereas for metalaxyl these values were 1.29 and 0.41 days at single and double the application rates, respectively.",Dissipation of residues of mancozeb and metalaxyl in tomato (Solanum lycopersicum L.). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242257/),d,0.41,143742,DB00160,L-Alanine
,20110013,AUC(0-t),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [h·ml],831.09,144338,DB00160,L-Alanine
,20110013,AUC(0-t),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [h·ml],903.46,144339,DB00160,L-Alanine
,20110013,AUC(0-infinity),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [h·ml],851.68,144340,DB00160,L-Alanine
,20110013,AUC(0-infinity),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [h·ml],923.58,144341,DB00160,L-Alanine
,20110013,C(max),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [ml],218.12,144342,DB00160,L-Alanine
,20110013,C(max),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),[ng] / [ml],220.57,144343,DB00160,L-Alanine
,20110013,T(max),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),h,2.05,144344,DB00160,L-Alanine
,20110013,T(max),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),h,2.10,144345,DB00160,L-Alanine
,20110013,t((1/2)),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),h,1.96,144346,DB00160,L-Alanine
,20110013,t((1/2)),"The mean AUC(0-t) for the test and reference formulations was 831.09 (329.52) and 903.46 (419.17) ng/mL/h, respectively; the AUC(0-infinity) was 851.68 (332.62) and 923.58 (423.21) ng/mL/h; the C(max) was 218.12 (93.90) and 220.57 (107.48) ng/mL; the T(max) was 2.05 (1.15) and 2.10 (0.76) hours; and the t((1/2)) was 1.96 (0.52) and 1.93 (0.49) hours.","Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110013/),h,1.93,144347,DB00160,L-Alanine
,28168382,potency,"Although the in vitro potency of the fusion protein was significantly reduced (1.26 ± 0.05 vs. 0.24 ± 0.03 ng/ml) but, the in vivo activity was considerably increased up to 1.58 × 105 IU/ml in normocythemic mice assay.","Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168382/),[ng] / [ml],1.26,145154,DB00160,L-Alanine
,28168382,potency,"Although the in vitro potency of the fusion protein was significantly reduced (1.26 ± 0.05 vs. 0.24 ± 0.03 ng/ml) but, the in vivo activity was considerably increased up to 1.58 × 105 IU/ml in normocythemic mice assay.","Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168382/),[ng] / [ml],0.24,145155,DB00160,L-Alanine
,28168382,plasma half-life,Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 ± 13.28 h) in comparison to epoetin α (8.5 ± 2.4 h) and darbepoetin α (25.3 ± 2.2h).,"Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168382/),h,83.16,145156,DB00160,L-Alanine
,28168382,plasma half-life,Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 ± 13.28 h) in comparison to epoetin α (8.5 ± 2.4 h) and darbepoetin α (25.3 ± 2.2h).,"Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168382/),h,8.5,145157,DB00160,L-Alanine
,28168382,plasma half-life,Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 ± 13.28 h) in comparison to epoetin α (8.5 ± 2.4 h) and darbepoetin α (25.3 ± 2.2h).,"Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28168382/),h,25.3,145158,DB00160,L-Alanine
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,455.00,145177,DB00160,L-Alanine
,18021335,Cmax,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),nm,425.00,145178,DB00160,L-Alanine
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1469.92,145179,DB00160,L-Alanine
,18021335,AUC,"The pharmacokinetics of MTX were also similar with the Cmax and AUC values being 455.00 +/- 101.00 nm and 1469.92 +/- 299.77 nm/h for MTX group and 425.00 +/- 169.60 nm and 1560.73 +/- 615.49 nm/h for MTX plus CQ group, respectively.",Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021335/),[nm] / [h],1560.73,145180,DB00160,L-Alanine
<,19604146,TBL,"The effect of obstructive jaundice on the distribution and elimination of propofol was studied in 15 patients with obstructive jaundice (total serum bilirubin, TBL >/= 17.1micromol.l(-1)) and in 15 control patients (TBL < 17.1micromol.l(-1)).",Propofol pharmacokinetics in patients with obstructive jaundice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[μM] / [l],17.1,145940,DB00160,L-Alanine
,19604146,volumes of distribution at steady state (V(SS)),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],12.3,145941,DB00160,L-Alanine
,19604146,volumes of distribution at equilibrium (V(r)),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],32.99,145942,DB00160,L-Alanine
,19604146,volumes of the central compartment (V),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],32.99,145943,DB00160,L-Alanine
,19604146,total body clearance (Cl),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[ml] / [min],28.8,145944,DB00160,L-Alanine
,31635105,maximum concentration (Cmax),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),[ng] / [ml],301,146083,DB00160,L-Alanine
,31635105,maximum concentration (Cmax),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),[ng] / [ml],43,146084,DB00160,L-Alanine
,31635105,area under the curve (AUC),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),[ng-h] / [ml],1297,146085,DB00160,L-Alanine
,31635105,area under the curve (AUC),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),[ng-h] / [ml],164,146086,DB00160,L-Alanine
,31635105,time to maximal concentration (Tmax),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),h,1.4,146087,DB00160,L-Alanine
,31635105,time to maximal concentration (Tmax),"Pharmacokinetics revealed a mean maximum concentration (Cmax) of 301 ng/mL and 43 ng/mL, area under the curve (AUC) of 1297 ng-h/mL and 164 ng-h/mL, and time to maximal concentration (Tmax) of 1.4 h and 2 h, for dogs and cats, respectively.",Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31635105/),h,2,146088,DB00160,L-Alanine
,17361077,peak plasma concentration,"Following intramuscular injection, imipenem was rapidly absorbed and the peak plasma concentration was 9.99 microg ml(-1) and the systemic bioavailability was 65.97%.",Pharmacokinetics of imipenem in sheep with special reference to its hepato-renal effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361077/),[μg] / [ml],9.99,147573,DB00160,L-Alanine
,17361077,systemic bioavailability,"Following intramuscular injection, imipenem was rapidly absorbed and the peak plasma concentration was 9.99 microg ml(-1) and the systemic bioavailability was 65.97%.",Pharmacokinetics of imipenem in sheep with special reference to its hepato-renal effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361077/),%,65.97,147574,DB00160,L-Alanine
,22177763,half-life,"The half-life is around 8 to 12 hours, with a peak activity 2 to 4 hours after ingestion.",[Pharmacologic heterogeneity of new anticoagulants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177763/),h,8 to 12,148054,DB00160,L-Alanine
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.70,148398,DB00160,L-Alanine
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.62,148399,DB00160,L-Alanine
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.18,148400,DB00160,L-Alanine
,30713054,clearance,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),[l] / [h·kg],1.08,148401,DB00160,L-Alanine
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,2.64,148402,DB00160,L-Alanine
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,2.86,148403,DB00160,L-Alanine
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,3.49,148404,DB00160,L-Alanine
,30713054,elimination half-life,"For doses of 10 and 20 mg kg-1, respectively, clearance values were 1.70 (1.15-2.27) and 1.62 (1.06-2.86) L kg-1 hour-1 for Beagles and 1.18 (0.70-1.39) and 1.08 (0.67-1.35) L kg-1 hour-1 for GE; elimination half-life values were 2.64 (0.52-4.46) and 2.86 (0.87-4.63) hours for Beagles and 3.49 (1.89-7.80) and 4.57 (2.08-8.90) hours for GE.",Comparative pharmacokinetics and a clinical laboratory evaluation of intravenous acetaminophen in Beagle and Galgo Español dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713054/),h,4.57,148405,DB00160,L-Alanine
,2115494,peak serum concentration,Serum concentrations of gamma-interferon were measured by radioimmunoassay in four patients after a subcutaneous injection of 10 million U (0.5 mg); the peak serum concentration of gamma-interferon (29 +/- 7 U/ml) was reached after 5 to 8 hr and gamma-interferon remained detectable for 24 to 36 hr.,"Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115494/),[u] / [ml],29,148744,DB00160,L-Alanine
,32961233,binding energy,Six compounds had desirable physicochemical and pharmacokinetic properties with excellent binding energy ranged between -12.27 and -10.09 kcal/mol.,Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32961233/),[kcal] / [mol],-,149033,DB00160,L-Alanine
,32961233,binding energy,Six compounds had desirable physicochemical and pharmacokinetic properties with excellent binding energy ranged between -12.27 and -10.09 kcal/mol.,Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32961233/),[kcal] / [mol],12.27,149034,DB00160,L-Alanine
,32961233,binding energy,Six compounds had desirable physicochemical and pharmacokinetic properties with excellent binding energy ranged between -12.27 and -10.09 kcal/mol.,Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32961233/),[kcal] / [mol],10.09,149035,DB00160,L-Alanine
,19396600,oral bioavailability,The oral bioavailability of brivanib varied among species (22-88%) and showed dissolution rate-limited absorption even when combined with organic co-solvents.,"Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396600/),%,22-88,149105,DB00160,L-Alanine
,19396600,oral bioavailability,"Administration of brivanib as brivanib alaninate allowed completely aqueous vehicles, and an improvement in the oral bioavailability (55-97%) was observed.","Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396600/),%,55-97,149106,DB00160,L-Alanine
<,19396600,hepatic extraction ratio,"The clearance of brivanib in humans is anticipated to be low to intermediate (hepatic extraction ratio < 0.7), while its volume of distribution is expected to be high.","Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396600/),,0.7,149107,DB00160,L-Alanine
>,25797054,solubility,The solubility of propofol in the semifluorinated alkane perfluorohexyloctane (F6H8) is very high (>300 mg/ml).,Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats--A comparative study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25797054/),[mg] / [ml],300,149780,DB00160,L-Alanine
,8053919,steady-state plasma 5-FU concentration,5-FU at 40 mg/kg/24 hr resulted in a steady-state plasma 5-FU concentration of 1.3 microM and was fatal with dogs dying from apparent neurotoxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,1.3,149785,DB00160,L-Alanine
,8053919,total clearance,5-Ethynyluracil lowered the total clearance of 5-FU from 9.9 to 0.2 L/hr/kg and enabled 1.6 mg/kg/24 hr 5-FU to achieve a steady-state plasma 5-FU concentration of 2.4 microM with no apparent toxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),[l] / [h·kg],9.9 to 0.2,149786,DB00160,L-Alanine
,8053919,steady-state plasma 5-FU concentration,5-Ethynyluracil lowered the total clearance of 5-FU from 9.9 to 0.2 L/hr/kg and enabled 1.6 mg/kg/24 hr 5-FU to achieve a steady-state plasma 5-FU concentration of 2.4 microM with no apparent toxicity.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,2.4,149787,DB00160,L-Alanine
,8053919,steady-state plasma 5-FU concentration,5-FU at 4 mg/kg/24 hr achieved a steady-state plasma 5-FU concentration of 5.3 microM and produced only mild gastrointestinal disturbances in 5-ethynyluracil-treated dogs.,5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053919/),μM,5.3,149788,DB00160,L-Alanine
,22993862,MPE,"MPE is 0.1% for scheme 6 and -0.6% for scheme 3, respectively.",[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),%,0.1,150645,DB00160,L-Alanine
,22993862,MAPE,MAPE is 0.7% for both schemes.,[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22993862/),,0,150646,DB00160,L-Alanine
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151074,DB00160,L-Alanine
,16940981,MTD/RD,"The MTD/RD were determined to be 1,200/1,000 mg m(-2), respectively.",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151075,DB00160,L-Alanine
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,200",151076,DB00160,L-Alanine
,16940981,MTD/RD,"The MTD/RD of pemetrexed were determined to be 1,200/1,000 mg m(-2), respectively, that is, a higher RD than without FA/VB(12) (500 mg m(-2)).",A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16940981/),[mg] / [(m)^2],"1,000",151077,DB00160,L-Alanine
,26645407,bioavailability,"Trastuzumab PK was described by a two-compartment model with parallel linear and nonlinear elimination and first-order SC absorption, with a bioavailability of 77 %.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),%,77,151103,DB00160,L-Alanine
,26645407,total clearance (CL),Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[l] / [d],0.18-0.22,151104,DB00160,L-Alanine
,26645407,steady-state trough/peak concentrations,Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[μg] / [ml],75-148,151105,DB00160,L-Alanine
,26645407,central volume of distribution,Estimated total clearance (CL) values were 0.18-0.22 L/day for steady-state trough/peak concentrations of 75-148 µg/mL; the estimate for central volume of distribution was 2.9 L.,"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),l,2.9,151106,DB00160,L-Alanine
,26645407,steady-state trough concentrations,"A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),[μg] / [ml],35-123,151107,DB00160,L-Alanine
,26645407,steady-state trough concentrations,"A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy.","Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous ""manual syringe"" injection or intravenously in women with HER2-positive early breast cancer. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26645407/),,20,151108,DB00160,L-Alanine
,8445218,plasma peak concentration,A significantly increased mean plasma peak concentration (40.0 +/- 13.6 ng/ml vs. 25.5 +/- 7.9 ng/ml; p < 0.05) and a decreased apparent oral clearance (7.8 +/- 6.0 l/h vs. 16.4 +/- 5.4 l/h; p < 0.05) of cilazapril were found in cirrhotic patients compared to healthy volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [ml],40.0,151497,DB00160,L-Alanine
,8445218,plasma peak concentration,A significantly increased mean plasma peak concentration (40.0 +/- 13.6 ng/ml vs. 25.5 +/- 7.9 ng/ml; p < 0.05) and a decreased apparent oral clearance (7.8 +/- 6.0 l/h vs. 16.4 +/- 5.4 l/h; p < 0.05) of cilazapril were found in cirrhotic patients compared to healthy volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [ml],25.5,151498,DB00160,L-Alanine
,8445218,apparent oral clearance,A significantly increased mean plasma peak concentration (40.0 +/- 13.6 ng/ml vs. 25.5 +/- 7.9 ng/ml; p < 0.05) and a decreased apparent oral clearance (7.8 +/- 6.0 l/h vs. 16.4 +/- 5.4 l/h; p < 0.05) of cilazapril were found in cirrhotic patients compared to healthy volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[l] / [h],7.8,151499,DB00160,L-Alanine
,8445218,apparent oral clearance,A significantly increased mean plasma peak concentration (40.0 +/- 13.6 ng/ml vs. 25.5 +/- 7.9 ng/ml; p < 0.05) and a decreased apparent oral clearance (7.8 +/- 6.0 l/h vs. 16.4 +/- 5.4 l/h; p < 0.05) of cilazapril were found in cirrhotic patients compared to healthy volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[l] / [h],16.4,151500,DB00160,L-Alanine
,8445218,plasma half-life,In both phases the plasma half-life was significantly longer in patients with cirrhosis (1st phase: 2.5 +/- 0.8 h vs. 1.7 +/- 0.6 h; p < 0.05; 2nd phase: 46.2 +/- 16.6 h vs. 28.8 +/- 4.7 h; p < 0.001).,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),h,2.5,151501,DB00160,L-Alanine
,8445218,plasma half-life,In both phases the plasma half-life was significantly longer in patients with cirrhosis (1st phase: 2.5 +/- 0.8 h vs. 1.7 +/- 0.6 h; p < 0.05; 2nd phase: 46.2 +/- 16.6 h vs. 28.8 +/- 4.7 h; p < 0.001).,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),h,1.7,151502,DB00160,L-Alanine
,8445218,plasma half-life,In both phases the plasma half-life was significantly longer in patients with cirrhosis (1st phase: 2.5 +/- 0.8 h vs. 1.7 +/- 0.6 h; p < 0.05; 2nd phase: 46.2 +/- 16.6 h vs. 28.8 +/- 4.7 h; p < 0.001).,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),h,46.2,151503,DB00160,L-Alanine
,8445218,plasma half-life,In both phases the plasma half-life was significantly longer in patients with cirrhosis (1st phase: 2.5 +/- 0.8 h vs. 1.7 +/- 0.6 h; p < 0.05; 2nd phase: 46.2 +/- 16.6 h vs. 28.8 +/- 4.7 h; p < 0.001).,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),h,28.8,151504,DB00160,L-Alanine
,8445218,concentrations,"Consequently, cilazaprilat concentrations at 24 h were higher in patients than in volunteers (1.42 +/- 0.33 ng/ml vs. 0.87 +/- 0.14 ng/ml; p < 0.001).",Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [ml],1.42,151505,DB00160,L-Alanine
,8445218,concentrations,"Consequently, cilazaprilat concentrations at 24 h were higher in patients than in volunteers (1.42 +/- 0.33 ng/ml vs. 0.87 +/- 0.14 ng/ml; p < 0.001).",Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [ml],0.87,151506,DB00160,L-Alanine
,8445218,activity,The predose activity of the ACE (26.3 +/- 7.3 U/l vs. 16.8 +/- 4.5 U/l; p < 0.005) and plasma renin activity (3.3 +/- 3.2 ng/ml/h vs. 1.4 +/- 1.0 ng/ml/h) were higher in patients than in volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[u] / [l],26.3,151507,DB00160,L-Alanine
,8445218,activity,The predose activity of the ACE (26.3 +/- 7.3 U/l vs. 16.8 +/- 4.5 U/l; p < 0.005) and plasma renin activity (3.3 +/- 3.2 ng/ml/h vs. 1.4 +/- 1.0 ng/ml/h) were higher in patients than in volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[u] / [l],16.8,151508,DB00160,L-Alanine
,8445218,plasma renin activity,The predose activity of the ACE (26.3 +/- 7.3 U/l vs. 16.8 +/- 4.5 U/l; p < 0.005) and plasma renin activity (3.3 +/- 3.2 ng/ml/h vs. 1.4 +/- 1.0 ng/ml/h) were higher in patients than in volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [h·ml],3.3,151509,DB00160,L-Alanine
,8445218,plasma renin activity,The predose activity of the ACE (26.3 +/- 7.3 U/l vs. 16.8 +/- 4.5 U/l; p < 0.005) and plasma renin activity (3.3 +/- 3.2 ng/ml/h vs. 1.4 +/- 1.0 ng/ml/h) were higher in patients than in volunteers.,Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445218/),[ng] / [h·ml],1.4,151510,DB00160,L-Alanine
,8688997,Clearance,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[ml] / [min],350,152437,DB00160,L-Alanine
,8688997,t1/2,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),h,4,152438,DB00160,L-Alanine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],0.7,152439,DB00160,L-Alanine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],1.7,152440,DB00160,L-Alanine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],4.4,152441,DB00160,L-Alanine
,15647411,CL(CR),"The authors evaluated the pharmacokinetics and safety of posaconazole in healthy subjects and in those with mild (CL(CR) = 50-80 mL/min), moderate (CL(CR) = 20-49 mL/min), and severe chronic renal disease (CL(CR) <20 mL/min; receiving outpatient hemodialysis) (n = 6/group).","Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647411/),,50-,153098,DB00160,L-Alanine
,15647411,Protein binding,Protein binding was similar in all groups (approximately 98%) and was unaffected by hemodialysis.,"Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647411/),%,98,153099,DB00160,L-Alanine
,18839779,Relative bioavailiability,Relative bioavailiability of the oral liquid compared with tablets or capsules was 46.6%.,A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18839779/),%,46.6,153167,DB00160,L-Alanine
>,18839779,trough level,Children carrying the CYP2B6-516-G/G genotype had a 50-70% probability of developing a subtherapeutic trough level of efavirenz and only 1-3% probability of developing a trough level >4 mg/l.,A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18839779/),[mg] / [l],4,153168,DB00160,L-Alanine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,292.2,154091,DB00160,L-Alanine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,163.2,154092,DB00160,L-Alanine
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,237.1,154093,DB00160,L-Alanine
>,8474102,bioavailability,"Both 25 and 32 showed excellent bioavailability in the rat and ferret (> 25%) and, while subject to hepatic elimination in the monkey, were efficacious in this species.","Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474102/),%,25,154225,DB00160,L-Alanine
,6740548,half-lives,"Mean half-lives were 5.5 +/- SD 3.5 hr and 10 +/- SD 3.5 hr, respectively.",Thrombus-related uptake and vascular clearance of 131 I-fibrin des-AABB as compared to 125 I-fibrinogen in patients with established venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740548/),h,5.5,155227,DB00160,L-Alanine
,6740548,half-lives,"Mean half-lives were 5.5 +/- SD 3.5 hr and 10 +/- SD 3.5 hr, respectively.",Thrombus-related uptake and vascular clearance of 131 I-fibrin des-AABB as compared to 125 I-fibrinogen in patients with established venous thrombosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740548/),h,10,155228,DB00160,L-Alanine
,6740548,Metabolic half-life,Metabolic half-life of fibrinogen in the total material was 62 +/- SD 19 hr.,Thrombus-related uptake and vascular clearance of 131 I-fibrin des-AABB as compared to 125 I-fibrinogen in patients with established venous thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740548/),h,62,155229,DB00160,L-Alanine
,33249379,Tmax,"Median Tmax (n = 16) was ∼6 h; geometric means of AUC0-24 h (n = 16) and Cmax (n = 16) at steady state were 22,000 ng*h/mL and 1080 ng/mL, respectively.",Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33249379/),h,∼6,155883,DB00160,L-Alanine
,33249379,AUC0-24 h,"Median Tmax (n = 16) was ∼6 h; geometric means of AUC0-24 h (n = 16) and Cmax (n = 16) at steady state were 22,000 ng*h/mL and 1080 ng/mL, respectively.",Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33249379/),[h·ng] / [ml],"22,000",155884,DB00160,L-Alanine
,33249379,Cmax,"Median Tmax (n = 16) was ∼6 h; geometric means of AUC0-24 h (n = 16) and Cmax (n = 16) at steady state were 22,000 ng*h/mL and 1080 ng/mL, respectively.",Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33249379/),[ng] / [ml],1080,155885,DB00160,L-Alanine
,33249379,progression-free survival,"The ORR was 41.7 % (95 % confidence interval [CI]: 32.1-51.9), and median progression-free survival was 7.2 months (95 % CI: 4.1-7.5).",Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33249379/),month,7,155886,DB00160,L-Alanine
,33249379,overall survival,Median overall survival was 17.5 months (95 % CI: 10.8-24.3).,Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33249379/),month,17.5,155887,DB00160,L-Alanine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00160,L-Alanine
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00160,L-Alanine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00160,L-Alanine
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00160,L-Alanine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00160,L-Alanine
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00160,L-Alanine
,20497746,clearance,"Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1.",Population pharmacokinetics of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497746/),[l] / [h],1.03,155926,DB00160,L-Alanine
,23609628,T(1/2),"Related to the long half-life (T(1/2) 71-91 h after SC dosing), repeated dosing at weekly intervals may result in drug accumulation and enhanced toxicity.",Intravenous and subcutaneous toxicity and absorption kinetics in mice and dogs of the antileishmanial triterpene saponin PX-6518. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609628/),h,71-91,157176,DB00160,L-Alanine
,30604333,oral bioavailability,Rebamipide has low oral bioavailability (10%) due to its low solubility and permeability.,"Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),%,10,158222,DB00160,L-Alanine
,30604333,globule size,"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),nm,230.3,158223,DB00160,L-Alanine
,30604333,polydispersity index (PDI),"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),nm,279.8,158224,DB00160,L-Alanine
,30604333,polydispersity index (PDI),"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),m,0.204,158225,DB00160,L-Alanine
,30604333,zeta potential (ZP),"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),m,0.246,158226,DB00160,L-Alanine
,30604333,zeta potential (ZP),"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),m,27.7,158227,DB00160,L-Alanine
,30604333,zeta potential (ZP),"The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and - 27.7 ± 2.05 to - 31.0 ± 1.87 mV, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),m,31.0,158228,DB00160,L-Alanine
,30604333,Entrapment efficiency,"Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),%,99.90,158229,DB00160,L-Alanine
,30604333,Entrapment efficiency,"Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),%,99.92,158230,DB00160,L-Alanine
,30604333,Entrapment efficiency,"Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),,99.3,158231,DB00160,L-Alanine
,30604333,Entrapment efficiency,"Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively.","Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30604333/),,99.6,158232,DB00160,L-Alanine
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,17,158525,DB00160,L-Alanine
,19650675,elimination half-life,"This approach was evaluated in silico and applied to imatinib and capecitabine, the pharmacokinetics of which are described in the literature, and which have quite different pharmacokinetic characteristics (imatinib has an elimination half-life of 17 hours, and alpha-fluoro-beta-alanine [FBAL], the metabolite of capecitabine, has an elimination half-life of 3 hours).",Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650675/),h,3,158526,DB00160,L-Alanine
,31366828,relative bioavailability,"The plasma concentration curve showed that compared with LEF group, the peak concentration of TEF microemulsion group was decreased, the half-life (t1/2) was prolonged, and the relative bioavailability of TEF microemulsion was 75.35%.",Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366828/),%,75.35,158954,DB00160,L-Alanine
,28750271,disease control rate,"Among the efficacy-evaluable population, two patients (5%) had a partial response; the disease control rate was 74% at cycle 2.","Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28750271/),%,74,159270,DB00160,L-Alanine
,21831954,MTD,The MTD in patients with HCC (Child-Pugh class A) was 600 mg QD.,"Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831954/),mg,600,159485,DB00160,L-Alanine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.0375,159981,DB00160,L-Alanine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.375,159982,DB00160,L-Alanine
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],3.75,159983,DB00160,L-Alanine
,24136086,Terminal half-lives,Terminal half-lives were about 22 h for unchanged safinamide and 80 h for radioactivity.,"Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24136086/),h,22,160041,DB00160,L-Alanine
,24136086,Terminal half-lives,Terminal half-lives were about 22 h for unchanged safinamide and 80 h for radioactivity.,"Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24136086/),h,80,160042,DB00160,L-Alanine
,15855512,50% effective concentration (EC(50)),"The 50% effective concentration (EC(50)) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 microM compared to an EC(50) of 5 microM for the parent drug, tenofovir.",Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),μM,0.005,160053,DB00160,L-Alanine
,15855512,EC(50),"The 50% effective concentration (EC(50)) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 microM compared to an EC(50) of 5 microM for the parent drug, tenofovir.",Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),μM,5,160054,DB00160,L-Alanine
,15855512,half-life,GS 7340 has a half-life of 90 min in human plasma at 37 degrees C and a half-life of 28.3 min in an MT-2 cell extract at 37 degrees C.,Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),min,90,160055,DB00160,L-Alanine
,15855512,half-life,GS 7340 has a half-life of 90 min in human plasma at 37 degrees C and a half-life of 28.3 min in an MT-2 cell extract at 37 degrees C.,Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),min,28.3,160056,DB00160,L-Alanine
,15855512,plasma bioavailability,"After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an intravenous dose of tenofovir was 17%.",Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),%,17,160057,DB00160,L-Alanine
,15855512,total intracellular concentration,The total intracellular concentration of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 microg-eq/ml compared to 0.2 microg-eq/ml in plasma.,Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),[μg-eq] / [ml],63,160058,DB00160,L-Alanine
,15855512,total intracellular concentration,The total intracellular concentration of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 microg-eq/ml compared to 0.2 microg-eq/ml in plasma.,Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855512/),[μg-eq] / [ml],0.2,160059,DB00160,L-Alanine
,11758009,plasma half-life,The plasma half-life of beta-IFN was found to be 6.91 +/- 2.80 (mean +/- SD) minutes.,Pharmacokinetic study of human natural beta-interferon in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758009/),min,6.91,160694,DB00160,L-Alanine
,11758009,volume of distribution,The initial volume of distribution was found to be 0.49 +/- 0.02 l/kg.,Pharmacokinetic study of human natural beta-interferon in patients with end-stage renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11758009/),[l] / [kg],0.49,160695,DB00160,L-Alanine
,14519628,activated partial thromboplastin time,There was a significant difference between the mean preinfusion and postinfusion activated partial thromboplastin time measurements (2.05 s; P = 0.029).,A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14519628/),s,2.05,160993,DB00160,L-Alanine
,15031301,BBB,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [g·min],0.0515,161317,DB00160,L-Alanine
,15031301,permeation influx rates,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [g·min],0.0515,161318,DB00160,L-Alanine
,15031301,permeation influx rates,"The in vivo BBB permeation influx rates of 125I-ADAB and 125I-ADAMB after an i.v. bolus injection into mice were determined to be 0.0515 +/- 0.0284 microl/(min.g of brain) and 0.0290 +/- 0.0059 microl/(min.g of brain), respectively, both rates being slower than that of 125I-Tyr-D-Arg-Phe-betaAla-OH (125I-TAPA), a [D-Arg2]dermorphin tetrapeptide analog.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),[μl] / [brain·g·min],0.0290,161319,DB00160,L-Alanine
,15031301,half-saturation constant (Kd),"The internalization of both 125I-ADAB and 125I-ADAMB into cells was concentration-dependent with half-saturation constant (Kd) values of 3.76 +/- 0.83 and 5.68 +/- 1.75 microM, respectively.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),μM,3.76,161320,DB00160,L-Alanine
,15031301,half-saturation constant (Kd),"The internalization of both 125I-ADAB and 125I-ADAMB into cells was concentration-dependent with half-saturation constant (Kd) values of 3.76 +/- 0.83 and 5.68 +/- 1.75 microM, respectively.",Blood-brain barrier permeability of novel [D-arg2]dermorphin (1-4) analogs: transport property is related to the slow onset of antinociceptive activity in the central nervous system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031301/),μM,5.68,161321,DB00160,L-Alanine
,1512928,plasma half-lives,"The following results were obtained: 1. Upon 30-minute intravenous drip infusion at a dose of 20 mg/kg, plasma concentrations of PAPM/BP reached their peaks at the end of drip infusion with average values of 62.94/47.32 micrograms/ml, and their plasma half-lives were 1.00/0.51 hour in the beta-phase.",[Studies on panipenem/betamipron in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),h,1.00,161538,DB00160,L-Alanine
,1512928,peak plasma concentrations,"Upon 30-minute intravenous drip infusion at a dose of 10 mg/kg, peak plasma concentrations were 32.10/23.76 micrograms/ml and plasma half-lives were 0.93/0.59 hour.",[Studies on panipenem/betamipron in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),[μg] / [ml],32.10,161539,DB00160,L-Alanine
,1512928,plasma half-lives,"Upon 30-minute intravenous drip infusion at a dose of 10 mg/kg, peak plasma concentrations were 32.10/23.76 micrograms/ml and plasma half-lives were 0.93/0.59 hour.",[Studies on panipenem/betamipron in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),h,0.93,161540,DB00160,L-Alanine
,1512928,urinary excretion rates,"2. The urinary excretion rates of PAPM/BP after 30-minute intravenous infusion at doses of 20 and 10 mg/kg were 25.09/81.04% and 32.14/84.66%, respectively.",[Studies on panipenem/betamipron in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),%,25.09,161541,DB00160,L-Alanine
,1512928,urinary excretion rates,"2. The urinary excretion rates of PAPM/BP after 30-minute intravenous infusion at doses of 20 and 10 mg/kg were 25.09/81.04% and 32.14/84.66%, respectively.",[Studies on panipenem/betamipron in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),%,32.14,161542,DB00160,L-Alanine
,1512928,eradication rate,"4. Bacteria identified from various diseases involved 11 strains of 6 species, and the eradication rate was 90.9%.",[Studies on panipenem/betamipron in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512928/),%,90.9,161543,DB00160,L-Alanine
,18927308,progression-free survival,Median progression-free survival was 9.2 months.,Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18927308/),month,9.2,161686,DB00160,L-Alanine
,16897970,area under the curve (AUC0-10h),"The area under the curve (AUC0-10h) of 5-FU on day 5 was 728 +/- 113 ng x hr/ml for PVI of 5-FU and 1,364 +/- 374 ng x hr/ml for S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],728,163169,DB00160,L-Alanine
,16897970,area under the curve (AUC0-10h),"The area under the curve (AUC0-10h) of 5-FU on day 5 was 728 +/- 113 ng x hr/ml for PVI of 5-FU and 1,364 +/- 374 ng x hr/ml for S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"1,364",163170,DB00160,L-Alanine
,16897970,AUC0-10h,"The AUC0-10h of FBAL on day 5 of PVI of 5-FU was 9,465 +/- 3,225 ng x hr/ml, AUC0-10h, as compared with 1,725 +/- 605 ng x hr/ml on day 5 of S-1 treatment.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"9,465",163171,DB00160,L-Alanine
,16897970,AUC0-10h,"The AUC0-10h of FBAL on day 5 of PVI of 5-FU was 9,465 +/- 3,225 ng x hr/ml, AUC0-10h, as compared with 1,725 +/- 605 ng x hr/ml on day 5 of S-1 treatment.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"1,725",163172,DB00160,L-Alanine
,16897970,AUC0-10h,"The AUC0-10h of uracil on day 5 was 252 +/- 60 ng x hr/ml with PVI of 5-FU and 12,582 +/- 3,060 ng x hr/ml with S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],252,163173,DB00160,L-Alanine
,16897970,AUC0-10h,"The AUC0-10h of uracil on day 5 was 252 +/- 60 ng x hr/ml with PVI of 5-FU and 12,582 +/- 3,060 ng x hr/ml with S-1.","[Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil]. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16897970/),[h·ng] / [ml],"12,582",163174,DB00160,L-Alanine
,31711752,plasma half-life (t1/2),"In part 1, ABI-H0731 reached maximum plasma concentrations (Tmax) in 2·50-4·17 h; the mean plasma half-life (t1/2) was 23·5-28·4 h.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),h,23·5-28·4,163183,DB00160,L-Alanine
,31711752,maximum,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),,1·7,163184,DB00160,L-Alanine
,31711752,maximum,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),i,2·1,163185,DB00160,L-Alanine
,31711752,maximum,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),,2·8,163186,DB00160,L-Alanine
,31711752,DNA declines,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),,1·7,163187,DB00160,L-Alanine
,31711752,DNA declines,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),i,2·1,163188,DB00160,L-Alanine
,31711752,DNA declines,"In part 2, mean maximum HBV DNA declines from baseline were 1·7 log10 IU/mL in the 100 mg dose cohort, 2·1 log10 IU/mL in the 200 mg dose cohort, and 2·8 log10 IU/mL in the 300 mg dose cohort.","Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31711752/),,2·8,163189,DB00160,L-Alanine
,20679501,AUC(0-∞),"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[h·μg] / [ml],279.7,163812,DB00160,L-Alanine
,20679501,AUC(0-∞),"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[h·μg] / [ml],374.9,163813,DB00160,L-Alanine
,20679501,peak concentrations,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],29.4,163814,DB00160,L-Alanine
,20679501,peak concentrations,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],33.5,163815,DB00160,L-Alanine
,20679501,24,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],2.8,163816,DB00160,L-Alanine
,20679501,24,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],4.2,163817,DB00160,L-Alanine
,20679501,concentrations,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],2.8,163818,DB00160,L-Alanine
,20679501,concentrations,"Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],4.2,163819,DB00160,L-Alanine
,20679501,AUC(0-24),"Following multiple 100-mg doses of caspofungin, day 21 geometric mean AUC(0-24) was 227.4 µg·h/mL, peak concentration was 20.9 µg/mL, and trough concentration was 4.7 µg/mL.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[h·μg] / [ml],227.4,163820,DB00160,L-Alanine
,20679501,peak concentration,"Following multiple 100-mg doses of caspofungin, day 21 geometric mean AUC(0-24) was 227.4 µg·h/mL, peak concentration was 20.9 µg/mL, and trough concentration was 4.7 µg/mL.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],20.9,163821,DB00160,L-Alanine
,20679501,trough concentration,"Following multiple 100-mg doses of caspofungin, day 21 geometric mean AUC(0-24) was 227.4 µg·h/mL, peak concentration was 20.9 µg/mL, and trough concentration was 4.7 µg/mL.",Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),[μg] / [ml],4.7,163822,DB00160,L-Alanine
,20679501,Beta-phase t(1/2),Beta-phase t(1/2) was ~8 to ~13 hours.,Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679501/),h,8 to,163823,DB00160,L-Alanine
,12015787,clearance (CL),"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),[ml] / [min],42.7,164124,DB00160,L-Alanine
,12015787,half lives,"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),min,0.48,164125,DB00160,L-Alanine
,12015787,half lives,"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),min,3.98,164126,DB00160,L-Alanine
,12015787,half lives,"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),[ml] / [min],48.0,164127,DB00160,L-Alanine
,12015787,half lives,"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),min,0.59,164128,DB00160,L-Alanine
,12015787,half lives,"The clearance (CL) and half lives of the distribution and elimination phases following the 0.28 microg (n=6) i.v. dose were 42.7+/-26.2 (S.D.) ml/min, 0.48+/-0.17 min, and 3.98+/-0.92 min, while those of the 500 microg dose (n=6) were 48.0+/-23.3 ml/min, 0.59+/-0.25, and 6.81+/-3.12 min, respectively, suggesting apparent linear kinetics.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),min,6.81,164129,DB00160,L-Alanine
,12015787,CL,The CL values were close to the cardiac output of rats (50 ml/min) indicating very rapid elimination from the body.,"The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),[ml] / [min],50,164130,DB00160,L-Alanine
,12015787,bioavailability (F),"Mean bioavailability (F) values following p.o. (n=15), jejunal (n=4), and ileal (n=16) administration were 0.40+/-0.24% (S.E.), 1.25+/-0.39, and 1.78+/-0.40, respectively, and were not significantly different (p<0.05) among three doses (1, 1000, 5000 microg).","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),%,0.40,164131,DB00160,L-Alanine
,12015787,bioavailability (F),"Mean bioavailability (F) values following p.o. (n=15), jejunal (n=4), and ileal (n=16) administration were 0.40+/-0.24% (S.E.), 1.25+/-0.39, and 1.78+/-0.40, respectively, and were not significantly different (p<0.05) among three doses (1, 1000, 5000 microg).","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),,1.25,164132,DB00160,L-Alanine
,12015787,bioavailability (F),"Mean bioavailability (F) values following p.o. (n=15), jejunal (n=4), and ileal (n=16) administration were 0.40+/-0.24% (S.E.), 1.25+/-0.39, and 1.78+/-0.40, respectively, and were not significantly different (p<0.05) among three doses (1, 1000, 5000 microg).","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),,1.78,164133,DB00160,L-Alanine
,12015787,F,"The F value of YdAGFdL following ileal administration in the presence of amastatin was 8.76+/-4.47% (n=6), a 22 fold increase over po administration and a five fold increase over ileal administration without an inhibitor.","The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12015787/),%,8,164134,DB00160,L-Alanine
,32423668,specific activity,The specific activity of SpIFTase was determined to be 420.84 ± 6.21 U mg-1 at pH 6.5 and 45 °C.,Biochemical characterization of a novel thermostable DFA I-forming inulin fructotransferases from Streptomyces peucetius subsp. caesius ATCC 27952. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423668/),[u] / [mg],420.84,164165,DB00160,L-Alanine
,32423668,half-life,The enzyme exhibited a prominent thermostability with a half-life of 70 min at 70 °C and a structural melting temperature (Tm) of 75.48 °C.,Biochemical characterization of a novel thermostable DFA I-forming inulin fructotransferases from Streptomyces peucetius subsp. caesius ATCC 27952. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423668/),min,70,164166,DB00160,L-Alanine
,32423668,structural melting temperature (Tm),The enzyme exhibited a prominent thermostability with a half-life of 70 min at 70 °C and a structural melting temperature (Tm) of 75.48 °C.,Biochemical characterization of a novel thermostable DFA I-forming inulin fructotransferases from Streptomyces peucetius subsp. caesius ATCC 27952. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423668/),°c,75.48,164167,DB00160,L-Alanine
,32423668,Km,"The values of Km and kcat/Km of SpIFTase against inulin substrate were 3.08 mM and 199.09 mM-1 s-1, respectively.",Biochemical characterization of a novel thermostable DFA I-forming inulin fructotransferases from Streptomyces peucetius subsp. caesius ATCC 27952. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423668/),mM,3.08,164168,DB00160,L-Alanine
,32423668,kcat/Km,"The values of Km and kcat/Km of SpIFTase against inulin substrate were 3.08 mM and 199.09 mM-1 s-1, respectively.",Biochemical characterization of a novel thermostable DFA I-forming inulin fructotransferases from Streptomyces peucetius subsp. caesius ATCC 27952. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423668/),1/[mM·s],199.09,164169,DB00160,L-Alanine
,24807346,fetal-to-maternal,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164557,DB00160,L-Alanine
,24807346,concentration ratio,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164558,DB00160,L-Alanine
,24807346,f,"The prodrug, dabigatran etexilate mesylate, had limited placental transfer as characterized by a fetal-to-maternal ratio of 0.17 (interquartile range 0.15-0.17) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.17,164559,DB00160,L-Alanine
,2810721,serum peak concentrations,The serum peak concentrations of CPDX in 5 patients were between 1.37 and 4.10 micrograms/ml (mean: 2.53 micrograms/ml) at 1 to 6 hours after dosing 3 mg/kg before meals.,[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),[μg] / [ml],1.37 and 4.10,166209,DB00160,L-Alanine
,2810721,serum peak concentrations,The serum peak concentrations of CPDX in 5 patients were between 1.37 and 4.10 micrograms/ml (mean: 2.53 micrograms/ml) at 1 to 6 hours after dosing 3 mg/kg before meals.,[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),[μg] / [ml],2.53,166210,DB00160,L-Alanine
,2810721,Portions,"Portions of CPDX excreted into urine within 6 hours ranged from 20.3 to 34.3% (mean 27.1%) in 5 patients who were given 3 mg/kg, and ranged from 24.1 to 65.7% (mean 41.1%) in 4 patients given 6 mg/kg.",[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),%,20.3 to 34.3,166211,DB00160,L-Alanine
,2810721,Portions,"Portions of CPDX excreted into urine within 6 hours ranged from 20.3 to 34.3% (mean 27.1%) in 5 patients who were given 3 mg/kg, and ranged from 24.1 to 65.7% (mean 41.1%) in 4 patients given 6 mg/kg.",[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),%,27.1,166212,DB00160,L-Alanine
,2810721,Portions,"Portions of CPDX excreted into urine within 6 hours ranged from 20.3 to 34.3% (mean 27.1%) in 5 patients who were given 3 mg/kg, and ranged from 24.1 to 65.7% (mean 41.1%) in 4 patients given 6 mg/kg.",[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),%,41.1,166213,DB00160,L-Alanine
,2810721,excreted into urine,"Portions of CPDX excreted into urine within 6 hours ranged from 20.3 to 34.3% (mean 27.1%) in 5 patients who were given 3 mg/kg, and ranged from 24.1 to 65.7% (mean 41.1%) in 4 patients given 6 mg/kg.",[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),%,27.1,166214,DB00160,L-Alanine
,2810721,excreted into urine,"Portions of CPDX excreted into urine within 6 hours ranged from 20.3 to 34.3% (mean 27.1%) in 5 patients who were given 3 mg/kg, and ranged from 24.1 to 65.7% (mean 41.1%) in 4 patients given 6 mg/kg.",[Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810721/),%,41.1,166215,DB00160,L-Alanine
,15965311,plasma half-life,The plasma half-life of LY450139 was approximately 2.5 hours.,"Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965311/),h,2.5,166383,DB00160,L-Alanine
,15965311,Cmax,"Pharmacokinetic analyses showed a linear relationship between dose and plasma concentrations, with a Cmax of 828 +/- 19.2 ng/mL after a 50-mg dose.","Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965311/),[ng] / [ml],828,166384,DB00160,L-Alanine
,31899602,time of maximum plasma concentration (tmax ),"Ubrogepant SD-OCT demonstrated linear PK appropriate for acute treatment of migraine, with rapid uptake (time of maximum plasma concentration (tmax ): 2-3 hours) and no accumulation with daily use.",Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31899602/),h,2-3,166711,DB00160,L-Alanine
,32286934,Imax,"The overall population Imax and IC50, together with 95% confidence interval, was estimated to be 0.913 (0.899-0.925) and 9.07 (8.08-10.1) ng/mL, respectively.","Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286934/),[ng] / [ml],0.913,167078,DB00160,L-Alanine
,32286934,IC50,"The overall population Imax and IC50, together with 95% confidence interval, was estimated to be 0.913 (0.899-0.925) and 9.07 (8.08-10.1) ng/mL, respectively.","Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32286934/),[ng] / [ml],9.07,167079,DB00160,L-Alanine
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.357,167174,DB00160,L-Alanine
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.017,167175,DB00160,L-Alanine
,25791895,mean transit time,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),d,9.5,167176,DB00160,L-Alanine
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.3,167177,DB00160,L-Alanine
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.03,167178,DB00160,L-Alanine
,7968592,clearances,"All dipeptides were cleared rapidly from the blood (clearances ranged from 42.9 +/- 3.28 mL/min/kg body weight for GlyGln to 278 +/- 70.7 for GlnAla, mean +/- SD).",The effect of dipeptide structure on dipeptide and amino acid clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7968592/),[ml] / [body·kg·min·weight],42.9,167238,DB00160,L-Alanine
,7968592,clearances,"All dipeptides were cleared rapidly from the blood (clearances ranged from 42.9 +/- 3.28 mL/min/kg body weight for GlyGln to 278 +/- 70.7 for GlnAla, mean +/- SD).",The effect of dipeptide structure on dipeptide and amino acid clearance in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7968592/),,278,167239,DB00160,L-Alanine
greater,2778650,oral LD50,It was also noted that the oral LD50 value of 1 was greater than 6 g/kg in mice.,A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778650/),[g] / [kg],6,167319,DB00160,L-Alanine
,23613432,terminal half-life,The pharmacokinetics of PEG-Ala in blood and plasma revealed a biphasic elimination with a terminal half-life of 20 h.,Biodistribution and excretion of radiolabeled 40 kDa polyethylene glycol following intravenous administration in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23613432/),h,20,168168,DB00160,L-Alanine
,22123335,maximum tolerated dose,The maximum tolerated dose was 12 mg/m and dose-limiting toxicity was grade 3 increased aspartate aminotransferase and alanine aminotransferase.,"Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22123335/),,12,168392,DB00160,L-Alanine
,19540299,maximum plasma concentrations,"The maximum plasma concentrations of AP and DIAP were 1.42+/-0.09 microg/ml and 1.31+/-0.04 microg/ml, respectively.",Absorption of andrographolides from Andrographis paniculata and its effect on CCl(4)-induced oxidative stress in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540299/),[μg] / [ml],1.42,168562,DB00160,L-Alanine
,19540299,maximum plasma concentrations,"The maximum plasma concentrations of AP and DIAP were 1.42+/-0.09 microg/ml and 1.31+/-0.04 microg/ml, respectively.",Absorption of andrographolides from Andrographis paniculata and its effect on CCl(4)-induced oxidative stress in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540299/),[μg] / [ml],1.31,168563,DB00160,L-Alanine
,7122685,half-time,"After i.v. administration of doses of 1-10 mg TAPAP/kg a biphasic course of the plasma level resulted, the second phase of which has a half-time of about 5 h.","[Animal experiments on the pharmacokinetics of N alpha-tosyl-(3-amidinophenyl)alanine piperidide (TAPAP), a new thrombin inhibitor]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122685/),h,5,169063,DB00160,L-Alanine
,7122685,Binding,Binding to plasma proteins amounted to about 50%.,"[Animal experiments on the pharmacokinetics of N alpha-tosyl-(3-amidinophenyl)alanine piperidide (TAPAP), a new thrombin inhibitor]. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7122685/),%,50,169064,DB00160,L-Alanine
,22861192,MTD,The MTD was 4·5 mg/kg.,"A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22861192/),[mg] / [kg],4·5,169895,DB00160,L-Alanine
≥,22861192,receptor occupancy,"At doses ≥3·0 mg/kg, sustained receptor occupancy (≥87%), observed throughout weekly infusions up to 5 weeks after the last infusion, correlated with an estimated half-life of 4-19 d.","A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22861192/),%,87,169896,DB00160,L-Alanine
,22861192,half-life,"At doses ≥3·0 mg/kg, sustained receptor occupancy (≥87%), observed throughout weekly infusions up to 5 weeks after the last infusion, correlated with an estimated half-life of 4-19 d.","A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22861192/),d,4-19,169897,DB00160,L-Alanine
,30336808,Cavg,"The Cavg values for OA and TD were 2.95 ± 1.60 ng/mL and 2.83 ± 1.43 ng/mL, respectively.","Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study . ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336808/),[ng] / [ml],2.95,170076,DB00160,L-Alanine
,30336808,Cavg,"The Cavg values for OA and TD were 2.95 ± 1.60 ng/mL and 2.83 ± 1.43 ng/mL, respectively.","Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study . ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336808/),[ng] / [ml],2.83,170077,DB00160,L-Alanine
,30336808,Cmax,"The Cmax values at steady state for OA and TD were 5.98 ± 2.27 ng/mL and 3.91 ± 2.23 ng/mL, respectively.","Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336808/),[ng] / [ml],5.98,170078,DB00160,L-Alanine
,30336808,Cmax,"The Cmax values at steady state for OA and TD were 5.98 ± 2.27 ng/mL and 3.91 ± 2.23 ng/mL, respectively.","Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336808/),[ng] / [ml],3.91,170079,DB00160,L-Alanine
,12942110,area under the curve (AUC(0-10 h)),The area under the curve (AUC(0-10 h)) of 5-FU on day 5 was 728+/-113 ng h ml(-1) for PVI of 5-FU and 1364+/-374 ng h ml(-1) for S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],728,170962,DB00160,L-Alanine
,12942110,area under the curve (AUC(0-10 h)),The area under the curve (AUC(0-10 h)) of 5-FU on day 5 was 728+/-113 ng h ml(-1) for PVI of 5-FU and 1364+/-374 ng h ml(-1) for S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],1364,170963,DB00160,L-Alanine
,12942110,ratio of the AUC(0-10 h),The median 5-FU PVI : S-1 ratio of the AUC(0-10 h) of 5-FU was 1.9.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),,1.9,170964,DB00160,L-Alanine
,12942110,AUC(0-10 h),"The AUC(0-10 h) of FBAL on day 5 of PVI of 5-FU was 9465+/-3225 ng h ml(-1), AUC(0-10 h), as compared with 1725+/-605 ng h ml(-1) on day 5 of S-1 treatment.","Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],9465,170965,DB00160,L-Alanine
,12942110,AUC(0-10 h),"The AUC(0-10 h) of FBAL on day 5 of PVI of 5-FU was 9465+/-3225 ng h ml(-1), AUC(0-10 h), as compared with 1725+/-605 ng h ml(-1) on day 5 of S-1 treatment.","Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],1725,170966,DB00160,L-Alanine
,12942110,AUC(0-10 h),The AUC(0-10 h) of uracil on day 5 was 252+/-60 ng h ml(-1) with PVI of 5-FU and 12 582+/-3060 ng h ml(-1) with S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],252,170967,DB00160,L-Alanine
,12942110,AUC(0-10 h),The AUC(0-10 h) of uracil on day 5 was 252+/-60 ng h ml(-1) with PVI of 5-FU and 12 582+/-3060 ng h ml(-1) with S-1.,"Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942110/),[h·ng] / [ml],12 582,170968,DB00160,L-Alanine
,24508897,Cmax,"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate.","Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24508897/),[ng] / [ml],13,171036,DB00160,L-Alanine
,24508897,Cmax,"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate.","Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24508897/),[ng] / [ml],207,171037,DB00160,L-Alanine
,24508897,AUC0-t,"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate.","Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24508897/),[h·ng] / [ml],383,171038,DB00160,L-Alanine
,24508897,AUC0-t,"Administration of 40 mg of tenofovir alafenamide for 14 days resulted in lower tenofovir Cmax (13 versus 207 ng/mL) and lower systemic exposures (AUC0-t, 383 versus 1810 ng · h/mL) compared with subjects who received tenofovir disoproxil fumarate.","Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24508897/),[h·ng] / [ml],1810,171039,DB00160,L-Alanine
,2197852,area under the plasma concentration-time curve (AUC),"Evaluation of the area under the plasma concentration-time curve (AUC) for phenylalanine also showed no significant difference between groups (197 +/- 49.1 vs 182 +/- 28.3 mumol.L-1.h for aspartame alone and aspartame plus sucrose, respectively).",Effect of sucrose on the metabolic disposition of aspartame. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197852/),[h·μM] / [l],197,171432,DB00160,L-Alanine
,2197852,area under the plasma concentration-time curve (AUC),"Evaluation of the area under the plasma concentration-time curve (AUC) for phenylalanine also showed no significant difference between groups (197 +/- 49.1 vs 182 +/- 28.3 mumol.L-1.h for aspartame alone and aspartame plus sucrose, respectively).",Effect of sucrose on the metabolic disposition of aspartame. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197852/),[h·μM] / [l],182,171433,DB00160,L-Alanine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.668,172319,DB00160,L-Alanine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.682,172320,DB00160,L-Alanine
,3151015,Plasma concentrations,Plasma concentrations of uridine were between 1 and 1.5 mM at 30 min after an iv bolus injection of 400 mg uridine/kg in rabbits and reached peak levels of 2 mM after a 1-hr infusion of 12 g uridine/m2 in man.,Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3151015/),mM,1 and 1.5,173630,DB00160,L-Alanine
,3151015,peak levels,Plasma concentrations of uridine were between 1 and 1.5 mM at 30 min after an iv bolus injection of 400 mg uridine/kg in rabbits and reached peak levels of 2 mM after a 1-hr infusion of 12 g uridine/m2 in man.,Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3151015/),mM,2,173631,DB00160,L-Alanine
,3151015,mean residence time,The mean residence time for uridine in patients and rabbits varied between 80 and 195 min.,Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3151015/),min,80 and 195,173632,DB00160,L-Alanine
,3151015,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) for uridine in rabbits was 2.0 mmol.hr/liter, and that for cytidine was 0.6 mmol.",Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3151015/),[h·mM] / [l],2.0,173633,DB00160,L-Alanine
,3151015,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) for uridine in rabbits was 2.0 mmol.hr/liter, and that for cytidine was 0.6 mmol.",Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3151015/),mM,0.6,173634,DB00160,L-Alanine
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,938",174365,DB00160,L-Alanine
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"2,002",174366,DB00160,L-Alanine
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,999",174367,DB00160,L-Alanine
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,913",174368,DB00160,L-Alanine
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,956",174369,DB00160,L-Alanine
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,958",174370,DB00160,L-Alanine
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],26.0,174371,DB00160,L-Alanine
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],27.3,174372,DB00160,L-Alanine
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],26.7,174373,DB00160,L-Alanine
,1346956,theoretical maximum serum concentration,The mean theoretical maximum serum concentration in the group taking gentamicin once daily (10.9 micrograms/ml) was significantly higher than in the group taking it twice daily (7.4 micrograms/ml).,Pharmacokinetics and antibacterial activity of daily gentamicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346956/),[μg] / [ml],10.9,175577,DB00160,L-Alanine
,1346956,theoretical maximum serum concentration,The mean theoretical maximum serum concentration in the group taking gentamicin once daily (10.9 micrograms/ml) was significantly higher than in the group taking it twice daily (7.4 micrograms/ml).,Pharmacokinetics and antibacterial activity of daily gentamicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346956/),[μg] / [ml],7.4,175578,DB00160,L-Alanine
,1346956,trough concentrations,Mean trough concentrations were comparable in both groups (once daily 0.8 micrograms/ml; twice daily 1.0 micrograms/ml).,Pharmacokinetics and antibacterial activity of daily gentamicin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346956/),[μg] / [ml],0.8,175579,DB00160,L-Alanine
,1346956,trough concentrations,Mean trough concentrations were comparable in both groups (once daily 0.8 micrograms/ml; twice daily 1.0 micrograms/ml).,Pharmacokinetics and antibacterial activity of daily gentamicin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346956/),[μg] / [ml],1.0,175580,DB00160,L-Alanine
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,23,176267,DB00160,L-Alanine
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,27,176268,DB00160,L-Alanine
,11805220,IC(50),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,49,176269,DB00160,L-Alanine
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,1.0,176270,DB00160,L-Alanine
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,3.0,176271,DB00160,L-Alanine
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.2,176272,DB00160,L-Alanine
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.8,176273,DB00160,L-Alanine
,11805220,ED(50),"In a rat model of ionophore-induced peritoneal eicosanoid production, SC-57461 inhibited LTB(4) production in a dose-dependent manner (ED(50) = 0.3-1 mg/kg) without affecting LTC(4) or 6-keto-prostaglandin F(1alpha) production.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.3-1,176274,DB00160,L-Alanine
,11805220,ED(90),"Oral pretreatment with SC-57461 in a rat reversed passive dermal Arthus model blocked LTB(4) production with an ED(90) value of 3 to 10 mg/kg, demonstrating good penetration of drug into skin.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],3 to 10,176275,DB00160,L-Alanine
,16741313,half-life at alpha-phase,"(111)In-DTPA-hEGF was cleared rapidly from the blood, with a half-life at alpha-phase of 2.7-6.2 min and a half-life at beta-phase of 24.0-36.3 min.","Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741313/),min,2.7-6.2,176277,DB00160,L-Alanine
,16741313,half-life at beta-phase,"(111)In-DTPA-hEGF was cleared rapidly from the blood, with a half-life at alpha-phase of 2.7-6.2 min and a half-life at beta-phase of 24.0-36.3 min.","Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741313/),min,24.0-36.3,176278,DB00160,L-Alanine
,16741313,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 340-375 mL/kg, and the volume of distribution at steady state was 430-685 mL/kg.","Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741313/),[ml] / [kg],340-375,176279,DB00160,L-Alanine
,16741313,volume of distribution at steady state,"The volume of distribution of the central compartment was 340-375 mL/kg, and the volume of distribution at steady state was 430-685 mL/kg.","Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16741313/),[ml] / [kg],430-685,176280,DB00160,L-Alanine
,17019740,clearance,"Plasma ultrafiltrate platinum pharmacokinetic parameters were similar to adults, with a median clearance of 12.2 L/hr (range, 4.4-30 L/hr) and median area under the curve (AUC(0-infinity)) of 9.4 microg/mL/hr (range, 6.2-13.9 microg/mL/hr).","Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17019740/),[l] / [h],12.2,176529,DB00160,L-Alanine
,17019740,area under the curve (AUC(0-infinity)),"Plasma ultrafiltrate platinum pharmacokinetic parameters were similar to adults, with a median clearance of 12.2 L/hr (range, 4.4-30 L/hr) and median area under the curve (AUC(0-infinity)) of 9.4 microg/mL/hr (range, 6.2-13.9 microg/mL/hr).","Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17019740/),[μg] / [h·ml],9.4,176530,DB00160,L-Alanine
,22139410,peak plasma concentration,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),[μM] / [l],82,176578,DB00160,L-Alanine
,22139410,peak plasma concentration,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),[μM] / [l],248,176579,DB00160,L-Alanine
,22139410,time to peak,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),h,1.0,176580,DB00160,L-Alanine
,22139410,time to peak,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),h,0.5,176581,DB00160,L-Alanine
,22139410,loss in urine,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),μM,202,176582,DB00160,L-Alanine
,22139410,loss in urine,"TAB resulted in a smaller peak plasma concentration than REF (82 vs. 248 μmol L(-1), p<0.001), delayed time to peak (1.0 vs. 0.5 h, p<0.01) no difference in area under the curve, reduced loss in urine (202 vs. 663 μmol, p<0.0001), and improved retention (98.9 vs. 96.3%, p<0.001).",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),μM,663,176583,DB00160,L-Alanine
,22139410,Tmax,"Symptoms described as ""pins and needles"" were perceived rapidly on the skin of the arms and trunk after REF (Tmax=15 min) and their time course nearly mimicked plasma concentrations.",Effect of slow-release β-alanine tablets on absorption kinetics and paresthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139410/),min,15,176584,DB00160,L-Alanine
less,15633260,trough concentration,"Among them, 8 of 56 (14.3%) at week 1, 12 of 56 (21.4%) at week 4, and 9 of 56 (16.1%) at week 12 had suboptimal LPV plasma concentrations, defined as trough concentration less than 4 microg/mL.",Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15633260/),[μg] / [ml],4,176630,DB00160,L-Alanine
,34392453,Clinical benefit rate (CBR),Clinical benefit rate (CBR) in 16 weeks was 23.1% (3/13).,Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34392453/),%,23.1,177540,DB00160,L-Alanine
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,4558,178766,DB00160,L-Alanine
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,"136,572",178767,DB00160,L-Alanine
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,2896,178768,DB00160,L-Alanine
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,"35,819",178769,DB00160,L-Alanine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1740,178770,DB00160,L-Alanine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1253,178771,DB00160,L-Alanine
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],127,178772,DB00160,L-Alanine
≥,31081020,Cmin,To evaluate the proportion of children with lopinavir Cmin ≥1 mg/L when receiving a novel 8-hourly lopinavir/ritonavir dosing strategy during rifampicin co-treatment.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179033,DB00160,L-Alanine
,31081020,Cmin,The median (IQR) lopinavir Cmin was 3.0 (0.1-5.5) mg/L. Seven (63.6%) of the 11 children had Cmin values ≥1 mg/L.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],3.0,179034,DB00160,L-Alanine
≥,31081020,Cmin,The median (IQR) lopinavir Cmin was 3.0 (0.1-5.5) mg/L. Seven (63.6%) of the 11 children had Cmin values ≥1 mg/L.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179035,DB00160,L-Alanine
<,31081020,Cmin,Children with a lopinavir mg/kg dose below the median 21.5 were more likely to have Cmin <1 mg/L (P = 0.02).,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179036,DB00160,L-Alanine
,16864999,C(20%T)>(MIC),"C(20%T)>(MIC) for a standard dosage regimen of panipenem was 4.3 microg/ml, and the optimal dosage regimen for the patients was established based on this value.",Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16864999/),[μg] / [ml],4.3,179066,DB00160,L-Alanine
,23575478,T(max),"IPI-926 pharmacokinetics were characterized by a slow absorption (T(max) = 2-8 hours) and a terminal half-life (t(1/2)) between 20 and 40 hours, supporting QD dosing.",Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575478/),h,2-8,179359,DB00160,L-Alanine
,23575478,terminal half-life (t(1/2)),"IPI-926 pharmacokinetics were characterized by a slow absorption (T(max) = 2-8 hours) and a terminal half-life (t(1/2)) between 20 and 40 hours, supporting QD dosing.",Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23575478/),h,20 and 40,179360,DB00160,L-Alanine
greater,1648946,drug delivery rates,Repeated low dose bolus injections did not cause down-regulation of the galactose receptor and targeted drug delivery rates of greater than or equal to 2 micrograms DOX g-1 liver h-1 were achieved.,N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1648946/),μg,2,179587,DB00160,L-Alanine
,27886532,t1/2,"The pharmacokinetic result indicated that elimination of (-)-R-benalaxyl in plasma was slightly faster with the t1/2 of 26.65 h and 28.88 h for (-)-R- and (+)-S-benalaxyl, respectively.",Enantioselective metabolism and enantiomerization of benalaxyl in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886532/),h,26.65,180021,DB00160,L-Alanine
,27886532,t1/2,"The pharmacokinetic result indicated that elimination of (-)-R-benalaxyl in plasma was slightly faster with the t1/2 of 26.65 h and 28.88 h for (-)-R- and (+)-S-benalaxyl, respectively.",Enantioselective metabolism and enantiomerization of benalaxyl in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886532/),h,28.88,180022,DB00160,L-Alanine
,28389275,half-life time,Pharmacokinetics researches demonstrated the half-life time of OMT HSPC liposomes was 17.10h in mice.,"Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28389275/),h,17.10,180477,DB00160,L-Alanine
,21590449,Plasma clearance,Plasma clearance and its between-subject variability was 43.7 L/h (34%).,Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590449/),[l] / [h],43.7,181232,DB00160,L-Alanine
,21590449,Volume of distribution at steady state,Volume of distribution at steady state was 822 L (117%).,Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590449/),l,822,181233,DB00160,L-Alanine
,16520988,MTD,The MTD of twice-daily schedule was determined as 300 mg/day.,Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520988/),[mg] / [d],300,181736,DB00160,L-Alanine
,31156041,circulating half-life,"In mice, the circulating half-life of AD-114 was extended from 0.18 h to 7.77 h following conjugation to PA600, and in cynomolgus monkeys, the circulating half-life of AD-114-PA600 was 24.27 h.",Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156041/),h,0.18,182280,DB00160,L-Alanine
,31156041,circulating half-life,"In mice, the circulating half-life of AD-114 was extended from 0.18 h to 7.77 h following conjugation to PA600, and in cynomolgus monkeys, the circulating half-life of AD-114-PA600 was 24.27 h.",Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156041/),h,7.77,182281,DB00160,L-Alanine
,31156041,circulating half-life,"In mice, the circulating half-life of AD-114 was extended from 0.18 h to 7.77 h following conjugation to PA600, and in cynomolgus monkeys, the circulating half-life of AD-114-PA600 was 24.27 h.",Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156041/),h,24.27,182282,DB00160,L-Alanine
,21294597,total clearance after oral administration (CL/F),"Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (V(d)/F) were 7.92 L/h and 248 L, respectively.",Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[l] / [h],7.92,182687,DB00160,L-Alanine
,21294597,volume of distribution after oral administration (V(d)/F),"Population estimates of total clearance after oral administration (CL/F) and volume of distribution after oral administration (V(d)/F) were 7.92 L/h and 248 L, respectively.",Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),l,248,182688,DB00160,L-Alanine
,21294597,MPE,MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL.,Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[μg] / [ml],0.206,182689,DB00160,L-Alanine
,21294597,MAPE,MPE was 0.206 μg/mL (not significantly different from zero) and MAPE was 0.99 μg/mL.,Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294597/),[μg] / [ml],0.99,182690,DB00160,L-Alanine
,11840401,extraction ratios,"In contrast, the final 5-FU catabolite alpha-fluoro-beta-alanine (FBAL) accumulated to a concentration of 276 micromol/L on day 5 (approximately twofold higher than expected from the literature) despite good removal by hemodialysis with extraction ratios of 0.6 to 0.85 over the filter membrane.",Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11840401/),,0.6 to 0.85,182968,DB00160,L-Alanine
,22036862,half-life,"The half-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively.",Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22036862/),h,1.26,183721,DB00160,L-Alanine
,22036862,half-life,"The half-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively.",Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22036862/),h,1.31,183722,DB00160,L-Alanine
,22036862,half-life,"The half-life of hemoporfin for doses of 2.5, 5, and 7.5 mg/kg was 1.26 h, 1.31 h, and 1.70 h, respectively.",Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22036862/),h,1.70,183723,DB00160,L-Alanine
less,22036862,Urinary excretion,Urinary excretion of hemoporfin within 12 h was less than 0.2%.,Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22036862/),%,0.2,183724,DB00160,L-Alanine
,33063303,absolute oral bioavailability,The absolute oral bioavailability of puerarin was approximately 1% in both preparations.,Comparative Pharmacokinetics of Puerarin Alone and in Pueraria mirifica Extract in Female Cynomolgus Monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063303/),%,1,185028,DB00160,L-Alanine
,25896688,systemic exposure,"The implant maintained a low systemic exposure to TAF (median, 0.85 ng ml(-1); interquartile range [IQR], 0.60 to 1.50 ng ml(-1)) and tenofovir (TFV; median, 15.0 ng ml(-1); IQR, 8.8 to 23.3 ng ml(-1)), the product of in vivo TAF hydrolysis.",Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25896688/),[ng] / [ml],0.85,185050,DB00160,L-Alanine
,25896688,systemic exposure,"The implant maintained a low systemic exposure to TAF (median, 0.85 ng ml(-1); interquartile range [IQR], 0.60 to 1.50 ng ml(-1)) and tenofovir (TFV; median, 15.0 ng ml(-1); IQR, 8.8 to 23.3 ng ml(-1)), the product of in vivo TAF hydrolysis.",Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25896688/),[ng] / [ml],15.0,185051,DB00160,L-Alanine
,16914578,maximum tolerated dose,The maximum tolerated dose for non-EIAED patients was 800 mg/d.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),mg,800,185829,DB00160,L-Alanine
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,3,185830,DB00160,L-Alanine
,16914578,progression-free survival,Six-month progression-free survival was 3% for glioblastoma multiforme and 10% for anaplastic glioma patients.,Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16914578/),%,10,185831,DB00160,L-Alanine
,25008848,Km,Uptake of Phe-Ψ-Ala in PEPT1-overexpressing HeLa cells was significantly higher than that in vector-transfected HeLa cells and the Km value was 275 ± 32 µM.,"Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),μM,275,186899,DB00160,L-Alanine
,25008848,clearance,"The clearance, distribution volume, and half-life of intravenously administered Phe-Ψ-Ala in rats were 0.151 ± 0.008 L/h/kg, 0.235 ± 0.012 L/kg, and 1.14 ± 0.07 h, respectively.","Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),[l] / [h·kg],0.151,186900,DB00160,L-Alanine
,25008848,distribution volume,"The clearance, distribution volume, and half-life of intravenously administered Phe-Ψ-Ala in rats were 0.151 ± 0.008 L/h/kg, 0.235 ± 0.012 L/kg, and 1.14 ± 0.07 h, respectively.","Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),[l] / [kg],0.235,186901,DB00160,L-Alanine
,25008848,half-life,"The clearance, distribution volume, and half-life of intravenously administered Phe-Ψ-Ala in rats were 0.151 ± 0.008 L/h/kg, 0.235 ± 0.012 L/kg, and 1.14 ± 0.07 h, respectively.","Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),h,1.14,186902,DB00160,L-Alanine
,25008848,maximum plasma concentration,"The maximum plasma concentration of orally administered Phe-Ψ-Ala (2.31 ± 0.60 µg/mL) in the presence of Gly-Sar was significantly decreased compared with that in the absence of glycylsarcosine (3.74 ± 0.44 µg/mL), suggesting that the intestinal absorption of Phe-Ψ-Ala is mediated by intestinal PEPT1.","Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),[μg] / [ml],2.31,186903,DB00160,L-Alanine
,25008848,maximum plasma concentration,"The maximum plasma concentration of orally administered Phe-Ψ-Ala (2.31 ± 0.60 µg/mL) in the presence of Gly-Sar was significantly decreased compared with that in the absence of glycylsarcosine (3.74 ± 0.44 µg/mL), suggesting that the intestinal absorption of Phe-Ψ-Ala is mediated by intestinal PEPT1.","Evaluation of a thiodipeptide, L-phenylalanyl-Ψ[CS-N]-L-alanine, as a novel probe for peptide transporter 1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25008848/),[μg] / [ml],3.74,186904,DB00160,L-Alanine
,2040035,t1/2 gamma,"Large interindividual differences were demonstrated (mean t1/2 gamma, 21.6 +/- 7.9 h; range, 10.6-69 h; n = 110).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,21.6,187706,DB00160,L-Alanine
,2040035,t1/2 gamma,"The metabolite epirubicinol appeared quickly after epirubicin administration and its half-lives were shorter than that of the parent compound (mean t1/2 gamma, 18.1 +/- 4.8 h; range, 8.2-38.4 h; n = 105).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,18.1,187707,DB00160,L-Alanine
,2040035,t1/2 gamma,"Formation of the aglycone metabolite was delayed and the half-life of this metabolite was shorter than that of epirubicin (mean t1/2 gamma, 13 +/- 4.6 h; range, 2.7-29 h; n = 104).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,13,187708,DB00160,L-Alanine
,29191916,time to maximum concentration,"Single-dose duvelisib was rapidly absorbed (time to maximum concentration, 1-2 hours), with a half-life of 5.2 to 10.9 hours.","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),h,1-2,188094,DB00160,L-Alanine
,29191916,half-life,"Single-dose duvelisib was rapidly absorbed (time to maximum concentration, 1-2 hours), with a half-life of 5.2 to 10.9 hours.","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),h,5.2 to 10.9,188095,DB00160,L-Alanine
,29191916,overall response rate,"Clinical responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n = 55) with 1 CR; peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19).","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),%,58,188096,DB00160,L-Alanine
,29191916,overall response rate,"Clinical responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n = 55) with 1 CR; peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19).","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),%,56,188097,DB00160,L-Alanine
,29191916,overall response rate,"Clinical responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n = 55) with 1 CR; peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19).","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),%,50,188098,DB00160,L-Alanine
,29191916,overall response rate,"Clinical responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n = 55) with 1 CR; peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19).","Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),%,32,188099,DB00160,L-Alanine
,29191916,time to response,Median time to response was ∼1.8 months.,"Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29191916/),month,∼1.8,188100,DB00160,L-Alanine
,27350068,overall response rate,"The overall response rate was 56.3%, suggesting that the combined treatment was effective.",Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350068/),%,56.3,188340,DB00160,L-Alanine
,12891228,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 15.7 ng/mL (range, 1.6-55.0 ng/mL), and the mean time to reach C(max) was 1.4 hours (range, 0.5-4 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),[ng] / [ml],15.7,188534,DB00160,L-Alanine
,12891228,time to reach C(max),"The mean peak plasma concentration (C(max)) of pravastatin was 15.7 ng/mL (range, 1.6-55.0 ng/mL), and the mean time to reach C(max) was 1.4 hours (range, 0.5-4 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),h,1.4,188535,DB00160,L-Alanine
,12891228,elimination half-life,"The mean elimination half-life of pravastatin was 1.6 hours (range, 0.85-4.2 hours).",Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),h,1.6,188536,DB00160,L-Alanine
,12891228,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of pravastatin ranged from 5.7 to 58.9 ng.,Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891228/),ng,5.7 to 58.9,188537,DB00160,L-Alanine
,11156226,total body clearance,"At this dose, the mean value +/- SD for total body clearance was 59 +/- 31 liters/h, and the mean t(1/2) was 89 +/- 41 h.",Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156226/),[l] / [h],59,188895,DB00160,L-Alanine
,11156226,t(1/2),"At this dose, the mean value +/- SD for total body clearance was 59 +/- 31 liters/h, and the mean t(1/2) was 89 +/- 41 h.",Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11156226/),h,89,188896,DB00160,L-Alanine
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],2534,188953,DB00160,L-Alanine
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1980,188954,DB00160,L-Alanine
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1831,188955,DB00160,L-Alanine
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1715,188956,DB00160,L-Alanine
,12520623,Cmax,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7216,188957,DB00160,L-Alanine
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[ng] / [ml],1980,188958,DB00160,L-Alanine
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],"11,957",188959,DB00160,L-Alanine
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],"10,781",188960,DB00160,L-Alanine
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7216,188961,DB00160,L-Alanine
,12520623,AUC,"The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng.h/ml after single doses and were 1831 and 1715 ng/ml and 7216 and 7838 ng.h/ml after multiple doses, respectively, in healthy subjects and patients.","Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520623/),[h·ng] / [ml],7838,188962,DB00160,L-Alanine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32-35,191092,DB00160,L-Alanine
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32,191093,DB00160,L-Alanine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4315-5027,191094,DB00160,L-Alanine
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4398,191095,DB00160,L-Alanine
,30074167,T1/2,"T1/2 of plasma baicalin in the model group was significantly extended to (11.09±1.84) h, with clearance dropping to 61.78% of that of the normal control group (P<0.01).",Pharmacokinetic Characteristics of Baicalin in Rats with 17α-ethynyl-estradiol-induced Intrahepatic Cholestasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30074167/),h,11.09,191231,DB00160,L-Alanine
,33508482,half-life,"Second, in the hollow fiber system model of TB [HFS-TB] using Mtb H37Ra strain, we recapitulated vancomycin intrapulmonary pharmacokinetics of eight doses administered twice daily over 28 days, mimicking a 6-h half-life.",Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),h,6,191523,DB00160,L-Alanine
,33508482,MICs,Vancomycin MICs were 12 and 48 mg/L in drug-susceptible clinical isolates but >96 mg/L in all MDR isolates.,Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),[mg] / [l],12,191524,DB00160,L-Alanine
,33508482,MICs,Vancomycin MICs were 12 and 48 mg/L in drug-susceptible clinical isolates but >96 mg/L in all MDR isolates.,Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),[mg] / [l],48,191525,DB00160,L-Alanine
>,33508482,MICs,Vancomycin MICs were 12 and 48 mg/L in drug-susceptible clinical isolates but >96 mg/L in all MDR isolates.,Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),[mg] / [l],96,191526,DB00160,L-Alanine
,33508482,AUC0-24/MIC,The EC50 was calculated as AUC0-24/MIC of 184.6 ± 106.5.,Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),,184.6,191527,DB00160,L-Alanine
,33508482,AUC0-24/MIC,"Compared with day 0, 1.0 and 2.0 log10 CFU/mL kill was achieved by AUC0-24/MIC of 168 and 685, respectively.",Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),,168,191528,DB00160,L-Alanine
,33508482,AUC0-24/MIC,"Compared with day 0, 1.0 and 2.0 log10 CFU/mL kill was achieved by AUC0-24/MIC of 168 and 685, respectively.",Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33508482/),,685,191529,DB00160,L-Alanine
,1518121,half-lives,"Drug concentrations then gradually decreased with half-lives of 1.08 +/- 0.09 hours and 0.98 +/- 0.02 hour, and reached 0.39 +/- 0.14 micrograms/ml and 0.62 +/- 0.06 micrograms/ml, respectively, after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),h,1.08,191699,DB00160,L-Alanine
,1518121,half-lives,"Drug concentrations then gradually decreased with half-lives of 1.08 +/- 0.09 hours and 0.98 +/- 0.02 hour, and reached 0.39 +/- 0.14 micrograms/ml and 0.62 +/- 0.06 micrograms/ml, respectively, after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),h,0.98,191700,DB00160,L-Alanine
,1518121,half-lives,"Drug concentrations then gradually decreased with half-lives of 1.08 +/- 0.09 hours and 0.98 +/- 0.02 hour, and reached 0.39 +/- 0.14 micrograms/ml and 0.62 +/- 0.06 micrograms/ml, respectively, after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),[μg] / [ml],0.39,191701,DB00160,L-Alanine
,1518121,half-lives,"Drug concentrations then gradually decreased with half-lives of 1.08 +/- 0.09 hours and 0.98 +/- 0.02 hour, and reached 0.39 +/- 0.14 micrograms/ml and 0.62 +/- 0.06 micrograms/ml, respectively, after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),[μg] / [ml],0.62,191702,DB00160,L-Alanine
,1518121,half-lives,"Plasma BP levels at the end of drip infusion was 18.93 +/- 3.75 micrograms/ml in the cases administered 10 mg/10 mg/kg and 37.09 +/- 2.68 micrograms/ml in the cases administered 20 mg/kg, and half-lives were 0.55 +/- 0.07 hour and 0.61 +/- 0.03 hour, respectively; the plasma BP level could not be determined in any cases after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),h,0.55,191703,DB00160,L-Alanine
,1518121,half-lives,"Plasma BP levels at the end of drip infusion was 18.93 +/- 3.75 micrograms/ml in the cases administered 10 mg/10 mg/kg and 37.09 +/- 2.68 micrograms/ml in the cases administered 20 mg/kg, and half-lives were 0.55 +/- 0.07 hour and 0.61 +/- 0.03 hour, respectively; the plasma BP level could not be determined in any cases after 5.5 hours.",[Studies on panipenem/betamipron in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),h,0.61,191704,DB00160,L-Alanine
,1518121,urinary recovery rates,"Mean urinary recovery rates of PAPM in the first 6 hours after the start of intravenous drip infusion were 33.0 +/- 6.1% in the cases administered 10 mg/10 mg/kg and 21.8 +/- 2.3% in the cases administered 20 mg/20 mg/kg and those of BP were 77.0 +/- 2.4% and 76.6 +/- 7.3%, respectively.",[Studies on panipenem/betamipron in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),%,33.0,191705,DB00160,L-Alanine
,1518121,urinary recovery rates,"Mean urinary recovery rates of PAPM in the first 6 hours after the start of intravenous drip infusion were 33.0 +/- 6.1% in the cases administered 10 mg/10 mg/kg and 21.8 +/- 2.3% in the cases administered 20 mg/20 mg/kg and those of BP were 77.0 +/- 2.4% and 76.6 +/- 7.3%, respectively.",[Studies on panipenem/betamipron in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),%,21.8,191706,DB00160,L-Alanine
,1518121,urinary recovery rates,"Mean urinary recovery rates of PAPM in the first 6 hours after the start of intravenous drip infusion were 33.0 +/- 6.1% in the cases administered 10 mg/10 mg/kg and 21.8 +/- 2.3% in the cases administered 20 mg/20 mg/kg and those of BP were 77.0 +/- 2.4% and 76.6 +/- 7.3%, respectively.",[Studies on panipenem/betamipron in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),%,77.0,191707,DB00160,L-Alanine
,1518121,urinary recovery rates,"Mean urinary recovery rates of PAPM in the first 6 hours after the start of intravenous drip infusion were 33.0 +/- 6.1% in the cases administered 10 mg/10 mg/kg and 21.8 +/- 2.3% in the cases administered 20 mg/20 mg/kg and those of BP were 77.0 +/- 2.4% and 76.6 +/- 7.3%, respectively.",[Studies on panipenem/betamipron in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518121/),%,76.6,191708,DB00160,L-Alanine
,20194702,MIC(90),"A MIC(90) value of 250 ng/ml, which encompasses the majority of common dermatophytes, was used to calculate the time above the MIC(90) in plasma and skin.",Skin concentrations and pharmacokinetics of posaconazole after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20194702/),[ng] / [ml],250,194250,DB00160,L-Alanine
,12429653,terminal plasma half-life,"A 30 mg/kg i.v. dose of LErafAON in human prostate tumor (PC-3)-bearing BALB/c athymic mice gave a terminal plasma half-life of 27 h, and intact rafAON could be detected in plasma and in normal and tumor tissues for up to at least 48 h.","Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12429653/),h,27,194393,DB00160,L-Alanine
,12429653,terminal plasma half-life,"In monkeys, the terminal plasma half-life of 30.36 +/- 23.87 h was observed at an i.v. dose of 6.25 mg/kg.","Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12429653/),h,30.36,194394,DB00160,L-Alanine
,2208578,volume of distribution,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),ml,"5,984",194611,DB00160,L-Alanine
,2208578,volume of distribution,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),ml,"9,084",194612,DB00160,L-Alanine
,2208578,AUC,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),[iu·min] / [ml],"32,643",194613,DB00160,L-Alanine
,2208578,AUC,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),[iu·min] / [ml],"22,397",194614,DB00160,L-Alanine
,2208578,beta-half-life,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),min,61,194615,DB00160,L-Alanine
,2208578,beta-half-life,"During the administration of repeated high doses of IL-2, we noted a progressive increase in the volume of distribution (from 5,984 +/- 1,850 to 9,084 +/- 4,345 ml) and a progressive decrease in the AUC (from 32,643 +/- 3,817 to 22,397 +/- 511 IU min ml-1) and beta-half-life (from 61 +/- 14 to 48 +/- 6 min); the peak serum IL-2 concentrations also decreased significantly.",Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208578/),min,48,194616,DB00160,L-Alanine
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,0.26,195078,DB00160,L-Alanine
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,12.1,195079,DB00160,L-Alanine
,1346985,half-lives,"Plasma disappearance curves for FBAL could be described by the sum of three exponentials, with half-lives of 0.26, 12.1, and 8426 min.",Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346985/),min,8426,195080,DB00160,L-Alanine
,18502018,t1/2,"Pharmacokinetic parameters were consistent with previous studies: t1/2, CL and V were 16 days, 1.36 L/(h kg) and 756 L/kg, respectively.",Toxicology and pharmacokinetics of piperaquine in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502018/),d,16,195553,DB00160,L-Alanine
,18502018,CL,"Pharmacokinetic parameters were consistent with previous studies: t1/2, CL and V were 16 days, 1.36 L/(h kg) and 756 L/kg, respectively.",Toxicology and pharmacokinetics of piperaquine in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502018/),[l] / [h·kg],1.36,195554,DB00160,L-Alanine
,18502018,V,"Pharmacokinetic parameters were consistent with previous studies: t1/2, CL and V were 16 days, 1.36 L/(h kg) and 756 L/kg, respectively.",Toxicology and pharmacokinetics of piperaquine in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502018/),[l] / [kg],756,195555,DB00160,L-Alanine
,27713169,RP2D,The RP2D for oral ridaforolimus in children was defined as 33 mg/m2.,A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27713169/),[mg] / [m2],33,196488,DB00160,L-Alanine
,6519152,plasma elimination half-life,"The peak level of alaproclate was reached after about 1.5 h, and after a distribution phase, its plasma elimination half-life was between 3.0 and 3.5 h.",Influence of alaproclate on antipyrine metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519152/),h,3.0 and 3.5,197415,DB00160,L-Alanine
,25700977,volume of distribution,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),l,14.2,198924,DB00160,L-Alanine
,25700977,clearance,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),[l] / [h],2.38,198925,DB00160,L-Alanine
,9687400,absorption rate constant,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),1/[h],0. 201,198972,DB00160,L-Alanine
,9687400,clearance/bioavailability (CL/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.9,198973,DB00160,L-Alanine
,9687400,volume of the central compartment/bioavailability,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,231,198974,DB00160,L-Alanine
,9687400,intercompartmental clearance,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),[l] / [h],60.3,198975,DB00160,L-Alanine
,9687400,volume of the peripheral compartment/bioavailability (Vp/F,"Parameter estimates were the absorption rate constant (0. 201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (Vp/F; 1,050 liters).",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),l,"1,050",198976,DB00160,L-Alanine
,9687400,distribution,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,1.24,198977,DB00160,L-Alanine
,9687400,elimination half-lives,"The distribution and elimination half-lives were 1.24 and 25.4 h, respectively.",Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687400/),h,25.4,198978,DB00160,L-Alanine
,1784076,half lives (T 1/2's),"With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively.",[Pharmacokinetic and clinical evaluations of flomoxef in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784076/),min,64.9,199726,DB00160,L-Alanine
,1784076,half lives (T 1/2's),"With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively.",[Pharmacokinetic and clinical evaluations of flomoxef in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784076/),min,130.3,199727,DB00160,L-Alanine
,1784076,half lives,"With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively.",[Pharmacokinetic and clinical evaluations of flomoxef in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784076/),min,70.8,199728,DB00160,L-Alanine
,1784076,half lives,"With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively.",[Pharmacokinetic and clinical evaluations of flomoxef in neonates]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784076/),min,110.1,199729,DB00160,L-Alanine
,27616538,dose-adjusted AUC0-12,"3. The median dose-adjusted AUC0-12 of MPA after renal transplantation was significantly lower than before transplantation (57.9 versus 76.5 μg h/mL, respectively, p = 0.002).",Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616538/),[h·μg] / [ml],57.9,201675,DB00160,L-Alanine
,27616538,dose-adjusted AUC0-12,"3. The median dose-adjusted AUC0-12 of MPA after renal transplantation was significantly lower than before transplantation (57.9 versus 76.5 μg h/mL, respectively, p = 0.002).",Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616538/),[h·μg] / [ml],76.5,201676,DB00160,L-Alanine
,17076695,C(max),"C(max) of S-3304 on day 1, whose geometric mean and 95% confidence interval were 66.3 microg ml(-1) (48.8, 90.0) for 800 mg, 82.6 microg ml(-1) (69.3, 98.6) for 1600 mg, 89.5 microg ml(-1) (79.5, 100.7) for 2400 mg, and 110.5 microg ml(-1) (88.9, 137.7) for 3200 mg, respectively, was correlated with the log-transformed peak ALT (P < 0.0001 for male and P = 0.048 for female volunteers).","Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076695/),[μg] / [ml],66.3,201836,DB00160,L-Alanine
,17076695,C(max),"C(max) of S-3304 on day 1, whose geometric mean and 95% confidence interval were 66.3 microg ml(-1) (48.8, 90.0) for 800 mg, 82.6 microg ml(-1) (69.3, 98.6) for 1600 mg, 89.5 microg ml(-1) (79.5, 100.7) for 2400 mg, and 110.5 microg ml(-1) (88.9, 137.7) for 3200 mg, respectively, was correlated with the log-transformed peak ALT (P < 0.0001 for male and P = 0.048 for female volunteers).","Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076695/),[μg] / [ml],82.6,201837,DB00160,L-Alanine
,17076695,C(max),"C(max) of S-3304 on day 1, whose geometric mean and 95% confidence interval were 66.3 microg ml(-1) (48.8, 90.0) for 800 mg, 82.6 microg ml(-1) (69.3, 98.6) for 1600 mg, 89.5 microg ml(-1) (79.5, 100.7) for 2400 mg, and 110.5 microg ml(-1) (88.9, 137.7) for 3200 mg, respectively, was correlated with the log-transformed peak ALT (P < 0.0001 for male and P = 0.048 for female volunteers).","Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076695/),[μg] / [ml],89.5,201838,DB00160,L-Alanine
,17076695,C(max),"C(max) of S-3304 on day 1, whose geometric mean and 95% confidence interval were 66.3 microg ml(-1) (48.8, 90.0) for 800 mg, 82.6 microg ml(-1) (69.3, 98.6) for 1600 mg, 89.5 microg ml(-1) (79.5, 100.7) for 2400 mg, and 110.5 microg ml(-1) (88.9, 137.7) for 3200 mg, respectively, was correlated with the log-transformed peak ALT (P < 0.0001 for male and P = 0.048 for female volunteers).","Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076695/),[μg] / [ml],110.5,201839,DB00160,L-Alanine
,27059951,half-life,PF-06291874 exposure was approximately dose-proportional with a half-life of ∼19.7-22.7 h.,Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27059951/),h,∼19.7-22.7,202516,DB00160,L-Alanine
,26093949,Volume of distribution at steady state,Volume of distribution at steady state and its between-subject variability (CV%) was estimated to be 6.56 L (28 %).,Population pharmacokinetics of kahalalide F in advanced cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093949/),l,6.56,202875,DB00160,L-Alanine
,26093949,Plasma clearance,Plasma clearance was estimated to be 6.25 L/h (43 %).,Population pharmacokinetics of kahalalide F in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093949/),[l] / [h],6.25,202876,DB00160,L-Alanine
,18651716,limit of detection (LOD),The limit of detection (LOD) was determined to 0.05 ng/mL.,Analysis of ethylenethiourea as a biomarker in human urine using liquid chromatography/triple quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651716/),[ng] / [ml],0.05,203759,DB00160,L-Alanine
,18651716,elimination half-life,The elimination half-life of ETU was estimated to 17-23 h.,Analysis of ethylenethiourea as a biomarker in human urine using liquid chromatography/triple quadrupole mass spectrometry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651716/),h,17-23,203760,DB00160,L-Alanine
,11158752,time to maximum concentration,"Gemifloxacin was rapidly absorbed, with a time to maximum concentration of approximately 1 h after dosing followed by a biexponential decline in concentration.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),h,1,204150,DB00160,L-Alanine
,11158752,AUC(0-tau),"Mean +/- standard deviation values of AUC(0-tau) on day 7 were 4.92 +/- 1.08, 9.06 +/- 2.20, 12.2 +/- 3.69, and 20.1 +/- 3.67 microg x h/ml following 160-, 320-, 480-, and 640-mg doses, respectively.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),[h·μg] / [ml],4.92,204151,DB00160,L-Alanine
,11158752,AUC(0-tau),"Mean +/- standard deviation values of AUC(0-tau) on day 7 were 4.92 +/- 1.08, 9.06 +/- 2.20, 12.2 +/- 3.69, and 20.1 +/- 3.67 microg x h/ml following 160-, 320-, 480-, and 640-mg doses, respectively.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),[h·μg] / [ml],9.06,204152,DB00160,L-Alanine
,11158752,AUC(0-tau),"Mean +/- standard deviation values of AUC(0-tau) on day 7 were 4.92 +/- 1.08, 9.06 +/- 2.20, 12.2 +/- 3.69, and 20.1 +/- 3.67 microg x h/ml following 160-, 320-, 480-, and 640-mg doses, respectively.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),[h·μg] / [ml],12.2,204153,DB00160,L-Alanine
,11158752,AUC(0-tau),"Mean +/- standard deviation values of AUC(0-tau) on day 7 were 4.92 +/- 1.08, 9.06 +/- 2.20, 12.2 +/- 3.69, and 20.1 +/- 3.67 microg x h/ml following 160-, 320-, 480-, and 640-mg doses, respectively.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),[h·μg] / [ml],20.1,204154,DB00160,L-Alanine
,11158752,terminal-phase half-life,"The terminal-phase half-life was approximately 7 to 8 h, independent of dose, and was similar following single and repeated administrations.",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),h,7 to 8,204155,DB00160,L-Alanine
,11158752,renal clearance,"The renal clearance was 160 ml/min on average after single and multiple doses, which was slightly greater than the accepted glomerular filtration rate (approximately 120 ml/min).",Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11158752/),[ml] / [min],160,204156,DB00160,L-Alanine
,32943461,MTD,The MTD of crizotinib was 250 mg twice a day.,Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),mg,250,204336,DB00160,L-Alanine
,32943461,progression-free survival,"Median progression-free survival was 5.5 months (95% confidence interval, 2.8-21.2).",Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),month,5.5,204337,DB00160,L-Alanine
,32943461,C max ss,"Pharmacokinetics analysis at the MTD (n = 12) revealed a mean C max ss of 104 ± 45 ng/mL and AUCτ ss of 1,000 ± 476 ng•h/mL, representing a 74% decrease in crizotinib systemic exposure relative to historical data (C max ss, 315 ng/mL and AUCτ ss, 3,817 ng•h/mL).",Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),[ng] / [ml],104,204338,DB00160,L-Alanine
,32943461,AUCτ ss,"Pharmacokinetics analysis at the MTD (n = 12) revealed a mean C max ss of 104 ± 45 ng/mL and AUCτ ss of 1,000 ± 476 ng•h/mL, representing a 74% decrease in crizotinib systemic exposure relative to historical data (C max ss, 315 ng/mL and AUCτ ss, 3,817 ng•h/mL).",Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),[h·ng] / [ml],"1,000",204339,DB00160,L-Alanine
,32943461,C max ss,"Pharmacokinetics analysis at the MTD (n = 12) revealed a mean C max ss of 104 ± 45 ng/mL and AUCτ ss of 1,000 ± 476 ng•h/mL, representing a 74% decrease in crizotinib systemic exposure relative to historical data (C max ss, 315 ng/mL and AUCτ ss, 3,817 ng•h/mL).",Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),[ng] / [ml],315,204340,DB00160,L-Alanine
,32943461,AUCτ ss,"Pharmacokinetics analysis at the MTD (n = 12) revealed a mean C max ss of 104 ± 45 ng/mL and AUCτ ss of 1,000 ± 476 ng•h/mL, representing a 74% decrease in crizotinib systemic exposure relative to historical data (C max ss, 315 ng/mL and AUCτ ss, 3,817 ng•h/mL).",Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32943461/),[h·ng] / [ml],"3,817",204341,DB00160,L-Alanine
,2614919,peak,"In the neonates, serum concentrations of CMX after intravenous administration reached peak levels of 48.2 to 90.7 micrograms/ml (mean 70.4 +/- 14.3 micrograms/ml) in 1/4 hour, then declined with half-lives of 1.27 to 5.19 hours (mean 2.28 +/- 1.56 hours), and were 3.6 to 16.9 micrograms/ml (mean 8.3 +/- 6.0 micrograms/ml) at 6 hours.",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],48.2 to 90.7,206436,DB00160,L-Alanine
,2614919,peak,"In the neonates, serum concentrations of CMX after intravenous administration reached peak levels of 48.2 to 90.7 micrograms/ml (mean 70.4 +/- 14.3 micrograms/ml) in 1/4 hour, then declined with half-lives of 1.27 to 5.19 hours (mean 2.28 +/- 1.56 hours), and were 3.6 to 16.9 micrograms/ml (mean 8.3 +/- 6.0 micrograms/ml) at 6 hours.",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],70,206437,DB00160,L-Alanine
,2614919,half-lives,"In the neonates, serum concentrations of CMX after intravenous administration reached peak levels of 48.2 to 90.7 micrograms/ml (mean 70.4 +/- 14.3 micrograms/ml) in 1/4 hour, then declined with half-lives of 1.27 to 5.19 hours (mean 2.28 +/- 1.56 hours), and were 3.6 to 16.9 micrograms/ml (mean 8.3 +/- 6.0 micrograms/ml) at 6 hours.",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),h,1.27 to 5.19,206438,DB00160,L-Alanine
,2614919,half-lives,"In the neonates, serum concentrations of CMX after intravenous administration reached peak levels of 48.2 to 90.7 micrograms/ml (mean 70.4 +/- 14.3 micrograms/ml) in 1/4 hour, then declined with half-lives of 1.27 to 5.19 hours (mean 2.28 +/- 1.56 hours), and were 3.6 to 16.9 micrograms/ml (mean 8.3 +/- 6.0 micrograms/ml) at 6 hours.",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),h,2.28,206439,DB00160,L-Alanine
,2614919,half-lives,"In the neonates, serum concentrations of CMX after intravenous administration reached peak levels of 48.2 to 90.7 micrograms/ml (mean 70.4 +/- 14.3 micrograms/ml) in 1/4 hour, then declined with half-lives of 1.27 to 5.19 hours (mean 2.28 +/- 1.56 hours), and were 3.6 to 16.9 micrograms/ml (mean 8.3 +/- 6.0 micrograms/ml) at 6 hours.",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],8.3,206440,DB00160,L-Alanine
,2614919,serum concentrations,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),,67.5 to 111.0,206441,DB00160,L-Alanine
,2614919,serum concentrations,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],95.5,206442,DB00160,L-Alanine
,2614919,half-lives,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),h,0.64 to 0.94,206443,DB00160,L-Alanine
,2614919,half-lives,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),h,0.81,206444,DB00160,L-Alanine
,2614919,serum concentrations,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],0.2 to 1.1,206445,DB00160,L-Alanine
,2614919,serum concentrations,"In the infants, serum concentrations at 1/4 hour were 67.5 to 111.0 micrograms/ml (mean 95.5 +/- 18.0 micrograms/ml); half-lives were 0.64 to 0.94 hour (mean 0.81 +/- 0.13 hour); and the serum concentrations at 6 hours were 0.2 to 1.1 micrograms/ml (mean 0.7 +/- 0.4 micrograms/ml).",[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),[μg] / [ml],0.7,206446,DB00160,L-Alanine
,2614919,Urinary recovery rates,Urinary recovery rates in the first 6 hours after intravenous administration ranged from 43.6 to 87.5% (mean 61.6 +/- 14.6%) in the neonates and from 52.1 to 90.8% (mean 78.0 +/- 15.1%) in the infants.,[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),%,43.6 to 87.5,206447,DB00160,L-Alanine
,2614919,Urinary recovery rates,Urinary recovery rates in the first 6 hours after intravenous administration ranged from 43.6 to 87.5% (mean 61.6 +/- 14.6%) in the neonates and from 52.1 to 90.8% (mean 78.0 +/- 15.1%) in the infants.,[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),%,61.6,206448,DB00160,L-Alanine
,2614919,Urinary recovery rates,Urinary recovery rates in the first 6 hours after intravenous administration ranged from 43.6 to 87.5% (mean 61.6 +/- 14.6%) in the neonates and from 52.1 to 90.8% (mean 78.0 +/- 15.1%) in the infants.,[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),%,52.1 to 90.8,206449,DB00160,L-Alanine
,2614919,Urinary recovery rates,Urinary recovery rates in the first 6 hours after intravenous administration ranged from 43.6 to 87.5% (mean 61.6 +/- 14.6%) in the neonates and from 52.1 to 90.8% (mean 78.0 +/- 15.1%) in the infants.,[Pharmacokinetic and clinical studies on cefmenoxime in neonates and infants]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614919/),%,78.0,206450,DB00160,L-Alanine
,24130086,maximum-tolerated dose,The maximum-tolerated dose was 30 mg/m(2)/day.,Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24130086/),,30,206708,DB00160,L-Alanine
,24130086,overall remission rate,The overall remission rate was 43%.,Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24130086/),%,43,206709,DB00160,L-Alanine
,24556419,AUClast,"Higher blood concentrations of 17-βE, higher accumulation in the tissues of interest - heart and aorta, and higher accumulation within the other tissues - liver and kidney was observed on delivering 17-βE using the CREKA-peptide-modified nanoemulsion system (AUClast in plasma - 263.89±21.81min*%/injected dose/ml) as compared to the cationic nanoemulsion (AUClast in plasma - 20.2±1.86min*%/injected dose/ml) and solution form (AUClast in plasma - 44.9±1.24min*%/injected dose/ml) respectively.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),[%·min] / [dose·injected·ml],263.89,207445,DB00160,L-Alanine
,24556419,AUClast,"Higher blood concentrations of 17-βE, higher accumulation in the tissues of interest - heart and aorta, and higher accumulation within the other tissues - liver and kidney was observed on delivering 17-βE using the CREKA-peptide-modified nanoemulsion system (AUClast in plasma - 263.89±21.81min*%/injected dose/ml) as compared to the cationic nanoemulsion (AUClast in plasma - 20.2±1.86min*%/injected dose/ml) and solution form (AUClast in plasma - 44.9±1.24min*%/injected dose/ml) respectively.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),[%·min] / [dose·injected·ml],20.2,207446,DB00160,L-Alanine
,24556419,AUClast,"Higher blood concentrations of 17-βE, higher accumulation in the tissues of interest - heart and aorta, and higher accumulation within the other tissues - liver and kidney was observed on delivering 17-βE using the CREKA-peptide-modified nanoemulsion system (AUClast in plasma - 263.89±21.81min*%/injected dose/ml) as compared to the cationic nanoemulsion (AUClast in plasma - 20.2±1.86min*%/injected dose/ml) and solution form (AUClast in plasma - 44.9±1.24min*%/injected dose/ml) respectively.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),[%·min] / [dose·injected·ml],44.9,207447,DB00160,L-Alanine
,24556419,relative targeting efficiency,"Both, the cationic nanoemulsion and the CREKA-peptide-modified nanoemulsion showed a higher relative targeting efficiency of 4.57 and 4.86 respectively for 17-βE than the relative targeting efficiency of 1.78 observed with the solution form.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),,4.57,207448,DB00160,L-Alanine
,24556419,relative targeting efficiency,"Both, the cationic nanoemulsion and the CREKA-peptide-modified nanoemulsion showed a higher relative targeting efficiency of 4.57 and 4.86 respectively for 17-βE than the relative targeting efficiency of 1.78 observed with the solution form.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),,4.86,207449,DB00160,L-Alanine
,24556419,relative targeting efficiency,"Both, the cationic nanoemulsion and the CREKA-peptide-modified nanoemulsion showed a higher relative targeting efficiency of 4.57 and 4.86 respectively for 17-βE than the relative targeting efficiency of 1.78 observed with the solution form.",Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24556419/),,1.78,207450,DB00160,L-Alanine
,32843329,terminal half-life,"In tumor-bearing mice, [3H]TAK-164 exhibited a terminal half-life of approximately 41 and 51 hours in plasma and blood, respectively, with low plasma clearance (0.75 ml/h per kilogram).","Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32843329/),h,41,208101,DB00160,L-Alanine
,32843329,terminal half-life,"In tumor-bearing mice, [3H]TAK-164 exhibited a terminal half-life of approximately 41 and 51 hours in plasma and blood, respectively, with low plasma clearance (0.75 ml/h per kilogram).","Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32843329/),h,51,208102,DB00160,L-Alanine
,32843329,plasma clearance,"In tumor-bearing mice, [3H]TAK-164 exhibited a terminal half-life of approximately 41 and 51 hours in plasma and blood, respectively, with low plasma clearance (0.75 ml/h per kilogram).","Pharmacokinetics and Catabolism of [3H]TAK-164, a Guanylyl Cyclase C Targeted Antibody-Drug Conjugate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32843329/),[ml] / [h·kg],0.75,208103,DB00160,L-Alanine
,22978593,relative bioavailability,3. Dox-LA had a high relative bioavailability (1200%).,Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),%,1200,208414,DB00160,L-Alanine
,22978593,Maximum serum concentrations,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],5·1,208415,DB00160,L-Alanine
,22978593,Maximum serum concentrations,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],6·1,208416,DB00160,L-Alanine
,22978593,half-life,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),h,73·0,208417,DB00160,L-Alanine
,22978593,half-life,"Maximum serum concentrations were not statistically different (5·1 ± 1·1 µg/ml for Dox-LA and 6·1 ± 1.4 µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0 ± 0·9 h and 2·0 ± 0·02 h, respectively).",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),h,2·0,208418,DB00160,L-Alanine
,22978593,minimum effective serum concentration,"4. In conclusion, considering the minimum effective serum concentration against Mycoplasma spp is 0·5 µg/ml, a dose-interval of 180 h can be achieved with Dox-LA, but only for 24 h after Dox-PO.",Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978593/),[μg] / [ml],0·5,208419,DB00160,L-Alanine
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,1.455,208515,DB00160,L-Alanine
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,2.344,208516,DB00160,L-Alanine
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],10.997,208517,DB00160,L-Alanine
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],7.014,208518,DB00160,L-Alanine
,31637669,Overall objective response rate,Overall objective response rate was 46%.,Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31637669/),%,46,210290,DB00160,L-Alanine
,33455290,vesicle size (VS),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),nm,145.78,210807,DB00160,L-Alanine
,33455290,ζ potential (ZP),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),mv,38.03,210808,DB00160,L-Alanine
,33455290,encapsulation efficiency (EE),"The optimized liposomes formulation (RL5) was spherical with a vesicle size (VS) of 145.78 ± 9.9 nm, ζ potential (ZP) of 38.03 ± 9.12 mV, and encapsulation efficiency (EE) of 78.14 ± 8.04%.",Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33455290/),%,78.14,210809,DB00160,L-Alanine
,18941750,Plasma clearance,Plasma clearance and its between subject variability (%) was 13.6 l/h (71).,Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941750/),[l] / [h],13.6,211790,DB00160,L-Alanine
,18941750,Volume of distribution at steady-state,Volume of distribution at steady-state was calculated to be 4791 l (59).,Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941750/),l,4791,211791,DB00160,L-Alanine
,18941750,B (max),"The parameters B (max) and C (50) of the non-linear blood distribution were 471 microg/l (56) and 41.6 microg/l, respectively.",Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941750/),[μg] / [l],471,211792,DB00160,L-Alanine
,18941750,C (50),"The parameters B (max) and C (50) of the non-linear blood distribution were 471 microg/l (56) and 41.6 microg/l, respectively.",Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18941750/),[μg] / [l],41.6,211793,DB00160,L-Alanine
,24861792,time to peak level,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,1-4,211970,DB00160,L-Alanine
,24861792,half-life,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,5 and 14,211971,DB00160,L-Alanine
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,66,211972,DB00160,L-Alanine
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,33,211973,DB00160,L-Alanine
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,25,211974,DB00160,L-Alanine
,8440768,terminal half-life,"After the last dose, a mean terminal half-life of 35 hours was observed.","Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440768/),h,35,212001,DB00160,L-Alanine
,27788591,peak concentration,"Chloroform was measured using headspace gas chromatograph mass spectrometry, with a peak concentration of 2.00 μg/mL, 4 h 20 min post-ingestion.","Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),[μg] / [ml],2.00,212444,DB00160,L-Alanine
,27788591,elimination half-life,The concentration-time data fitted a 1-compartment model with elimination half-life 6.5 h.,"Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),h,6.5,212445,DB00160,L-Alanine
,7406481,Oral bioavailability,Oral bioavailability was approximately 50% and was largely independent of dose.,"Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406481/),%,50,212753,DB00160,L-Alanine
,7406481,elimination half-life,Alafosfalin has an elimination half-life of about 60 min and does not accumulate during chronic administration.,"Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406481/),min,60,212754,DB00160,L-Alanine
,7406481,recovery,"The recovery was dose dependent and increase from 6 +/- 1% after 50-mg doses to 17 +/- 1% after 2,500-mg doses.","Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406481/),%,6,212755,DB00160,L-Alanine
,7406481,recovery,"The recovery was dose dependent and increase from 6 +/- 1% after 50-mg doses to 17 +/- 1% after 2,500-mg doses.","Pharmacokinetics of alafosfalin, alone and in combination with cephalexin, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7406481/),%,17,212756,DB00160,L-Alanine
,20430774,maximum-tolerated dose,The maximum-tolerated dose was 15 mg/m(2).,A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430774/),[mg] / [m],15,213036,DB00160,L-Alanine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,17144,214135,DB00160,L-Alanine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,75,214136,DB00160,L-Alanine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,128,214137,DB00160,L-Alanine
,1440617,peak plasma concentrations,RHA/jj rats demonstrated respective 230- and 7-fold increases in the peak plasma concentrations of ALT (17144 +/- 1014 vs 75 +/- 10) and BUN (128 +/- 23 vs 18.4 +/- 0.2) compared to congenic normal controls (RHA/++) (p < 0.05).,Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1440617/),,18.4,214138,DB00160,L-Alanine
,16736150,Response rate,"Response rate in 23 patients was 4% (95% CI: 0-24%), and in 8 of 11 patients stable disease lasted > 6 months.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,4,214233,DB00160,L-Alanine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,48,214234,DB00160,L-Alanine
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,28,214235,DB00160,L-Alanine
,16736150,overall survival,"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),weeks,37,214236,DB00160,L-Alanine
,8725803,Rmax,"In the 9-hour method, mean +/- SD of ICG Rmax in healthy dogs was 0.24 +/- 0.09 mg/kg/min in male (n = 62) and was 0.23 +/- 0.06 mg/kg/min in female (n = 21) Beagles, and was 0.21 +/- 0.10 mg/kg/min in male (n = 11) and 0.20 +/- 0.07 mg/kg/min in female (n = 7) mixed-breed dogs.",Calculation of maximal removal rate of indocyanine green to measure hepatic functional mass in dogs by use of the nine-hour method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725803/),[mg] / [kg·min],0.24,215282,DB00160,L-Alanine
,8725803,Rmax,"In the 9-hour method, mean +/- SD of ICG Rmax in healthy dogs was 0.24 +/- 0.09 mg/kg/min in male (n = 62) and was 0.23 +/- 0.06 mg/kg/min in female (n = 21) Beagles, and was 0.21 +/- 0.10 mg/kg/min in male (n = 11) and 0.20 +/- 0.07 mg/kg/min in female (n = 7) mixed-breed dogs.",Calculation of maximal removal rate of indocyanine green to measure hepatic functional mass in dogs by use of the nine-hour method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725803/),[mg] / [kg·min],0.23,215283,DB00160,L-Alanine
,8725803,Rmax,"In the 9-hour method, mean +/- SD of ICG Rmax in healthy dogs was 0.24 +/- 0.09 mg/kg/min in male (n = 62) and was 0.23 +/- 0.06 mg/kg/min in female (n = 21) Beagles, and was 0.21 +/- 0.10 mg/kg/min in male (n = 11) and 0.20 +/- 0.07 mg/kg/min in female (n = 7) mixed-breed dogs.",Calculation of maximal removal rate of indocyanine green to measure hepatic functional mass in dogs by use of the nine-hour method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725803/),[mg] / [kg·min],0.21,215284,DB00160,L-Alanine
,8725803,Rmax,"In the 9-hour method, mean +/- SD of ICG Rmax in healthy dogs was 0.24 +/- 0.09 mg/kg/min in male (n = 62) and was 0.23 +/- 0.06 mg/kg/min in female (n = 21) Beagles, and was 0.21 +/- 0.10 mg/kg/min in male (n = 11) and 0.20 +/- 0.07 mg/kg/min in female (n = 7) mixed-breed dogs.",Calculation of maximal removal rate of indocyanine green to measure hepatic functional mass in dogs by use of the nine-hour method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725803/),[mg] / [kg·min],0.20,215285,DB00160,L-Alanine
,23892959,maximum tolerated dose,"The maximum tolerated dose of AZD7762 in combination with gemcitabine, 1,000 mg/m(2) was determined as 21 mg in Japanese patients.","Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892959/),mg,21,217025,DB00160,L-Alanine
,8573686,elimination half-life,"Before surgery, the mean elimination half-life was about 1.1 h and total clearance averaged 6 L h-1.",Pharmacokinetic parameters of antipyrine in dog after hepatectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573686/),h,1.1,218035,DB00160,L-Alanine
,8573686,total clearance,"Before surgery, the mean elimination half-life was about 1.1 h and total clearance averaged 6 L h-1.",Pharmacokinetic parameters of antipyrine in dog after hepatectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573686/),[l] / [h],6,218036,DB00160,L-Alanine
,30325567,Cmax,"As a result, the mean exposure of TAF among treatment groups was 125 to 154 ng/mL for Cmax and 119 to 179 ng·h/mL for AUCinf , which were comparable with the historical data in non-Japanese.","Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30325567/),[ng] / [ml],125 to 154,218539,DB00160,L-Alanine
,30325567,AUCinf,"As a result, the mean exposure of TAF among treatment groups was 125 to 154 ng/mL for Cmax and 119 to 179 ng·h/mL for AUCinf , which were comparable with the historical data in non-Japanese.","Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30325567/),[h·ng] / [ml],119 to 179,218540,DB00160,L-Alanine
,28369415,plasma AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[h·ng] / [ml],52.8,218682,DB00160,L-Alanine
,28369415,plasma AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[h·ng] / [ml],78.1,218683,DB00160,L-Alanine
,28369415,plasma AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[h·ng] / [ml],169.7,218684,DB00160,L-Alanine
,28369415,AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[fmol·h] / [10·6·cells],2268,218685,DB00160,L-Alanine
,28369415,AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[fmol·h] / [10·6·cells],4584,218686,DB00160,L-Alanine
,28369415,AUC 0-14 days,"Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC 0-14 days was 52.8 (49.5-59.6), 78.1 (68.2-86.9) and 169.7 (131.2-211.4) ng·h/mL and tenofovir-dp PBMC AUC 0-14 days was 2268 (1519-4090), 4584 (3113-5734) and 9306 (6891-10785) fmol·h/10 6 cells, respectively.",Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28369415/),[fmol·h] / [10·6·cells],9306,218687,DB00160,L-Alanine
,11234874,maximum plasma concentration,"Pharmacokinetic parameters determined at 1050 microg/m2 were (mean +/- SD): maximum plasma concentration, 318 +/- 147 pg/ml; initial disposition phase half-life, 9.0 +/- 10.3 min; terminal phase half-life, 69.0 +/- 56.7 h; and total plasma clearance, 28.4 +/- 22.5 liters/h/m2.",Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234874/),[pg] / [ml],318,219470,DB00160,L-Alanine
,11234874,initial disposition phase half-life,"Pharmacokinetic parameters determined at 1050 microg/m2 were (mean +/- SD): maximum plasma concentration, 318 +/- 147 pg/ml; initial disposition phase half-life, 9.0 +/- 10.3 min; terminal phase half-life, 69.0 +/- 56.7 h; and total plasma clearance, 28.4 +/- 22.5 liters/h/m2.",Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234874/),min,9.0,219471,DB00160,L-Alanine
,11234874,terminal phase half-life,"Pharmacokinetic parameters determined at 1050 microg/m2 were (mean +/- SD): maximum plasma concentration, 318 +/- 147 pg/ml; initial disposition phase half-life, 9.0 +/- 10.3 min; terminal phase half-life, 69.0 +/- 56.7 h; and total plasma clearance, 28.4 +/- 22.5 liters/h/m2.",Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234874/),h,69.0,219472,DB00160,L-Alanine
,11234874,total plasma clearance,"Pharmacokinetic parameters determined at 1050 microg/m2 were (mean +/- SD): maximum plasma concentration, 318 +/- 147 pg/ml; initial disposition phase half-life, 9.0 +/- 10.3 min; terminal phase half-life, 69.0 +/- 56.7 h; and total plasma clearance, 28.4 +/- 22.5 liters/h/m2.",Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11234874/),[l] / [h·m2],28.4,219473,DB00160,L-Alanine
,16842311,Cmax,"Panadol Extend produced lower Cmax (0.208 mmol/L +/- 0.02 vs 0.48 mmol/L +/- 0.02, P = 0.0001) and AUC(0-12 h) when compared with APAP-IR.",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),[mM] / [l],0.208,221043,DB00160,L-Alanine
,16842311,Cmax,"Panadol Extend produced lower Cmax (0.208 mmol/L +/- 0.02 vs 0.48 mmol/L +/- 0.02, P = 0.0001) and AUC(0-12 h) when compared with APAP-IR.",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),[mM] / [l],0.48,221044,DB00160,L-Alanine
,16842311,Tmax,"Tmax was delayed with Panadol Extend (2.83 h +/- 0.26 vs 0.94 h +/- 0.17, P = 0.0001).",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,2.83,221045,DB00160,L-Alanine
,16842311,Tmax,"Tmax was delayed with Panadol Extend (2.83 h +/- 0.26 vs 0.94 h +/- 0.17, P = 0.0001).",Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,0.94,221046,DB00160,L-Alanine
,16842311,Elimination t(1/2),Elimination t(1/2) was 1.69 +/- 0.09 h for APAP-IR and 1.65 +/- 0.13 h for Panadol Extend (not significant).,Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,1.69,221047,DB00160,L-Alanine
,16842311,Elimination t(1/2),Elimination t(1/2) was 1.69 +/- 0.09 h for APAP-IR and 1.65 +/- 0.13 h for Panadol Extend (not significant).,Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842311/),h,1.65,221048,DB00160,L-Alanine
≤,25707624,Tmax,Plasma concentration-time profiles of TAK-438 at all dose levels showed rapid absorption (median Tmax ≤2 h).,"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707624/),h,2,221117,DB00160,L-Alanine
up to,25707624,elimination half-life,Mean elimination half-life was up to 9 h.,"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707624/),h,9,221118,DB00160,L-Alanine
,17922277,base,"Mean predicted (%SEM) baseline ALT (ALT(o)) and t (1/2) in plasma were 31.5 (5.1) IU/L and 1.5 days, respectively.",Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922277/),[iu] / [l],31.5,221243,DB00160,L-Alanine
,17922277,ALT (ALT(o)),"Mean predicted (%SEM) baseline ALT (ALT(o)) and t (1/2) in plasma were 31.5 (5.1) IU/L and 1.5 days, respectively.",Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922277/),[iu] / [l],31.5,221244,DB00160,L-Alanine
,17922277,t (1/2),"Mean predicted (%SEM) baseline ALT (ALT(o)) and t (1/2) in plasma were 31.5 (5.1) IU/L and 1.5 days, respectively.",Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922277/),d,1.5,221245,DB00160,L-Alanine
,34304911,protein binding,Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist with high protein binding of 94%.,Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),%,94,223166,DB00160,L-Alanine
,34304911,protein binding,"Mean protein binding of DEX in the critically ill patients was 90.4% (95% CI, 89.1-91.7), which was 4% lower than that in the healthy control.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),%,90.4,223167,DB00160,L-Alanine
,34304911,systemic clearance (CL),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],38.6,223168,DB00160,L-Alanine
,34304911,volume of distribution of the central compartment (V2),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,32.1,223169,DB00160,L-Alanine
,34304911,volume of distribution of the central compartment (V2),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],114.5,223170,DB00160,L-Alanine
,34304911,intercompartmental clearance (Q),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,32.1,223171,DB00160,L-Alanine
,34304911,intercompartmental clearance (Q),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),[l] / [h],114.5,223172,DB00160,L-Alanine
,34304911,Vd in the peripheral compartment (V3),"The estimated population mean (relative standard error [RSE]) values of systemic clearance (CL), volume of distribution of the central compartment (V2), intercompartmental clearance (Q), and Vd in the peripheral compartment (V3) were 38.6 (11.7) L/h, 32.1 (46.1) L, 114.5 (58.3) L/h and 95.1 (30.6) L, respectively.",Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34304911/),l,95.1,223173,DB00160,L-Alanine
,1770213,half-life,It was shown that the distribution phase after an i.v. administration is very short with a half-life of 2.1 min.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,2.1,223495,DB00160,L-Alanine
,1770213,half-life of elimination phase,"The half-life of elimination phase after the i.v. administration is about 2.85 hours, that is longer than those of MDP and its derivatives.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),h,2.85,223496,DB00160,L-Alanine
,1770213,total body clearance,The total body clearance (30 ml/min/kg) is caused predominantly by metabolism of the compound.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),[ml] / [kg·min],30,223497,DB00160,L-Alanine
shorter,1770213,half-life,The concentration curve after a s.c. administration is characterized by a very fast absorption with a half-life shorter than 1 minute.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,1,223498,DB00160,L-Alanine
,1770213,distribution,"The distribution and elimination phases are prolonged (20 min, 11 hours respectively) in comparison with an i.v. injection.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),min,20,223499,DB00160,L-Alanine
,1770213,elimination phases,"The distribution and elimination phases are prolonged (20 min, 11 hours respectively) in comparison with an i.v. injection.","Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),h,11,223500,DB00160,L-Alanine
,1770213,absolute bioavailability,The decreased absolute bioavailability after a s.c. administration (65%) is probably not biologically significant because of a slower release of the compound from the site of the s.c. administration.,"Pharmacokinetic profile of the immunomodulating compound adamantylamide dipeptide (AdDP), a muramyl dipeptide derivative in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1770213/),%,65,223501,DB00160,L-Alanine
,29897629,serum concentration,"Median phenobarbital dose was enteral = 2.6 (IQR 1.9, 3.9) mg kg-1 dose-1 ; intravenous = 2.6 (IQR 2.2, 4.9) mg kg-1 dose-1 ) and mean serum concentration was 41.1 ± 23.9 mg/L at median 6.5 (IQR 2.9, 11.1) hours after a dose.",Phenobarbital population pharmacokinetics across the pediatric age spectrum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897629/),[mg] / [l],41.1,223760,DB00160,L-Alanine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],384.2,223848,DB00160,L-Alanine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],392.0,223849,DB00160,L-Alanine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223850,DB00160,L-Alanine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],96.0,223851,DB00160,L-Alanine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],98.0,223852,DB00160,L-Alanine
,12395976,Cmax,"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223853,DB00160,L-Alanine
,12395976,C(max-DN10mg),These values were 7-8 times higher than the normalized value of C(max-DN10mg) for the control group (13.7 ng/ml).,Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],13.7,223854,DB00160,L-Alanine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1228.2,223855,DB00160,L-Alanine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1214.1,223856,DB00160,L-Alanine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],345.9,223857,DB00160,L-Alanine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],157.5,223858,DB00160,L-Alanine
,18274961,clearances,"Following intravenous administration of ICAM1988, clearances in mice, rats, dogs, and monkeys were 17.8, 3.31, 15.4, and 6.85 ml min(-1) kg(-1), respectively.","Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18274961/),[ml] / [kg·min],17.8,224478,DB00160,L-Alanine
,18274961,clearances,"Following intravenous administration of ICAM1988, clearances in mice, rats, dogs, and monkeys were 17.8, 3.31, 15.4, and 6.85 ml min(-1) kg(-1), respectively.","Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18274961/),[ml] / [kg·min],3.31,224479,DB00160,L-Alanine
,18274961,clearances,"Following intravenous administration of ICAM1988, clearances in mice, rats, dogs, and monkeys were 17.8, 3.31, 15.4, and 6.85 ml min(-1) kg(-1), respectively.","Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18274961/),[ml] / [kg·min],15.4,224480,DB00160,L-Alanine
,18274961,clearances,"Following intravenous administration of ICAM1988, clearances in mice, rats, dogs, and monkeys were 17.8, 3.31, 15.4, and 6.85 ml min(-1) kg(-1), respectively.","Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18274961/),[ml] / [kg·min],6.85,224481,DB00160,L-Alanine
,18274961,systemic bioavailability,"In rats, the systemic bioavailability of ICAM1988 was improved to 0.28 when the drug was administered orally as its isobutyl ester, ICAM2660.","Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18274961/),,0.28,224482,DB00160,L-Alanine
,16521861,maximal plasma concentrations,"After single oral dosing at 0.3 or 1.5 mg/kg, maximal plasma concentrations of meloxicam were achieved at 6 to 8 h and were 0.14 and 0.3 microg/ml, respectively.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),[μg] / [ml],0.14,224797,DB00160,L-Alanine
,16521861,maximal plasma concentrations,"After single oral dosing at 0.3 or 1.5 mg/kg, maximal plasma concentrations of meloxicam were achieved at 6 to 8 h and were 0.14 and 0.3 microg/ml, respectively.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),[μg] / [ml],0.3,224798,DB00160,L-Alanine
,16521861,elimination half-life,"The elimination half-life was approximately 8 h at both dose levels, suggesting that metabolism was not saturated.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),h,8,224799,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.35,224860,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.63,224861,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.86,224862,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.75,224863,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.37,224864,DB00160,L-Alanine
,8309063,Mean plasma concentrations at 30 minutes,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),[μg] / [ml],0.09,224865,DB00160,L-Alanine
,8309063,half life,"Mean plasma concentrations at 30 minutes, 1, 2, 4, 6 and 8 hours after dose were 0.35, 0.63, 0.86, 0.75, 0.37 and 0.09 microgram/ml, respectively, with a half life of 1.14 hours.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),h,1.14,224866,DB00160,L-Alanine
,8309063,urinary recovery rate,The urinary recovery rate in the first 8 hours was 25.5%.,[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),%,25.5,224867,DB00160,L-Alanine
,8309063,eradication rate,"Bacteriologically, all causative organisms except two of Staphylococcus aureus and Haemophilus influenzae were eradicated, with an eradication rate of 80%.",[Laboratory and clinical evaluation of S-1108 in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8309063/),%,80,224868,DB00160,L-Alanine
,31636065,90% effective concentration,"The results showed that the steady-state trough concentration of multiple dosing of GLS4 alone was significantly lower than the 90% effective concentration of 55.7 ng/ml, even with increasing dosing frequency and dosage.","A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31636065/),[ng] / [ml],55.7,225380,DB00160,L-Alanine
,31636065,trough concentration,"The pharmacokinetics change in GLS4 persisted after 9 days of chronic dosing, with a trough concentration of 182 ng/ml.","A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31636065/),[ng] / [ml],182,225381,DB00160,L-Alanine
,10778948,CL,"CL of docetaxel varied nearly 6-fold (mean, 21.0 liters/h/m2; range, 5.4-29.1 liters/h/m2).",The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778948/),[l] / [h·m2],21.0,225683,DB00160,L-Alanine
,32914879,maximum concentration,"The median values of the maximum concentration, half-life, and area under the curve from zero to infinity for DM1 were 0.87 µg/mL, 35 hours, and 27.9 µg/mL h, respectively.","ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914879/),[μg] / [ml],0.87,227725,DB00160,L-Alanine
,32914879,half-life,"The median values of the maximum concentration, half-life, and area under the curve from zero to infinity for DM1 were 0.87 µg/mL, 35 hours, and 27.9 µg/mL h, respectively.","ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914879/),h,35,227726,DB00160,L-Alanine
,32914879,area under the curve from zero to infinity,"The median values of the maximum concentration, half-life, and area under the curve from zero to infinity for DM1 were 0.87 µg/mL, 35 hours, and 27.9 µg/mL h, respectively.","ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914879/),[μg] / [h·ml],27.9,227727,DB00160,L-Alanine
,8357917,serum peak concentrations,"Following intramuscular administration of CP at 100 and 200 mg/kg of body weight, serum peak concentrations of 35.3 and 90.7 micrograms/ml, respectively, were obtained 0.25 hr following injection, and these values declined with a terminal half-life of 2.5 and 2.7 hr, respectively.",Pharmacokinetics and tolerability of chloramphenicol in budgerigars (Melopsittacus undulatus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8357917/),[μg] / [ml],35.3,228684,DB00160,L-Alanine
,8357917,serum peak concentrations,"Following intramuscular administration of CP at 100 and 200 mg/kg of body weight, serum peak concentrations of 35.3 and 90.7 micrograms/ml, respectively, were obtained 0.25 hr following injection, and these values declined with a terminal half-life of 2.5 and 2.7 hr, respectively.",Pharmacokinetics and tolerability of chloramphenicol in budgerigars (Melopsittacus undulatus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8357917/),[μg] / [ml],90.7,228685,DB00160,L-Alanine
,8357917,terminal half-life,"Following intramuscular administration of CP at 100 and 200 mg/kg of body weight, serum peak concentrations of 35.3 and 90.7 micrograms/ml, respectively, were obtained 0.25 hr following injection, and these values declined with a terminal half-life of 2.5 and 2.7 hr, respectively.",Pharmacokinetics and tolerability of chloramphenicol in budgerigars (Melopsittacus undulatus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8357917/),h,2.5,228686,DB00160,L-Alanine
,8357917,terminal half-life,"Following intramuscular administration of CP at 100 and 200 mg/kg of body weight, serum peak concentrations of 35.3 and 90.7 micrograms/ml, respectively, were obtained 0.25 hr following injection, and these values declined with a terminal half-life of 2.5 and 2.7 hr, respectively.",Pharmacokinetics and tolerability of chloramphenicol in budgerigars (Melopsittacus undulatus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8357917/),h,2.7,228687,DB00160,L-Alanine
,17828713,t(1/2),"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),min,43.83,230476,DB00160,L-Alanine
,17828713,V(d),"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[l] / [kg],0.37,230477,DB00160,L-Alanine
,17828713,Cl,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[ml] / [kg·min],129.21,230478,DB00160,L-Alanine
,17828713,AUC,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[μg] / [min·ml],25.62,230479,DB00160,L-Alanine
,17828713,AUC,"In nonintoxicated rats, t(1/2) was 43.83 +/- 4.95 min, V(d) was 0.37 +/- 0.04 l/kg, Cl was 129.21 +/- 9.20 ml/min kg, AUC(i.v.) was 25.62 +/- 1.45 microg/min ml, and AUC(p.o.) was 20.21 +/- 1.03.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),,20.21,230480,DB00160,L-Alanine
,17828713,t(1/2),"One day after intoxication, when the liver was damaged and regenerating, the metabolism was decreased: diclofenac t(1/2) was increased to 258.21 +/- 30.80 min but V(d) did not change significantly, therefore Cl was reduced to 32.81 +/- 3.38 ml/min kg.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),min,258.21,230481,DB00160,L-Alanine
,17828713,Cl,"One day after intoxication, when the liver was damaged and regenerating, the metabolism was decreased: diclofenac t(1/2) was increased to 258.21 +/- 30.80 min but V(d) did not change significantly, therefore Cl was reduced to 32.81 +/- 3.38 ml/min kg.","Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17828713/),[ml] / [kg·min],32.81,230482,DB00160,L-Alanine
,20150385,PFS,The 6-month PFS was 7% for patients with glioblastoma and 16% for patients with anaplastic glioma.,A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150385/),%,7,230515,DB00160,L-Alanine
,20150385,PFS,The 6-month PFS was 7% for patients with glioblastoma and 16% for patients with anaplastic glioma.,A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150385/),%,16,230516,DB00160,L-Alanine
,21629245,overall response rate,"Of 62 patients, 6 (9.7%) had objective radiographic partial responses, with an overall response rate of 10%.","Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),%,10,230734,DB00160,L-Alanine
,21629245,duration of response,Median duration of response was 9.2 months; median progression-free survival was 3.9 months.,"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),month,9.2,230735,DB00160,L-Alanine
,21629245,progression-free survival,Median duration of response was 9.2 months; median progression-free survival was 3.9 months.,"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21629245/),month,3.9,230736,DB00160,L-Alanine
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],3445,230846,DB00160,L-Alanine
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],844,230847,DB00160,L-Alanine
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],4436,230848,DB00160,L-Alanine
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],4237,230849,DB00160,L-Alanine
,17303396,Percent cumulative drug release,Percent cumulative drug release in 24h was low (34.8+/-2.6%).,"Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303396/),%,34.8,231949,DB00160,L-Alanine
,17303396,uptake,Enhanced hepatic cellular d4T uptake (27.96+/-2.41pg d4T/million cells) was seen in case of galactosylated liposomal d4T.,"Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303396/),pg,27.96,231950,DB00160,L-Alanine
,17303396,residence,Galactosylated liposomes maintained a significant level of d4T in tissues rich in galactose specific receptors and had a prolonged residence (11.44+/-1.25h) in the body resulting in enhanced half-life of d4T (23.07+/-1.25h).,"Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303396/),h,11.44,231951,DB00160,L-Alanine
,17303396,half-life,Galactosylated liposomes maintained a significant level of d4T in tissues rich in galactose specific receptors and had a prolonged residence (11.44+/-1.25h) in the body resulting in enhanced half-life of d4T (23.07+/-1.25h).,"Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17303396/),h,23.07,231952,DB00160,L-Alanine
,33709626,area under the plasma concentration-time curve (mAUC0-inf),The mean docetaxel area under the plasma concentration-time curve (mAUC0-inf) was 461 ng/mL × h with 1 dose limiting toxicity (DLT); grade 3 alanine transferase increase.,"ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],461,232532,DB00160,L-Alanine
,33709626,mAUC0-inf,"In cohort 2 (n = 6, ModraDoc006/r 30-20/200-200), the mAUC0-inf was 1687 ng/mL × h with 2 DLTs; grade 3 diarrhea and mucositis.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],1687,232533,DB00160,L-Alanine
,33709626,mAUC0-inf,"In cohort 3A (n = 6, ModraDoc006/r 30-20/200-100), the mAUC0-inf was 1517 ng/mL × h with 1 DLT; grade 3 diarrhea.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],1517,232534,DB00160,L-Alanine
,33709626,mAUC0-inf,"In cohort 3B (n = 3, ModraDoc006/r 20-20/200-100), the mAUC0-inf was 558 ng/mL × h without DLTs.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],558,232535,DB00160,L-Alanine
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[mg] / [h·kg],22.6,232722,DB00160,L-Alanine
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[ml] / [h·kg],36.1,232723,DB00160,L-Alanine
,7550107,total clearance,"The area under the serum concentration-time curve of theophylline was increased significantly in fibrotic rats compared with that of the control, and the total clearance of drug in fibrotic rats was low, averaging 22.6 mg/kg/h vs. 36.1 and 60.9 ml/kg/h in the control and the normal rat, respectively.",Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550107/),[ml] / [h·kg],60.9,232724,DB00160,L-Alanine
,11579300,CL/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),[l] / [h],5.75,232822,DB00160,L-Alanine
,11579300,CL/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),[l] / [h],44,232823,DB00160,L-Alanine
,11579300,V/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),l,617,232824,DB00160,L-Alanine
,1576805,metabolic clearance rate under steady state conditions,"The metabolic clearance rate under steady state conditions was highest for the analogue with the highest receptor affinity, 26.8 +/- 0.8 (+/- SE) vs 19.8 +/- 0.7 ml kg-1 min-1 for insulin (p less than 0.001), and lowest for the analogue with the lowest receptor affinity, 13.3 +/- 0.8 vs 25.1 +/- 2.0 ml kg-1 min-1 for insulin (p less than 0.001).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),[ml] / [kg·min],26.8,233482,DB00160,L-Alanine
,1576805,metabolic clearance rate under steady state conditions,"The metabolic clearance rate under steady state conditions was highest for the analogue with the highest receptor affinity, 26.8 +/- 0.8 (+/- SE) vs 19.8 +/- 0.7 ml kg-1 min-1 for insulin (p less than 0.001), and lowest for the analogue with the lowest receptor affinity, 13.3 +/- 0.8 vs 25.1 +/- 2.0 ml kg-1 min-1 for insulin (p less than 0.001).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),[ml] / [kg·min],19.8,233483,DB00160,L-Alanine
,1576805,metabolic clearance rate under steady state conditions,"The metabolic clearance rate under steady state conditions was highest for the analogue with the highest receptor affinity, 26.8 +/- 0.8 (+/- SE) vs 19.8 +/- 0.7 ml kg-1 min-1 for insulin (p less than 0.001), and lowest for the analogue with the lowest receptor affinity, 13.3 +/- 0.8 vs 25.1 +/- 2.0 ml kg-1 min-1 for insulin (p less than 0.001).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),[ml] / [kg·min],13.3,233484,DB00160,L-Alanine
,1576805,metabolic clearance rate under steady state conditions,"The metabolic clearance rate under steady state conditions was highest for the analogue with the highest receptor affinity, 26.8 +/- 0.8 (+/- SE) vs 19.8 +/- 0.7 ml kg-1 min-1 for insulin (p less than 0.001), and lowest for the analogue with the lowest receptor affinity, 13.3 +/- 0.8 vs 25.1 +/- 2.0 ml kg-1 min-1 for insulin (p less than 0.001).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),[ml] / [kg·min],25.1,233485,DB00160,L-Alanine
,1576805,apparent plasma half-life,"The apparent plasma half-life was prolonged for the low affinity analogue compared with human insulin (12.6 +/- 0.6 vs 1.9 +/- 0.2 min, p less than 0.001), and significantly shorter for the higher affinity analogue (1.6 +/- 0.1 vs 3.1 +/- 0.4 min, p less than 0.05).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),min,12.6,233486,DB00160,L-Alanine
,1576805,apparent plasma half-life,"The apparent plasma half-life was prolonged for the low affinity analogue compared with human insulin (12.6 +/- 0.6 vs 1.9 +/- 0.2 min, p less than 0.001), and significantly shorter for the higher affinity analogue (1.6 +/- 0.1 vs 3.1 +/- 0.4 min, p less than 0.05).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),min,1.9,233487,DB00160,L-Alanine
,1576805,apparent plasma half-life,"The apparent plasma half-life was prolonged for the low affinity analogue compared with human insulin (12.6 +/- 0.6 vs 1.9 +/- 0.2 min, p less than 0.001), and significantly shorter for the higher affinity analogue (1.6 +/- 0.1 vs 3.1 +/- 0.4 min, p less than 0.05).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),min,1.6,233488,DB00160,L-Alanine
,1576805,apparent plasma half-life,"The apparent plasma half-life was prolonged for the low affinity analogue compared with human insulin (12.6 +/- 0.6 vs 1.9 +/- 0.2 min, p less than 0.001), and significantly shorter for the higher affinity analogue (1.6 +/- 0.1 vs 3.1 +/- 0.4 min, p less than 0.05).",Metabolic effects of monomeric insulin analogues of different receptor affinity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576805/),min,3.1,233489,DB00160,L-Alanine
,16284921,Maximum relative bioavailability,Maximum relative bioavailability (relative to s.c - 0.26 U/kg) of spray-instilled insulin was 46%.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),%,46,234244,DB00160,L-Alanine
,16284921,"basal zero order production rate of glucose (k(G, prod))","The basal zero order production rate of glucose (k(G, prod)) was estimated as 0.98 mg/dl/min.",Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),[mg] / [dl·min],0.98,234245,DB00160,L-Alanine
,16284921,SC50,The SC50 was fixed at 80 mu U/ml based on literature reports and the S(max) was estimated to be 6.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),[mu·u] / [ml],80,234246,DB00160,L-Alanine
,16284921,S(max),The SC50 was fixed at 80 mu U/ml based on literature reports and the S(max) was estimated to be 6.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),,6,234247,DB00160,L-Alanine
,18094935,MTD,"The MTD was determined to be 1,200 mg BID.",Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094935/),mg,"1,200",234259,DB00160,L-Alanine
,18094935,time to maximum concentration,"PK results indicated that oral absorption of R-etodolac was rapid (time to maximum concentration ranged from 2 to 4 h), and the half-life ranged from 5 to 7 h.",Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094935/),h,2 to 4,234260,DB00160,L-Alanine
,18094935,half-life,"PK results indicated that oral absorption of R-etodolac was rapid (time to maximum concentration ranged from 2 to 4 h), and the half-life ranged from 5 to 7 h.",Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18094935/),h,5 to 7,234261,DB00160,L-Alanine
,22726209,zeta potential,Results showed that a narrow size distributed nanomicelles with a mean particle size of 82.99 ± 7.5 nm and a zeta potential of -32.23 ± 1.05 mV was obtained.,Improvement of oral bioavailability of glycyrrhizin by sodium deoxycholate/phospholipid-mixed nanomicelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22726209/),mv,-,234435,DB00160,L-Alanine
,22726209,zeta potential,Results showed that a narrow size distributed nanomicelles with a mean particle size of 82.99 ± 7.5 nm and a zeta potential of -32.23 ± 1.05 mV was obtained.,Improvement of oral bioavailability of glycyrrhizin by sodium deoxycholate/phospholipid-mixed nanomicelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22726209/),mv,32.23,234436,DB00160,L-Alanine
,2080936,recovery,The recovery from plasma was 75 +/- 5% for the hormone-linked CNC-alanine-estradiol-17-ester and 70 +/- 5% for the unlinked CNC-alanine.,"A new comprehensive technique of catheterisation, blood sampling, sample preparation and sample analysis by means of high-pressure liquid chromatography for pharmacokinetic studies with estradiol-linked nitrosoureas and their metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080936/),%,75,234772,DB00160,L-Alanine
,2080936,recovery,The recovery from plasma was 75 +/- 5% for the hormone-linked CNC-alanine-estradiol-17-ester and 70 +/- 5% for the unlinked CNC-alanine.,"A new comprehensive technique of catheterisation, blood sampling, sample preparation and sample analysis by means of high-pressure liquid chromatography for pharmacokinetic studies with estradiol-linked nitrosoureas and their metabolites. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2080936/),%,70,234773,DB00160,L-Alanine
,16049639,half-life,"The half-life of the dipeptide was 0.26 hours (range, 0.15-0.63 h).",Elimination kinetics of L-alanyl-L-glutamine in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049639/),h,0.26,234963,DB00160,L-Alanine
,25467181,AUC,"At 8 mg/m(2), the median temsirolimus AUC was 2,946 ng • h/mL (range, 937-5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245-3,675).",A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25467181/),[h·ng] / [ml],"2,946",235616,DB00160,L-Alanine
,25467181,AUC,"At 8 mg/m(2), the median temsirolimus AUC was 2,946 ng • h/mL (range, 937-5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245-3,675).",A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25467181/),[h·ng] / [ml],767,235617,DB00160,L-Alanine
,12390595,clearance,The mean (SD) ICG clearance during acute malaria was not significantly different to that in convalescence (21.6 +/- 9.3 vs. 34.1 +/- 15.5 ml/min/kg; P = 0.25).,Alanine metabolism in acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12390595/),[ml] / [kg·min],21.6,235807,DB00160,L-Alanine
,12390595,clearance,The mean (SD) ICG clearance during acute malaria was not significantly different to that in convalescence (21.6 +/- 9.3 vs. 34.1 +/- 15.5 ml/min/kg; P = 0.25).,Alanine metabolism in acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12390595/),[ml] / [kg·min],34.1,235808,DB00160,L-Alanine
,6589560,CSF: plasma ratio,"The CSF: plasma ratio of MTX measured during 58 infusions did not exceed 11% in patients with ALL in remission, but was above this value in 13/34 infusions in patients with leukemia of the central nervous system (CNS).","Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589560/),%,11,237004,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],2.5,237316,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3,237317,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3.6,237318,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],12,237319,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3.2,237320,DB00160,L-Alanine
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],11,237321,DB00160,L-Alanine
,32030892,maximal plasma concentration,"A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration-time curve of 8152 ng·h/mL in monkeys.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[ng] / [ml],3011,237322,DB00160,L-Alanine
,32030892,area under the 24 hours concentration-time curve,"A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration-time curve of 8152 ng·h/mL in monkeys.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[h·ng] / [ml],8152,237323,DB00160,L-Alanine
,28272302,IC50,"In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC50 = 3.13 µg/mL).",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[μg] / [ml],3.13,237694,DB00160,L-Alanine
,28272302,LD50,"The acute toxicity test showed that LD50 and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73-798.73 mg/kg via intraperitoneal injection in mice, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[mg] / [kg],714.83,237695,DB00160,L-Alanine
,28272302,LD50,"The acute toxicity test showed that LD50 and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73-798.73 mg/kg via intraperitoneal injection in mice, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[mg] / [kg],639.73-798.73,237696,DB00160,L-Alanine
exceeded,28272302,LD50,The LD50 value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice.,A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[mg] / [kg],2000,237697,DB00160,L-Alanine
,28272302,time to reach peak concentration,"After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (Cmax = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[μg] / [ml],8.18,237698,DB00160,L-Alanine
,28272302,Cmax,"After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (Cmax = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[μg] / [ml],8.18,237699,DB00160,L-Alanine
,28272302,elimination half-life,"After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (Cmax = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),h,2.19,237700,DB00160,L-Alanine
,28272302,area under the concentration-time curve from t = 0 to the last time,"After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (Cmax = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively.",A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28272302/),[h·μg] / [ml],90.21,237701,DB00160,L-Alanine
,31452734,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively.",Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452734/),[l] / [h],3.19,238188,DB00160,L-Alanine
,31452734,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 3.19 l/h and 165 liters, respectively.",Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452734/),l,165,238189,DB00160,L-Alanine
,3401577,bioavailability,"Absolute dalargin bioavailability was 15% and 8%, while its elimination half-life was 23.2 min and 21.3 min, respectively.",[Bioavailability of dalargin and its metabolism during intranasal administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3401577/),%,15,239129,DB00160,L-Alanine
,3401577,bioavailability,"Absolute dalargin bioavailability was 15% and 8%, while its elimination half-life was 23.2 min and 21.3 min, respectively.",[Bioavailability of dalargin and its metabolism during intranasal administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3401577/),%,8,239130,DB00160,L-Alanine
,3401577,elimination half-life,"Absolute dalargin bioavailability was 15% and 8%, while its elimination half-life was 23.2 min and 21.3 min, respectively.",[Bioavailability of dalargin and its metabolism during intranasal administration to rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3401577/),min,23.2,239131,DB00160,L-Alanine
,3401577,elimination half-life,"Absolute dalargin bioavailability was 15% and 8%, while its elimination half-life was 23.2 min and 21.3 min, respectively.",[Bioavailability of dalargin and its metabolism during intranasal administration to rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3401577/),min,21.3,239132,DB00160,L-Alanine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],65,239666,DB00160,L-Alanine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [g],74.1,239667,DB00160,L-Alanine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],61.6,239668,DB00160,L-Alanine
,32945851,concentrations,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),,2,239669,DB00160,L-Alanine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,51.1,239670,DB00160,L-Alanine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,44.6,239671,DB00160,L-Alanine
,32945851,protein-unbound fractions,"The median total bictegravir concentrations in SP, RT, and CVF were 65.5 (20.1-923) ng/mL, 74.1 (6.0-478.5) ng/g, and 61.6 (14.4-1760.2) ng/mL, representing 2.7%, 2.6%, and 28% of the BP concentration, while protein-unbound fractions were 51.1%, 44.6%, and 42.6%, respectively.","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),%,42.6,239672,DB00160,L-Alanine
,32945851,EC50,"Protein-unbound bictegravir concentrations in SP, RT, and CVF highly exceeded the EC50 value (1.1 ng/mL).","Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32945851/),[ng] / [ml],1.1,239673,DB00160,L-Alanine
,23022224,half-lives,"Pharmacokinetic studies showed that VEGF(121)/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6h for the alpha and beta phases, respectively.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),h,0.3,239703,DB00160,L-Alanine
,23022224,half-lives,"Pharmacokinetic studies showed that VEGF(121)/rGel cleared from the circulation in a biphasic manner with calculated half-lives of 0.3 and 6h for the alpha and beta phases, respectively.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),h,6,239704,DB00160,L-Alanine
,23022224,blood retention,"Pharmacokinetic evaluation of (64)Cu-DOTA-VEGF(121)/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),[%·id] / [g],26.6,239705,DB00160,L-Alanine
,23022224,blood retention,"Pharmacokinetic evaluation of (64)Cu-DOTA-VEGF(121)/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),%,11.8,239706,DB00160,L-Alanine
,23022224,blood retention,"Pharmacokinetic evaluation of (64)Cu-DOTA-VEGF(121)/rGel showed relatively high blood retention 30 min after injection (26.6 ± 1.73% ID/g), dropping to 11.8 ± 2.83% and 0.82 ± 0.11% ID/g at 60 and 240 min post injection, respectively.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),[%·id] / [g],0.82,239707,DB00160,L-Alanine
,23022224,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD), based on a QOD×5 i.v. administration schedule, was found to be 18 mg/kg with an LD(50) of 25mg/kg.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),[mg] / [kg],18,239708,DB00160,L-Alanine
,23022224,LD(50),"The maximum tolerated dose (MTD), based on a QOD×5 i.v. administration schedule, was found to be 18 mg/kg with an LD(50) of 25mg/kg.","Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23022224/),[mg] / [kg],25,239709,DB00160,L-Alanine
,1518122,maximum plasma concentrations,"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),[μg] / [ml],36.6,240931,DB00160,L-Alanine
,1518122,maximum plasma concentrations,"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),[μg] / [ml],92.5,240932,DB00160,L-Alanine
,1518122,half lives (T 1/2 beta),"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),h,1.17,240933,DB00160,L-Alanine
,1518122,half lives (T 1/2 beta),"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),h,0.88,240934,DB00160,L-Alanine
,1518122,urinary excretion,"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),%,29,240935,DB00160,L-Alanine
,1518122,urinary excretion,"Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of PAPM/BP for 30 minutes resulted in maximum plasma concentrations of 36.6 micrograms/ml and 92.5 micrograms/ml, half lives (T 1/2 beta) of 1.17 hours and 0.88 hours, and urinary excretion until 6 hours of 29% and 17.7%, respectively.",[Evaluation of panipenem/betamipron in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),%,17.7,240936,DB00160,L-Alanine
,1518122,overall efficacy rate,The overall efficacy rate was 94.1%.,[Evaluation of panipenem/betamipron in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1518122/),%,94.1,240937,DB00160,L-Alanine
,29348128,Overall response rate (ORR),"Overall response rate (ORR) based on an intent-to-treat analysis was 50% (20 complete remissions [CRs], 5 complete remission with incomplete peripheral count recovery, 7 partial remissions [PRs]), with an 8.3-month median duration of remission.","Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29348128/),%,50,241125,DB00160,L-Alanine
<,15778742,steady state K(d),"GW274150 and GW273629 are arginine competitive, NADPH-dependent inhibitors of human iNOS with steady state K(d) values of <40 and <90 nM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),nM,40,241644,DB00160,L-Alanine
<,15778742,steady state K(d),"GW274150 and GW273629 are arginine competitive, NADPH-dependent inhibitors of human iNOS with steady state K(d) values of <40 and <90 nM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),nM,90,241645,DB00160,L-Alanine
,15778742,IC(50),"2 GW274150 and GW273629 inhibited intracellular iNOS in J774 cells in a time-dependent manner, reaching IC(50) values of 0.2+/-0.04 and 1.3+/-0.16 microM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),μM,0.2,241646,DB00160,L-Alanine
,15778742,IC(50),"2 GW274150 and GW273629 inhibited intracellular iNOS in J774 cells in a time-dependent manner, reaching IC(50) values of 0.2+/-0.04 and 1.3+/-0.16 microM, respectively.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),μM,1.3,241647,DB00160,L-Alanine
,15778742,terminal half-life,3 The pharmacokinetic profile of GW274150 was biphasic in healthy rats and mice with a terminal half-life of approximately 6 h.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),h,6,241648,DB00160,L-Alanine
,15778742,terminal half-life,"That of GW273629 was also biphasic in rats, producing a terminal half-life of approximately 3 h.",GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),h,3,241649,DB00160,L-Alanine
>,15778742,oral bioavailability,Both compounds show a high oral bioavailability (>90%) in rats and mice.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),%,90,241650,DB00160,L-Alanine
,15778742,ED(50),4 GW274150 was effective in inhibiting LPS-induced plasma NO(x) levels in mice with an ED(50) of 3.2+/-0.7 mg kg(-1) after 14 h intraperitoneally (i.p.) and 3.8+/-1.5 mg kg(-1) after 14 h when administered orally.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],3.2,241651,DB00160,L-Alanine
,15778742,ED(50),4 GW274150 was effective in inhibiting LPS-induced plasma NO(x) levels in mice with an ED(50) of 3.2+/-0.7 mg kg(-1) after 14 h intraperitoneally (i.p.) and 3.8+/-1.5 mg kg(-1) after 14 h when administered orally.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],3.8,241652,DB00160,L-Alanine
,15778742,ED(50),GW273629 showed shorter-lived effects on plasma NO(x) and an ED(50) of 9+/-2 mg kg(-1) after 2 h when administered i.p.,GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778742/),[mg] / [kg],9,241653,DB00160,L-Alanine
,28898054,T1/2,"The entities were functionalized with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator via a l-lysine and β-alanine linker moiety using solid-phase peptide chemistry and labeled with 177Lu (T1/2 = 6.65 days), a clinically established radiometal.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),d,6.65,241701,DB00160,L-Alanine
,28898054,"T1/2,β","177Lu-DOTA-PPB-01 showed the slowest blood clearance (T1/2,β: >15 h) followed by 177Lu-DOTA-PPB-03 (T1/2,β: ∼2.33 h) and 177Lu-DOTA-PPB-02 (T1/2,β: ∼1.14 h), which was excreted relatively fast.","Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28898054/),h,∼2.33,241702,DB00160,L-Alanine
,6412274,elimination half-life,"The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated.",Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6412274/),h,7.1,241853,DB00160,L-Alanine
,6412274,Plasma protein binding,Plasma protein binding for alaproclate was 82 +/- 1%.,Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6412274/),%,82,241854,DB00160,L-Alanine
,26879594,apparent clearance (CL/F),"The population mean value for lenvatinib apparent clearance (CL/F) was 6.56 l h(-1) [percent coefficient of variation (%CV) 25.5], and was independent of dose and time.",Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26879594/),[l] / [h],6.56,241900,DB00160,L-Alanine
,26879594,relative bioavailability,The relative bioavailability of lenvatinib in capsule form was 90% vs. tablets (%CV 30.2).,Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26879594/),%,90,241901,DB00160,L-Alanine
,17409986,Terminal half-life,Terminal half-life was about 90-115 hours.,"A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17409986/),h,90-115,242805,DB00160,L-Alanine
,19226654,systemic clearance,"After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively.",Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19226654/),[ml] / [kg·min],4.6-6.4,242897,DB00160,L-Alanine
,19226654,volume of distribution at the steady state,"After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively.",Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19226654/),[ml] / [kg],244-412,242898,DB00160,L-Alanine
,19226654,volume of distribution at the steady state,"After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively.",Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19226654/),[ml] / [kg],1990-4567,242899,DB00160,L-Alanine
,19226654,volume of distribution at the steady state,"After the intravenous injection of Py-Im polyamide (A) at 1.3, 2.0, 7.5 and 15.0 mg/kg, Py-Im polyamides (B) and (C) at 1.0, 2.0, 3.0 and 5.0 mg/kg, the average systemic clearance and the volume of distribution at the steady state obtained by a non-compartmental method were in the ranges of 4.6-6.4 ml/min/kg and 244-412 ml/kg, 8.9-10.3 ml/min/kg and 1990-4567 ml/kg, and 7.3-11.9 ml/min/kg and 407-667 ml/kg, respectively.",Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19226654/),[ml] / [kg·min],7.3-11.9,242900,DB00160,L-Alanine
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,6.4,242929,DB00160,L-Alanine
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,5.5-8.0,242930,DB00160,L-Alanine
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,46.7,242931,DB00160,L-Alanine
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,43.5-45.5,242932,DB00160,L-Alanine
below,6527230,bioavailability,"When comparing the mean dissolution time in vitro to the total area under the plasma drug concentration-time curve attained after different types of tablets, it is obvious that the extent of bioavailability of alaproclate will not fall below 80% of the value found for an aqueous solution until the mean dissolution time in vitro exceeds approximately 3 hr.",Correlations between in vitro dissolution rate and bioavailability of alaproclate tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527230/),%,80,243941,DB00160,L-Alanine
,24347,half-time,"After infusion, the plasma norepinephrine concentration fell with a mean (+/-SD) half-time of 2.4 +/- 0.7 min.",Norepinephrine: hormone and neurotransmitter in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),min,2.4,244207,DB00160,L-Alanine
,24347,metabolic clearance rate,"The mean (+/-SD) norepinephrine metabolic clearance rate was 3,070 +/- 200 ml/min.",Norepinephrine: hormone and neurotransmitter in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),[ml] / [min],"3,070",244208,DB00160,L-Alanine
,24347,basal plasma,The calculated basal plasma norepinephrine production rate was 0.7 microgram/min.,Norepinephrine: hormone and neurotransmitter in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24347/),[μg] / [min],0.7,244209,DB00160,L-Alanine
,33404989,minimum inhibitory concentration,"Monte Carlo simulations based on area under the plasma concentration-time curve over 24 h showed that patients must be administered at least 200 and 250 mg micafungin daily to reach minimum inhibitory concentration breakpoints of 0.032 and 0.064 mg/L for Candida glabrata and Candida tropicalis, respectively.",Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404989/),[mg] / [l],0.032,244703,DB00160,L-Alanine
,33404989,minimum inhibitory concentration,"Monte Carlo simulations based on area under the plasma concentration-time curve over 24 h showed that patients must be administered at least 200 and 250 mg micafungin daily to reach minimum inhibitory concentration breakpoints of 0.032 and 0.064 mg/L for Candida glabrata and Candida tropicalis, respectively.",Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404989/),[mg] / [l],0.064,244704,DB00160,L-Alanine
,17679773,AUC,"When VP-0502 was intravenously administered at 20 mg/kg, the analyte appeared in low levels with an AUC of 0.3 microg . h/ml, and C(0) of 0.2 microg/ml in plasma.",Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[h·μg] / [ml],0.3,245782,DB00160,L-Alanine
,17679773,C(0),"When VP-0502 was intravenously administered at 20 mg/kg, the analyte appeared in low levels with an AUC of 0.3 microg . h/ml, and C(0) of 0.2 microg/ml in plasma.",Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[μg] / [ml],0.2,245783,DB00160,L-Alanine
,17679773,V(d),VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[l] / [kg],4.6,245784,DB00160,L-Alanine
,17679773,AUC,VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[h·μg] / [ml],3,245785,DB00160,L-Alanine
,17679773,t(1/2),VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),h,0.5,245786,DB00160,L-Alanine
,17679773,C(0),VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[μg] / [ml],6,245787,DB00160,L-Alanine
,17679773,CL(tot),VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[l] / [h·kg],7,245788,DB00160,L-Alanine
,17679773,MRT,VP-0502AL's pharmacokinetic parameters were V(d): 4.6 l/kg; AUC: 3 microg . h/ml; t(1/2): 0.5 h; C(0): 6 microg/ml; CL(tot): 7 l/h/kg; and MRT: 0.6 h.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),h,0.6,245789,DB00160,L-Alanine
,17679773,maximum plasma concentration (C(max)),"Following oral administration of VP-0502 (100 mg/kg), it was not detectable in plasma (<50 ng/ml), while after the oral administration of VP-0502AL, VP-0502 was quantitatively detected as an active metabolite for the first 7 h, with a maximum plasma concentration (C(max)) of 0.8 microg/ml, and an area under the concentrationtime curve (AUC) of 2 microg .",Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[μg] / [ml],0.8,245790,DB00160,L-Alanine
,17679773,area under the concentrationtime curve (AUC),"Following oral administration of VP-0502 (100 mg/kg), it was not detectable in plasma (<50 ng/ml), while after the oral administration of VP-0502AL, VP-0502 was quantitatively detected as an active metabolite for the first 7 h, with a maximum plasma concentration (C(max)) of 0.8 microg/ml, and an area under the concentrationtime curve (AUC) of 2 microg .",Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),μg,2,245791,DB00160,L-Alanine
,17679773,maximum concentration time (t(max)),The oral pharmacokinetic parameters of VP-0502AL were calculated to be: maximum concentration time (t(max)) 2.7 h; C(max) 0.2 microg/ml; elimination half-life (t(1/2)): 0.8 h; and AUC 0.5 microg . h/ml.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),h,2.7,245792,DB00160,L-Alanine
,17679773,C(max),The oral pharmacokinetic parameters of VP-0502AL were calculated to be: maximum concentration time (t(max)) 2.7 h; C(max) 0.2 microg/ml; elimination half-life (t(1/2)): 0.8 h; and AUC 0.5 microg . h/ml.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[μg] / [ml],0.2,245793,DB00160,L-Alanine
,17679773,elimination half-life (t(1/2)),The oral pharmacokinetic parameters of VP-0502AL were calculated to be: maximum concentration time (t(max)) 2.7 h; C(max) 0.2 microg/ml; elimination half-life (t(1/2)): 0.8 h; and AUC 0.5 microg . h/ml.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),h,0.8,245794,DB00160,L-Alanine
,17679773,AUC,The oral pharmacokinetic parameters of VP-0502AL were calculated to be: maximum concentration time (t(max)) 2.7 h; C(max) 0.2 microg/ml; elimination half-life (t(1/2)): 0.8 h; and AUC 0.5 microg . h/ml.,Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17679773/),[h·μg] / [ml],0.5,245795,DB00160,L-Alanine
,31232278,clearance (CL),"The mean values of clearance (CL) and distribution volume (Vd) of MTX were 6.53 L/h and 67.88 L, respectively.",Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia . ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31232278/),[l] / [h],6.53,245952,DB00160,L-Alanine
,31232278,distribution volume (Vd),"The mean values of clearance (CL) and distribution volume (Vd) of MTX were 6.53 L/h and 67.88 L, respectively.",Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia . ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31232278/),l,67.88,245953,DB00160,L-Alanine
,33584296,apparent oral clearance,"The apparent oral clearance and central volume of distribution were 13.8 l·h-1 and 188 l, respectively.",Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33584296/),[l] / [h],13.8,248234,DB00160,L-Alanine
,33584296,central volume of distribution,"The apparent oral clearance and central volume of distribution were 13.8 l·h-1 and 188 l, respectively.",Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33584296/),l,188,248235,DB00160,L-Alanine
,33584296,bioavailability (F),The bioavailability (F) of yimitasvir decreased 12.9% for each 100 mg dose increase.,Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33584296/),%,12.9,248236,DB00160,L-Alanine
,33584296,Zero-order absorption duration,Zero-order absorption duration was longer in healthy volunteers (2.17 h) than that in patients (1.43 h).,Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33584296/),h,2.17,248237,DB00160,L-Alanine
,33584296,Zero-order absorption duration,Zero-order absorption duration was longer in healthy volunteers (2.17 h) than that in patients (1.43 h).,Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33584296/),h,1.43,248238,DB00160,L-Alanine
,2920758,bioavailability,The bioavailability of the estradiol-linked drug was determined to be 52%.,New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920758/),%,52,248472,DB00160,L-Alanine
,10367751,half-lives,"Local drug disposition was biexponential in four of six tumors where the half-lives of the fast and slow components of disposition ranged from 4 to 26 and from 33 to 289 min, respectively.",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,4 to 26,248478,DB00160,L-Alanine
,10367751,half-lives,"Local drug disposition was biexponential in four of six tumors where the half-lives of the fast and slow components of disposition ranged from 4 to 26 and from 33 to 289 min, respectively.",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,33 to 289,248479,DB00160,L-Alanine
,10367751,half-lives,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,49,248480,DB00160,L-Alanine
,10367751,half-lives,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,128,248481,DB00160,L-Alanine
,10367751,half-life,"It was monoexponential in the remaining two tumors (half-lives 49 and 128 min) and in the s.c. injection experiments (n = 4, half-life 6-9 min).",Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),min,6-9,248482,DB00160,L-Alanine
,10367751,fraction,5-Fluorouracil could be quantitated in three of six tumors; the estimated fraction of floxuridine converted intratumorally into 5-fluorouracil was 11-23%.,Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367751/),,11-23,248483,DB00160,L-Alanine
≈,26307570,T(max),CSL112 resulted in rapid (T(max)≈2 hours) and dose-dependent increases in apoA-I (145% increase in the 6.8-g group) and total cholesterol efflux (up to 3.1-fold higher than placebo) (P<0.001).,"Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26307570/),h,2,248597,DB00160,L-Alanine
,8588953,no observable adverse effect level (NOAEL),"The no observable adverse effect level (NOAEL) for r-metHuIL-2[ala-125] via intravenous administration was 6 micrograms kg-1 day-1, while that for subcutaneous administration was 30 micrograms kg-1 day-1.","Pharmacokinetic, pharmacodynamic, and pharmacotoxic profiles of recombinant-methionyl human interleukin-2[alanine-125] (r-metHuIL-2[ala-125]) following intravenous and subcutaneous administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588953/),,6,249594,DB00160,L-Alanine
,28088251,Cmax,"Lucerastat Cmax values were comparable between studies, with geometric mean Cmax 10.5 (95% CI: 7.5, 14.7) and 11.1 (95% CI: 8.7, 14.2) μg/mL in the SAD and MAD study, respectively, after 1000 mg lucerastat b.i.d. tmax (0.5 - 4 h) and t1/2 (3.6 - 8.1 h) were also within the same range across dose groups in both studies.","Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28088251/),[μg] / [ml],10.5,249678,DB00160,L-Alanine
,28088251,Cmax,"Lucerastat Cmax values were comparable between studies, with geometric mean Cmax 10.5 (95% CI: 7.5, 14.7) and 11.1 (95% CI: 8.7, 14.2) μg/mL in the SAD and MAD study, respectively, after 1000 mg lucerastat b.i.d. tmax (0.5 - 4 h) and t1/2 (3.6 - 8.1 h) were also within the same range across dose groups in both studies.","Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28088251/),[μg] / [ml],11.1,249679,DB00160,L-Alanine
,28088251,tmax,"Lucerastat Cmax values were comparable between studies, with geometric mean Cmax 10.5 (95% CI: 7.5, 14.7) and 11.1 (95% CI: 8.7, 14.2) μg/mL in the SAD and MAD study, respectively, after 1000 mg lucerastat b.i.d. tmax (0.5 - 4 h) and t1/2 (3.6 - 8.1 h) were also within the same range across dose groups in both studies.","Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28088251/),h,0.5 - 4,249680,DB00160,L-Alanine
,28088251,t1/2,"Lucerastat Cmax values were comparable between studies, with geometric mean Cmax 10.5 (95% CI: 7.5, 14.7) and 11.1 (95% CI: 8.7, 14.2) μg/mL in the SAD and MAD study, respectively, after 1000 mg lucerastat b.i.d. tmax (0.5 - 4 h) and t1/2 (3.6 - 8.1 h) were also within the same range across dose groups in both studies.","Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28088251/),h,3.6 - 8.1,249681,DB00160,L-Alanine
,1998989,Km,"A concentration-dependent 5-FU elimination was observed, indicating saturation of 5-FU elimination according to Michaelis-Menten kinetics (Km 14-22 microM).",Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998989/),μM,14-22,249962,DB00160,L-Alanine
,1998989,maximal velocity (Vmax),The maximal velocity (Vmax) values ranged from 0.025 to 0.13 nmol 5-FU/10(6) cells per minute.,Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1998989/),nM,0.025 to 0.13,249963,DB00160,L-Alanine
,16988201,half-life,"Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI, and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical control group and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively.",Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988201/),h,4.5,250213,DB00160,L-Alanine
,16988201,half-life,"Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI, and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical control group and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively.",Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988201/),h,4.4,250214,DB00160,L-Alanine
,16988201,half-life,"Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI, and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical control group and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively.",Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988201/),h,6.1,250215,DB00160,L-Alanine
,16988201,half-life,"Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI, and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical control group and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively.",Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988201/),h,10.6,250216,DB00160,L-Alanine
,16988201,half-life,"Area under the concentration-time curve from time zero to infinity increased 7% in mild, 53% in moderate, 158% in advanced RI, and 192% in ESRD; end of infusion concentration changed minimally; half-life was 4.5 hours in the historical control group and 4.4, 6.1, 10.6, and 14.1 hours in mild RI, moderate RI, advanced RI, and ESRD, respectively.",Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988201/),h,14.1,250217,DB00160,L-Alanine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,2,250726,DB00160,L-Alanine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,over,250727,DB00160,L-Alanine
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,8,250728,DB00160,L-Alanine
,2452249,latencies,The 50-mg/kg dose elevated latencies to approximately 5 sec after 24 hr.,Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,5,250729,DB00160,L-Alanine
,34122070,absolute bioavailability,"Pharmacokinetic results showed that arsenite (AsIII) reached a maximum plasma concentration rapidly after initial dosing, and the absolute bioavailability of AsIII was 81.03%.","Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34122070/),%,81.03,250968,DB00160,L-Alanine
,30117129,wash-out time,The wash-out time was 14 days.,Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117129/),d,14,251370,DB00160,L-Alanine
,30117129,Cmax,"After single doses of 0.5 and 0.75 μg eldecalcitol, the maximum serum concentration (Cmax) of eldecalcitol was reached within 3.0-4.0 h (Cmax was 0.0638 ± 0.0076 ng/ml in the 0.5-μg group and 0.0944 ± 0.0126 ng/ml in the 0.75-μg group, area under the concentration-time curve from 0 to 24 h (AUC(0-24h)) was 1.02 ± 0.15 ng·h/mL in the 0.5-μg group and 1.57 ± 0.26 ng·h/mL in the 0.75-μg group).",Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117129/),[ng] / [ml],0.0638,251371,DB00160,L-Alanine
,30117129,Cmax,"After single doses of 0.5 and 0.75 μg eldecalcitol, the maximum serum concentration (Cmax) of eldecalcitol was reached within 3.0-4.0 h (Cmax was 0.0638 ± 0.0076 ng/ml in the 0.5-μg group and 0.0944 ± 0.0126 ng/ml in the 0.75-μg group, area under the concentration-time curve from 0 to 24 h (AUC(0-24h)) was 1.02 ± 0.15 ng·h/mL in the 0.5-μg group and 1.57 ± 0.26 ng·h/mL in the 0.75-μg group).",Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117129/),[ng] / [ml],0.0944,251372,DB00160,L-Alanine
,30117129,area under the concentration-time curve from 0 to 24 h (AUC(0-24h)),"After single doses of 0.5 and 0.75 μg eldecalcitol, the maximum serum concentration (Cmax) of eldecalcitol was reached within 3.0-4.0 h (Cmax was 0.0638 ± 0.0076 ng/ml in the 0.5-μg group and 0.0944 ± 0.0126 ng/ml in the 0.75-μg group, area under the concentration-time curve from 0 to 24 h (AUC(0-24h)) was 1.02 ± 0.15 ng·h/mL in the 0.5-μg group and 1.57 ± 0.26 ng·h/mL in the 0.75-μg group).",Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117129/),[h·ng] / [ml],1.02,251373,DB00160,L-Alanine
,30117129,area under the concentration-time curve from 0 to 24 h (AUC(0-24h)),"After single doses of 0.5 and 0.75 μg eldecalcitol, the maximum serum concentration (Cmax) of eldecalcitol was reached within 3.0-4.0 h (Cmax was 0.0638 ± 0.0076 ng/ml in the 0.5-μg group and 0.0944 ± 0.0126 ng/ml in the 0.75-μg group, area under the concentration-time curve from 0 to 24 h (AUC(0-24h)) was 1.02 ± 0.15 ng·h/mL in the 0.5-μg group and 1.57 ± 0.26 ng·h/mL in the 0.75-μg group).",Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117129/),[h·ng] / [ml],1.57,251374,DB00160,L-Alanine
,34302760,AUCtau,The mean bictegravir AUCtau was 89 100 ng × h/mL (coefficient of variation 31·0%) in adolescents (cohort 1) and 128 000 ng × h/mL (27·8%) in children (cohort 2).,"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302760/),[h·ng] / [ml],89 100,251671,DB00160,L-Alanine
,34302760,AUCtau,The mean bictegravir AUCtau was 89 100 ng × h/mL (coefficient of variation 31·0%) in adolescents (cohort 1) and 128 000 ng × h/mL (27·8%) in children (cohort 2).,"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302760/),[h·ng] / [ml],128 000,251672,DB00160,L-Alanine
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,71,252127,DB00160,L-Alanine
,10430071,Total urinary recovery,Total urinary recovery of capecitabine and its metabolites was 71% of the administered dose in patients with normal hepatic function and 77% in patients with hepatic impairment.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,77,252128,DB00160,L-Alanine
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,42,252129,DB00160,L-Alanine
,10430071,absolute bioavailability,The absolute bioavailability of 5'-deoxy-5-fluorouridine was estimated as 42% in patients with normal hepatic function and 62% in patients with impaired hepatic function.,Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430071/),%,62,252130,DB00160,L-Alanine
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,54,252663,DB00160,L-Alanine
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,90,252664,DB00160,L-Alanine
,17184895,accumulative bile excretion,"It was observed that there was significant difference in the accumulative bile excretion of KPGs between the CCl(4) intoxicated rats and the normal rats (54+/-18.3% versus 90+/-6.9%), while it was extremely inhibited in ANIT intoxicated rats (2.0+/-3.1% versus 90+/-6.9%).",Ketoprofen glucuronidation and bile excretion in carbon tetrachloride and alpha-naphthylisothiocyanate induced hepatic injury rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17184895/),%,2.0,252665,DB00160,L-Alanine
,21724950,time to maximum plasma concentration (t(max)),"For all formulations, the median time to maximum plasma concentration (t(max)) was generally 1.0 hour.","Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724950/),h,1.0,253609,DB00160,L-Alanine
,21724950,half-life,"Plasma elimination was rapid, with a half-life of approximately 2.5 hours.","Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724950/),h,2.5,253610,DB00160,L-Alanine
,21724950,bioavailability (F),"Tablet form II bioavailability (F) relative to capsule was approximately 100% (F = 1.03 [90% confidence interval (CI), 0.96-1.10]).","Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724950/),%,100,253611,DB00160,L-Alanine
,21724950,t(max),"No significant change in exposure (AUC(0-∞) [area under the concentration-time curve from 0 to infinity] ratio = 1.02, [90% CI, 0.990-1.05]) occurred with food, whereas maximum plasma concentration (C(max)) declined approximately 15%, and median t(max) was delayed to 1.5 hours.","Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724950/),h,1.5,253612,DB00160,L-Alanine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],3.64,254927,DB00160,L-Alanine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],5.17,254928,DB00160,L-Alanine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],11.25,254929,DB00160,L-Alanine
,22762844,AUC(τ),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],5.06,254930,DB00160,L-Alanine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],1599.0,254931,DB00160,L-Alanine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],2378.7,254932,DB00160,L-Alanine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],4540.1,254933,DB00160,L-Alanine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],2479.1,254934,DB00160,L-Alanine
,26395347,MTD,"The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3 weeks, the same as the recommended single-agent dose of volasertib in solid tumors.","A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26395347/),,300,256335,DB00160,L-Alanine
,11222570,plasma half-life,"The plasma half-life of the drug was very short, varying between 0.25 and 1.1 h.",A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11222570/),h,0.25 and 1.1,256454,DB00160,L-Alanine
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],1051.8,256545,DB00160,L-Alanine
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],335.9,256546,DB00160,L-Alanine
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],11150,256547,DB00160,L-Alanine
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,4,256548,DB00160,L-Alanine
,26512724,Tmax,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,5.3,256549,DB00160,L-Alanine
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,13.3,256550,DB00160,L-Alanine
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,1.8,256551,DB00160,L-Alanine
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,18.7,256552,DB00160,L-Alanine
,14749543,steady-state trough plasma concentration (C(pss)),"A steady-state trough plasma concentration (C(pss)) was achieved approximately 4 weeks after the initiation of treatment, but the value was scattered among patients in a range from 1100 to 4200 ng/mL.",Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749543/),[ng] / [ml],1100 to 4200,257380,DB00160,L-Alanine
,14749543,C(pss),The high C(pss) of ribavirin of approximately 4000 ng/mL decreased hemoglobin concentrations to less than 8.5 g/dL.,Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749543/),[ng] / [ml],4000,257381,DB00160,L-Alanine
,29987203,flow rate,The chromatographic separation was achieved on a Waters Atlantis&reg; Hilic Silica column with an optimum mobile phase consisting of 5 mM ammonium acetate in water (pH 3.0 adjusted with acetic acid) and acetonitrile at a flow rate of 0.2 mL/min.,Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987203/),[ml] / [min],0.2,257477,DB00160,L-Alanine
,29987203,m/z,"Mass spectrometric analyses were carried out by monitoring multiple reaction monitoring transitions at m/z 265.2&rarr;102.9 for KD and m/z 174.0&rarr;128.0 for l-phenyl-d₅-alanine-2,3,3-d₃ (IS).",Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987203/),,265.2,257478,DB00160,L-Alanine
,29987203,m/z,"Mass spectrometric analyses were carried out by monitoring multiple reaction monitoring transitions at m/z 265.2&rarr;102.9 for KD and m/z 174.0&rarr;128.0 for l-phenyl-d₅-alanine-2,3,3-d₃ (IS).",Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987203/),,102.9,257479,DB00160,L-Alanine
,29987203,absolute oral bioavailability,The absolute oral bioavailability for KD was determined to be 27.6%.,Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29987203/),%,27.6,257480,DB00160,L-Alanine
,1535385,Maximum blood levels,"Maximum blood levels of PAPM/BP were observed at the completion of drip infusion and were 26.72 +/- 8.78 micrograms/ml/18.33 +/- 8.54 micrograms/ml (mean +/- S.D.) with administration of 10 mg/10 mg, 64.80 +/- 18.50 micrograms/ml/38.74 +/- 16.41 micrograms/ml with administration of 20 mg/20 mg and 91.70 +/- 29.42 micrograms/ml/50.08 +/- 22.41 micrograms/ml with administration of 30 mg/30 mg.",[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),[μg] / [ml],26.72,257673,DB00160,L-Alanine
,1535385,Maximum blood levels,"Maximum blood levels of PAPM/BP were observed at the completion of drip infusion and were 26.72 +/- 8.78 micrograms/ml/18.33 +/- 8.54 micrograms/ml (mean +/- S.D.) with administration of 10 mg/10 mg, 64.80 +/- 18.50 micrograms/ml/38.74 +/- 16.41 micrograms/ml with administration of 20 mg/20 mg and 91.70 +/- 29.42 micrograms/ml/50.08 +/- 22.41 micrograms/ml with administration of 30 mg/30 mg.",[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),[μg] / [ml],18.33,257674,DB00160,L-Alanine
,1535385,Maximum blood levels,"Maximum blood levels of PAPM/BP were observed at the completion of drip infusion and were 26.72 +/- 8.78 micrograms/ml/18.33 +/- 8.54 micrograms/ml (mean +/- S.D.) with administration of 10 mg/10 mg, 64.80 +/- 18.50 micrograms/ml/38.74 +/- 16.41 micrograms/ml with administration of 20 mg/20 mg and 91.70 +/- 29.42 micrograms/ml/50.08 +/- 22.41 micrograms/ml with administration of 30 mg/30 mg.",[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),[μg] / [ml],64.80,257675,DB00160,L-Alanine
,1535385,Maximum blood levels,"Maximum blood levels of PAPM/BP were observed at the completion of drip infusion and were 26.72 +/- 8.78 micrograms/ml/18.33 +/- 8.54 micrograms/ml (mean +/- S.D.) with administration of 10 mg/10 mg, 64.80 +/- 18.50 micrograms/ml/38.74 +/- 16.41 micrograms/ml with administration of 20 mg/20 mg and 91.70 +/- 29.42 micrograms/ml/50.08 +/- 22.41 micrograms/ml with administration of 30 mg/30 mg.",[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),[μg] / [ml],38.74,257676,DB00160,L-Alanine
,1535385,Maximum blood levels,"Maximum blood levels of PAPM/BP were observed at the completion of drip infusion and were 26.72 +/- 8.78 micrograms/ml/18.33 +/- 8.54 micrograms/ml (mean +/- S.D.) with administration of 10 mg/10 mg, 64.80 +/- 18.50 micrograms/ml/38.74 +/- 16.41 micrograms/ml with administration of 20 mg/20 mg and 91.70 +/- 29.42 micrograms/ml/50.08 +/- 22.41 micrograms/ml with administration of 30 mg/30 mg.",[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),[μg] / [ml],91.70,257677,DB00160,L-Alanine
,1535385,half-life,The half-life was about 1 hour for PAPM and about 0.5 hour for BP.,[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),h,1,257678,DB00160,L-Alanine
,1535385,half-life,The half-life was about 1 hour for PAPM and about 0.5 hour for BP.,[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),h,0.5,257679,DB00160,L-Alanine
,1535385,overall bacterial eradication rate,The overall bacterial eradication rate for the pathogenic bacteria was 93.4%.(ABSTRACT TRUNCATED AT 400 WORDS),[Overall clinical evaluation of panipenem/betamipron against infections in pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535385/),%,93.4,257680,DB00160,L-Alanine
,15968885,Cmax,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"63,167",258530,DB00160,L-Alanine
,15968885,AUC0-infinity,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[h·ng] / [ml],"311,960",258531,DB00160,L-Alanine
,15968885,tmax,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,2 - 3,258532,DB00160,L-Alanine
,15968885,t1/2,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,9.5 - 15.5,258533,DB00160,L-Alanine
,15968885,Cmax,"High-fat diets reduced Cmax from 21,565 ng/ml to 14,095 ng/ml but did not alter AUC0-infinity.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"21,565",258534,DB00160,L-Alanine
,15968885,Cmax,"High-fat diets reduced Cmax from 21,565 ng/ml to 14,095 ng/ml but did not alter AUC0-infinity.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"14,095",258535,DB00160,L-Alanine
,15968885,t1/2,The AUC of one dosing interval and Cmax did not change after multiple doses but t1/2 increased from 9.5 - 10.0 hours to 12.5 - 13.5 hours.,"Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,9.5 - 10.0,258536,DB00160,L-Alanine
,15968885,t1/2,The AUC of one dosing interval and Cmax did not change after multiple doses but t1/2 increased from 9.5 - 10.0 hours to 12.5 - 13.5 hours.,"Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,12.5 - 13.5,258537,DB00160,L-Alanine
,18397690,t(max),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,1.19,258538,DB00160,L-Alanine
,18397690,C(max),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,4.49,258539,DB00160,L-Alanine
,18397690,C(min),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,1.35,258540,DB00160,L-Alanine
,18397690,AUC(ss),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,74.74,258541,DB00160,L-Alanine
,18397690,C(av),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,3.11,258542,DB00160,L-Alanine
,18397690,t(1/2beta),"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,20.75,258543,DB00160,L-Alanine
,18397690,PTF,"The pharmacokinetics parameters at steady state were: t(max)1.19 A+/- 0.59 h, C(max) 4.49 A+/- 0.81 mg/l, C(min) 1.35 A+/- 0.33 mg/l, AUC(ss) 74.74 A+/- 12.58 mg/l A h, C(av) 3.11 A+/- 0.52 mg/l, t(1/2beta) 20.75 A+/- 2.93 h, PTF 102.13 A+/- 23.92%.",Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),a,102.13,258544,DB00160,L-Alanine
,18397690,urinary elimination,The urinary elimination of antofloxacin over 120 h after the last dose was approximately 62%.,Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397690/),%,62,258545,DB00160,L-Alanine
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.1,258624,DB00160,L-Alanine
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.6,258625,DB00160,L-Alanine
,17001183,clearance,Five children with Down's syndrome had a median clearance of 13.6 ml/min/m (P=0.067 compared with non-Down's syndrome children).,Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],13.6,258626,DB00160,L-Alanine
,19647176,T(1/2)alpha,Biokinetic studies showed a rapid blood clearance (T(1/2)alpha=21 min).,Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19647176/),min,21,259569,DB00160,L-Alanine
,19647176,MTD,The liver MTD in mice was approximately 40 Gy after 7.4 MBq of (188)Re-HA injection.,Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19647176/),gy,40,259570,DB00160,L-Alanine
,10211864,renal clearance (Cl(r)),"This resulted in significantly greater percentages of intravenous DA-1131 excreted in urine as unchanged drug, 60.9 versus 40.1%, and significantly faster renal clearance (Cl(r)) of DA-1131 (6.10 versus 3.22 mL/min/kg) by treatment with betamipron.","Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211864/),[ml] / [kg·min],6.10,260789,DB00160,L-Alanine
,10211864,renal clearance (Cl(r)),"This resulted in significantly greater percentages of intravenous DA-1131 excreted in urine as unchanged drug, 60.9 versus 40.1%, and significantly faster renal clearance (Cl(r)) of DA-1131 (6.10 versus 3.22 mL/min/kg) by treatment with betamipron.","Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211864/),[ml] / [kg·min],3.22,260790,DB00160,L-Alanine
,24583798,plasma half-life,SAR245409 had a relatively short plasma half-life (2.96-7.52 hours).,"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24583798/),h,2.96-7.52,261079,DB00160,L-Alanine
,34156160,Clearance (Cl),Clearance (Cl) was found to be 18 L/h with an IIV of 45.3%.,ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34156160/),[l] / [h],18,261269,DB00160,L-Alanine
,10794923,bioavailability (BA),"The bioavailability (BA) of radio-labelled N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) was low when administered by oral gavage as an aqueous solution to conscious male Sprague-Dawley rats (8.3+/-4.4% (mean+/-S.D., n=3)).",Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794923/),%,8.3,262648,DB00160,L-Alanine
,10794923,permeability coefficient (p(app)),"The permeability coefficient (p(app)) of GMDP in isolated sections of rabbit ileum was 1.67x10(-6) cm/s in the mucosal to serosal direction and was not significantly different in the serosal to mucosal direction, indicating that GMDP is poorly permeable and passively transported across the intestinal wall.",Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794923/),[cm] / [s],1.67x10(-6),262649,DB00160,L-Alanine
,10868298,Half Life,"The pharmacokinetic parameters in these population are given below: CLPAPM; 0.239 +/- 0.206 (L/hr), VdPAPM; 0.97 +/- 0.80 (L), Half Life; 3.1 +/- 0.5 (hr).",[Pharmacokinetics of panipenem in neonates and dosage recommendation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868298/),h,3.1,262979,DB00160,L-Alanine
,10868298,Half life,Half life in the patients with PCA < 34 (2.66 +/- 0.44 hr) were significantly lower (p < 0.001) than that with PCA > or = 34 (3.39 +/- 0.23 hr).,[Pharmacokinetics of panipenem in neonates and dosage recommendation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868298/),h,2.66,262980,DB00160,L-Alanine
,10868298,Half life,Half life in the patients with PCA < 34 (2.66 +/- 0.44 hr) were significantly lower (p < 0.001) than that with PCA > or = 34 (3.39 +/- 0.23 hr).,[Pharmacokinetics of panipenem in neonates and dosage recommendation]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868298/),h,3.39,262981,DB00160,L-Alanine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,2.6,263341,DB00160,L-Alanine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,5.1,263342,DB00160,L-Alanine
,32953880,retention times,"The HPLC/UV analysis of the decoction revealed the presence of dihydroxycoumarin, quinine, and scopoletin with the following retention times: 2.6, 5.1, and 7.01 min, respectively.",Hepatoprotective Activity of Leptadenia hastata (Asclepiadaceae) on Acetaminophen-Induced Toxicity in Mice: In Vivo Study and Characterization of Bioactive Compounds through Molecular Docking Approaches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32953880/),min,7.01,263343,DB00160,L-Alanine
,17315456,elimination half-life,"For the i.v. study, the elimination half-life was 5.0 hr.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),h,5.0,263769,DB00160,L-Alanine
,17315456,apparent volume of distribution,"The apparent volume of distribution and plasma clearance were 0.17 L/kg and 0.0218 L/hr/kg, respectively.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),[l] / [kg],0.17,263770,DB00160,L-Alanine
,17315456,plasma clearance,"The apparent volume of distribution and plasma clearance were 0.17 L/kg and 0.0218 L/hr/kg, respectively.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),[l] / [h·kg],0.0218,263771,DB00160,L-Alanine
,17315456,time to maximum plasma concentrations,"For the i.m. study, mean time to maximum plasma concentrations ranged from 1.7 ( +/- 0.58) hr in the 50 mg/kg group to 3.7 (+/- 2.5) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),h,1.7,263772,DB00160,L-Alanine
,17315456,time to maximum plasma concentrations,"For the i.m. study, mean time to maximum plasma concentrations ranged from 1.7 ( +/- 0.58) hr in the 50 mg/kg group to 3.7 (+/- 2.5) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),h,3.7,263773,DB00160,L-Alanine
,17315456,bioavailability,"Mean bioavailability ranged from 45% ( +/- 15%) in the 50 mg/kg group to 58% (+/- 12%) in the 100 mg/kg group, and the mean residence time ranged from 7.5 ( +/- 2.6) hr in the 25 mg/kg group to 16 (+/- 6.8) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),%,45,263774,DB00160,L-Alanine
,17315456,bioavailability,"Mean bioavailability ranged from 45% ( +/- 15%) in the 50 mg/kg group to 58% (+/- 12%) in the 100 mg/kg group, and the mean residence time ranged from 7.5 ( +/- 2.6) hr in the 25 mg/kg group to 16 (+/- 6.8) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),%,58,263775,DB00160,L-Alanine
,17315456,mean residence time,"Mean bioavailability ranged from 45% ( +/- 15%) in the 50 mg/kg group to 58% (+/- 12%) in the 100 mg/kg group, and the mean residence time ranged from 7.5 ( +/- 2.6) hr in the 25 mg/kg group to 16 (+/- 6.8) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),h,7.5,263776,DB00160,L-Alanine
,17315456,mean residence time,"Mean bioavailability ranged from 45% ( +/- 15%) in the 50 mg/kg group to 58% (+/- 12%) in the 100 mg/kg group, and the mean residence time ranged from 7.5 ( +/- 2.6) hr in the 25 mg/kg group to 16 (+/- 6.8) hr in the 100 mg/kg group.",Pharmacokinetics of ticarcillin in the loggerhead sea turtle (Caretta caretta) after single intravenous and intramuscular injections. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315456/),h,16,263777,DB00160,L-Alanine
<,16278403,half-life,Tasidotin decayed from plasma in a biphasic fashion with a half-life of <45 minutes in most cases.,A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278403/),min,45,263788,DB00160,L-Alanine
,25278451,MTD,The MTD was determined as 400 mg once daily.,"A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25278451/),mg,400,264610,DB00160,L-Alanine
,28066880,apparent clearance (CL/F),The typical value of apparent clearance (CL/F) was 5.7 L/h (1.58% relative standard error [RSE]) and of apparent volume of the central compartment (V c/F) was 58.6 L (2.00% RSE).,Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066880/),[l] / [h],5.7,265383,DB00160,L-Alanine
,28066880,apparent volume of the central compartment (V c/F),The typical value of apparent clearance (CL/F) was 5.7 L/h (1.58% relative standard error [RSE]) and of apparent volume of the central compartment (V c/F) was 58.6 L (2.00% RSE).,Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066880/),l,58.6,265384,DB00160,L-Alanine
,15855500,clearance,"Pharmacokinetic studies indicated that clearance was stable over the dose range of 1.0 to 10 mg/kg of body weight (0.249 +/- 0.023 ml/kg/h) but was higher for the 0.1-mg/kg dose (0.540 +/- 0.078 ml/kg/h), suggesting saturable elimination.",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),[ml] / [h·kg],0.540,265438,DB00160,L-Alanine
,15855500,volume of distribution,"A similar nonlinear trend was observed for the volume of distribution, where average values ranged from 0.064 +/- 0.015 liter/kg for the 1.0- to 10-mg/kg doses and 0.043 +/- 0.005 for the 0.01-mg/kg dose.",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),[l] / [kg],0.064,265439,DB00160,L-Alanine
,15855500,volume of distribution,"A similar nonlinear trend was observed for the volume of distribution, where average values ranged from 0.064 +/- 0.015 liter/kg for the 1.0- to 10-mg/kg doses and 0.043 +/- 0.005 for the 0.01-mg/kg dose.",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),,0.043,265440,DB00160,L-Alanine
,15855500,half-life,"The mean half-life was 165 +/- 66 h, with lowest values observed for the 0.1-mg/kg dose (56.2 +/- 9.7 h) and the highest values reported for the 10.0-mg/kg dose (206.4 +/- 12.4 h).",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),h,165,265441,DB00160,L-Alanine
,15855500,half-life,"The mean half-life was 165 +/- 66 h, with lowest values observed for the 0.1-mg/kg dose (56.2 +/- 9.7 h) and the highest values reported for the 10.0-mg/kg dose (206.4 +/- 12.4 h).",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),h,56.2,265442,DB00160,L-Alanine
,15855500,half-life,"The mean half-life was 165 +/- 66 h, with lowest values observed for the 0.1-mg/kg dose (56.2 +/- 9.7 h) and the highest values reported for the 10.0-mg/kg dose (206.4 +/- 12.4 h).",Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855500/),h,206.4,265443,DB00160,L-Alanine
,22935583,maximum tolerated dose,The maximum tolerated dose was defined as 90 mg BID.,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935583/),,90,265508,DB00160,L-Alanine
,22935583,maximum tolerated dose,The maximum tolerated dose for AZD8055 is 90 mg BID.,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935583/),,90,265509,DB00160,L-Alanine
,19301006,peak plasma concentration,Rh2 administered at a dose of 120 mg/kg exhibited a peak plasma concentration of 19.0 +/- 2.0 microg/ml.,"Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301006/),[μg] / [ml],19.0,266001,DB00160,L-Alanine
,17431927,weight-corrected dose,"The mean clozapine dose was significantly higher in the Caucasian subjects (432.5+/-194.7 mg) as compared to the Asian subjects (175.6+/-106.9 mg) (p<0.001) while the mean weight-corrected dose for Asian patients was lower (3.0+/-1.9 and 5.0+/-2.1 mg/kg, respectively, p=0.005).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),,3.0,266026,DB00160,L-Alanine
,17431927,weight-corrected dose,"The mean clozapine dose was significantly higher in the Caucasian subjects (432.5+/-194.7 mg) as compared to the Asian subjects (175.6+/-106.9 mg) (p<0.001) while the mean weight-corrected dose for Asian patients was lower (3.0+/-1.9 and 5.0+/-2.1 mg/kg, respectively, p=0.005).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),,5.0,266027,DB00160,L-Alanine
,17431927,plasma clo,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],415.3,266028,DB00160,L-Alanine
,17431927,concentration,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],415.3,266029,DB00160,L-Alanine
,17431927,concentration,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],417.1,266030,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[ng] / [ml],248.5,266583,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[ng] / [ml],275.7,266584,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to infinity (AUC0-∞ ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[ng] / [ml],275.7,266585,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to infinity (AUC0-∞ ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],148.1,266586,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to infinity (AUC0-∞ ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],157.8,266587,DB00160,L-Alanine
,34352149,area under the concentration-time curve from time 0 to infinity (AUC0-∞ ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],148.4,266588,DB00160,L-Alanine
,34352149,maximum concentration (Cmax ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],148.4,266589,DB00160,L-Alanine
,34352149,maximum concentration (Cmax ),"The mean values of the area under the concentration-time curve from time 0 to the last time point with blood sample collection (AUC0-t ), area under the concentration-time curve from time 0 to infinity (AUC0-∞ ), and maximum concentration (Cmax ) for the test and reference products of TAF were 248.5 and 275.7 ng/mL, 148.1 and 157.8 ng • h/mL, and 148.4 and 158.1 ng • h/mL, respectively, under the fasting condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],158.1,266590,DB00160,L-Alanine
,34352149,Cmax,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[ng] / [ml],244.6,266591,DB00160,L-Alanine
,34352149,AUC0-t,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[ng] / [ml],246.7,266592,DB00160,L-Alanine
,34352149,AUC0-t,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],230.4,266593,DB00160,L-Alanine
,34352149,AUC0-t,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],244.9,266594,DB00160,L-Alanine
,34352149,AUC0-∞,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],244.9,266595,DB00160,L-Alanine
,34352149,AUC0-∞,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],233.2,266596,DB00160,L-Alanine
,34352149,AUC0-∞,"On the other hand, the mean value of Cmax , AUC0-t , and AUC0-∞ for the test and reference formulations of TAF were 244.6 and 246.7 ng/mL, 230.4 and 244.9 ng • h/mL, and 233.2 and 246.2 ng • h/mL, respectively, under the fed condition.",Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34352149/),[h·ng] / [ml],246.2,266597,DB00160,L-Alanine
>,7741789,LD50,5-ASA sulfate can be considered as a non-toxic agent after single oral intake in rats (14-day LD50 > 6000 mg/kg b.w.).,Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),[mg] / [kg],6000,266725,DB00160,L-Alanine
,7741789,excretion,"After a single oral administration of 1800 mg 5-ASA sulfate to 5 healthy human test subjects, 5-ASA sulfate was almost completely metabolized by all test subjects within 3 days; mean urinary and faecal excretion of unchanged 5-ASA sulfate amounted to only 6.7% of the administered dose.",Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741789/),%,6.,266726,DB00160,L-Alanine
,7418965,half-life,"At plasma concentrations below 10 micrograms/ml, elimination was monoexponential with a half-life of 32 +/- 11 min (mean +/- SD).",Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418965/),min,32,266913,DB00160,L-Alanine
,20919560,elimination half life,The peak of hopantenic acid in blood plasma was achieved at 1.56 h and the elimination half life was 6.68 h.,[Pharmacokinetics of hopantenic acid upon peroral administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919560/),h,6.68,269197,DB00160,L-Alanine
,17317834,peritoneal,"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],"82,612",269866,DB00160,L-Alanine
,17317834,area under the concentration versus time curve (AUC),"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],"82,612",269867,DB00160,L-Alanine
,17317834,plasma AUC,"At 120 mg/m(2), the median peritoneal area under the concentration versus time curve (AUC) was 82,612 ng/mL x h (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range, 47.6-259.5).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),[ng] / [h·ml],231,269868,DB00160,L-Alanine
,17317834,peritoneal advantage (AUC(peritoneal)/AUC(plasma)),"The mean peritoneal advantage (AUC(peritoneal)/AUC(plasma)) was 847 (range, 356-1,385).",Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317834/),,847,269869,DB00160,L-Alanine
,11021740,distribution,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,0.63,269925,DB00160,L-Alanine
,11021740,terminal elimination half-lives,"The pharmacokinetics of pemetrexed disodium were best characterized by a two-compartment model with initial distribution and terminal elimination half-lives of 0.63 h and 2.73 h, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),h,2.73,269926,DB00160,L-Alanine
,11021740,central volume (V(c)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),1,11.3,269927,DB00160,L-Alanine
,11021740,distributional CL (Q),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),[l] / [h],3.21,269928,DB00160,L-Alanine
,11021740,peripheral volume (V(p)),"Typical values of central volume (V(c)), distributional CL (Q), and peripheral volume (V(p)) were 11.3 1, 3.21 l/h, and 5.20 l, respectively.",Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021740/),l,5.20,269929,DB00160,L-Alanine
below,2959359,platelet nadirs,"Three patients developed platelet nadirs below 100,000/microliters.",Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959359/),,100,271757,DB00160,L-Alanine
,6407991,corrected transfer,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,56,272010,DB00160,L-Alanine
,6407991,corrected transfer,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,113,272011,DB00160,L-Alanine
,6407991,pool size,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,67,272012,DB00160,L-Alanine
,6407991,pool size,"(5) Analogously, the average corrected transfer was 56% and 113% of normal; the pool size was 67% and 139% of normal.",[Metabolism of parenterally administered amino acids in chronic kidney failure in childhood]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407991/),%,139,272013,DB00160,L-Alanine
,22775412,first-order absorption rate constant,Parent drug was absorbed orally with a population estimate first-order absorption rate constant of 0.457 h(-1).,Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),1/[h],0.457,272031,DB00160,L-Alanine
,22775412,apparent oral clearance (CL/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],231,272032,DB00160,L-Alanine
,22775412,apparent central compartment volume of distribution after oral administration (V(1)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],315,272033,DB00160,L-Alanine
,22775412,apparent central compartment volume of distribution after oral administration (V(1)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,325,272034,DB00160,L-Alanine
,22775412,apparent peripheral compartment volume of distribution after oral administration (V(2)/F),"The population estimates of apparent oral clearance (CL/F) of atorvastatin acid to atorvastatin lactone, intercompartmental clearance (Q/F), apparent central compartment volume of distribution after oral administration (V(1)/F) and apparent peripheral compartment volume of distribution after oral administration (V(2)/F) for atorvastatin acid were 231 L/h, 315 L/h, 325 L and 4910 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,4910,272035,DB00160,L-Alanine
,22775412,apparent total clearance of atorvastatin lactone (CL(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],85.4,272036,DB00160,L-Alanine
,22775412,apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],166,272037,DB00160,L-Alanine
,22775412,apparent volume of distribution of,"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),[l] / [h],166,272038,DB00160,L-Alanine
,22775412,V(M)/F),"The population estimates of apparent total clearance of atorvastatin lactone (CL(M)/F), apparent intercompartmental clearance of atorvastatin lactone (Q(M)/F) and apparent volume of distribution of atorvastatin lactone after oral administration (V(M)/F) were 85.4 L/h, 166 L/h and 249 L, respectively.",Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775412/),l,249,272039,DB00160,L-Alanine
less,29641159,oral bioavailability,"Rebamipide (RBP) is a potent anti-ulcer and anti-oxidative agent, which is a BCS class IV drug with a low oral bioavailability of less than 10%.",Capmul MCM/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29641159/),%,10,272584,DB00160,L-Alanine
,25103614,trough level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],69.3,273242,DB00160,L-Alanine
,25103614,peak level,The average dabigatran trough level was 69.3 ± 55.5 ng/ml and the average dabigatran peak level was 112.7 ± 66.6 ng/ml.,Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25103614/),[ng] / [ml],112.7,273243,DB00160,L-Alanine
,1164825,elimination half-life,The elimination half-life of hexobarbital was 490 +/- 186 min in the hepatitis patients and 261 +/- 69 min in the control group.,Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164825/),min,490,273538,DB00160,L-Alanine
,1164825,elimination half-life,The elimination half-life of hexobarbital was 490 +/- 186 min in the hepatitis patients and 261 +/- 69 min in the control group.,Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164825/),min,261,273539,DB00160,L-Alanine
,16305582,elimination half-life,"The elimination half-life of [2-(13)C]5,6-dihydrouracil was 0.9-1.4 h, whereas that of [2-(13)C]uracil was 0.2-0.3 h.",Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305582/),h,0.9-1.4,273572,DB00160,L-Alanine
,16305582,elimination half-life,"The elimination half-life of [2-(13)C]5,6-dihydrouracil was 0.9-1.4 h, whereas that of [2-(13)C]uracil was 0.2-0.3 h.",Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16305582/),h,0.2-0.3,273573,DB00160,L-Alanine
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,7.5,273848,DB00160,L-Alanine
,23134470,MTDs,Daily and weekly MTDs were 7.5 mg and 70 mg respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),mg,70,273849,DB00160,L-Alanine
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,71.4,273850,DB00160,L-Alanine
,23134470,Disease control rates,Disease control rates in the daily and weekly cohorts were 71.4% and 44.4% respectively.,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23134470/),%,44.4,273851,DB00160,L-Alanine
,1398851,clearance,"The 50 mg/kg/day dosage schedule was terminated midway through the study, as blood levels were consistently low and two patients with typhoid relapsed, children with typhoid had significantly lower clearance of CS in comparison with those with non-typhoidal illness (0.29 +/- 0.1 versus 0.5 +/- 0.37 1/kg/hr, P 0.05).",Chloramphenicol clearance in typhoid fever: implications for therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1398851/),[1] / [h·kg],0.29,274017,DB00160,L-Alanine
,1398851,clearance,"The 50 mg/kg/day dosage schedule was terminated midway through the study, as blood levels were consistently low and two patients with typhoid relapsed, children with typhoid had significantly lower clearance of CS in comparison with those with non-typhoidal illness (0.29 +/- 0.1 versus 0.5 +/- 0.37 1/kg/hr, P 0.05).",Chloramphenicol clearance in typhoid fever: implications for therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1398851/),[1] / [h·kg],0.5,274018,DB00160,L-Alanine
greater,1398851,trough concentrations,"However, two children on 100 mg/kg/day dosage developed trough concentrations greater than 20 mcg/ml.",Chloramphenicol clearance in typhoid fever: implications for therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1398851/),[mcg] / [ml],20,274019,DB00160,L-Alanine
